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Phenanthropiperidine Alkaloids: Methodology Development, Synthesis 
and Biological Evaluation 
Micah J. Niphakis, Ph. D.
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The phenanthropiperidines are remarkably potent anti-proliferative alkaloids.  Only  one 
member of this class has been tested in the clinic, but the trials were terminated shortly 
thereafter due to adverse neurological side-effects.  This work is directed towards the 
development of safe phenanthropiperidines for the treatment of cancer.  It focuses on 
synthetic methodologies that facilitate their preparation and biological studies to better 
understand their neurological effects.    
The preparation of cyclic enaminones in high enantiomeric purity is made possible 
through a one-flask, two-step protocol that uses mild Boc-deprotection conditions to suppress 
racemization.  This reaction enables the preparation of monocyclic and bicyclic, six- and 
seven-membered enaminones, some of which can be used as precursors to 
phenanthropiperidine alkaloids.  
Elaboration of the enaminone scaffold was made possible with a direct palladium(II)-
catalyzed arylation using aryltrifluoroborates as coupling partners.  Combined with the 
enaminone methodology this approach gives rapid access to enantiomerically  pure 3-
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arylpiperidines.  The utility of these scaffolds were demonstrated in the synthesis of two 
natural products: (+)-ipalbidine and (+)-antofine. 
A short and high-yielding synthetic route has also been devised to provide tylocrebrine, 
the only phenanthropiperidine to enter clinical trials.  We report the first enantioselective 
synthesis of tylocrebrine which uses a novel aryl-alkene oxidative coupling reaction that 
surmounts the historical challenge of obtaining a single phenanthrene regioisomer.  A small 
collection of tylocrebrine analogs were prepared and studied along with tylocrebrine to 
elucidate the cause of tylocrebrine’s neurological side-effects.  Although the causes remain 
elusive, tylocrebrine and several of its analogs were found to bind to key biogenic amine 
receptors, disclosing another potential risk factor for their therapeutic use.  The phenanthrene 
substitution pattern, however, had an marked influence on binding and could be used to 
minimize these off-target interactions.                    
                               
 
6
TABLE OF CONTENTS 
.................................................................................................................List of Figures 12
...............................................................................................List of Tables and Graphs 15
..........................................................................................................List of Compounds 18
..................................................................................................................Abbreviations 26
CHAPTER 1
INTRODUCTION TO PHENANTHROPIPERIDINE ALKALOIDS
.....................................................................................................................1.1   Introduction 31
.....................................................................................................................1.2   Background 32
.........1.2.1 Discovery of tylophorine, tylophorinine, cryptopleurine and tylocrebrine 32
.......................................1.2.2 Phenanthropiperidine isolation and structural features 35
........................................................................................................1.2.4  Biosynthesis 38
...........................................................................................1.3  Biology of Tylophora indica 41
....................................................................................................1.3.1  Clinical studies 41
...........................................................1.3.2   In vitro and in vivo studies with T. Indica 44
.....................................................................1.4   Biology of phenanthropiperidine alkaloids 47
.............................................................................................1.4.1  Anti-cancer activity 48
.........................................................................................1.4.1.1 In vivo studies 48
.........................................................................................1.4.1.2 In vitro studies 50
...............................................................1.4.1.3 Structure-activity relationships 52
...........................................................................................1.4.2  Mechanism of action 61
 
7
.....................................1.4.2.1 Protein, DNA and RNA biosynthesis inhibition 61
................................................................1.4.2.2 Apoptosis and cell cycle arrest 67
...........................................................................................1.4.2.3 Angiogenesis 70
..................................................................................1.4.2.4 Cell differentiation 70
......................................................................1.4.2.5 NF-κB Signaling pathway 71
........................................................................................1.4.2.6 DNA and RNA 72
...........................................................................1.4.2.7 Other molecular targets 73
.................................................................................1.4.3  Anti-inflammatory activity 74
........................................................................................1.4.4  Miscellaneous activity 75
..........................................................................1.4.5  Summary of biological activity  76
...........................................................................................1.5  Obstacles to clinical success 77
..................................................................1.6  Synthesis of phenanthropiperidine alkaloids 80
........................................1.6.1  First synthetic efforts towards phenanthropiperidines 81
.......................................................................................1.6.2  Phenanthrene synthesis 83
.............................................................1.6.3.  Indolizidine and quinolizidine synthesis 90
...............................................................1.6.3.1 C3–C4 bond forming reactions 91
...............................................................1.6.3.2 C2–C3 bond forming reactions 95
...............................................................1.6.3.3 C4–C5 bond forming reactions 98
...............................................................1.6.3.4 N–C2 bond forming reactions 102
.......................................................1.6.3.5 N–C8(C9) bond forming reactions 103
...........................................................1.6.3.6 C5a–C6 bond forming reactions 106
....................................................................1.6.3.7 Angular OH or Me groups 107
................................................................................................1.6.4  Closing remarks 108




SYNTHESIS OF SIX- AND SEVEN-MEMBERED CYCLIC ENAMINONES: OPTIMIZATION, 
SCOPE AND MECHANISTIC STUDIES
...................................................................................................................2.1  Introduction 111
...................................................................................................................2.2  Background 112
...................................................................................................2.3   Reaction development 116
................................2.3.1 Strategy and considerations for enaminone methodology  116
......................................2.3.2 Synthesis of Weinreb amide and ynone intermediates 119
..............................................................2.3.3 Optimization of enaminone formation 122
.....................2.3.4 Mitigating stereochemical damage during enaminone formation 124
..............................................................................................................2.3 Reaction scope 132
...............................................................................2.3.1 Six-membered enaminones 132
...........................................................2.3.2 Seven- and five-membered enaminones 136
...............................................................................2.3.3 Summary of reaction scope 137
......................................................................................................2.4 Mechanistic insights 138
.......................................................................................................................2.5  Summary  142
CHAPTER 3
PALLADIUM(II)-CATALYZED CROSS-COUPLING OF CYCLIC ENAMINONES AND 
ORGANOTRIFLUOROBORATES
...................................................................................................................3.1 Introduction 144
.................................................................3.2  Background to Pd-catalyzed cross-coupling 145
..........................................................................................................3.3  Synthetic strategy 148
.....................................................................3.4  Activation and classical Suzuki approach 150
..................................................................................................3.5  C–H Functionalization 153
...................................................................................................3.6  Reaction optimization 161
 
9
...............................................................................................3.6.1 Reoxidant screen 161
..................................................................................3.6.2 Palladium-catalyst screen 165
...................................................................................................3.6.3 Solvent screen 166
..................................................................................................3.6.4 Additive screen 167
...............................................................................................3.7  Scope of trifluoroborates 170
....................................................................................................3.8  Scope of enaminones 174
........................................................................3.9  Extensions and directions for the future 176
.......................................................................................................................3.10  Summary  179
CHAPTER 4
SYNTHESIS OF (+)-ANTOFINE AND (+)-IPALBIDINE
...................................................................................................................4.1  Introduction 180
...................................................................................4.2  Total synthesis of (+)-ipalbidine 182
.........................................................4.2.1 First attempt to synthesize (+)-ipalbidine 182
....................................................................4.2.2 Second approach to (+)-ipalbidine 185
.......................................................................4.2.3 Third approach to (+)-ipalbidine 188
......................................................................................4.3  Total synthesis of (+)-antofine 189
.......................................................................................................................4.4  Summary  190
CHAPTER 5
SYNTHESIS AN BIOLOGICAL EVALUATION OF (R)-TYLOCREBRINE AND RELATED 
ANALOGS
...................................................................................................................5.1  Introduction 192
..............................................................5.2   Possible mechanisms for neurological effects 193
...........................................................................5.3  Synthesis of tylocrebrine and analogs 196
.................................................5.4  Biological studies of tylocrebrine and related analogs 207
...............................................................................................................5.4.1  Cancer 207
 
10
................................................................5.4.2  Neurological side-effects hypothesis 209
...............................................................................5.4.2.1 MPTP-like toxicity 209
...............................................5.4.2.2 Dopaminergic and other CNS receptors 215
.......................................................................................................................5.5  Summary  221
CHAPTER 6
EXPERIMENTAL DATA
..................................................................................................6.1  Materials and methods 223
.......................................................................................................................6.2  Chapter 2 224
...........................................................................6.3.1 Preparation of Weinreb amides: 224
..........................................................................................6.3.2 Preparation of ynones: 241
........................................................................6.3.3 Preparation of cyclic enaminones 250
.........................................................................................6.3.4 Supplementary studies 264
.......................................................................................................................6.3  Chapter 3 276
.......................................................................6.3.1 Preparation of starting materials 276
......................................................6.3.2 Pd(II)-catalyzed C3-arylation of enaminones 278
.......................................................................................................................6.4  Chapter 4 292
.......................................................................................................................6.5  Chapter 5 307
...........................................................6.5.1 Preparation of tylocrebrine and analogs 307
.......................................................................................6.5.2 Biological procedures 330
.........................................................................6.5.2.1 Anti-proliferation assay  330
.............................................................................................6.5.2.2 MOA assay 330




LIST OF FIGURES 
CHAPTER 1
Fig. 1–1.  Structure of first discovered phenanthropiperidines. 34
Fig. 1–2.  General structural features of the phenanthropiperidines. 36
Fig. 1–3.  Under- and over-oxidized scaffolds. 37
Fig. 1–4.  Unusual structures of tyloindicines F–I. 38
Fig. 1–5.  Structures of several NCI-tested phenanthropiperidines. 49
Fig. 1–6.  Scaffolds of phenanthropiperidines and analogs. 55
Fig. 1–7.  Structure of PBT-1. 59
Fig. 1–8.  Structure of emetine. 64
Fig. 1–9.  Structures of tylophorinidine and boehmeriasin A. 69
Fig. 1–10.  Antofine’s affinity for DNA structures. 73
Fig. 1–11.  Key-step bond formations. 91
CHAPTER 2
Fig. 2–1.  Generic structure of the enaminone. 112
Fig. 2–2.  Select synthetic transformations of the 6-membered cyclic enaminone. 114
Fig. 2–3.  Possible modes of addition for 6-endo-dig cyclization. 117
Fig. 2–4.  Potential modes of α- and β-racemization/epimerization. 118
Fig. 2–5.  X-ray crystal structure of vinyl iodide 2.38. 128
 
12
Fig. 2–6.  Two potential mechanistic pathways of cyclization. 139
CHAPTER 3
Fig. 3–1.  Examples of 3-aryl piperidine medicinal agents. 144
Fig. 3–2.  Applications of Pd chemistry. 146
Fig. 3–3.  Postulated general cross-coupling catalytic cycle. 147
Fig. 3–4.  Postulated Heck-Mizokori catalytic cycle. 148
Fig. 3–5.  Plausible mechanisms for Pd-catalyzed C–H functionalization reactions. 154
Fig. 3–6.  Directing group-assisted C–H palladation via electrophilic substitution. 155
Fig. 3–7.  Reactivity-assisted C–H palladation. 157
Fig. 3–8.  C3/C2 Pd-migration of palladated indoles. 159
Fig. 3–9.  C3/C2 palladium migration of palladated enaminones. 160
Fig. 3–10.  Homocoupling product of trifluoroborate 3.3. 164
Fig. 3–11.  Proposed catalytic cycle for direct-arylation of enaminones. 164
Fig. 3–12.  Mechanism of Pd(II)-catalyzed olefination. 177
CHAPTER 4




Fig. 5–1.  Promising sites for derivatization. 195
Fig. 5–2.  Mechanism for MPTP-induced toxicity. 210
Fig. 5–3.  Structure of MPTP, MPP+ and dehydrotylocrebrine. 211
Fig. 5–4.  Structurally related molecules of interest. 215
 
14
LIST OF TABLES AND GRAPHS
CHAPTER 1
Table 1–1.  Clinical studies with T. indica for the treatment of asthma. 43
Table 1–2.  In vivo and in vitro studies with T. indica extracts. 45
Table 1–3.  Best NCI in vivo results for L1210 leukemia model. 49
Table 1–4.  Growth inhibitory activity for antofine and NCI tested 
phenanthropiperidines. 51
Table 1–5.  Growth inhibitory activity in drug resistance cell lines. 52
Table 1–6.  Structure and average GI50 over select cell lines.  53
Table 1–7.  Inhibition of protein, DNA and RNA synthesis. 63
Table 1–8.  Apoptosis and cell cycle arrest by phenanthropiperidine alkaloids. 68
Table 1–9.  CNS drugs and tylocrebrine’s physicochemical properties. 79
Graph 1–1.  Anti-proliferative activity of phenanthropiperidines in fourteen 
select cell lines. 54
CHAPTER 2
Table 2–1.  Preparation of ynones from Weinreb amides. 121
Table 2–2.  Optimization of deprotection and cyclization. 123
Table 2–3.  Boc-deprotection and β-epimerization. 125
Table 2–4.  Substrate scope for the preparation of six-membered enaminones. 134




Table 3–1.  Suzuki cross-coupling conditions of iodoenaminone. 152
Table 3–2.  Screen of reoxidants. 162
Table 3–3.  Screen of palladium catalysts. 166
Table 3–4.  Screen of solvents. 167
Table 3–5.  Screen of additives. 168
Table 3–6.  Successfully coupled aryltrifluoroborates. 171
Table 3–7.  Aryltrifluoroborates that did not couple.  172
Table 3–8.  Successfully coupled of enaminones. 175
Table 3–9.  Enaminones that did not couple. 176
CHAPTER 4
Table 4–1.  Optimization of dehydration conditions. 187
CHAPTER 5
Table 5–1.  Synthesis of biaryl fragment. 202
Table 5–2.  Oxidative aryl-alkene coupling optimization. 205
Table 5–3.  Final two steps to prepare (±)-tylocrebrine and its analogs. 207
 
16
Table 5–4.  Cytotoxicity of phenanthroindolizidines. 208
Table 5–5.  Phenanthropiperidine affinity for monoamine transporters. 213
Table 5–6.  Comprehensive CNS target primary screen from NIHM-PDSP. 217
Table 5–7.  Affinity for phenanthropiperidine for biogenic amine receptors. 218
Table 5–8.  Tylocrebrine’s and dehydrotylocrebrine’s affinity for muscarinic 
receptors. 220
Graph 5–1. Phenanthropiperidines as a substrate for MAO-A and MAO-B. 212
 
17
























tert-Butyl 3-(Methoxy(methyl)amino)-3-oxopropylcarbamate (2.11) 121
tert-Butyl Benzyl(3-(methoxy(methyl)amino)-3-oxopropyl)carbamate (2.12) 121




tert-Butyl Benzyl ((1 - (2- (methoxy (methyl)amino) 2 - oxoethyl) cyclohexyl) 
methyl) carbamate 121
tert-Butyl Benzyl(2-(4-chlorophenyl)–4-(methoxy (methyl) amino)-4-oxobutyl) 
carbamate 121
(S)-tert-Butyl 2-(2-Oxobut-3-yn-1-yl)piperidine-1-carboxylate (2.14) 121
(S)-tert-Butyl 2-(2-Oxopent-3-yn-1-yl)piperidine-1-carboxylate (2.15) 121
(S)-tert-Butyl 2-(2-Oxo-4-phenylbut-3-yn-1-yl)piperidine-1-carboxylate (2.16) 121
(S)-tert-Butyl 2-(2-Oxobut-3-yn-1-yl)pyrrolidine-1-carboxylate (2.17) 121















tert-Butyl 3-(2-Oxobut-3-ynyl)morpholine-4-carboxylate (2.25) 121
tert-Butyl Methyl((1R*, 2S*)-2-propioloylcyclohexyl)carbamate (2.26) 121
tert-Butyl Methyl((1R*, 2R*)-2-propioloylcyclohexyl)carbamate (2.27) 121
(R)-tert-Butyl 3-Oxo-1-phenylpent-4-ynylcarbamate (2.28) 121
(S)-tert-Butyl (4-Oxo-1-phenylhex-5-yn-2-yl)carbamate (2.29) 121
(S)-tert-Butyl (4-Oxo-1-phenylhept-5-yn-2-yl)carbamate (2.30) 121
tert-Butyl 3-Oxopent-4-ynylcarbamate (2.31) 121
tert-Butyl Benzyl(3-oxopent-4-ynyl)carbamate (2.32) 121
tert-Butyl 3-Oxopent-4-ynyl(phenyl)carbamate (2.33) 121
tert-Butyl 2-(3-Oxopent-4-ynyl)pyrrolidine-1-carboxylate (2.57) 137
tert-Butyl 2-(3-Oxopent-4-ynyl)piperidine-1-carboxylate (2.58) 137
tert-Butyl Benzyl((1-(2-oxobut-3-ynyl)cyclohexyl)methyl)carbamate (2.59) 137








































































(S)-tert-Butyl 2-(2-Diazoacetyl)pyrrolidine-1-carboxylate (4.3) 183
(S)-2-(1-(tert-Butoxycarbonyl)pyrrolidin-2-yl)acetic acid (4.4) 183
(S)-tert-Butyl 2-(2-Methoxy-2-oxoethyl)pyrrolidine-1-carboxylate (4.5) 183















1,2,3,5,8,8a-Hexahydroindolizin-7-yl Trifluoromethanesulfonate (5.5) 198
 
24
tert-Butyl 2-Oxopyrrolidine-1-carboxylate (5.6) 198
tert-Butyl 2-Hydroxypyrrolidine-1-carboxylate (5.7) 200



































CAN ammonium cerium (IV) nitrate
Cbz carbobenzyloxy
CDK cyclin-dependent kinase 



















DTH delayed-type hypersensitivity 
e.r. enantiomeric ratio
EDCI 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
EtOAc ethyl acetate 
EtOH ethanol
FEV1 forced expiratory volume in 1 second 
fod 6,6,7,7,8,8,8-heptafluoro-2,2-dimethyl-3,5-octanedionate
GPCR G-protein coupled receptor 
h hour
HASPO 4,4,5,5-tetramethyl-1,3,2-dioxaphospholane 2-oxide
HBD hydrogen bond donor
HIF-1 hypoxia-inducible factor I
HIR humoral immune response







KD dissociation constant 
LAH lithium aluminum hydride 















MRP multidrug resistance protein
Ms mesyl
MW molecular weight 
NADH nicotinamide adenine dinucleotide
NBS N-bromosuccinamide
NCI National Cancer Institute 
NET norepinephrine transporter 
NMM N-methylmorpholine 
NMR nuclear magnetic resonance
PDSP psychoactive drug screening program 








PNS peripheral nervous system
PPA polyphosphoric acid








SERT serotonin transporter 
SN-38 7-ethyl-10-hydroxycamptothecin








TFAA trifluoroacetic anhydride 
THF tetrahydrofuran
TMS trimethylsilyl
TMV tobacco mosaic virus 
Topo I topoisomerase I
Topo II topoisomerase II
TsOH toluenesulfonic acid
VEGF vascular endothelial growth factor 
 
29
VC vital capacity 
VP-16 etoposide
XRCC1 X-ray repair cross-complementing gene I
 
30
CHAPTER 1  
INTRODUCTION TO PHENANTHROPIPERIDINE ALKALOIDS
1.1   Introduction
With the historical success of pharmacognosy, nature continues to be scoured for new 
drug leads.  The discovery of a medicinally  active natural product, however, is only the 
beginning of the arduous venture of drug development.  Nature-derived drug leads often 
require considerable optimization before they are of any  instrumental value and the 
phenanthropiperidines, the subject  of this work, are a case in point.  These alkaloids have 
been pursued as leads for the treatment of cancer and immune-related diseases for over 50 
years yet not a single member has emerged for clinical use.  Some have abandoned the effort, 
while others tenaciously pursue next generation phenanthropiperidines with hope that this 
class is still redeemable.  The reasons that undergird both of these positions will be explored 
in the following pages.                
Like many bioactive natural products, the phenanthropiperidines were isolated from 
plants that had been used in folk medicine for untold centuries.1 The reputed therapeutic 
value of Tylophora indica (asthmatica) spurred early scientific activity that sought to validate 
and characterize its biological effects.  In spite of periodic lapses of interest over the past six 
decades, these alkaloids are now receiving more attention than ever.  This renewed interest is 
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attributable to recent advances in biotechnology that have just begun to uncover the profound 
biochemical remodeling induced by these alkaloids in living systems that could be harnessed 
to treat disease.  Herein, we give an extensive review of the literature related to the chemistry 
and biology of the phenanthropiperidine class.  This review differs from previous ones2-5 in 
that it is not limited to recent findings, and its scope extends deeper into the pharmacology of 
these alkaloids.  The purpose of this work is to consolidate the widely dispersed literature on 
this subject to encourage a holistic understanding of what contributes to their potential use as 
medicinal agents.  In this regard, special attention will be given to pharmacologically 
relevant details in order to comprehend better the poorly understood mechanism of action to 
assess therapeutic value.  Considering that drug or lead accessibility  is a major contributor to 
the success of natural product- and naturally-derived medicinal agents, we will also discuss 
precedent for the preparation of these alkaloids.  Ideally, this compendium will expose 
impediments to clinical success and will encourage and guide the refinement process in a 
preclinical environment. 
1.2   Background
1.2.1 Discovery of tylophorine, tylophorinine, cryptopleurine and tylocrebrine   
Folk medicines are a rich source of incipient drugs that are laden with clues for 
therapeutic use.  The phenanthropiperidines owe their discovery to an Indian household 
remedy, now called T. indica that was brought to the attention of Western scientists in the late 
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19th century.6 The roots and leaves of this perennial climbing plant have been used for a 
broad spectrum of medical conditions, and it is listed as an important member of the Indian 
materia medica.7 In 1935, with the aim of isolating the active constituents of this natural 
remedy, Ratnagiriswaran et al. extracted and purified two alkaloids, naming them tylophorine 
and tylophorinine (Fig. 1–1).7 The structure of tylophorine was not determined until 1960 
after several years of degradation studies and comparison with the synthetically-derived 
natural product.8-12 The proposed structure contained an indolizidine heterocycle fused to a 
symmetrically  substituted phenanthrene.13 The stereochemistry, which had been mistakenly 
assigned earlier,14 was unambiguously assigned as R following a total synthesis and 
comparison of the optical rotation with the isolated alkaloid.15  Although tylophorine was the 
first member of its class to be isolated, another phenanthropiperidine had been characterized 
several years before its structure was determined.
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In 1948 de la Lande reported the isolation of a highly toxic substance named 
cryptopleurine that  had been extracted from Cryptocarya pleurosperma, a walnut tree 
indigenous to Austrailia.16 Seminal pharmacological studies demonstrated that  cryptopleurine 
was lethal in rat, mouse, rabbit, dog and cat models (LD50 1.5 to 5 mg/kg).  It also became 
apparent that the alkaloid was a potent skin irritant.  Upon oral administration, rats developed 
blisters on the face and feet.  Furthermore, topical administration in human volunteers 
produced vessication on the arm and face that lasted over two weeks.  Moreover, 



































Fig. 1–1. Structure of first discovered phenanthropiperidines.
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had received oral dosages of the alkaloid.  In 1954, the structure of cryptopleurine was 
determined through X-ray diffraction studies of its methiodide congener making it the first 
member in its class with a known structure.17-19  
In any discussion of the history of phenanthropiperidines a fourth member of this class, 
tylocrebrine, is worthy  of note.  This alkaloid was isolated in 1962 from a North Queensland 
vine, T. crebriflora which also had vesicant properties.20 The major alkaloid, tylocrebrine, 
was found to be a regioisomer of tylophorine.  With accumulating evidence that 
phenanthropiperidine alkaloids have anti-cancer properties, tylocrebrine was tested and found 
to be considerably  more effective than tylophorine, tylophorinine and crytopleurine in the 
several cancer models.21 Clinical testing began in 1965, only three years after its isolation.2 
Unfortunately, there were unforeseen problems with the alkaloid and the clinical trials were 
terminated before tylocrebrine’s therapeutic efficacy could be established.  Suffness reported 
that the studies were terminated due to CNS side-effects.2 It is of no surprise that  medicinal 
interest in these alkaloids waned in the years to follow.  Cryptopleurine was an 
undiscriminating poison, tylophorine and tylophorinine had only  mediocre activity, and 
worse yet, tylocrebrine, the most promising candidate, was potentially neurotoxic. 
1.2.2 Phenanthropiperidine isolation and structural features
Since 1965, over 60 phenanthropiperidines and closely related analogs have been isolated 
and characterized.  To date, they have been found primarily in two plant families, the 
Asclepiadaceae and Moraceae.  Five genera (Tylophora, Cynanchum, Vincetoxicum, 
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Pergularia, and Antitoxicum) out of the 300 genera in the Asclepiadacea family  are known to 
contain these alkaloids compared with only  one genus (Ficus) from the Moraceae family.5 
These plants are found throughout Asia, Africa, Australia and the Pacific Islands (e.g. 
Taiwan, Japan and the Philippines).  The details of the isolation studies fall outside of the 
scope of this work.  Fortunately, there are several reviews on this subject already.2, 4 
The general structural features of these alkaloids are a bicyclic nitrogenous heterocycle 
and a polyoxygenated phenanthrene system (Fig. 1–2).  The phenanthrene portion is 
generally  substituted with three to five methoxy or hydroxy groups, although methylenedioxy 
substituents have been isolated as well.22, 23 A pyrrolidine or a piperidine make up the 
terminal aliphatic heterocycle (ring E), hence the names phenanthroindolizidine and 
phenanthroquinolizidine.  (4a,4b)-Seco- and dehydro-derivatives (Fig. 1–3)—where ring D is 


















































phenanthroindolizidine phenanthroquinolizidine R1-6 = H, OH, OMe, -OCH2O-
R7 = H, OH
R8 = H, Me, OH
n = 1,2
Fig. 1–2.  General structural features of the phenanthropiperidines.
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compounds showing a spectrum of oxidation states that exist within the plant.3, 4 
Oxygenation can also occur as evidenced by indolizidines and quinolizidines bearing a 
hydroxyl functionality at C14 or C15, respectively.  Moreover, an oxygen atom can be 
introduced at the nitrogen resulting in phenanthroindolizidine N-oxides.24  Johns et al. 
isolated a rare phenanthroquinolizidine alkaloid, cryptopleuridine, which possesses a C12-
hydroxyl group.25  To date, this is the only known, natural phenanthropiperidine that has a 
functionalized ring E system.      
 
In 1984, another structural anomaly was observed in the alkaloids of cultivated T. hirsuta.
26, 27 These natural products were essentially identical to several phenanthroindolizidines 
already isolated except they had a 13a-methyl substitution (R8 = Me).  Recently, Pettit and 
coworkers isolated and characterized several more of these alkaloids from Hypoëstes 
verticillaris.28  Interestingly, in wild populations of T. hirsuta, the principal alkaloidal 
constituent bears a hydroxyl group at the ring juncture (R8 = OH) in lieu of an angular methyl 





















isolated in 1991 by  Ali and coworkers (Fig. 1–4).30 Besides the rare 13a-hydroxy  group that 
appears in tyloindicine F and G, these anomalous members also have a precariously 
positioned olefin (15, 15a) that is out of conjugation with ring C.  
The natural variety  that is found within this class has aided an understanding of structure-
activity relationships (SARs) and provided swathes of targets for synthetic organic chemists. 
These will be discussed in detail later on.  For our current purposes it is important to point 
out that practical synthetic routes have provided a sustainable source of many  of these 
alkaloids and, in those cases, total syntheses have supplanted isolation efforts.   
1.2.4  Biosynthesis 
Although the biosynthesis of the phenanthroindolizdines is better understood than that of 
the phenanthroquinolizidines, it  is likely  that the pathways are analogous.31 A representative 
biosynthetic pathway is outlined in Scheme 1–1.  It should be noted that the extent of 




























Fig. 1–4.  Unusual structures of tyloindicines F–I.






















































































as evidenced by the diversity seen in the natural products, the representative structures in 
Scheme 1–1 notwithstanding. These pentacyclic alkaloids are thought to be derived from 
tyrosine,32 phenylalanine33 and ornithine.32 The phenanthroquinolizidine biosynthesis varies 
only with respect to the latter precursor, which is derived from lysine instead.  In the 
indolizidine class, the pyrrolidine carbons originate from ornithine which decarboxylates, 
deaminates and cyclizes to pyrroline (1.5).  This cyclic imine further reacts with cinnamic 
acid 1.634—synthesized from phenylalanine—affording a carboxylic acid intermediate (not 
shown).  Following decarboxylation and alcohol oxidation, amine 1.7 undergoes 
condensation with 3,4-dihydroxyphenylacetaldehyde (1.8) which is derived from tyrosine.35 
The resultant enamine  (1.9) cyclizes and upon dehydration yields the seco-derivative 1.10. 
As already discussed, isolation of the seco-derivatives is relatively facile and gives support to 
this biosynthetic pathway.  The final transformation is thought to proceed through an 
oxidative coupling and subsequent rearrangement,34 but no direct evidence has been garnered 
to support or contradict this hypothesis.  
Mulchandani et al. suggest that  this process is initiated with the formation of dienones 
1.11 or 1.12 through ortho- or para-phenolic couplings.  The strained spirocycles then 
undergo a 1,2-alkyl shift to consummate the biosynthetic sequence of tylophorine or 
tylocrebrine.  Another fate for spirocyle 1.11 was also proposed to explain the formation of 
tylophorinine.  In this scenerio, dienone 1.11 is reduced to dienol 1.13 prior to rearrangement 
resulting in the elimination of hydroxide upon phenanthrene formation.  Despite the 
remaining ambiguities of the latter sequence, this mechanistic hypothesis is plausible when 
considering its resemblance to the phenolic couplings seen in the biogenesis of morphine.36 
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Furthermore, this hypothesis has considerable explanatory power, needing minimal revision 
to explain the biogenetic origins of multiple naturally occurring phenanthropiperidines.           
1.3  Biology of Tylophora indica
Tylophora extracts have gained considerable attention for the treatment of inflammatory 
diseases and, to a much lesser extent, cancer.  Chitnis et al. investigated the cytotoxic 
properties of leaf and plant extract of T. indica in mice presenting transplantable leukemia 
tumors (either L1210 or P388).37 Notably, mice receiving daily doses of extract survived 
longer than those treated with a placebo.  Since the anti-cancer properties of T. indica have 
been attributed primarily  to specific phenanthropiperidine alkaloids, most investigations have 
focused on the pharmacology of the purified alkaloids rather than on plant-derived mixtures 
and hence will be discussed later.  On the other hand, the efficacy and mode of action of T. 
indica for the treatment of immune disorders, such as asthma, have been extensively 
investigated.
1.3.1  Clinical studies 
Six clinical studies have been conducted using the extracts of T. indica for the treatment 
of asthma (Table 1–1).  Shivpuri et al. conducted two double-blind clinical investigations of 
T. indica.38, 39 In these studies, the leaves of T. indica were administered to over 100 patients 
with asthma and allergic rhinitis.  After a six-day regimen, patients experienced significant 
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symptomatic relief that lasted for several weeks.  In a follow-up study, ethanolic extracts 
were administered to 195 asthmatics.40 Over 50% experienced moderate to complete 
symptomatic cessation compared with 31% of patients taking a placebo.  Four other clinical 
investigations have been conducted with either extracts or powdered plant material.41-43 Two 
studies showed appreciable symptomatic remission, while the other reported no statistically 
significant difference between patients receiving the treatment and placebo.  In pursuit of a 
physiological explanation for the apparent symptomatic relief, Gore et al. demonstrated that 
dried leaf powder had immunosuppressive properties.44 Interestingly, the immunosuppression, 
as judged by an eosinophil count, coincided with elevated 17-ketosteroid secretion, 
suggesting an indirect effect through stimulation of the adrenal cortex.  Notably, increased 





 An assessment of the methodologies used in five of these clinical trials has recently  
been reported by Huntley and Ernst.46 Although positive effects of T. indica in asthmatics are 
clear, the authors conclude that the clinical relevance of several of these studies was 
undermined by poorly  designed experiments or the omission of important details (e.g. age 
range of participants, dropouts/withdrawals, etc.).  Considering the prevalence of asthma and 
the appeal of complementary  medicine,47 there is a great need for further characterization of 
the efficacy  and safety  of T. indica, which is currently marketed in products such as 
AsmaAideTM, Ultra Asthmatica and T. Asthmatica Plus.
FEV1 = forced expiratory volume (in 1 second); MBC = maximum breathing capacity; VC = vital capacity; 






Shivpuri39 leaves 166 6 days 50–100% Symptomatic relief
Shivpuri38 leaves 110 12 weeks
62% vs. 28% (control) Improvement at 6 days;
16% Improvement at 12 weeks
Shivpuri40 EtOH extract 195 12 weeks
50% of participants experienced symptomatic relief 
vs.  31% of placebo
Mathew43 alkaloid extract 123 12 weeks
Improvement in symptomatic relief and FEV1
Effects peak at 4 weeks
Gupta41 powdered plant 135 3 weeks No significant improvement of symptoms
Thiruvengadam42 dried leaf powder 30 16 days
Nocturnal dyspnea symptoms improved
 Sustained rise in MBC, VC and PEFR
Gore44 dried leaf powder 29 4 weeks
Decreased eosinophile count;
 Increased 17-ketosteroid secretion
Table 1–1. Clinical studies with T. indica for the treatment of asthma.
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1.3.2   In vitro and in vivo studies with T. Indica
Preclinical studies have been instrumental in uncovering the intricacies of the anti-
asthmatic effects of Tylophora extracts.  A summary of these investigations is presented in 
Table 1–2.  Haranath and Shyamalakumari studied the effect of T. indica on in vivo 
immunosuppression.48 Aqueous extracts administered intraperitoneally prevented 
anaphylaxis in guinea-pigs 10 days after its administration and caused leucocytosis and 
leucopenia—indicative signs of immunosuppression—in dogs upon i.v. administration.  Atal 
et al. later reported the immunomodulating properties of ethanolic extracts of T. indica.49 
Significant inhibition of the humoral immune response (HIR), stimulation of phagocytic 
function and a significant increase in survival time for a foreign skin graft were reported. 
Adrenergic effects were noted by  Udupa et al.50 Upon treatment of male albino rats with the 
extracts of T. indica, the adrenals increased in weight and decreased in cholesterol and 
vitamin C content  indicating direct stimulation of the adrenal cortex. These findings are 




 With evidence that T. indica can be used for the treatment of pathologies arising from 
aberrant immune responses (i.e. asthma, anaphylaxis, arthritis, etc.) Ganguly and Sainis 
sought to further characterize the immunogenic effects of the alkaloids in T. indica.51 They 
found that the alkaloid mixture mitigated delayed-type hypersensitivity (DTH) to sheep  red 
blood cells (SRBC) and contact sensitivity  to dinitrofluorobenzene (DNFB), indicating a 
suppression of T cell-mediated response.  Additionally, the alkaloids inhibited mast cell 
degranulation and suppressed the discharge of pro-inflammatory  mediators.  Lending further 
credence to their therapeutic value, prophylactic and remedial benefits were noted in the 
i.p. = intraperitoneal; i.v.  = intravenous; DTH = Delayed-type hypersensitivity; HIR = Humoral immune 
response; DNFB = dinitrofluorobenzene.
Table 1–2. In vivo and in vitro studies with T. indica extracts.
reference extract route/dose model result
Haranath48 aqueous
i.p. guinea pig prevented anaphylaxis
i.v. dog leucocytosis and leucopenia
Atal49 ethanolic oral mouse
↓ DTH
↓ HIR
↑ survival time in skin allograft rejection
Udupa50 multiple oral, i.p. rat stimulation of adrenal cortex
Ganguly51 alkaloidal oral
rat ↓ DTH
mouse ↓ DNFB-contact sensitivity↓ IgM response
Ganguly52 alkaloidal
> 300 pg/mL T cells ↓ IL-2, ↓ proliferation
19-300 pg/mL macrophage  ↑ IL-2,  ↑ proliferation
39 ng/mL macrophage  ↑ IL-1, macrophage activation
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sensitized rodent models.  Contrary to previous findings,49 however, the alkaloids did not 
suppress primary humoral (IgM) immune response to SRBC.  
The effect of the extracts was also investigated in rodent splenocytes.52  Concanavalin A, 
a mitogen, was used to induce splenocyte proliferation as a model for the cellular immune 
response.  Interestingly, a biphasic response was observed where proliferation was inhibited 
at high concentrations (> 300 pg/mL) and stimulated at lower concentrations (19–300 pg/
mL).  Both T cells and macrophages were shown to be perturbed by the alkaloid extracts. As 
an aside, this result is reminiscent of cryptopleurine’s dual effect on motor nerve sprouting 
reported by Hoffman in 1952.53 In addition to T cell mitogenic inhibition, IL-2 secretion was 
independently inhibited whereas IL-1 production increased.  Furthermore, the alkaloids 
activated macrophages and hence were thought to exert their immunosuppressive activity via 
production of reactive oxygen and nitrogen species.  
The molecular basis for T. indica’s anti-inflammatory effects is clearly not 
straightforward.  These preclinical and clinical studies have provided insight into the 
pharmacologic mechanisms by which T. indica alleviates asthma.  The use of raw plant 
material or plant extracts, however, muddies the water in discussions of the mechanism of 
action.  The chemical composition of any given plant is a complex mixture of biomolecules, 
and although the most profound effects are often attributed to a primary active constituent, it 
is conceivable that a few components, if not many, contribute to the overall physiological 
outcome.  A second major challenge arises from the variation among plants of the same 
species.  It  is well-known that subtle environmental factors can dramatically  change the 
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biochemical landscape within a given plant species, thus, reproducibility may be difficult  to 
attain.        
1.4   Biology of phenanthropiperidine alkaloids
Investigation of the pure alkaloidal constituents of T. indica has resolved some of the 
ambiguities that arise from studying complex botanical mixtures.  Tylophorine, perhaps due 
to its relatively high abundance (0.015–0.036%),7, 30, 54 early  discovery, and ease of synthesis, 
has received the greatest attention in this regard.  The physiological effects of tylophorine are 
not subtle.  The earliest isolation attempts report  severe contact dermatitis and blistering upon 
exposure to the alkaline extracts of T. indica.7 Notably, other plant  species containing 
phenanthropiperidines and, indeed, the alkaloids themselves are notorious for their vesicant 
properties.16, 20 These noxious effects, however, have not deterred scientists from exploring 
their therapeutic potential.  With the already established anti-inflammatory, 
immunosuppressive and cytotoxic properties of the plant extracts it  was fitting that the pure 
alkaloids should be appropriated in the same therapeutic areas.  The following section will 
discuss their biological effects and mechanism of action.   
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1.4.1  Anti-cancer activity
1.4.1.1 In vivo studies
The phenanthropiperidines have long been touted as promising anti-cancer agents due to 
their broad-spectrum and potent cytotoxicity.  As seen already, tylophorine, tylocrebrine and 
cryptopleurine were the first members to enter the limelight.  Out  of these three alkaloids, 
cryptopleurine was found to be the most toxic and tylophorine the least.  The general toxicity 
of cryptopleurine was studied in guinea-pig, rat, mouse, rabbit, cat and dog.16  The alkaloid 
proved to be lethal at doses as low as 1 mg/kg with little regard for species or the mode of 
administration.   
A non-selective toxin is obviously a poor drug.  Nevertheless, fatal diseases such as 
cancer have greater leeway with respect to selectivity if the final outcome with the drug is 
more desirable than that of the untreated disease.  In spite of its potent cytotoxicity, low doses 
of cryptopleurine (1 mg/kg i.p., twice daily for 8 days) inhibited the growth of Ehrlich ascite 
tumors in mice without killing the host.55 Preclinical studies at the NCI (Table 1–3), however, 
showed that cryptopleurine had only marginal activity in vivo.2 Tylocrebrine, on the other 
hand, was a more promising lead and became a clinical candidate soon after its discovery. 
Still, this alkaloid was found to be inactive in sarcoma 180, adenocarcino 755, B16 
melanoma, Lewis lung, P1534 leukemia and Walker 256 carcinosarcoma models.  It was 
tylocrebrine’s structural novelty and superior efficacy  to tylophorine and cryptopleurine21 in 
lymphoid leukemia L1210 mouse models that justified its entry into clinical trials.2 In 1966, 
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less than a year after the clinical trials began, the studies were aborted before its therapeutic 
value could be determined. Suffness reported that this was because of central nervous system 
(CNS) toxicity  evidenced by ataxia and disorientation.2 Unfortunately, the original clinical 
data from these studies could not be obtained. 
  
compound NSC # dose (mg/kg) life extension (%)
(R)-cryptopleurine 19912 1.0 140
(R)-tylocrebrine 60387 20.0 155
(S)-tylophorine 717335 30.0 150
tylophorinine 100055 6.0 130
demethyltylophorinine 94739 15.0 153




















Fig. 1–5. Structures of several NCI-tested phenanthropiperidines.
(R)-antofine DCB-3503 demethyltylophorinine
1.4.1.2 In vitro studies
Over the next few decades, medicinal interest in tylocrebrine and other 
phenanthropiperidines waned.  Recently, however, there has been a resurgence of activity 
with regard to these natural products.  This can be traced back to a NCI 60 human tumor cell-
line screen in the early  nineties that  included several phenanthropiperidines.  To date, eleven 
naturally  occurring members of this class have been tested in this screen.  The structures of 
these can be found in Fig. 1–1, 1–4 and 1–5.  Contrary to earlier speculation, many of these 
alkaloids were found to have potent and broad-spectrum cytotoxicity.  Salient members of 
this class inhibited tumor growth with GI50 values in the low nanomolar to picomolar range, 
on par with currently used anticancer drugs. 
Since the disclosure of this finding, the phenanthropiperidines have been intensely 
pursued as anti-cancer drug leads.  Thus far, a vast majority  of these studies have been 
limited to in vitro anti-proliferative experiments, and the NCI has acquired the majority of the 
data.  A cross-section of the 60-tumor cell line panel screen results is shown in Table 1–4. 
From this, it should be clear that the alkaloids endowed with activity show little 
discrimination between cell lines.  This is exemplified by  the fact that the GI50 ranges over 
the 60-tumor cell line panel show moderate selectivity between the most and least susceptible 
cell lines.  To put this in perspective, paclitaxel, under the same assay, has a GI50 range of 2 to 
1000 nM, a 500-fold difference.  Although this is not direct evidence, selectivity within the 




A second observation that can be made from the collective data is that  these alkaloids 
retain their potency in drug-sensitive and multidrug-resistant  (MDR) cell lines (Table 1–5).24, 
56-58 Antofine and several closely related analogs, for instance, have equipotent growth-
inhibitory activity against common and MDR cell lines.56, 57 Furthermore, in a KB cell line 
panel containing strains resistant to many  of the conventional anti-cancer drugs, tylophorine 
and its hydroxylated analog, DCB-3503, showed no bias in their anti-proliferative effects.58 
Besides the obvious pertinence to therapeutic utility, this suggests that these alkaloids have a 
different mechanism of action from drugs that are ineffective in these refractory cancers.  To 
add to this, an earlier evaluation of tylophorine in the NCI’s COMPARE analysis bears 
further witness to the unique mechanism of action and  potentially novel cellular target(s).59
CEM = leukemia, A549 = non-small cell lung carcinoma, MCF-7 = breast carcinoma, HCT  116 = colon 
carcinoma, NA = Not applicable, ND = No data. Unless otherwise specified, data were gathered from NCI-DTP 
Database. a Gao et al.62  b Fu et al.63 c Su et al.56 
60-cell line panel GI50 (nM) individual cell line GI50 (nM)
compound NSC # mean range CEM A549 MCF-7 HCT 116
tylophorine 717335 17.5 10–400 10, 15a 10 10 10
antofine NA ND ND 5.2a 10.4,b 0.44c 12.4c 9.9b
cryptopleurine 19912 5.1 1.3–50 5.0, 2a 5.0 5.0 5.0
tylocrebrine 60387 29.5 10–126 25 25 50 25
DCB-3503 716802 29.1 10–160 25 25 16 20
tylophorinine 100055 57.6 10–500 40 63 63 40
demethyltylophorinine 94739 1.13 1.0–16 1.0 1.0 1.0 1.0
tyloindicine F 650393 0.10 0.1–0.1 0.10 0.10 0.10 0.10
tyloindicine G 650394 0.10 0.10–0.16 0.10 0.10 0.10 0.10
tyloindicine H 650395 0.50 0.10–20 0.40 0.63 3.98 0.50
tyloindicine I 650396 4.40 1.6–20.0 3.16 3.98 5.01 2.00




1.4.1.3 Structure-activity relationships  
The size of the phenanthropiperidines class has grown significantly  since the discovery of 
tylophorine.  There are over sixty  members in this class, including seco-analogs and closely 
related isomers, from which SARs have begun to emerge.  For the purpose of this discussion, 
fifty-one natural and unnatural analogs belonging to eleven scaffolds will be considered.  In 
Table 1–6, the compounds are ordered from the most to the least potent according their 
average GI50 activity in up to fourteen of the most commonly used cell lines or, for those that 
have been tested by the NCI, the mean GI50 value in the 60-tumor cell line is used.  It should 
be cautioned that  compounds in Table 1–6 may not have been tested in the same assay  or 






KB (parental) - - 12, 214a 28 16a, 1.2b
KB-MDR gp 170 ↑ VP-16, taxol, adriamycin, vincristine 14 26 –
KB-7D Topo II ↓, MRP ↑ VP-16, adriamycin, vincristine 12 45 –
KB-7D-Rev Topo II ↓ VP-16, adriamycin 11 25 –
KB-Ha-R RR ↑, dCK ↓ HU, araC, gemcitabine 25 36 –
KB-Ha-Rev dCK ↓ araC, gemcitabine 16 28 –
KB-100 Topo I ↓, XRCC1 ↑ CPT, topotecan, SN-38 20 38 –
KB-100-Rev Topo I ↓ CPT, topotecan, SN-38 10 41 –
KB-VI P-gp ↑ adriamycin, vinblastine, colchicine 173a – 14a, 2.3b
aStærk et al.57 bSu et al.56 MRP, multidrug resistance protein; VP-16, etoposide; HU, hydroxyurea; RR, 
ribonucleotide reductase; dCK, deoxycytidine kinase; Topo II, topoisomerase II; Topo I, topoisomerase I; 
XRCC1, X-ray repair cross-complementing gene I protein; araC, aravinoside cytosine; CPT, camptothecin; 
SN-38, 7-ethyl-10-hydroxycamptothecin; P-gp, P-glycoprotein. 





entry common name codea scaffoldb R1 R2 R3 R4 R5 R6 R7 R8 n Avg GI50 (nM)c
1 tyloindicine F 43 F H OMe H H OMe OMe H OHd 1 0.1
2 tyloindicine G 44 E OMe OMe H H OMe OMe H OHd 1 0.1
3 – 38 A H OH OMe H OMe OMe S-OH S-H 1 0.2
4 tyloindicine H 45 E H OMe OH H OMe OMe H Hd 1 0.5
5 demethyltylophorinine 39 A H OH H H OMe OMe R-OH S-H 1 1.1
6 (±)-cryptopleurine ±-11 A OMe OMe H H OMe H H rac 2 2.0
7 6-demethylantofine 37 A OMe OMe H H OH H H rac 1 4.1
8 tyloindicine I 46 G OMe OMe OH H OMe OMe H Hd 1 4.4
9 (R)-cryptopleurine R-11 A OMe OMe H H OMe H H R-H 2 5.1
10 boehmeriasin A 16 A H OMe H H OMe OMe H rac 2 5.2
11 (R)-antofine R-6 A OMe OMe H H OMe H H R-H 1 10.1
12 (±)-antofine ±-6 A OMe OMe H H OMe H H rac 1 14.0
13 – 2 A OMe OMe H H OMe OH H R-H 1 16.0
14 (S)-tylophorine S-1 A OMe OMe H H OMe OMe H S-H 1 17.2
15 – 34 A OMe OMe H H i-PrO H H rac 1 27.8
16 tylocrebrine 18 A OMe OMe H OMe OMe H H rac 1 29.5
17 DCB-3503 22 A OMe OMe H H OMe OMe S-OH S-H 1 29.5
18 – 36 A OMe OH H H OMe H H rac 1 30.3
19 deoxytylophorinidine 27 A H OMe H H OH OMe H R-H 1 35.7
20 – 33 A OMe i-PrO H H OMe H H rac 1 38.7
21 isotylocrebrine 20 A H OMe OMe H OMe OMe H S-H 1 41.0
22 deoxypergularine 19 A H OMe H H OMe OMe H rac 1 64.3
23 demethoxyantofine 7 A OMe OMe H H H H H rac 1 69.5
24 – 35 A OH OMe H H OMe H H rac 1 80.3
25 tylophorine-N-oxide 5 B OMe OMe H H OMe OMe H R-H 1 97.0
26 DCB-3501 21 A OMe OMe H H OMe OMe R-OH S-H 1 108.0
27 (R)-tylophorine R-1 A OMe OMe H H OMe OMe H R-H 1 109.7
28 – 3 A OMe OMe H H OMe OMe H rac 2 117.3
29 – 10 A OMe OMe H H OMe H R-OH R-H 1 130.0
30 antofine-N-oxide 9 B OMe OMe H H OMe H H R-H 1 135.0
31 tylophorinine 28 A H OMe H H OMe OMe R-OH S-H 1 160.1
32 (±) -tylophorine ±-1 A OMe OMe H H OMe OMe H rac 1 254.7
33 (R)-ficuseptine C R-12 A –OCH2O– H H OMe H H R-H 1 283.3
34 (±) -ficuseptine C ±-12 A –OCH2O– H H OMe H H rac 1 521.4
35 DCB-3506 23 A OMe OH H H OMe OMe S-OH S-H 1 600.0
36 – 32 A i-PrO OMe H H OMe H H rac 1 927.7
37 – 13 H OMe OMe H H OMe H H R-H 1 1064.7
38 tylophorinidine 29 A H OMe H H OH OMe S-OH S-H 1 1832.7
39 dehydroantofine 17 D OMe OMe H H OMe H H rac 1 2360.0
40 (R)-secoantofine 8 C OMe OMe H H OMe H H R-H 1 2535.0
41 tylophoridicine E 24 A H OH H H OMe OMe S-OH S-H 1 3336.7
42 – 30 A H H H H H H H rac 1 3571.2
43 tylophoridicine F 26 B H OMe H H OMe OMe R-OH S-H 1 6378.0
44 tylophoridicine C 25 B H OMe H H OH OMe S-OH S-H 1 8388.3
45 – 31 A H H H H H H H rac 1 9460.0
46 – 15 I OMe OMe H H OMe H H R-H 1 9645.0
47 – 14 I OMe OMe H H OMe H H S-H 1 9685.0
48 – 40 J OMe OMe H H OMe OMe H rac 1 15600.0
49 – 42 K OMe OMe H H OMe OMe H rac 2 42000.0
50 dehydrotylophorine 4 D OMe OMe H H OMe OMe H rac 1 > 50000
51 – 41 K OMe OMe H H OMe OMe H rac 1 > 50000
a Refers to number in Graph 1–1.  b See Fig. 1–6.  c Average GI50 in HepG2, Panc-1, CEM, A549, MCF-7, KB, KB-VI, 
KB-3-1, HCT 116, HT-1080, MDA-MB-231, COLO-205, NUGC-3 and HONE-1.  d  Unknown stereochemistry













































































































































   




































































































































































normalization of these results is virtually  impossible.  Because of this lack of standardization, 
a more detailed understanding of the variables specific to each anti-proliferative assay is 
required to assess the reliability of activity ranking across this class.  
 
 Graph 1–1 accounts for a number of these variables by incorporating information about 
each compounds anti-proliferative activity in relation to the specific cell line and assay (i.e. 
which compound have been tested simultaneously in the same assay).  A crude comparison of 



















































































Fig. 1–6.  Scaffolds of phenanthropiperidines and analogs.  
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activity (the center of the blue bar which corresponds to the “Avg. GI50” column in Table 1–
6) of each compound.  The innate differences between the cell lines, however, make this type 
of ranking rather inaccurate.  An extreme example of this is seen with reported data for 
compounds 24 and 25.  In HepG2 and Panc-1 cells, compound 25 exhibits more than 50 fold 
greater activity compared with compound 24,60 whereas in KB cells compound 24 is at least 
25,000 times more active than compound 25.61 Whether this dramatic difference is a function 
of the particular cell lines or the different  sources of each compound remains unknown, but is 
clear that simply averaging the GI50 values obscures this peculiar finding.  In order to address 
this, the activity of the individual cell lines are presented in Graph 1–1 and are distinguished 
based on the color and shape of each point.
 Another concern is that even among common cell lines there can be a significant amount 
of variation between assays.  In A549 cells, racemic antofine (±-6) was reported to have a 
GI50 value of 25 nM in one report and 0.44 nM  in another, over a 50 fold difference.  This 
discrepancy demonstrates the wide variation that can exist between independently acquired 
data in anti-proliferative assays.  In this regard, we have indicated the compounds that have 
been tested in the same assay by linking them with a line, where the color and stroke (i.e. 
solid or dashed) of the line refers to the cell line, and the lowercase letter corresponds to the 
reference for a particular comparative study.  In other words, all points that fall along a line 
of the same style (cell line) and letter (reference) were tested simultaneously.  This not only 
allows the most accurate comparisons between each compound but provides a means to 
assess the relative activity of compounds that have not been compared in the same assay by 
finding commonalities between data sets.  For instance, (R)-tylophorine (R-1) and (R)-
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cryptopleurine (R-11), which have not  been tested together, can be compared, because both 
compounds have been tested along with (S)-tylophorine (S-1) in CEM  cell lines which can be 
used as the standard.  On the other hand, a comparison of boehmeriasin A (16) with other 
compounds should be taken with reservation since it has not been tested along with any other 
members of this class.  Nevertheless, by piecing together GI50 values for particular cell lines 
that have been reported in the literature, we gain a better, albeit  incomplete, understanding of 
structural features that contribute to the phenanthropiperidine’s anti-cancer activity.
The phenanthrene system (rings A, B and C) has been studied most extensively.  The 
seco-analogs are almost universally less active (e.g. Table 1–6, entries 11 and 40). There may, 
however, be other ways to compensate for this loss in activity as evidenced by tyloindicine F 
and I (entry 1 and 8) which are extremely cytotoxic in spite of their rings A and C being 
disconnected.  Disrupting the aromaticity  of ring B as in DCB-3502 (not shown) can also 
reduce activity.58, 62 Furthermore, the location and type of substituents on the phenanthrene 
has a profound effect on its activity.57, 61, 63 From Table 1–6, it should be apparent that 
formulating strict phenanthrene SARs without considering the rest of the scaffold inevitably 
leads to irreconcilable data. From the fact that when methoxy or hydroxy substituents are 
removed completely, the naked scaffold is significantly less active (entries 42 and 45), it  can 
be surmised that the presence of these substituents substantially boosts activity.64  Although 
this may be due to the requirement of an electron-rich arene, the incorporation of surrogate 
electron donators, such as amines, has not been investigated.    
The position of the substituents is also important but data gathered from different sources 
and cell lines make it difficult to discern precise correlations.  Nevertheless, some 
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generalizations can be made.  First, the 2,3,6-trisubstituted system seems to be favorable as 
evidenced by the remarkable potency of antofine and cryptopleurine (entries 6, 9, 11 and 12). 
A hydroxyl group at C6 can increase potency as in 6-desmethoxyantofine63 (entry 7 and 12). 
Depending on the scaffold, C3-hydroxy groups will either increase (entries 5 and 43)65 or 
decrease activity57, 63 (entries 12 and 18). Fu et al. reported a systematic study of antofine’s 
(entry  12) phenanthrene substituents and found that the C2 position was particularly sensitive 
to alteration.  Replacement of the methoxy group with either a methylenedioxy bridge (entry 
34), hydroxy (entry  24) or an isopropoxy  group (entry 36) resulted in a significant loss of 
potency.62, 66 On the other hand, replacing the methoxy groups at C3 and C6 with hydroxy 
(entries 7 and 18) or isopropoxy (entries 15 and 20) was well-tolerated. 
There are several piperidine (ring D) modifications that can be made without losing 
activity.  A 14-hydroxy group (R7 = OH) seems to be tolerated with only  a several-fold loss 
of activity (entries 14 and 17),24, 58, 60, 65 but the stereochemistry of C14 does seem to affect 
the activity  (entries 3 and 41; 17 and 26).  There are probably multiple factors determining 
the most active diastereomer.58, 60, 67 Despite the slightly diminished activity of C14-hydroxyl 
analogs, demethyltylophorinine (entry 5) is among the most potent  members of this class to 
be tested in the 60-tumor cell line screen (see Table 1–4 also).67 Interestingly, Gao et al. 
discovered that a hydroxylated DCB-3503 (entry 17) showed superior activity in vivo 
compared with its non-hydroxylated parent, tylophorine (entry 14), thus, hydroxylation may 
ultimately prove to be beneficial.58, 60   
Several groups have constructed N-oxide analogs which, surprisingly, produced only a 2–
10-fold reduction in activity (entries 25 and 27; 11 and 30).24, 65  Amide analogs, however, are 
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almost completely  inactive (entries 48, 49 and 51).64, 68 Dehydro-analogs, where the 
piperidine is aromatized to a pyridinium, are also inactive (entries 12 and 39; 32 and 50).64
It is worth mentioning that several tylophorine-based analogs have been designed that do 
not contain an intact ring D piperidine (entries 37, 46 and 47).  Multiple-bond scissions have 
been investigated but all permutations of this type have reduced the alkaloid’s anti-
proliferative effects.  Nevertheless, the ease of preparing these simplified analogs has enabled 
extensive SAR studies and, through these, the discovery of moderately potent analogs such 
as PBT-1 (Fig. 1–7)  which have IC50 values of 200–400 nM.69, 70 Despite their close 
structural-relatedness, evidence suggests that these unnatural derivatives are mechanistically 
distinct.62, 71
There is evidence that the stereochemistry of the bridgehead carbon does contribute to the 
activity.  Only a few labs, however, have tested two enantiomers in the same assay.  Gao et 
al. were able to acquire both enantiomers of tylophorine and found the (S)-isomer (entry  14) 
to be 3–5-fold more active than the (R)-isomer (entry 27) in HepG2, Panc-1 and CEM cells.62 
Moreover, the anti-proliferative activities of each enantiomer paralleled their inhibitory 








effects on key  transcription factors.  In a separate study, (R)-antofine (entry 11) was tested 
with its racemate (entry  12) in A549, HCT 116 and HT-1080 cells showing the former to be 
three-fold more active in all three cell lines.63 From this it may be inferred that, in contrast to 
tylophorine, the (R)-enantiomer is most active.  If this is true, the phenanthrene substituents 
have differing effects on the activity  of each enantiomer and, therefore, the absolute 
stereochemistry of the eutomer is not uniform across this class.  Anecdotal evidence suggests 
that substitution requirements for C2- and C7- substituents are reversed upon changing the 
stereochemistry of the indolizidine, but this is still to be borne out in comparative studies.3       
Indeed, there is still a superficial understanding of SARs that, if better understood, could 
be profitable for the design of improved therapeutic agents.  One reason for our poor 
understanding of SARs is that the available data are disjointed.  Over fifty members of this 
class have been tested in anti-proliferation assays, but most of the results are compiled using 
specialized cell lines or lack an internal standard resulting in tenuous comparisons between 
most analytes.  Another part of the problem is that SAR studies have been confined to a 
somewhat homogenous collection of alkaloids.  Although the effect of substituent location 
has been explored, the type of substitution has not strayed beyond hydroxy or alkoxy groups. 
Surprisingly, even the incorporation of an additional nitrogen atom or halogen has yet to be 
investigated.  There is also a paucity of SAR studies on ring E (Fig. 1–2) other than the 
observation that indolizidine and quinolidine analogs appear to be comparable in activity.64, 68 
Many of these limitations are understandable in light of the challenge of preparing such 
analogs.3    
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1.4.2  Mechanism of action
The effect of phenanthropiperidines on living systems has been investigated at  the 
biochemical level.  From these studies, several targets have been proposed, but none ratified. 
Notwithstanding the likelihood that these alkaloids interact with multiple targets, some of the 
alleged targets are needlessly invoked, only  being perturbed at concentrations far above those 
required to exert the desired effect.  Others that are supported by compelling experimental 
evidence, are unduly overlooked.  Accordingly, this discussion will attempt to unify the body 
of work aimed at identifying the mechanism of action of the phenanthropiperidines with the 
aim of facilitating a critical analysis of the putative biological targets.
   
1.4.2.1 Protein, DNA and RNA biosynthesis inhibition
The most extensively studied mechanism for the phenanthropiperidine’s anti-cancer 
activity is protein biosynthesis inhibition.  Beginning in 1968, Donaldson et al. reported that 
tylophorine, tylocrebrine and cryptopleurine inhibited protein synthesis in Ehrlich ascites-
tumor cells but did not markedly affect RNA synthesis (entry  1, Table 1–7).72 Paralleling the 
order of their anti-proliferative effects, cryptopleurine exhibited the most  potent inhibition 
whereas tylophorine was the least active.  (–)-Antofine has recently  been shown to inhibit 
protein biosynthesis with remarkable potency (entry 2).62 In spite of its potency  in eukaryotic 
systems, cryptopleurine did not inhibit protein synthesis in E. coli (entry 1).72 It was 
hypothesized that phenanthropiperidines were exerting their growth inhibitory activity via 
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80S ribosomal inhibition thus explaining their inactivity in prokaryotes that  have instead 70S 
ribosomes.  To confirm this hypothesis, a systematic study  explored the activity of the three 
phenenanthropiperidines in S. cerevisiae, a model eukaryote, and E. coli (entry 3).73  The 
order of cytostasis was identical to that in the previous studies with cryptopleurine again 
being the most potent.  Ribosomal inhibition studies clearly showed that the alkaloids 
inhibited protein synthesis with a noticeable preference for yeast cytoplasmic ribosomes over 
mitochondrial and E. coli ribosomes.  Furthermore, cryptopleurine was shown to irreversibly 




Delving deeper into the mechanism of inhibition, Huang et al. examined the effects of 
tylocrebrine in HeLa cells and rabbit reticulocytes, a cell-free model for protein biosynthesis 
(entry  4).74 Tylocrebrine, like cryptopleurine, irreversibly inhibited protein biosynthesis. 
Studies of several phenanthropiperidines corroborate that the inhibition takes place during 
the translocation step  of chain elongation.74-77 When tylocrebrine was compared with a small 
collection of emetine-like alkaloids, its ameobocidal activity closely correlated with the 
activity of compounds that inhibited cell-free protein synthesis to the same extent (entry 5).78
IC50 (nM)
entry reference model compound PS RS DS
1 Donaldson72
Ehrlich ascites-tumor cells CP 20 > 100000 -
Ehrlich ascites-tumor cells TC 200 > 100000 -
Ehrlich ascites-tumor cells TP 1000 > 100000 -
E. coli CP > 10000 - -
2 Gao62 HepG2 cells
AF 12 > 50 8
FS 2500 2500 1000
3 Haslam73 S. cerevisiae; E. coli
CP < 1000; > 100000 - -
TC 1000; > 100000 - -
TP 20000; > 100000 - -
4 Huang74
HeLa cells TC 50 300 60
reticulocytes TC < 1000 - -
5 Entner78 reticulocytes; reticulocyte lysate
CP 150; 700 - -
TC 300; 800 - -
6 Skogerson76 S. cerevisiae; cry mutant ribosomes CP 180; 18000 - -
7 Gupta80 CHO cell wild type; EmtR mutant
CP 330; 660 - -
TC 400; 1800 - -
Table 1–7. Inhibition of protein, DNA and RNA synthesis.  
CP = cryptopleurine, TC = tylocrebrine, TP = tylophorine, AF = antofine, FS = ficuseptine C, PS = Protein 




The juxtaposition of emetine (Fig. 1–8) and the Tylophora alkaloids is not arbitrary. 
Emetine’s natural source, ipecacuanha, and T. indica have both been used in traditional 
medicine as natural emetics.  Their similar therapeutic properties even earned T. indica the 
name “Indian ipecacuanha.”  On a chemical level, there are also some similarities that have 
caused speculation about common binding sites on the ribosome.79  
In 1973, mounting evidence for ribosomal inhibition emerged from the identification of 
the cry gene that conferred resistance in S. cerevisiae (entry 6).76 Ribosomes isolated from 
cry mutants required 100 fold more cryptopleurine to produce the same inhibitory response 
as parent ribosomes.  Interestingly, the normal (uninhibited) activity of 40S ribosomal 
subunits in cry mutants was impaired revealing the biochemical outcome of the mutation.76, 77 
This finding, however, did not elucidate the ribosomal subunit selectivity  of these alkaloids, 
nor does it identify a specific binding site.  
Evidence for this was gathered from genetic studies that found the cryptopleurine (CryR) 
and tylocrebrine (TylR) resistant CHO cells bore a remarkably similar cross-resistance profile 
to emetine-resistant (EmtR) mutants (entry 7).80 The fact that EmtR cell’s resistance could be 












traced to a modified 40S ribosomal subunit and that emetine bore structural resemblance to 
the phenanthropiperidines was adduced as analogical evidence that these protein synthesis 
inhibitors shared a common binding site.79, 80 The proposed common pharmacophore of the 
emetine and cryptopleurine, however, was not predictive of biological activity in synthetic 
analogs endowed with the alleged essential structural features.81  
Addressing this, evidence for a ribosomal binding site was finally provided by Dolz et al. 
in 1982.82, 83 Displacement assays with tritiated cryptopleurine confirmed the existence of a 
single high-affinity binding site on the 40S and 80S subunits that are shared with tylocrebrine 
and tylophorine.  Emetine and tubulosine, however, only displaced cryptopleurine at very 
high concentrations, suggesting separate binding locations in spite of their similar effects on 
translocation.  These experiments also showed that non-specific, low-affinity interactions 
exist on the 40S, 80S and 60S subunits, explaining cryptopleurine’s discrete (peptide bond 
formation vs. translocation) inhibitory effects at high concentrations.  
Besides protein synthesis, tylocrebrine-induced inhibition of RNA and DNA synthesis in 
HeLa cells (entry 4).74 It  should be emphasized that protein and DNA synthetic pathways are 
interdependent and, consequently, inhibitors of protein synthesis.  For example, anisomycin, 
cycloheximide and emetine, which are potent protein synthesis inhibitors, inhibit DNA 
synthesis as well.  Antofine, a closely  related analog, has recently been shown to 
simultaneously  inhibit protein and DNA biosynthesis as well (entry  2).62 Thus, the effect on 
DNA synthesis is likely a secondary consequence of tylocrebrine’s and antofine’s ribosomal 
inhibition.    
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These studies as a whole provide compelling evidence not only  for a mechanism of action
—namely protein biosynthesis inhibition—but also for the specific molecular target, the 40S 
ribosome.  The question naturally  arises: Is this explanation sufficient to explain the 
pharmacological effects of these alkaloids?  This is difficult to answer since protein synthesis 
is an integral part of a cells normal growth and division and, as such, perturbation of the 
normal ribosomal function has vast repercussions.  To borrow Pestka’s analogy, inhibiting 
protein synthesis is like sticking a wrench into a very complicated gearbox, “almost anything 
can happen.”84 Therefore, it is not unfounded that protein synthesis inhibitors like the 
phenanthropiperidines are cytostatic to the cells they target. 
Another important stipulation for anti-cancer therapeutics must also be met.  That is, they 
must exhibit an appropriate level of selectivity for tumor cells.  There is accumulating 
evidence that this can be achieved with protein synthesis inhibitors.85 First, aberrantly 
regulated protein synthesis is highly contributive to tumorigenesis86 and metastatic 
progression.87 Second, there is a higher critical threshold for protein synthesis in transformed 
cells than in normal cells that grow more slowly.  Indeed, the rate of cell proliferation 
positively correlates with the level and rate of translation.  Clinical studies have already 
borne witness to the therapeutic potential of several such inhibitors despite being limited by 
cardiovascular and other complications88-90—hypotension, ventricular tachycardia, atrial 
irritability, ST-T wave changes and premature ventricular contractions, for example.90  Still, 
there is significant interest in developing more selective agents.85 
That multiple phenanthropiperidines potently inhibit  protein synthesis and that their anti-
proliferative effects correlate with this inhibition evinces the notion that these alkaloids exert 
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their cytotoxic effect, primarily  but not exclusively, through protein biosynthesis inhibition. 
Moreover, as evidenced from studies with tritiated cryptopleurine, one molecular targets of 
the phenanthropiperidines is the 40S ribosome. 
            
1.4.2.2 Apoptosis and cell cycle arrest
Characterizing cellular events associated with anti-cancer lead molecules provides a 
window into their mechanism of action.  Protein biosynthesis inhibitors will, by their nature, 
abate cell growth, but they  are not inherently cytotoxic.  Even though cytostatic agents can 
effectively treat malignancies by subverting the accelerated proliferation in neoplastic 
growth, cancer cell death or differentiation is required for complete remission. In 2002, it was 
reported that an alkaloidal extract of T. indica, containing mainly tylophorine, tylophorinine 
and tylophorinidine, completely inhibited cell growth in K562 (human erythroleukemic) cells 
at 0.1 µg/mL (entry 1, Table 1–8).91 Interestingly, when the alkaloidal concentration was 
increased by  ten-fold, the cells underwent apoptosis.  Indeed, apoptotic agents engage a 
strategic battlefront for chemotherapeutic intervention, but the higher concentrations used 
here to achieve cell death may not be therapeutically practicable.  Moreover, since an 
alkaloidal mixture was used, synergy  cannot be ruled out.  Lee et al. simplified analysis by 
using a single alkaloid: antofine (entry 2).92 Antofine showed potent inhibition of growth and 
colony  formation in A549 and Col2 cancer cells.  No evidence of apoptosis or necrosis was 
observed at these low concentrations suggesting that antofine is primarily  cytostatic.  In Col2 
 
67
cells, morphological changes and G2/M  cell cycle arrest  were noted at concentrations as low 
as 0.1 nM.
  
The Cheng group observed that tylophorine and DCB-3503 did not  cause DNA damage 
as concluded from the fact that p53 was not induced during treatment with either of these 
alkaloids (entry  3).58 Both alkaloids (0.03-1 µM) induced S-phase accumulation in KB cells, 
whereas in HepG2 cells, the cells did not accumulate at any particular phase.  Notably, 
analog DCB-3503 does not induce apoptosis or necrosis at up  to 3 µM  concentrations, and 
both tylophorine and DCB-3503 produced complete and sustained growth inhibition in 
HepG2 cells over 8 days.  This persistency of activity was also demonstrated for tylophorine 
in HONE-1 and NUGC-3 cell lines (entry 4).93 These long lasting effects are noteworthy 
considering these alkaloids induce irreversible protein synthesis inhibition.  
TP = tylophorine, AF = antofine, BA = boehmeriasin A, DCB-3503 = 14-hydroxytylophorine.
entry reference cell line compound concentration result at cytostatic concentrations
1 Ganguly91 K562 T. indica extract
0.1 µg/mL no apoptosis
1 µg/mL apoptosis
2 Lee92 
A549, Col2 AF < 30 nM no apoptosis
Col2 AF 0.1 nM G2/M phase arrest; morphological changes
3 Gao58
KB TP, DCB-3503 0.03-1 µM S phase accumulation







TP 2 µM sustained growth inhibitionG1 phase arrest
5 Yan94 MDA-MB-231 BA 19 nM G1 phase arrest, no apoptosis
Table 1–8. Apoptosis and cell cycle arrest by phenanthropiperidine alkaloids.  
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In HepG2, HONE-1 and NUGC-3 carcinoma cells, tylophorine induced G1-phase arrest 
that was linked to a suppression of cyclin A2 expression (entry 4).93  Furthermore, DCB-3503 
and tylophorinidine (Fig. 1–9) were shown to down-regulate cyclin D1.60  It was noted that 
cyclin D1 suppression correlated with each compound’s growth inhibitory effects. In breast 
cancer cell line MDA-MB-231, boehmeriasin A (Fig. 1–9) exerts its potent anti-proliferative 
effects via G1 cell cycle arrest and not by  apoptosis (entry 5).94 In this study, cyclins D1 and 
E2 were found to be under-expressed in the treated cells.  Given the role of cyclin-dependent 
kinases (CDKs) in the governance of cell cycle progression, modulators of CDK pathways 
could potentially correct the faulty regulation that leads to unmitigated cell division in cancer.
95-98 From these data, it is apparent that the archetypal phenanthropiperidines are not 
apoptotic agents but  rather induce cytostasis by overriding a cancer cell’s replicative 
















Another hallmark of cancer is “sustained angiogenesis”.99 Highly metabolically active 
cells, such as those in many types of tumors, require sufficient vasculature to meet their 
exorbitant aerobic demands.  Even slow-growing and anaerobic tumors rely on a blood 
supply for their basic sustenance.  This need is met by actively recruiting blood vessels 
through the release of growth factors such as VEGF which is triggered by hypoxia.  Targeting 
angiogenesis is, therefore, a highly effective way to suppress tumor growth.  Cai et al. 
investigated cryptopleurine’s and 15R-hydroxycryptopleurine’s effects on hypoxia-inducible 
factor-1 (HIF-1),100 a key  regulator of a cell’s response to hypoxia and a promising drug 
target.101, 102 Both alkaloids potently inhibit HIF-1-mediated gene expression under anaerobic 
conditions (IC50 = 8.7 and 48.1 nM, respectively).  Furthermore, VEGF expression is also 
suppressed in a dose-dependent manner.  Unfortunately, attempts to determine 
cryptopleurine’s anti-angiogenic properties in vitro were hampered by its poor solubility.103 
A number of seco-analogs did, however, inhibit angiogenesis in rat aorta blood vessel 
fragments at low micromolar concentrations.103, 104 It is still unclear if the anti-angiogenic 
effects of these alkaloids are independent of their anti-proliferative properties.
1.4.2.4 Cell differentiation
When considering the pervasive impact within a cell resulting from protein synthesis 
inhibition, it is not surprising that the phenanthropiperidines elicit patent phenotypic changes 
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in transformed cells. The possibility that tylophorine induced cell differentiation was 
investigated through monitoring the expression levels of two tumor biomarkers, alpha-
fetoprotein (AFP) and albumin.58  Treatment with tylophorine (1 µM) resulted in a 
suppression of AFP expression and an increase in albumin expression which is consistent 
with cell differentiation. Boehmeriasin A also induced cell differentiation that manifested as 
morphological changes, lipid droplet accumulation and modulation of gene expression.94, 105, 
106
1.4.2.5 NF-κB Signaling pathway
A recent effort  has led to the discovery that tylophorine potently inhibits NF-κB–
promoted transcription (IC50 = 30 nM) and, to a lesser extent, that of AP-1 and CRE (IC50 = 
500 nM).58 Several closely related analogs, including DCB-3503, were also discovered with 
similar effects.60 It  is unclear if these events are related through overlapping signaling 
networks but it  does provide deeper insight into the root cause of tylophorine’s 
pharmacological effects.  NF-κB–signaling pathways are an integral part  of normal cell 
growth and immunological function.107-109 A large cohort of cytokines, growth factors and 
effector enzymes associated with immune responses are strictly  regulated by  this 
transcription factor.  Furthermore, a growing body of evidence has linked the dysregulation 
of NF-κB to the onset of cancer and immune-related disorders.107-109 Thus, the discovery  that 
tylophorine inhibits NF-κB provides a hypothetical link between tylophorine’s seemingly 
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disparate pharmacologies—namely, anti-cancer and anti-inflammatory/immune—and 
demonstrates therapeutic potential through a validated target.
 
1.4.2.6 DNA and RNA
Other targets for the phenanthropiperidines that  have been explored recently are DNA 
and RNA.  Xi et al. prepared a small library of DNA oligonucleotides containing a variety  of 
secondary  structures, such as hairpin bends and bulges, and studied antofine’s associative 
properties.110 Antofine showed clear preference for duplex oligonucleotides as measured by 
dissociation from and stability of the DNA-alkaloid complex.  Moreover, the alkaloid binds 
with moderate selectivity for DNA bulges in a 1:1 stoichiometry  (Fig. 1–10) and shows slight 
sequence selectivity. The significance of antofine’s selectivity toward bulged DNA and RNA 
lies in the fact that these abnormalities are implicated in the etiology of numerous diseases.111, 
112 Docking studies with the bulged structures give reason to conclude that this association is 
intercalative.  It is worth reiterating here that tylophorine does not induce DNA damage as 
DNA-bulge–selective agent neocarzinostatin does.  Tylophorine’s affinity for DNA, however, 
has yet  to be investigated.  In addition to DNA binding, antofine has also shown high affinity 
for the assembly origin of Tobacco Mosaic Virus (TMV) RNA.113 This RNA motif contains 
hairpin loop structures with several bulges.  Antofine was found to bind to with a KD of 9 nM 




The high affinity of antofine for DNA and RNA structures impels consideration in 
discussions of its mechanism of action and warrants further characterization in more complex 
systems such as cells.  Furthermore, in view of the homogeneity  within this class, these 
interactions should be determined for other members and correlated with their anti-
proliferative activities.  Considering the planarity  of the phenanthrene system and structural 
similarity to other DNA intercalators (e.g. ethidium bromide), the question of intercalation is 
an obvious one and should be addressed.  
1.4.2.7 Other molecular targets
In addition to the 40S ribosomal subunit and polynucleotides, several other molecular 
targets have been proposed for the phenanthropiperidines.  Thymidylate synthase114, 115 and 















Fig. 1–10. Antofine’s affinity for DNA structures.
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µM) of tylophorinidine.  Since the phenanthropiperidine’s activity is in the low nanomolar 
range, invoking these targets to explain its anti-cancer activity is seemingly gratuitous.
1.4.3  Anti-inflammatory activity
Like anti-cancer properties, the basis for the anti-inflammatory and immunosuppressive 
effects is not straightforward.  The plant extracts were clearly shown to suppress the 
inflammatory response in cell, animal and human models.  With this in mind, the first task 
was to demonstrate that the pure alkaloids retained the anti-inflammatory  effects of T. indica 
and its extracts.  This was borne out in several studies that confirmed that pure tylophorine 
allayed immunopathological and inflammatory reactions in vitro and in vivo.117, 118      
In pursuit  of a novel anti-rheumatic agent, Yin and coworkers identified the promising 
tylophorine analog, DCB-3503.119 The compound was chosen based on its inhibitory effects 
on TNFα-induced NF-κB activity  (IC50 = 100 nM).  Although the reason for choosing this 
analog over tylophorine, in spite of its inferior NF-κB activity, was not disclosed, it is 
noteworthy  that this hydroxylated analog outperformed tylophorine in animal studies, 
presumably due to improved pharmacokinetics.58 Mice injected with collagen or 
lipopolysaccharide (LPS) to induce arthritis were treated with DCB-3503 and closely 
monitored for signs of efficacy.  It was found that the development, onset and severity of 
LPS- and collagen-induced arthritis were  abated with no signs of toxicity.  TNFα and IL-1β, 
two important pro-inflammatory cytokines, were down-regulated at the systemic and local 
level.  Furthermore, immune-cell production of key inflammatory signaling molecules, such 
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as TNFα, IL-12, IL-6, MCP-1, iNOS and COX-2, was significantly  impaired, demonstrating 
DCB-3503’s multifaceted approach to suppressing the arthritic immune response.  
Indeed, inhibition of NF-κB transcription is a plausible explanation for these extensive 
biological effects, but this conclusion may be reductionistic.  Earlier work in LPS/IFNγ-
induced RAW264.7 cells (a murine macrophage cell line), found that tylophorine 
significantly reduced TNFα, iNOS and COX-2 production at 3-10 µM  without causing NF-
κB inhibition.120 AP1 activation, however, was significantly inhibited.  This result was 
accounted for by measuring the levels of upstream signaling factors MEKK1, Akt and c-Jun. 
Although tylophorine blocked MEKK1 activation, which normally inhibits NF-κB, 
concurrent Akt activation counteracted its effect.  While the relation of these events to the 
attenuation of inflammatory responses is discernible, the molecular basis for such a response 
remains elusive.  Indeed, the complex network of biochemical processes within this pathway 
that are constitutively  interlaced with feedback loops and other regulatory events makes the 
search for molecular target an immense challenge. 
1.4.4  Miscellaneous activity
In addition to their anti-cancer and anti-inflammatory effects, the phenanthropiperidines 
have been investigated for activity in several other systems.  In some of the earliest biological 
studies with these alkaloids, Barnard reported that cryptopleurine had colchicine-like c-
mitotic activity in the root tips of germinating onion seeds.121 In oyster embryos and yeast, in 
spite of inhibiting growth, its activity  at 10–6 to 10–3 M  did not seem to resemble that of 
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colchicine.122 Anti-fungal activity was also observed for cryptopleurine and some closely 
related analogs.123 Amoebicidal,78, 124 insecticidal125 and anti-feedant126 properties have also 
been reported.  
Anti-viral effects have also been noted.  When kidney cells were exposed to crytopleurine 
and subsequently inoculated with herpes virus hominis, viral growth was stunted.127 The 
alkaloid did not, however, have any antiviral activity  in coxsackie B-5 or polio-type I viruses. 
Antofine was also found to exhibit anti-TMV activity in the low micromolar range, 
presumably due to its affinity  for RNA.128  Following up  this discovery, Wang et al. studied 
tylophorine (racemic, S and R), (±)-antofine and (±)-deoxytylophorine, finding that they also 
possessed anti-TMV activity.  With the goal of improving solubility and stability, a series of 
tylophorine salt derivatives were prepared.129  These salinized analogs, besides being more 
soluble and stable, had improved in vitro and in vivo anti-TMV activity, surpassing that of 
commercial Ningnanmycin. 
1.4.5  Summary of biological activity    
The prodigious effects of the phenanthropiperidines on living systems are indisputable, 
but they have yet to be harnessed to treat disease in the clinic.  Within the past decade, a there 
has been a concerted effort to validate their therapeutic potential in both cancer and immune/
inflammatory-related diseases. Although the literature is replete with studies on the 
phenanthropiperidines, the data extracted from different assays, cell-lines and animal models 
have led to a fragmented understanding of the mechanism by which these alkaloids modulate 
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immune responses and inhibit the growth of cancer cells.  Nevertheless, protein biosynthesis 
inhibition and modulation of key transcription-factor activity are among the best validated 
mechanisms of action.  This is not to say, however, that there is a single molecular target. 
Increasing evidence suggests that the phenanthropiperidines perturb multiple 
macromolecules.  For instance, some of the most well-studied members of this class have 
affinity for the 40S ribosomal subunit, DNA and RNA.  Therefore, the identification of 
specific targets may not be sufficient to explain the extent of their pharmacology.     
1.5  Obstacles to clinical success 
While many phenanthropiperidines exhibit promising activity  in vitro, this activity has 
not translated well into animal models.  The NCI has conducted multiple in vivo studies with 
the salient members in this class: tylophorine, tylocrebrine and tylophorinine.  These 
alkaloids provide up to 150% life-extension in the most responsive tumor model, L1210 
leukemia.  Unfortunately, other tumor models such as adenocarcinoma 755 and Sarcoma 180 
were much less responsive.  The basis for this in vitro/in vivo discrepancy is undoubtedly 
multifactorial and is just beginning to be understood.       
Cheng and coworkers noticed that despite comparable activities in vitro, tylophorine and 
DCB-3503 behaved differently in animal studies.58 Notably, previous assessment in the NCI 
hollow fiber assay scored DCB-3503 higher than tylophorine (26 vs. 4).  Compounds that 
score above 20 are generally considered for further animal studies.130 It was posited that this 
difference was linked to drug delivery  or stability.  Both compounds were subsequently 
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tested in a HepG2 xenograph murine model using multiple dose regimens.  Again, 
DCB-3503 had superior antitumor activity compared with tylophorine.58 This idiosyncrasy 
could result from differing pharmacokinetic profiles, but no extensive PK studies have been 
reported.  Indeed, PK data would be invaluable to understanding why  such potent compounds 
fail to perform in vivo.            
In addition to the aforementioned toxicity of cryptopleurine,16 the therapeutic window is 
another important consideration in this discussion.  Some toxicological data can be gathered 
from the NCI database that reports the mortality  in each model system.  From this and other 
in vivo studies it seems that an effective dose can be reached without causing overt toxic 
effects.  Tylophorine has been studied most extensively  with respect to its toxicity.  One 
study reported that an oral administration of tylophorine (1.25-2.5 mg/kg/day) over 15 days 
produced no toxic effects in rats, whereas an oral dose of 35 mg/kg was lethal in 50% of the 
animals.131  In another study, rats and hamsters receiving seven oral doses of 5 mg/kg result 
had a 50 and 80% mortality  rate, respectively.124 Contrasting with these reports, a dose as 
high as 500 mg/kg of (R)-tylophorine was found to be non-toxic in rats.117 
In addition to acute toxicity, another impediment to the therapeutic potential of these 
compounds is their neurological effects.  It was observed that at high doses, rodent models 
experienced CNS depression (ptosis, sedation, decreased motor activity and staggered gait).
117 This is noteworthy  because of the CNS effects—namely, ataxia and disorientation—
experienced by  subjects in tylocrebrine’s clinical trials.2 In light of tylophorine’s similar 
physicochemical properties, it is clear why this is such a concern.  In a recent review, 
Hitchcock and Pennington show that the degree of passive diffusion across the blood-brain 
 
78
barrier (BBB) correlates with a molecule’s polar surface area (PSA), number of H-bond 
donors (HBD), cLogP, cLogD and molecular weight.132 Calculating these properties for 
tylophorine and tylocrebrine reveals that each value falls well within the suggested 
parameters for CNS drugs on all accounts (Table 1–9).  Of course, if the aim is to reduce 
CNS-mediated side effects the alkaloids should be endowed with properties less conducive to 
BBB permeation. 
 
Another concern which is intimately related to physicochemical properties is low 
solubility.  The high lipophilicity of these molecules is a likely contributor.  Fortunately, 
mitigating BBB permeation by incorporating polar functional groups will probably improve 
solubility as well.  The planarity of the phenanthrene system is probably another culprit.  In a 
recent review, Loverling et al. show that increasing sp3 character in drug candidates 
correlates with improved solubility and hence its clinical success.133 Whether this strategy 
can be successfully  employed for phenanthropiperidines is still to be realized.  If these 
alkaloids exert their effects through intercalation, relying on sheer planarity, improving 
PSA = polar surface area, HBD = hydrogen-bond donors, MW = molecular weight.
Table 1–9.  CNS drugs and tylocrebrine’s physicochemical properties.
property
top 25 CNS drugs 
mean values suggested limits tylocrebrine
PSA (Å2) 47 < 90 40
HBD 0.8 < 3 0
cLogP 2.8 2-5 4.3
MW 293 < 500 394
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solubility by  increasing saturation may ultimately be counterproductive.  Although these 
impediments to clinical success seem daunting, there are still many “tricks of the trade” that 
have yet to be explored.             
                
1.6  Synthesis of phenanthropiperidine alkaloids
The accessibility of bioactive molecules largely determines the feasibility  of drug 
development.  Without an adequate supply, even the most active medicinal agents are 
rendered useless.  Currently, supply is not a limitation for preclinical investigations of the 
phenanthropiperidines.  Compared with many  natural products, these alkaloids are 
structurally  simple, and reliable synthetic routes have—for the most part—replaced isolation 
methods.  Spurred by unique structural features and biological properties, organic and 
medicinal chemists have endeavored to provide a sustainable source of these alkaloids and to 
give access to novel synthetic analogs with improved therapeutic potential.  Indeed, these 
routes have greatly  facilitated lead optimization.  With this in mind, the obstacles to clinical 
success seem less daunting.    
Synthetic approaches to the phenanthropiperidines have matured since the first efforts. 
Advancements in transition metal catalysis and heterocycle synthesis have been crucial to 
this enterprise.  There is no shortage of total syntheses for many of the well-known members 
of this class.  Owing to their long history and archetypal structures, tylophorine and 
cryptopleurine boast over twenty distinct routes.  Antofine is another popular target due to its 
extremely potent cytotoxicity.  The number of synthetic undertakings that have been 
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successfully  used to prepare these alkaloids far exceeds the scope of this work, so, we will 
focus only on key sequences within the total syntheses that have led to the construction of the 
phenanthrene system and indolizidine/quinolizidine scaffolds.  Reactions used to prepare 
parts of these systems (i.e. naphthyl, pyrrolidines, piperidines, etc.) or reactions that elaborate 
these two substructures will receive minimal attention.  Conceivably, improved reaction 
sequences could be devised by piecing together parts of others.          
1.6.1  First synthetic efforts towards phenanthropiperidines
Less than five years after the structural elucidation of crytopleurine, Bradsher and Berger 
reported its synthesis.134, 135 Slightly delayed because of structural uncertainties, the synthesis 
of tylophorine followed closely behind.13 With these methods already established, the 
synthesis of tylocrebrine could be reported simultaneously with isolation giving strong 
evidence for its proposed chemical structure.20 All of these synthetic approaches used the 



























1.16 (X = NO2)
1.17 (X = NH2)
1.18 (R2 = CO2H)
1.19 (R1 = H; R2 = CH2Br)
1.20 (R1 = OMe; R2 = CH2Cl)
1.14 (R1 = H or OMe)
1.15
Scheme 1–2. Original method to prepare phenanthrene system.
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nitroveratraldehyde 1.15 (Scheme 1–2).  The nitro group was reduced to the amine with 
ferrous sulfate in preparation for phenanthrene formation (1.16 → 1.17).  The biaryl coupling 
was realized using a Pschorr coupling protocol, involving conversion of amine 1.17 into the 
corresponding diazonium salt.  Subsequent treatment with copper mediated a radical 
decomposition and bond formation to furnish acid 1.18.  The acid was then reduced to an 
alcohol, and this was displaced by either a bromide or chloride ion. Diverging slightly at this 
point, cryptopleurine was synthesized via N-alkylation of picolinic aldehyde with the 
phenanthrene 1.19 and cyclized in PPA (Scheme 1–3).  The fully oxidized pentacycle 1.21 
was then hydrogenated to (±)-cryptopleurine (1.3) in the final step.  Tylophorine (1.1), on the 
other hand, was prepared through a C-alkylation of pyrrylmagnesium bromide and reduction 
and then completed using the Bischler-Napieralski protocol from amine 1.22.  The synthesis 
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1.6.2  Phenanthrene synthesis
The phenanthrene is a relatively  rare component of natural products in comparison to the 
indolizidine.  In most cases, this structure has been constructed using robust biaryl coupling 
reactions.  The point in the syntheses at which the full phenanthrene core is realized varies 
considerably from route to route.  There are several things that should be considered when 
deciding when to incorporate this moiety.  In comparison with the indolizidine amine which 
often requires protection, the phenanthrene system is remarkably stable and is unperturbed in 
most reaction conditions.  Furthermore, compounds containing a phenanthrene moiety  are 
generally  stable crystalline solids and hence simplify  purification.  On the other hand, these 























Scheme 1–4. Phenanthrene synthesis via dimerization. 
1.23
1.24 (X = I) 1.26





The substitution pattern on the phenanthrene system determines the accessibility  of each 
alkaloid by any given approach.  Because of its symmetrical methoxy substituents, 
tylophorine can be synthesized through dimerization.  Deiters and coworkers exploited this 
symmetry in their synthesis of tylophorine, beginning with a dimerization of 4-iodoveratrole 
(1.23) and subsequent conversion to the diyne 1.25 (Scheme 1–4).136  This intermediate was 
desymmetrized using a [2+2+2]-cyclotrimerization with a judiciously chosen nitrile.  Upon 
cycloaddition, the resulting pyridine spontaneously cyclized by displacing the tethered 
mesylate and furnished dehydrotylophorine (1.26), which was reduced to the natural product 
(1.1).  In another example, Chelmer and coworkers used a radical-induced dimerization of 
benzyl bromide 1.27 followed by an oxidative-coupling reaction to prepare symmetrical 
phenanthrene 1.30 (Scheme 1–5).137  Alternatively, the benzyl dimer 1.29 can be derived 
from an alkyne reduction of symmetrical acetylene 1.28 and carried through to phenanthrene 






















Scheme 1–5. Phenanthrene synthesis via dimerization. 
1.30 (X = H)
ClSO3H
 70%
1.32 (X = SO2Cl )





bromination with NBS138 or sulfonylation with chlorosulfonic acid to furnish phenanthrene 
1.31 and 1.32, respectively.137 Pearson and Walavalkar demonstrated that  the oxidative 
dimerization of homoveratric acid (1.33) can be used to prepare the necessary precursor 
(1.34) to (±)-tylophorine (Scheme 1–6).139  
     
The symmetrical phenanthrene substitution pattern has expedited the latter parts of total 
syntheses as well.  Comins140, 141 and Padwa142 have reported the use of Pd-catalyzed bis-
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Despite the advantages of dimerization, desymmetrization can be challenging.  The 
earliest strategies for phenanthrene construction used a different approach.  As shown in 
Schemes 1–3 and 1–4, the first total syntheses of tylophorine and cryptopleurine used aldol 
reactions and Pschorr couplings to prepare the phenanthrene.  Although the Pschorr reaction 
has been replaced with more efficient biaryl coupling reactions, the aldol method is still 
widely  used3, 4 because of its simplicity  and amenability to scale up.143 Notably, the tactic 
permits substituent variability  on either the aldehyde or carboxylate arenes allowing the 
synthesis of unsymmetrical phenanthrene substitution patterns as in cryptopleurine.  The 
stilbene aldol product is typically  converted directly  into the corresponding phenanthrene 

































and hypervalent iodine reagents have all been successfully  used.  Thallium works remarkably 
well for this transformation but is extremely toxic and, hence, is often replaced with less 
toxic reagents such as iron or PIFA.  Photoirradiation can also be used but with poor 
regioselective control.144, 145  
This oxidative biaryl coupling approach is synthetically  attractive due to its atom 
economy but regioselectivity  is a concern.  Free rotation around the aryl-alkene bond is 
responsible for the formation of regioisomers which can make purification extremely 
difficult.  Fortunately, this problem can be mitigated at low temperatures.  Another caveat is 
that the use of oxidative couplings limits the accessibility of phenanthrenes with C4- or C5-
substituents.
It is true that tylocrebrine, which bears a C5-methoxy group, was among the first 
phenanthropiperidines to be synthesized, but this approach relied on the isolation of the 







 1. isopentyl nitrite
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protocol to construct the tetramethoxyphenanthrene system (Scheme 1–8).146 This synthesis 
provides less than 1% of racemic tylocrebrine over ten steps and required significant effort to 
separate it from the other regioisomer (recrystallized three times).  There is a clear need to 
surmount this historic challenge.
Alternative approaches have been used to form the aryl-aryl bond which show promise 
for the preparation of phenanthrenes with these difficult  substitution patterns.  For instance, 
Kibayashi and coworkers prepared seco-analog 1.35 with a strategically placed bromide to 
direct C–C bond formation (Scheme 1–9).147, 148 The phenanthrene could then be formed 
using either light or Bu3SnH/AIBN to initiate the desired biaryl coupling.  Since the position 
of the bromide determines the position of bond formation—this is analogous to the function 
of the amine in the Pschorr protocol—a single regioisomer (1.36) is obtained.  This approach 
has not been used to synthesize phenanthrenes with C4- or C5-substituents.
It is without question that  biaryl coupling strategies have dominated phenanthrene 
synthesis.  Fürstner and Kennedy, however, reported an alternative route to four Tylophora 






















approach relied on the assembly of the biaryl system, first via Suzuki cross-coupling.  Their 
judicious use of simple, readily  available building blocks (boronic acids and aryl-1,2-
dihalides) gives this method the versatility required to access multiple analogs in a divergent 
manner, a feature that is conducive to lead optimization.  Once alkyne 1.37 has been 
prepared, a Pt(II)-catalyzed cyclization provides phenanthrene 1.38  in up to 97% yield 
depending on the substrate.  Hypothetically, this strategy  could give access to the 
aforementioned phenanthrenes with C4- or C5-substituents, but this has not been reported.
 Among the reactions discussed, a single example departs from the conventional strategy 
of piecing together two oxygenated arenes (Scheme 1–11).150 In this example the tricyclic 
nucleus arises from a cascade process with well-placed functionalities.  The sequence 
commences with the coupling of alkyne 1.39 and carbenoid 1.40.  The newly formed 
chromium carbene complex 1.41 is ideally situated to the γ-ketone oxygen and furnishes 
diene 1.42.  A strategically placed alkene undergoes a [4+2]-cycloaddition with the pendant 























dihydrophenanthrene system (1.44) is obtained.  Using this approach, (±)-antofine could be 
prepared in 7 steps, but attempts to synthesize (+)-antofine were unsuccessful.                      
1.6.3.  Indolizidine and quinolizidine synthesis
With the many creative and elegant approaches to the phenanthrenes discussed, we will 
now turn to the aliphatic heterocycle.  As before, we will speak generally, emphasizing the 
diversity of approaches to the indolizidine or quinolizidine nuclei rather than dwelling on the 
intricacies of each.  The strategies will be divided based on the position of the bond that is 
formed to fully  assemble the indolizidine or quinolizidine core.  Where possible, the 
heterocycles will be treated as isolated entities and, accordingly, are numbered as such. 





































prepared in a wide variety of ways.  The following discussion will be divided based on the 
location of the bond that is formed in the key step (Fig. 1–11).  
  
1.6.3.1 C3–C4 bond forming reactions
The C3–C4 bond is the one point of confluence between the phenanthrene and piperidine 
structures.  These carbons have been successfully  conjoined using basic intramolecular aldol 
condensations.151-157        
Biocatalytic approaches have successfully condensed cylic imines 1.46 and 1.47 which 
were enzymatically formed from putrescine and cadaverine in situ, with 3-oxopropionic acid 
1.45 (Scheme 1–12).158-160 Alternatively, pyrroline 1.46 can be prepared from 4-aminobutanal 
diethylacetal and isolated as a stable complex with zinc iodide (not shown).151, 161 In another 
example, the N-oxides of imines 1.46 and 1.47 have also proven to be viable precursors to 
















the indolizidine145, 162 and quinolizidine144 alkaloids.  Iida et al. used these nitrones (1.46 and 
1.47) in a [1,3]-dipolar cycloaddition reaction yielding isoxazolidine 1.52 or its homologue 
1.53.  The N-O bond was then reduced, providing β-amino alcohol 1.54.  A limitation of 
these strategies is their lack of stereoselectivity.  To address this, Georg and coworkers 


















85% (n = 1)
79% (n = 2)





93% (n = 2)
MeO
OMe
86% (n = 1)





















1.56 (R = Boc)
1.481.46 (n =1)
1.47 (n = 2)




1.51 (n = 2)
1.52 (n =1)
1.53 (n = 2)
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From amine intermediates 1.48, 1.54 and 1.57 there have been two general approaches to 
the access the natural products.  The one that most resembles the biosynthetic pathway begins 
by treating amine 1.48 with a substituted phenylacetaldehyde (Scheme 1–13).35, 151, 155, 163-167 
The enamine condensation product (1.58) then reacts further to furnish bisarylated 
indolizidine 1.59.  Seco-analog 1.60 is prepared upon reduction with NaBH4, situating the 
intermediate for the final biaryl coupling.  This approach is remarkably concise but suffers 
from low yields (24%).  In an alternative approach, amine 1.54 or 1.57 is acylated in 
preparation for cyclization.144, 145, 151-153, 162 Diketone 1.61 is then treated with KOH in an 







































Scheme 1–13. C3–C4 Bond formation via aldol reaction.
1.48













A significant limitation was discovered in this approach when the supposedly 
enantiomerically  pure products were found to have undergone partial racemization.152, 154 
Further inquiry into this unexpected result revealed that racemization occurred upon Boc-
deprotection (1.56 → 1.57) and during the base-promoted aldol condensation (1.61 → 1.62).
152 It was proposed that a retro-Michael/Michael process was at  play that could evidently 
occur in either acidic or basic conditions (Scheme 1–14).  This unfortunate side-reaction has 
limited the utility of the intramolecular aldol approach.
  
Padwa and coworkers developed a unique Rh(II)-catalyzed [1,3]-dipolar cycloaddition 
for the preparation of highly-substituted 2(1H)-pyridones that forms the C2–C3 and C5–C5a 
bonds of the indolizidine simultaneously  (Scheme 1–15).168  Treatment of pyrrolidinone 1.63 
with Rh(OAc)2 generates a cyclic ylide 1.64 in situ, which reacts further with substituted 
alkenes, providing unstable bridged-bicyclic intermediate 1.65 that spontaneously 
decomposes to form indolizidine 1.66.  This intermediate was then used to complete a formal 
synthesis of (±)-septicine (see Scheme 1–7).























1.6.3.2 C2–C3 bond forming reactions
The C2–C3 connection was considered by the first chemists to synthesize these natural 
products.  As already discussed this approach relied on the Bischler-Napieralski isoquinoline 
synthesis in the penultimate step.  This reaction, with a few exceptions,150 has since been 
replaced with higher yielding and more direct approaches. Very recently Orito and coworkers 
reported a Pd-catalyzed aromatic carbonylation reaction, which gave access to a variety  of 
benzolactams (1.68, Scheme 1–16).169 The reactions were generally low yielding unless 
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  Reactions of this kind that generate lactams require a subsequent reduction—almost 
always performed with LAH—to obtain the natural products.  A more direct approach, 
however, has managed to circumvent this final reduction step.  This approach, which is now 
in common usage, relies on the Pictet-Spengler reaction for C2–C3 bond-formation.63, 137, 143, 
149, 170, 62, 171-173 Generally  speaking, an amine (1.69) is treated with formaldehyde under 
acidic conditions to form an electrophilic iminium species (1.70), which reacts further in a 6-
endo-trig fashion to afford the phenanthropiperidine 1.71 (Scheme 1–17).  Since acidic 
conditions are used, amines protected with acid-labile protecting groups (e.g. Boc) undergo 
deprotection in situ.62, 149
                    
The intramolecular Diels-Alder reaction is another way to construct the C2–C3 bond. 
Like the Pictet-Spengler approach, this strategy exploits a reactive imine (1.74 and 1.75, 
Scheme 1–18).  Weinreb and coworkers were the first to employ this strategy.  The imine 
dienophile was generated by  thermal decomposition of methylol acetate 1.72, which 
underwent a [4+2]-cycloaddition to form quinolizidine scaffold 1.76.174, 175 The foregoing 













Scheme 1–17.  Pictet-Spengler approach to conjoin the C2–C3 bond.  
1.69





more reminiscent of the Pictet-Spengler approach, Grieco and Parker generated imine 1.75 
upon treatment of phenanthrene 1.73 with formaldehyde.176 After heating the reaction for 10 
h at 180 ºC, (±)-cryptopleurine was isolated in excellent yield without the need to reduce an 
amide.
 
Pearson and Walavalkar have used an intramolecular [1,3]-dipolar cycloaddition reaction 
to assemble the indolizidine core (Scheme 1–19).139 This reaction is initiated by an azide-
alkene cycloaddition of phenanthrene 1.77 to form a triazoline intermediate 1.78, which upon 
fragmentation reveals a reactive imine (1.79).  The pendant electrophile then alkylates the 






















220 ºC, 5 h
H2O/EtOH 
180 ºC, 10 h•HCl
Scheme 1–18. Diels-Alder reaction to prepare quinolizidine.
1.72
1.73
1.74 (X = O)
1.75 (X = H2)
1.76 (X = O)
(±)-cryptopleurine (X = H2)
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1.80 with NaBH4 provides (±)-tylophorine.  Kim et al. have recently  adopted a similar 
strategy in the synthesis of (±)-antofine and (±)-cryptopleurine from azide 1.81.170
 
1.6.3.3 C4–C5 bond forming reactions
The intramolecular Diels-Alder approach is an efficient way to impart complexity in a 
single reaction.  In the aforementioned cycloadditions, however, stereochemical complexity 
was not addressed.  One tactic that has been used to confront the challenge of asymmetric 
synthesis involves the use of chiral auxiliaries.  With previous success in preparing (±)-







































(±)-cryptopleurine (n = 2)
(±)-tylophorine
(±)-antofine (n = 1)
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route.178  This approach relies on the synthesis of stilbene amide 1.83 featuring a tethered 
(E)-unsaturated ester (Scheme 1–20).  Using chiral auxiliaries A or B, the desired 
indolizidine (1.85) could be prepared upon treatment with TBSOTf and TEA.  This reaction 
was deemed an “intramolecular double Michael addition”, but a formal Diels-Alder 
mechanism has not been ruled out.  Although a 4:1 mixture of C3-epimers was obtained, both 
benzylic stereocenters were destroyed upon oxidation to the phenanthrene system with 
Tl(CF3CO2)3, and in a few steps, the first asymmetric synthesis of (R)-tylophorine was 
completed.
    
Recently, Chemler and coworkers developed a novel Cu(II)-catalyzed enantioselective 
carboamination reaction that gives rapid access to sulfam (1.86, Scheme 1–21).137  Upon 
elimination of sulfur dioxide and Pictet-Spengler reaction, tylophorine could be prepared 










































recently  reported by  Herr and coworkers.138 In this example, phenanthryl bromide 1.31 
undergoes oxidative insertion resulting in coordination of the carbamate and pendant alkene. 
Nucleophilic attack onto the Pd-activated olefin provides pyrrolidine 1.88 and subsequent 
reductive elimination conjoins the pyrrolidine to the phenanthrene system affording precursor 
1.89.  This convergent approach was used to construct (±)-tylophorine in only six total steps 
and with a 35% overall yield. 
Successful methods to link the C4- and C5-carbons date back to the earliest 
phenanthropiperidine total syntheses—the first total synthesis of crytopleurine, for instance.
134, 135 This transformation is a Friedel-Crafts–type acylation.  The first  examples of this 

























































reaction provides the product in relatively poor yields (22–35%).  When the acid chloride 
was used instead the yields greatly improved but were highly dependent on the Lewis acid 
used.15 Using SnCl4, for example, allowed the desired product to be isolated in near 
quantitative yields, whereas AlCl3 gave lower yields and caused partial demethylation of the 
aromatic ethers.  The former strategy (i.e. SnCl4) has been reported by several other groups 
with similar results.60, 179
 
The preparation of the Friedel-Crafts starting materials has made this approach quite 
practical (Scheme 1–22).  Akin to the first synthesis of cryptopleurine, simple displacement 
of the halide of phenanthrene 1.90 with an amino acid (1.91) gives rise to the requisite 
cyclization substrate (1.92).  Thus, the stereochemistry can arise from the chiral pool using 
amino acids such proline or pipecolic acid.  The stereochemical integrity during the Friedel-
Crafts reaction is an obvious concern considering the well-known susceptibility  of α-amino 
acid chlorides to racemization.180 Although the final natural products are reported to be 













Scheme 1–22.  General method to prepare Friedel-Crafts starting material. 
1.90





impossible to deduce the enantiomeric purity  within a reasonable margin of error.  Analytical 
chiral resolution will be necessary to settle this.              
It is worth noting that an intermolecular Friedel-Crafts strategy has also been used that 
did not  result in stereochemical damage (Scheme 1–23).  Nordlander and Njoroge used N-
trifluoroacetylprolyl chloride (1.93) in the presence of AlCl3 to acylate symmetrical 
phananthrene 1.30.173 Using a lanthanoid chiral shift reagent the enantiomeric purity of the 
product 1.94 was determined by NMR and found to be greater than 98%.  
1.6.3.4 N–C2 bond forming reactions
One particular total synthesis effort demonstrates striking ingenuity in constructing the 
N–C2 bond.  Iwao and coworkers reported a directed ortho-metallation strategy in the 
synthesis of (±)-cryptopleurine and (±)-antofine (Scheme 1–24).181, 182 The appropriate 

























aromatic aldehyde.  The oxygen of the newly  formed alcohol was then translocated upon 
lactone formation and C-O bond reduction with Zn-Cu.  With all the carbons in place, acid 
1.97 was converted to the (±)-antofine and acid 1.98 into (±)-cryptopleurine.  The 
penultimate step  is the key reaction in this final sequence which forms the N–C2 bond 
through an acylation of the heterocyclic amine.         
1.6.3.5 N–C8(C9) bond forming reactions
The piperidine heterocycle (ring D) fused to the phenanthrene is completely conserved 
within all of these alkaloids whereas the distal heterocycle (ring E) adds a new element of 
structural diversity.  The wealth of reliable C–N bond-forming reactions makes this 
disconnection an obvious choice.  Indolizidine formation via pyridine alkylation has been 





































Scheme 1–24. Lactamization strategy to form indolizidine and quinolizidine.
1.961.95
1.97 (Ar = 2-pyrrolyl)
(±)-antofine
(±)-cryptopleurine
1.98 (Ar = 2-pyridinyl)
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demand cycloaddition using styrenes 1.99 and 1.100 furnished pyran 1.101 which could be 
converted to the pyridine (1.102) upon treatment with hydroxylamine (Scheme 1–25). 
Further elaboration provided the tethered primary alcohol which was displaced upon 
treatment with mesyl chloride.  Treatment with NaBH4 reduced the resultant pyridinium 
species to the desired indolizidine 1.103.  This strategy was applied to indolizidine and 




































































Achieving similar ends in an asymmetric fashion, Comins et al. prepared enaminone 
1.105 from pyridine 1.104 enantioselectively using N-acylpyridinium chemistry.141 Upon 
deprotection of the carbamate chiral auxiliary the resultant amine spontaneously cyclized. 
The enaminone intermediate 1.106 was then used to prepare (S)-tylophorine.  Similarly, an 
intramolecular Mitsunobu reaction of Cbz-aminoalcohol 1.107 was employed in the 
synthesis of (R)-cryptopleurine by Kim and coworkers.184 
Cascade reactions have a strong reputation for being able to rapidly assemble complex 
molecules.  To construct the indolizidine in tylophorine, Leipa et al. developed a cascade 
process using hydrogenation conditions (Scheme 1–26).185  The starting material was easily 
prepared via Michael-addition of cyanide 1.109 into unsaturated ketone 1.108.  Under 
reductive conditions, cyanide 1.110 was first reduced to primary amine (not shown), which 
triggered a tandem condensation/reduction/acylation sequence, providing an excellent yield 
(86%) of bicyclic product 1.112.
Preparing heterocycles can often be facilitated through ring expansion reactions and this 
too has been aptly used in the synthesis of the indolizidine core.  Yerxa and coworkers 























Stereochemistry was not reported.
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The necessary aryl groups were installed sequentially in a 5-step sequence yielding 
cylcohexadienone 1.117.  Desymmetrization takes place upon addition of N-lithiopyrrole into 
a single carbonyl of diketone 1.114 and trapping the alkoxide with TMS-Cl yields pyrrole 
1.115.  Upon heating in p-xylene, pyrrole 1.115 is thought to undergo an electrocyclization 
ring-opening to generate an electrophilic ketene 1.116 that  intramolecularly acylates the 
pyrrole system.  Reduction of the resultant seco-analog 1.117 yields (±)-septicine.
1.6.3.6 C5a–C6 bond forming reactions
Only one report  of a C5a–C6 bond formation reaction exists to construct the indolizidine 














































quinolizidine nucleus by way of a radical cyclization reaction (Scheme 1–28).56, 68 Alkyl 
iodides 1.118 (n = 1 and 2) were treated with AIBN as a radical initiator to yield the desired 
indolizidine and quinolizidine intermediates 1.119.  This reaction provides the immediate 
precursors to the phenanthropiperidine alkaloids. 
 
1.6.3.7 Angular OH or Me groups
The rare 13α-methylphenanthroindolizidines, such as the hypoestestatins, are attractive 
targets because of their unique structures, low abundance and therapeutic potential.26-28 The 
methyl group at  the ring juncture, however, presents a formidable challenge for synthetic 
chemists.  A singular report discloses a possible route to these alkaloids.187 Phenanthryl 
bromide 1.120 was treated with azobis-cyclohexanecarbonitrile (ACN) triggering a 6-endo/5-
endo radical cascade cyclization yielding amide 1.121 (Scheme 1–29).  To prepare 
hypoestestatin 1, the amide was reduced with LAH.  The NMR spectra, however, did not 
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Phenanthroindolizidines bearing 13α-hydroxy  groups are also uncommon but 
considerably more challenging to synthesize.29, 188 The labile aminal functionality  and 
susceptibility to oxidation have most likely hampered synthetic efforts.  Interest in the 
biological activity  of these alkaloids is still of great interest considering the extraordinary 
anti-proliferative activity of tyloindicine F and G.
     
1.6.4  Closing remarks
The synthetic interest in the phenanthropiperidine alkaloids has given rise to a plethora of 
novel reactions that accentuates the artistic nature of organic chemistry.  We have attempted 
to present these strategies in a new light, focusing on key transformations rather than on 
complete reaction sequences.  More specifically, we opted to address reactions that result  in 
the consummation of predefined substructures (i.e. the phenanthrene or fused heterocycle 
core) and by  doing so have, unfortunately, excluded some creative methods used to construct 
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improved reaction sequences to address limitations in yield, stereoselectivity and economy, 
and to encourage the preparation of novel structures with improved therapeutic utility. 
     
1.7   Summary
This review featured a class of alkaloids, the phenanthropiperidines, which have long 
been known for their medicinal properties but have yet to be refined into a clinically  useful 
drug.  These alkaloids show remarkably potent anti-proliferative and anti-inflammatory/
immune activity, providing impetus for their development as therapeutic agents.  Their 
mechanism of action likely involves multiple targets.  Evidence suggests that inhibition of 
protein synthesis through the 40S ribosomal subunit may play a role in their anti-proliferative 
effects.  Moreover, the best-studied phenanthropiperidines perturb NF-κB–mediated 
transcription and other major signal transduction pathways.  There is also evidence that these 
planar alkaloids intercalate DNA and RNA.  Whatever the cause, the upshot is cytostasis and 
cell differentiation—not death—that leads to long lasting suppression of cell growth. 
Despite this positive outlook there is still need for refinement.  In regard to cancer, there is a 
marked difference between activity in cell cultures and activity in animal models. 
Presumably, the alkaloid’s poor PK properties, acute toxicity and low solubility  are 
contributing to this.  There is also uncertainty about neurological side effects that could arise 
as they did in tylocrebrine’s clinical trials.  The design of new analogs, therefore, should 
proceed with the goal of addressing these obstacles.  
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To serve this end, modern synthetic routes have given ready access to the alkaloids and 
their unnatural congeners, providing a better understanding of SARs and a foundation for 
designing analogs with improved pharmaceutical and pharmacokinetic profiles.  These are 
formidable challenges, but there is not one here that medicinal chemists have not overcome 
in the past for already approved drugs.  It is hoped that this review will stimulate and guide 




SYNTHESIS OF SIX- AND SEVEN-MEMBERED CYCLIC ENAMINONES: OPTIMIZATION, SCOPE 
AND MECHANISTIC STUDIES  
2.1  Introduction
The foregoing chapter described a number of obstacles that have thwarted efforts to 
develop a phenanthropiperidine drug.  Challenges of both the biological and chemical nature 
have emerged and undoubtedly exacerbated one another.  In particular, a dearth of novel 
structures within this class—whether because of synthetic limitations or a failure of synthetic 
chemists to apply established routes to new targets—has made iterative lead optimization 
burdensome and left SAR studies in a rather inchoate state.  New methodologies that enable 
the synthesis of well-designed libraries and that diverge from the structurally homogenous 
collection of already-known phenanthropiperidines would prove a boon to the effort to 
remedy these alkaloid’s undesirable properties and improve upon desirable ones.  Joining this 
effort, we have developed a cyclization reaction for the synthesis of enantiomerically pure 
cyclic enaminones and have set precedent for their use in the synthesis of these alkaloids. 
This chapter will discuss our investigations into the mechanism and scope of this reaction.       
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2.2  Background 
Enaminones or vinylogous amides (Fig. 2–1) are highly versatile functional groups.  As 
their name suggests they are composed of an alkene, an amine and a ketone.  Their reactivity, 
however, is orthogonal to each of these functional groups in isolation.  Remove one of these 
functional groups and the molecule adopts a completely different nature.  For instance, 
enamines, which lack the carbonyl, are typically prone to hydrolysis or oxidation,189 whereas 
enaminones are quite stable and easily isolated.  Conversely, enaminones are not as stable as 
the conventional amide.  This, however, makes them more tractable and versatile synthetic 
intermediates.   
 In addition to their distinct reactivity profile, enaminones have also attracted attention in 
pharmaceutical development, particularly as anti-convulsants and P-gp modulators.190-194 
Moreover, their stability and favorable physicochemical properties are exemplified by their 
use as orally active medicinal agents.193 A combination of the above factors and our interest 
in anti-cancer natural products encouraged us to develop a synthetic route to previously 
inaccessible or laboriously synthesized enaminone scaffolds. 
O
N
Fig. 2–1.  Generic structure of the enaminone.
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Cyclic enaminones, particularly 6-membered enaminones (2,3-dihydro-4-pyridones), are 
extraordinarily versatile intermediates for the synthesis of piperidine-containing target 
molecules.  Furthermore, this heterocycle exists in numerous drugs and drug candidates as an 
indispensable binding element.  The piperidine moiety is also prevalent in structural classes 
of numerous bioactive natural products.195-199 Considering the ubiquity of biologically active 
piperidine-containing compounds, practical methodologies for the synthesis of these 
structures, especially those bearing stereogenic centers, are of great value.  
The synthetic utility of the enaminone is clear when considering the reactivity of each 
component (amine, enamine, enone, and alkene) in isolation.  The coalescence of these four 
functional groups in the typical enaminone endows it with four nucleophilic and two 
electrophilic sites.  As depicted in Fig. 2–2, exploiting the unique reactivity of each position 
on the 6-membered, cyclic enaminone has made possible a plethora of chemoselective 
transformations (i.e. N-functionalization,200, 201 O-functionalization,202-204 C3,205-208 C4 [1,2-




Many approaches have been developed to construct the 6-membered enaminone core yet 
only a few are capable of affording non-racemic products (Scheme 2–1).  Comins and co-
workers have set precedent for the asymmetric synthesis of enaminones employing chiral N-
acylpyridinium intermediates.222 This method has proven to be enormously effective in 
providing advanced intermediates in the synthesis of numerous natural products.140, 141, 223-229 
More recent efforts have expanded the scope of this chemistry by using an assortment of 
chiral auxiliaries.203, 220, 230-236 Another approach, which predates Comins’ method, is the 
asymmetric hetero-Diels–Alder reaction of imines with Danishefsky's diene.237-249 In this 
reaction, the imputed chirality can be derived from various chiral auxiliaries appended to the 
imine203, 204, 237-242 or through the use of chiral catalysts.243-249  A noteworthy corollary of this 
Fig. 2–2. Select synthetic transformations of the 6-membered cyclic enaminone.
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classic [4+2] approach has recently been reported by the Rovis group in which alkynes and 
alkenylisocyanates undergo [2+2+2]-cycloaddition in the presence of a chiral rhodium 
catalyst.250-254  Although currently limited  to the synthesis of the indolizidine enaminones, 
this method provides rapid access to these bicyclic molecules with impressive 
enantioselectivity.  Despite the success of these asymmetric approaches, innate limitations, 
such as ring-size and substituent constraints, warranted an exploration of new avenues for the 



























































In pursuit of this goal, a novel ring-forming reaction of amino acid-derived ynones to 
yield cyclic enaminones has been developed.255 Our route accesses the target molecules in 
high enantiomeric purity by utilizing the chiral pool strategy to take advantage of the 
chirality of readily available starting materials.  A notable feature of this methodology is its 
ability to generate previously unavailable or circuitously-constructed substrates, namely, 
bicylic enaminones, 2,5-disubstituted enaminones, and enaminones with α- and β-
stereocenters.  This concise and operationally facile pathway gives ready access to novel 6- 
and 7-membered enaminones.    
2.3   Reaction development 
2.3.1 Strategy and considerations for enaminone methodology
As previously said, methods for the construction of non-racemic dihydropyridones (i.e. 6-
membered cyclic enaminones) are scarce and the existing few, although highly contributive 
to this area, have left many structurally simple enaminones out of reach.  Thus, we 
envisioned a complementary route to these molecules using the chiral pool strategy (Scheme 
2–2).  An amine tethered to an ynone could potentially serve as the requisite precursor to our 
desired scaffold through an intramolecular Michael reaction.  The amino-ynone substrates 
could conceivably be obtained from β-amino acid precursors.  This approach was attractive 
to us not only because it could furnish pyridones with four distinct appendages and two 
stereogenic centers, but also because it uses easily accessible chiral starting materials.  The 
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strategic use of β-amino acids and their immediate precursors entrusts the chiral pool and 
well-established asymmetric chemistry256-263 to provide the desired diversity and complexity 
of the final products.
  Despite the numerous examples of intermolecular 1,4-additions of amines to ynones, 
precedent for an intramolecular reaction as proposed is rare.  From the outset, we questioned 
if suitable amine/ynone orbital overlap could be achieved and were concerned about adverse 
modes of addition that would yield undesired products.















































Fig. 2–3.  Possible modes of addition for 6-endo-dig cyclization.361
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Taking Baldwin’s rules for ring closing reactions into account,264 there are several 
alternative pathways for this reaction that needed to be considered.  Although the proposed 6-
endo-dig mode of cyclization appeared to be favored, there remained some uncertainty about 
our system’s propensity towards the (also favored) 5-exo-dig pathway.  We expanded our 
literature search to reactions of other first-row periodic elements that could undergo 6-endo-
dig ring-closures.  The few successful examples that we found relied on either metals or π-
acids to activate the alkyne for nitrogen addition.265-273 Deslongchamps and co-workers, 
however, reported the intramolecular 1,4-addition of β-ketoester nucleophiles into ynones.274 
A new, stereoelectronically-controlled pathway was proposed for this cyclization where, 
instead of an ordinary addition into the conjugated π-system, the nucleophile adds to the 
orthogonal π-orbitals to generate a vinylic anion, thereby, circumventing the formation of a 
highly strained, allenic enolate (Fig. 2–3).  This mode of addition was predicted to be 
applicable for cyclizations of rings smaller than eight atoms275 and, hence, would be relevant 
for our system. 



























 Besides the questions about the mode of addition, concerns arose about racemization and 
epimerization of the pre-established stereocenters also had to be investigated.  Enolization 
processes leading to loss of α-chiral centers are commonplace and would need to be avoided. 
We also considered the likelihood of β-amino ketone intermediates to undergo retro-Michael/
retro-Mannich-type processes (Fig. 2–4).276-278 If this occurred, both the α- and β-
stereocenters would be at risk.  Worse yet, substrate decomposition could occur if the retro-
Michael and Mannich processes were not reversible.  With these potential hurdles in mind we 
ventured to construct the requisite ynone starting materials.  
2.3.2 Synthesis of Weinreb amide and ynone intermediates  
Scheme 2–3.  Methods for preparing Weinreb amides 2.1–2.13.
1) TEA, ClCO2Et, Et2O;
   then CH2N2
















































Three routes were devised to obtain β-amino Weinreb amides, the immediate precursors 
of the desired ynone starting materials.  In the cases where the Boc-β-amino acid was 
commercially available, an EDCI coupling with N,O-dimethylhydroxylammonium chloride 
in the presence of N-methylmorpholine (NMM) furnished the corresponding amide in a 
single step (Method A, Scheme 2–3).  Alternatively, Boc-α-amino acids were converted to 
diazoketones which, in the presence of catalytic silver(I) trifluoroacetate, collapsed to the 
corresponding ketene.  The ketene intermediate was trapped in situ with N,O-
dimethylhydroxylamine providing the desired Weinreb amides (Method B).  Unsubstituted 
Weinreb amides were synthesized through a one-pot Michael-addition/Boc-protection 
sequence to afford Boc-β-aminomethylesters (Method C).  Treatment of the methylesters 
with N,O-dimethylhydroxylammonium chloride and isopropylmagnesium chloride (i-
PrMgCl) afforded the desired amides.279 In the event that the Boc-protected amines required 
N-alkylation, this was accomplished subsequent to amide formation using sodium hydride 
and an appropriate alkyl halide.  In the final step, the desired ynones were obtained from the 
Weinreb amides through the addition of excess (5 equiv) alkynylmagnesium reagents 
(Scheme 2–4).  These simple steps could be conducted on multi-gram scale with minimal 
diminution of yield.























Table 2–1.  Preparation of ynones from Weinreb amides.












2.14 H B 60
2 2.15 Me B 62













2.17 H A, B 95, 68
5 2.18 Me A, B 93, 66















2.20 H B 65
8 2.21 Me B 64













R 2.23 α-OH B 52




























H 2.26 cis A 87

























2.29 H B 30











2.31 H A 85
20 2.12 2.32 PhCH2 C 67
21 2.13 2.33 Ph C 46
a See Scheme 2–3. b Isolated multi-step yield from commercially available starting materials. 
c Stereocenter was inverted from Weinreb amide precursor using the Mitsunobu reaction.
Due to our interest in indolizidine and quinolizidine natural products, we chose to 
synthesize ynones 2.14–2.19 as potential precursors to these important heterocycles (entries 
1–6, Table 2–1).  The isolated stereogenic center on the pyrrolidine ring of ynones 2.20–2.24 
was to be used to facilitate detection of the β-epimerization (entries 7–11).  Likewise, 
cyclohexyl systems 2.26 and 2.27 would allow α-epimerization to be detected (entries 13 and 
14).  Finally, acyclic ynones 2.28–2.33 were synthesized to obtain monocyclic enaminones 
(entries 15–21).  Although the enaminones to be generated from ynones 2.31–2.33 will be 
relatively unembellished, we were attracted to these targets because of a surprising lack of 
general routes to obtain them in spite of their simplicity.
2.3.3 Optimization of enaminone formation
Seminal optimization studies for this reaction were conducted by B. J. Turunen who 
envisioned a protocol in which the Boc-protecting group would be removed to liberate a 
nucleophilic amine that would, in turn, react with the tethered ynone moiety.  Turunen found 
success in a two-step deprotection/cyclization protocol to provide enaminone 2.34 (Table 2–
2).255 The use of 4N HCl (entries 4–7, Table 2–2) or TMS-I (entry 8) consistently gave higher 
yields than when TFA was used to deprotect (entries 1–3), regardless of the cyclization 
method.  We were initially perplexed by this result.  The putative ammonium salt 
intermediates of each method would only differ with respect to their counter ions (Cl-, I- or 
CF3CO2-).  Upon closer scrutiny it became clear that HCl and TMS-I were acting bi-
functionally.  In addition to deprotecting the Boc-group, these reagents also prompted 
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conjugate additions of their halides (Scheme 2–5).  Isolation of the deprotected intermediates 
revealed that, prior to cyclization, the ynone moiety had been converted by HCl and TMS-I 
to a mixture of vinyl halide I and dihaloketone II.  Trifluoroacetic acid (TFA), however, left 
the ynone intact (III).  The addition of chloride or iodide into the ynone prior to cyclization 
was evidently favoring ring-closure.
Another important observation that was made during Turunen’s studies was the apparent 
dependency of the cyclization on water or MeOH.255  Regardless of the deprotection method, 
the enaminone would not form in THF or CH2Cl2 (entries 2, 3, 5 and 6, Table 2–2) unless 
water was used as a co-solvent (entries 4, 7 and 8).  Although these wet solvents were 
Table 2–2.  Optimization of deprotection and cyclization.255
a Reaction time of cyclization step.  b Isolated yield. c Sat. aqueous NaHCO3. d Reaction 
proceeded in a separatory funnel upon work-up.
entry 1. deprotection 2. cyclization timea yieldb
1 TFA, CH2Cl2 CH2Cl2, NaHCO3c nad 30
2 TFA, CH2Cl2 CH2Cl2, K2CO3 20 h 0
3 TFA, CH2Cl2 THF, K2CO3 20 h 0
4 TFA, CH2Cl2 CH2Cl2, H2O, K2CO3 5 h 38
5 4N HCl/dioxane CH2Cl2, K2CO3 20 h 0
6 4N HCl/dioxane THF, K2CO3 20 h 0
7 4N HCl/dioxane CH2Cl2, H2O, K2CO3 1 h 74
8 4N HCl/dioxane THF, H2O, K2CO3 1 h 75
9 4N HCl/dioxane MeOH, K2CO3 15 min 87









proficient in affecting cyclization, MeOH proved to be the best solvent and was chosen to 
further explore this reaction (entries 9 and 10).  With these optimized conditions we 
proceeded to establish the scope of this reaction.
2.3.4 Mitigating stereochemical damage during enaminone formation 
 
Shortly after we embarked on our study of reaction scope we encountered a formidable 
challenge. As we had feared, ynones bearing α- or β-stereocenters, when subjected to our 
one-pot procedure, yielded mixtures of diastereomers or partial racemates. We suspected 
enolization or β-amino elimination processes were at hand; if not overcome, this would 
negate the principal advantage of the chiral pool approach.  Although both acid- and base-
induced epimerizations of this type are possible, we initially focused our attention on the 
acidic deprotection conditions.  Since the most profound stereochemical damage was 
observed in proline-derived enaminones, hydroxylated ynone 2.23 was employed as our 
model system to assess the extent of β-epimerization under an array of deprotection 
conditions (Table 2–3).   
























The previously optimized deprotection conditions had epimerized 15% of the isolated 
product (entry 1, Table 2–3).  In neat and dilute TFA, the yields and diastereomeric ratios of 
enaminone 2.35 showed no improvement (entries 2 and 3).  Slow addition of HCl in ether 
until all the starting material was consumed also failed to give satisfactory results (entry 4). 
Positing an acid-induced mode of racemization we attempted to suppress the stereochemical 
deterioration using basic and neutral conditions (entries 5–7).  These too were ineffective. 
When TMS-I was used to induce Boc-deprotection we observed a marked reduction of 
epimerization and improvement in yields (entries 8 and 9).  It should be noted that ynones 
have been shown to react with TMS-I at –78 ºC to form β-iodo–allenolates that, upon 
entry conditions yield %a (d.r.)b
1 4N HCl, dioxane 77 (85:15)
2 TFA (neat) 31 (67:33)
3 TFA/CH2Cl2 (1:1) 18 (88:12)
4 1N HCl, ether 36 (67:33)
5 1.  TBSOTf, 2,5-lutidine, CH2Cl2  2. TBAF 0
6 TESOTf, 2,6-lutidine, CH2Cl2 21 (83:17)
7 CAN, MeCN, reflux 0
8 TMS-I (3 equiv), CH2Cl2, 0 ºC 99 (75:25)
9 TMS-I (1 equiv), CH2Cl2, –78 to 0 ºC; TMS-I (2 equiv) 60 (94:6)
10 HCO2H, rt 0
11 NaI (3 equiv), HCO2H, rt 93 (> 95:5)
a Isolated yield.  b 1H NMR integration.













warming to 0 ºC, tautomerizes to afford a Danishefsky-type diene (Scheme 2–6).280 Although 
this would not directly compromise the integrity of the β-stereocenter, substrates bearing α-
stereocenters would be affected.
 
To test this, we subjected enolizable substrate 2.26 to the same conditions, and observed 
that epimerization was even more profound than when using HCl (Scheme 2–7).  In addition 
to the detrimental stereochemical effects of TMS-I, the necessity of rigorously dried solvents, 
glassware, and cryogenic temperatures provoked a search for a new, simple protocol that 
would tolerate epimerizable substrates.
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With a wealth of known Boc-deprotection protocols to explore, we were attracted to the 
use of formic acid to avert epimerization.281 The simple technique of this method was 
attractive considering it could accomplish the desired deprotection at ambient temperature 
and in open-air.  Furthermore, we hoped that this relatively weak acid would lessen 
epimerization.  Applying these conditions to ynone 2.23, the Boc-group could be easily 
removed, yet upon treatment with base, we did not observe any enaminone formation (entry 
10, Table 2–3).  As shown in earlier experiments, the success of this reaction is not only 
contingent on the removal of the Boc-group, but also on ynone “activation”  with halides 
(Scheme 2–2).  To this end, NaI was added as a nucleophilic halide source and the reaction 
was repeated (entry 11, Table 2–3).  To our delight, the desired enaminone was formed in 
excellent yield (92%) and without any detectable epimerization.  Conceivably, the remote 
hydroxy group could resist epimerization by directing the re-addition of the eliminated amine 
to the most favored anti-substituted product.  We were encouraged to find that, in the absence 
of diasteromeric control, enaminones could be obtained in high enantiopurity (Scheme 2–8). 
When ynone 2.17 was subjected to these deprotection conditions a crystalline solid formed in 
the reaction media and was determined by X-ray analysis to be the desired deprotected, vinyl 
iodide intermediate (2.38, Fig. 2–5).  Upon treatment of this salt with base, enaminone 2.37 
was formed in less than 2 minutes.  More importantly, the product was obtained with an 
enantiomeric ratio of 98.5:1.5 showing that this protocol had effectively mitigated β-
epimerization.   
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We next investigated these new conditions on enolizable ynone 2.26 as a model for α-
epimerization (Scheme 2–8).  The new conditions yielded the desired product (2.36) with a 
d.r. of 94:6.  This was a considerable improvement over the previous method where the d.r. 
was 80:20.  Interestingly, we also saw a time-dependent increase of epimerization indicating 
that the acid step was indeed responsible, at least in part, for α-epimerization.  Enolate 
formation during the basic step could also potentiate epimerization and was investigated 
further.  
2. K2CO3, MeOH












1. NaI, HCO2H, 
time (t)
2. K2CO3, MeOH N
O
Me83% yield, d.r. = 94:6 (t = 6 h) 



















Vinyl iodides A, B, and C were chosen as model substrates to examine enolization 
(Scheme 2–9).  These substrates were subjected to the cyclization conditions using deuterated 
methanol (CD3OD) as a solvent and the extent of α-deuteration was determined.  Deuterium 
incorporation at the α-position is indicative of enolate formation revealing another potential 
source of epimerization.  When intermediate A was treated with methanol-d4 and K2CO3, 
enaminone 2.37 was immediately formed and no deuteration was observed.  Once formed, 
this enaminone was resistant to deuterium incorporation for up to 24 h (i.e. to form 
enaminone 2.37-d2).  With the intent of slowing the cyclization we used substituted vinyl 
iodides B and C.  For these cases, the cyclized products 2.39-d5 and 2.40-d2 were obtained 
with complete α-deuteration.  Furthermore, as observed before, enaminones 2.39 and 2.40, 
which were formed in non-deuterated solvent, did not undergo α-deuteration under the 
prescribed conditions. 
The point has already been made that enaminones are reluctant to undergo deuteration in 
the presence of K2CO3; however, an anomaly was noted when investigating enaminone 2.39 
(Scheme 2–10).  This substrate underwent selective and complete γ-deuteration to provide 
enaminone 2.39-d3 in 2 hours.  Although it is out of the scope of this work, this finding 
reveals another handle on this versatile scaffold for chemoselective modification.282, 283          
The collective data from the deuterium exchange reactions hinted at another liability in 
our approach.  We feared that the extent of α-deuteration might be diagnostic of pre-cyclized 
intermediates that would undergo β-amino elimination.  Thus, ynones 2.20, 2.21 and 2.22 
were subjected to the two-step procedure (Scheme 2–11).  Terminal ynone 2.20 cyclized with 
no observable epimerization whereas the methyl and phenyl substituted ynones (2.21 and 
2.22) were obtained as diastereomeric mixtures.    
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In retrospect, these findings are not surprising.  The principles of vinylogy would indeed 
predict an attenuated acidity of the enaminone α-position in relation to that of its ketone 
progenitor.  Thus, α-epimerization or β-amino elimination is precluded by rapid formation of 
the vinylogous amide.  When the rate of cyclization is retarded with sterically encumbered 
alkynes there is a significant increase in epimerization, thus showing the vulnerability of the 
enaminone precursors in basic media.  Despite the use of mild deprotection conditions, these 















































Scheme 2–9.  Deuterium exchange during cyclization.
D (R = Me)
E (R = Ph)
2.39 (R = Me)




A (R = H)
B (R = Me)
C (R = Ph)
 
130
Suspicions immediately arose concerning the putative role of the acid in β-amino 
elimination.  Perhaps the discrepancies in the stereochemical outcome of each deprotection 
condition were attributable to the dissimilar haloketone intermediates and their particular 
reactivities under basic conditions.  For instance, a conspicuous difference exists when 
considering the halides (Cl vs. I).  Furthermore, double chloride addition into the ynone 
occurs in the presence of HCl whereas the diiodo congener is not formed in formic acid and 
NaI (Scheme 2–5).  We were cognizant that these dissimilarities, rather than the strength of 
the acid used for deprotection, could dictate the extent of epimerization by governing the rate 










CH3 > 95% conversion
















Scheme 2–11.  Epimerization of β-stereocenters on terminal and internal ynones.
R yield d.r.
 H (2.41) 92% > 95:5
Me (2.42) 94% 2.1:1
Ph (2.43) 88% 1.5:1
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Experimental evidence suggests that the primary cause of β-epimerization for terminal 
ynones is the strongly acidic HCl conditions.  When ynone 2.20 was subjected to 4N HCl the 
resultant ammonium salts (2.44 and 2.45) were each generated as 2:1 diastereomeric 
mixtures (Scheme 2–12).  From this we conclude that the acid is directly responsible for 
inducing amino-elimination.  As such, this process can be mitigated when using a weaker 
acid such as HCO2H.  It is important to note that the use of HCO2H and NaI does not assuage 
the stereochemical damage in cases where cyclization is slow (i.e. substituted ynones).  Thus, 
this mild protocol is most appropriate for terminal ynones.  With these insights we next 
investigated the reaction scope to validate the utility and generality of this protocol.  
2.3 Reaction scope
2.3.1 Six-membered enaminones 
As can be seen in Table 2–4, a diverse collection of enaminones can be constructed using 
these developed methods.  From this data set we intended to establish a basis for choosing 
appropriate deprotection conditions.  Bicyclic enaminones are formed efficiently, providing a 



















2.44 (d.r. = 2:1) 2.45 (d.r. = 2:1)2.20
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facile route to quinolizidine (entries 1–3) and indolizidine (entries 4–11) scaffolds.  Synthesis 
of morpholino-enaminone 2.49 was also feasible (entry 12).  Pyrrolidine substrates were 
particularly susceptible to stereochemical damage; however, this could be mitigated in 
terminal ynone substrates by using a HCO2H and NaI during the deprotection step.  Although 
the reason for this sensitivity has not been directly assessed, we believe this is due, in part, to 
the alleviation of pyrrolidine ring-strain.  Not surprisingly, anti-substitued pyrrolidines were 
less prone to epimerization than their syn-counterparts (entries 10 and 11), evidencing 
thermodynamic control of the retro-Michael/Michael process.  Installation of aliphatic and 
aromatic substituents adjacent to the ring-fused nitrogen was also accomplished by 
employing terminally substituted ynones (entries 5, 6, 8 and 9).  As expected, cyclization was 
relatively slow (15 min to 3 h) in these substrates, but all proceeded in excellent yields.  In 
these cases, however, the HCO2H-based deprotection method was ineffective at preventing 
β-epimerization.  
Enolizable stereocenters were also a potential liability considering our protocol featured 
both an acidic and a basic step.  As shown before, the use of HCl and TMS-I were destructive 
when attempting to establish the cis-fused enaminone 2.36.  We were pleased to find that α-
epimerization could also be suppressed in this case under the milder conditions with HCO2H 
and NaI (entry 13).  It should be noted that since the trans-substituted product is expected to 
be more stable, epimerization is likely to be thermodynamically preferred.  With this in mind, 
it was expected that trans-fused enaminone 2.50 was more resistant to epimerization in both 
deprotection conditions and could be acquired in high diasteromeric purity (entry 14).     
We next investigated the synthesis of monocyclic enaminones.  These compounds would 
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a Method A: a) 4N HCl/dioxane, 15 min. b) K2CO3, MeOH;  Method B: a) NaI (3 equiv), formic acid, 6-24 h.  b) 
K2CO3, MeOH;  Method C: a) TMS-I, CH2Cl2, –78 to 0 ºC. b) K2CO3, MeOH. b Isolated yield. c Chiral HPLC. 
d 1H NMR integration.
Table 2–4.  Substrate scope for the preparation of six-membered enaminones.
ring-closure.  In this regard, acyclic β-aminoynones were found to be viable substrates 
(entries 15–22).  Even sterically encumbered, internal ynones undergo cyclization to form 
monocyclic products (entry 18).  In cases where the extruded amine is not tethered to the 
ynone, as in bicylic substrates (entries 1–12), the retro-Michael process leads to degradation 
instead of epimerization.  Hence, it was observed that several monocyclic products were 
obtained in lower yields than their bicyclic analogs were.   
The observation that a subtle ring expansion had profound effects on the extent of β-
racemization  (entry 1 vs. 4) led us to attempt the construction of phenylglycine-derived 
enaminone 2.51 (entry 15).  We envisioned that this substrate would be particularly 
susceptible to β-amino elimination.  Expecting to see a distinct improvement in yield when 
formic acid was used instead of HCl, we were surprised that both deprotection methods were 
equally suited for this sensitive substrate.  By conducting this reaction in an NMR tube and 
carefully monitoring its progression, it became apparent that degradation (i.e. β-amino 
elimination) occurred upon the addition of methanolic K2CO3 and not during deprotection. 
The complete retention of stereochemistry suggests that this process was irreversible in 
contrast to cases where the extruded amine remains tethered to the resultant Michael acceptor 
(entries 1–12).  From these results we suggest alternative methods be used to access 
enaminones of this type.  Fortunately, this is well within the scope of both the Comins’  N-
acylpyridinium230-236 and the hetero Diels-Alder approach.237-249  
 In addition to introducing steric bulk, attenuating the nucleophilicity of the amine would 
seemingly impede an efficient ring-closure.  The synthesis of enaminone 2.56 demonstrates 
that despite the use of a significantly less reactive anilino nitrogen, cyclization still occurs 
(entry 22), albeit in lower yields.  
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2.3.2 Seven- and five-membered enaminones
With these favorable results for constructing 6-membered enaminones, we next explored 
the feasibility of constructing 5- and 7-membered rings.  This method lacks the strict confines 
of ring size for the alternative routes to cyclic enaminones.  Our initial attempts to cyclize α-
amino ynones to form 5-membered enaminones were unsuccessful.  This is consistent with 
our hypothesis that this reaction proceeds through an endo-trig mode of cyclization (5-endo-
trig is disfavored).  The synthesis of 5-membered enaminones remains a limitation of this 
methodology.  
Previously reported methods for the construction of cyclic enaminones have not been 
amenable to the synthesis of 7-membered rings either.  Furthermore, to our knowledge, there 
is no general method for their construction.  Without any alteration of our protocol, γ-amino 
ynones 2.57–2.2.60 rendered four novel 7-membered enaminones (entries 1–4, Table 2–5). 
Notably, pyrrolo[1,2-a]azepine 2.61 bears resemblance to the core and distinguishing feature 
of the well-studied Stemona alkaloids.284, 285 This unique molecule and its piperidino 
congener 2.62 were both attainable in good yields (entries 1 and 2).  Spirocyclic enaminone 
2.63 and baclofen-derived enaminone 2.64 were also readily obtained via our deprotection/
cyclization protocol (entries 3 and 4).  Although all of these enaminones were constructed in 
racemic form—hence, their stereochemical liabilities were not investigated—we have no 





2.3.3 Summary of reaction scope
In summary, we have developed two complementary protocols for synthesizing 6- and 7-
membered enaminones.  The first method, using HCl, is rapid and able to activate and 
deprotect internal and terminal ynones in under 15 minutes.  It is best suited for substrates 
without α-stereocenters or those that are not sensitive to acid-induced β-amino elimination. 
The second method, using formic acid and NaI, although requiring longer reaction times 
(6-24 h), is ideal for terminal ynones with sensitive α- and β-stereocenters.  Both procedures 
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Table 2–5.  Seven-membered enaminone preparation.








































a See Chapter 6 for the synthesis of ynones 2.57-2.60. b Method A: a) 4N HCl/dioxane, 15 
min. b) K2CO3, MeOH;  Method B: a) NaI (3 equiv), formic acid, 6-24 h. b) K2CO3, MeOH; 
c Isolated yield.
are operationally facile and can be carried out in a single vessel.  Furthermore, these 
experimentally simple and environmentally benign conditions are conducive to production of 
multi-gram quantities of these enaminone scaffolds.286      
2.4 Mechanistic insights
During early optimization studies, Turunen stumbled across two notable features of this 
reaction during optimization that lay the groundwork for our mechanistic studies.  Firstly, 
when the deprotection reaction did not result in vinyl halide intermediate, the yields were 
significantly lower.  Second, the desired enaminone could was not formed unless water or 
MeOH were used during the cyclization step.  
By isolating the pre-cyclized intermediates A and B (Fig. 2–6) and verifying a complete 
consumption of the ynone moiety, the first stipulation (i.e. the need for a halide source while 
deprotecting the Boc-group) became clear.  In sufficiently acidic conditions, halides add into 
the ynone group forming a vinyl halide that readily undergoes ring-closure to form the 
desired enaminone.  When the ynone remains intact, cyclization is not efficient and 
intermolecular processes (i.e. polymerization) predominate.  Therefore, pre-activation is 
required for a successful reaction. 
The discovery that the ynone group was transformed in the presence of halogenic acids 
demanded a reevaluation of our originally proposed 6-endo-dig mechanism.  With direct 
evidence for the formation of halides A and B, a direct 1,4-addition 6-endo-trig cyclization/
halide elimination would be one plausible mechanism (Fig. 2–6, Pathway A).  We were 
initially impressed, however, by the strong solvent dependence of this reaction.255  When the 
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reaction was carried out in bulky alcoholic (s-BuOH or i-PrOH) or non-nucleophilic solvents 
(CH2Cl2 or THF) the reaction was significantly impaired.  On the other hand, the use of water 
or MeOH was highly beneficial and independent of the mode of deprotection.  In the first 
disclosure of this reaction, a mechanism was proposed in which an oxygen nucleophile 
directly involved in bond-making and bond-breaking.255 Therein, it was suggested that an 
addition of MeOH into vinyl chloride C occurred.  Then, upon extrusion of the chloride ion 
the resultant oxonium intermediate E could undergo ring-closure in a 6-exo-trig fashion 
(Pathway B, Fig. 2–6). 














































In an attempt to gain mechanistic insight through detecting transient intermediates, 
Turunen dissolved the mixture of A and B in methanol-d4 and monitored the reaction mixture 
via 1H NMR after adding a solution of K2CO3 dropwise.  Dichloride B was first converted 
into vinyl chloride A and subsequent additions led to the formation of enaminone 2.34 with 
no other detectible intermediates.  When vinyl iodide analog of A, generated from NaI and 
formic acid, was subjected to these same conditions the product was also formed with no 
detectable intermediates.  
Although Pathway B provided a plausible explanation for the aforementioned solvent 
effects, dissimilarities in the solubilizing powers of each solvent would still need to be 
ascertained.  Impaired yields would be expected if the protonated amine intermediates (A and 
B) or the base (K2CO3) were poorly soluble.  Whether or not a nucleophilic solvent was 
necessary, however, was difficult to directly assess due the insolubility of the reaction 
constituents in most organic solvents.  To answer this question, we explored alternative 
organic bases that we expected would allow the reaction to be carried out in non-nucleophilic 
solvents.  Our first success demonstrated that triethylamine (TEA) could be used instead of 
K2CO3 (Scheme 2–13).  As hoped, this base was not only compatible with MeOH but could 
be used with non-nucleophilic solvents, such as MeCN and DMSO, resulting in the 
1. 4 N HCl/dioxane
2. Base: TEA











formation of enaminone 2.34.  Since these solvents are hygroscopic, adventitious water could 
potentially facilitate the cyclization in a catalytic manner.  To rule out this possibility, we 
constructed ynone 2.65 to determine the fate of the electrophile in the absence of a tethered 
nitrogen nucleophile (Scheme 2–14).  Following treatment with 4N HCl, which formed a 1:6 
mixture of ketones 2.66 and 2.67, the residue was dissolved in MeCN and TEA was added. 
The NMR spectrum revealed vinyl chloride 2.66 as the sole product.  Moreover, upon 
addition of excess D2O, vinyl chloride 2.66 remained intact.  Clearly, trace amounts of water 
were not facilitating the cyclization when the reaction was carried out in MeCN.
Delving further we examined the reactivity of intermediates 2.66 and 2.67 in the presence 
of methanolic K2CO3.  If MeOH facilitated the cyclization through a conjugate addition it 
would be expected that the isolated vinyl halide 2.66 would be consumed more rapidly than 
the vinyl chloride A (Fig. 2–6) could form the enaminone.  In other words, if the rate of 





















33% conversion after 2 h
2.68:2.66 = 1:2
Scheme 2–14.  Reactivity of ynone in the absence of an amine.
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obviate the latter.  To test this, a mixture of intermediates 2.66 and 2.67 were reacted in 
MeOH and K2CO3 (Scheme 2–14).  After 2 hours the composition of the crude reaction 
mixture consisted of a 1:2 mixture of vinyl ether 2.68 and unreacted vinyl chloride 2.66 (33% 
conversion).  Thus, the addition of MeOH to the vinyl chloride is much slower than the 
cyclization process which occurs in less than 5 minutes.  From this data, it is reasonable to 
suggest that the addition of MeOH into a vinyl chloride should not be invoked in the reaction 
mechanism.  Thus, we suggest that these results are strong evidence for a direct 6-endo-trig 
mode of cyclization (Pathway A, Fig. 2–6).
 
2.5  Summary
We have developed a practical route to non-racemic 6- and 7-membered enaminones 
starting from amino acids, providing a complementary approach to preexisting methods. 
Using this approach, asymmetry can be derived from the rich supply of commercially 
available amino acids.  Moreover, access is gained to enaminones that are substituted at four 
positions, two of which are stereogenic centers. 
The key reaction and final step in this sequence is a novel one-flask deprotection/
cyclization reaction of Boc-aminoynones.  Two methods were developed to achieve the Boc-
deprotection that are suitable for different substrates.  The use of 4N HCl in dioxane is most 
fitting for internal ynones or those without sensitivity to acid-mediated side-reactions. 
Alternatively, for those substrates that have enolizable stereocenters or are susceptible to 
acid-promoted β-amino elimination (i.e. retro-Michael) processes, NaI and formic acid are 
well-suited.  The latter conditions provide a mild alternative and work best for terminal 
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ynones.  Both protocols are economic and operationally facile, having no need for dry 
solvents/reagents and can be conducted at room temperature.  Furthermore, both methods can 
be carried out on multi-gram scale with comparable yields.  
The substrate scope of this reaction was also assessed.  It appears that this reaction is 
general for the construction of 6- and 7-membered enaminones. When the deprotection 
conditions are judiciously chosen, monocyclic and bicyclic heterocycles can be obtained 
from amino-ynones in high enantiomeric or diastereomeric purity.  Many of the heterocyclic 
scaffolds reported here, though structurally simple, are unprecedented in the literature.  
The mechanism of the final cyclization sequence has also been investigated.  The success 
of this reaction relies on the conversion of the ynone moiety into a vinyl halide species and 
trapping of the protected amine as an ammonium salt following Boc-degredation.  This pre-
activation, allows for an efficient intramolecular 1,4-addition once the free amine is released 
upon the addition of base.  Thus, this reaction is thought to proceed through a 6-endo-trig 
ring-closing process.  We believe that the asymmetric scaffolds constructed herein will be of 
great synthetic value for library development and complex molecule synthesis.  Specifically, 
the synthesis of the phenanthropiperidines will be expedited by this direct route.  This will be 




PALLADIUM(II)-CATALYZED CROSS-COUPLING OF CYCLIC ENAMINONES AND 
ORGANOTRIFLUOROBORATES
3.1 Introduction
To expand our method for constructing enantiomerically pure enaminones, we began to 
investigate practical methods for elaborating this scaffold.  Our goal was to install aryl 
groups at the C3-position, which we envisioned to be an essential transformation en route to 
the phenanthrene system of the phenanthropiperidine alkaloids.  Importantly, this approach, if 
successful, would be applicable to a broad range of useful 3-arylpiperidine scaffolds besides 
the phenanthropiperidines.  Indeed, many compounds which feature this scaffold are known 
to have high affinity for an array of validated targets (Fig. 3–1).198, 287
 




















Palladium-catalyzed carbon-carbon (C–C) bond formation has been widely used in 
organic synthesis for arylation reactions, and, therefore, it was an obvious choice for this 
transformation.  Arylation of the C3-position has been accomplished via a two-step sequence 
involving halogenation and subsequent coupling using a Pd(0)-catalyst, but we realized a 
more direct arylation protocol that allowed us to avoid preactivation of the enaminone was 
possible.  Herein, we describe our efforts to circumvent the halogenation by taking advantage 
of the inherent nucleophilicity of the enaminone, which led us to the discovery of a Pd(II)-
catalyzed C–H arylation reaction using trifluoroborates. 
3.2  Background to Pd-catalyzed cross-coupling
Palladium-catalyzed cross-coupling reactions have emerged as an incredibly versatile 
method for constructing C–C and carbon-heteroatom (C–X) bonds. Applications of cross-
coupling in complex natural product syntheses and commercial scale production have 
demonstrated the utility of this methodology (Fig. 3–2).288, 289 Materials as far reaching as 
electron conductive polymers and liquid crystals have relied on cross-couplings for their 
preparation.289 Moreover, the routes to numerous drugs, including Eniluracil, Losartan and 
Rofecoxib, have these coupling reactions as key steps.288
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Following the initial reports of cross-coupling reactions by Kumada and Curriu in the 
1970s, the number of publications related to this field have grown dramatically.289 The 
versatility of these methodologies can be attributed to the tremendous amount of work done 
to expand the scope of palladium catalysts and coupling partners.  The mechanism of the 
reaction has received much attention and, although the details may be uncertain, is thought to 
proceed through three general steps (Fig. 3–3): 
 1.  Oxidative addition of an organic electrophile (R–X) into Pd(0)  
 2.  Transmetallation between Pd(II) and an organometallic nucleophile (MR’) 
 3.  Reductive elimination to regenerate Pd(0) and form the C–C σ-bond
Highlighted bonds were formed using a Pd-catalyzed coupling reaction.


















































Cross-coupling reactions that share this mechanism have been categorized based on the 
nature of the organometallic nucleophile (M–R’).  Among these are the Suzuki-Miyaura 
(boron-mediated), Migita-Kosugi-Stille (Sn-mediated), Hiyama (Si-mediated), Negishi (Zn-
mediated), Kumada (Mg-mediated) and Sonogashira (Cu-mediated) reactions.  Each of the 
organometallic species involved in these reactions exhibit unique reactivity and 
chemoselectivity profiles allowing reactions to proceed in a broad range of environments—
pH and temperature, for example.  The Heck-Mizokori reaction is mechanistically distinct 
from the other cross-coupling reactions and proceeds via carbometallation and subsequent β-
hydride elimination, thus, avoiding transmetallation (Scheme 3–4).  










R = sp3, sp2 or sp
X = I, Br, Cl, OTf, etc.
M = B (Suzuki-Miyaura) 
       Sn (Migita-Kosugi-Stille)
       Si (Hiyama)
       Zn (Negishi)
       Mg (Kumada-Curriu)
RX = 






In the past decade, advancements in Pd-catalyzed cross-coupling have focused on 
expanding the substrate scope of these traditional methods and developing mechanistically 
distinct coupling reactions.  Through the fine-tuning of ligands, coupling partners, transition 
metals and additive mixtures, some of the typical constraints seen in cross-coupling reactions 
have been surmounted.  The use of well-chosen catalysts and substrates has even allowed the 
carbon-hydrogen (C–H) bond to substitute as a reactive electrophile or nucleophile in C–C 
and C–X bond formations.  
3.3  Synthetic strategy 
With such extensive precedent for C–C bond formation using palladium, we laid out our 
plans to elaborate the enaminone scaffolds discussed in Chapter 2.  The Suzuki-Miyaura 
reaction, which uses organoboron reagents, was chosen to install the aryl moiety based on its 




















well-known versatility.  Boronic acids and esters, the most commonly used coupling partners 
in this reaction, are significantly more stable than their Mg, Zn or Cu counterparts, yet they 
are sufficiently reactive under mild conditions.  Furthermore, these reagents are non-toxic—a 
limitation for organostannanes—and hundreds, if not thousands, are commercially available
—a practical bonus not shared with organosilanes.  The latter advantage was particularly 
attractive because of our desire to access phenanthrene substituents other than the overly-
exploited hydroxy or alkoxy groups. 
To prepare the natural products, we planned to pre-activate the amino acid-derived 
enaminone (A) for the Suzuki protocol via halogenation (Scheme 3–1).  This would allow a 
subsequent installation of the arene (Ar1) using an appropriately substituted arylboronic acid 
(B→C).  The final three steps of the synthesis could be completed in a manner that is not 
completely foreign to the synthesis of these natural products.140, 141 From aryl enaminone C, 

















































Scheme 3–1. Synthetic strategy for preparation of phenanthropiperidines.
amino





time pre-activation would generate a triflate (D), which we envisioned happening through a 
1,4-reduction and enolate trapping.  Triflate D could then react in a cross-coupling reaction to 
provide seco-analog E.  Following the second arylation, the sequence could be completed 
with an oxidative biaryl coupling reaction furnishing the desired phenanthropiperidine.  
The proposed sequence has some distinct advantages over previous syntheses.  First, the 
phenanthropiperidines are constructed from three simple building blocks—an amino acid and 
two boronic acids—that constitute the three extremities of the natural product.  These 
building blocks could be easily interchanged with others from a massive collection of 
commercially available precursors, giving access to novel permutations of the natural 
products.  As a corollary of this, since the piperidine system (ring D) is derived from amino 
acids, many of which are available in enantiomerically pure form, asymmetric syntheses will 
be less daunting.  Finally, using various amino acids, unnatural ring E analogs could be 
prepared and used to probe SARs in this largely unexplored position.   
3.4  Activation and classical Suzuki approach 
In Chapter 2, the reactivity of the enaminone was discussed.  From this it is clear why the 
C3-position is particularly susceptible to electrophilic halogenation.  The nitrogen’s 
nonbonding electrons are conjugated with the π-system explaining this position’s enhanced 
nucleophilicity.  Furthermore, the α, β-unsaturated ketone amplifies the selectivity of this 
transformation by deactivating the C2-position.  Indeed, halogenation of α, β-unsaturated 
ketones without appended heteroatoms occurs almost exclusively at the α-position.  
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Using enaminone 2.37 as a model substrate, we explored this promising mode of pre-
activation.  Treatment of the bicyclic system with iodine in the presence of DMAP furnished 
iodoenaminone 3.1 in near quantitive yield (Scheme 3–2).  Bromination was also possible 
using Br2 and TEA, but given that C–I bonds are more susceptible to oxidative insertion than 
are C–Br bonds, iodoenaminone 3.1 was used for the cross-coupling.  
Previous work in our laboratory had demonstrated that the Suzuki-Miyaura reaction is 
one possible method for installing the C3-aryl moiety.213 Under optimized conditions using 
Pd(PPh3)4 as a catalyst, the coupling proceeds in 14 h at 100 ºC (entry 1, Table 3–1). 
Although microwave irradiation could be used to remedy the long reaction times without 
reduction (or increase) in yield, this demanded a further increase in temperature (entry 2). 
Observing a considerable amount of degradation under both conditions, we thought it would 
be profitable to pursue mild alternatives.  The necessity of such high temperatures and long 
reaction times in spite of our use of an iodide electrophile—the most reactive of the halides
—is explicable.  Oxidative insertion, which is typically the rate-determining step of the 
Suzuki-Miyaura reaction, proceeds best when the organic electrophile (halide or 
pseudohalide) is electron-deficient.  Since the iodide is located at the most electron-rich 











Scheme 3–2.  Iodination of enaminone in preparation for Suzuki reaction. 
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character of C3 is a two-edged sword; it accommodates pre-activation but hinders cross-
coupling.  
Besides increasing the reaction temperature, oxidative insertion may also be promoted 
through the use of Pd-catalysts with higher reductive potentials.  This can be achieved 
through the use of electron-rich ligands.  In this regard, we attempted to compensate for the 
enaminone’s low reactivity by using the highly-nucleophilic S-Phos ligand.290 We chose to 
use conditions which had been successful in the coupling of aryl chlorides—generally 
unreactive substrates.291 Using the prescribed organotrifluoroborate coupling partner, we 
were pleased to discover this reaction proceeded at 50 ºC in 5 h (entry 3).  Unfortunately, the 
yield was not improved over the previous conditions despite using lower temperatures. 
Moreover, attempts at improving the yield through additive modifications were unsuccessful. 
Although the best conditions would probably suffice for our purposes, a reconsideration of 
the enaminone’s innate nucleophilicity led us to pursue a more direct approach through C–H 
entry Z conditions time yield (%)a
1b -B(OH)2 Pd(PPh3)4, Ba(OH)2, dioxane/H2O, 100 ºC 14 h 70
2b -B(OH)2 Pd(PPh3)4, Ba(OH)2, dioxane/H2O, 150 ºC, µW 15 min 70













Table 3–1. Suzuki cross-coupling conditions of iodoenaminone. 
3.1 3.2
a  Isolated yield.  b Reaction conditions: iodoenaminone (0.1 M), Pd(PPh3)4 (20 mol%), 
boronic acid (1.7 equiv), Ba(OH)2 (2.0 equiv). c Conditions: iodoenaminone (0.07 M), 
Pd(OAc)2 (1.0 mol%),  S-Phos (2.0 mol%), trifluoroborate (1.4 equiv), K2CO3 (3.0 equiv).
 
152
functionalization.  A word about this nascent field will explain our rational for using 
enaminones as C–H donors.                                
3.5  C–H Functionalization
The direct conversion of C–H to C–C bonds is one of the final frontiers of organic 
synthesis.  Recent developments in this field have allowed concise and economical routes to 
valuable materials and synthetic intermediates.292-296 The use of stoichiometric transition 
metal complexes to carry out C–H bond functionalization is well-precedented.  However, it 
was not until the early 1990s that catalytic systems were first reported.  Ruthenium-, 
rhodium- and iridium-based catalyst systems are prevalent in scientific literature for 
activation of C–H bonds—that is, processes that involve oxidative insertion into a C–H bond. 
Palladium, on the other hand, has proven to be quite effective for processes involving 
electrophilic palladation and ultimately C–H functionalization.            
Despite early examples of C–H functionalization, this field remains largely unexplored 
due to four major challenges.297 First, the typical C–H bond, sometimes referred to as the 
“un-functional group”,298 is relatively unreactive.  Secondly, over-functionalization 
(chemoselectivity) is often a favorable side-reaction.  Third, the ubiquity of C–H bonds has 
made regioselectivity a significant challenge as organic molecules typically contain many C–
H motifs that are difficult to differentiate.  Finally, the functionalization of sp3 carbons allows 
for the prospect, and hence the challenge, of generating stereogenic centers with high 
stereoselectivity.
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From a mechanistic standpoint, the essential feature of Pd-catalyzed C–H 
functionalization reactions is the generation of a C–Pd bond from a C–H bond.  Once this 
occurs, the fate of the palladium complex parallels that of the classical Pd-catalyzed cross-
coupling reactions, and the desired C–C bond is ultimately formed upon reductive 
elimination (Fig. 3–5) or β-hydride elimination (not shown).  The point in the catalytic cycle 
at which the coupling partner is introduced varies and is dependent on the substrate’s 
reactivity towards the Pd-catalyst.  Coupling partners, such as aryl halides, will undergo 
oxidative insertion in the presence of Pd(0) prior to palladation of the C–H donor (Fig. 3–5, 
Pathway A).  Alternatively, if an organic nucleophile, such as a boronic acid, is used, 
transmetallation may occur before (Pathway B) or after (Pathway C) palladation.  A key 
distinction between these catalytic cycles is that Pathway A begins with a Pd(0)-catalyst 
whereas Pathways B and C begin with a Pd(II)-catalyst.  The significance of this lies in the 
fact that Pd(0) is generated upon reductive elimination—the final step for all pathways—
allowing catalytic turnover for only one (Pathway A).  Unless an oxidant is present for 
(OI = oxidative insertion; PA = palladation; RE = reductive elimination; TM = transmetallation) 































processes initiated with Pd(II)-mediated palladation or transmetallation (Pathway B and C), 
the catalytic cycle will not be reiterated.  Fortunately, this can be accommodated for by 
adding an external oxidant which oxidizes Pd(0) into the active Pd(II)-catalyst.
 
Their are two main strategies that have been used to selectively functionalize C–H bonds 
in Pd-catalyzed cross-couplings.  The first strategy is to exploit Lewis basic directing groups 
to guide palladation.  By taking advantage of chelating functionalities, such as acetamides, 
carboxylates and pyridines, the electrophilic catalyst is guided into close proximity of the C–
H bond.  There are several plausible mechanisms that can be proposed for palladation, but the 
exact pathway is highly dependent on the substrate, catalyst, solvent and other additives.299 
The most common and relevant for our purposes is electrophilic substitution (Fig. 3–6).  In 
this process, the electrophilic Pd(II)-complex, which is coordinated to the directing group, 
reacts with the π-electrons from an appropriately situated olefin resulting in a cationic 
intermediate.  The positive charge is then quenched upon loss of a proton which marks the 
cleavage of the key C–H bond.  When the olefin is embedded within an aromatic system, 
besides quenching the positive charge, the C–H bond scission is also driven by 
rearomatization.  Once palladation has occurred the palladacycle can be intercepted with a 
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variety of coupling partners.  This is better demonstrated using case studies.  Pathway A 
(Scheme 3–3) is illustrated well in a reaction reported by Daugulis and Zaitsev.300  Here, aryl 
iodides are coupled with anilides in excellent yields.  In this reaction the σ-bonded aryl-
Pd(II) complex that is formed from oxidative insertion of the active Pd(0)-catalyst into the 
C–I bond is directed by the acetamide group for palladation.  Product formation results from 
a reductive elimination of the resultant palladacycle.  In this example, the ortho methyl group 
prevents this process from recurring on the opposite side.
Pathway B is exemplified in a reaction reported by Shi et al., in which, like before, 
acetamides are used as directing groups (Scheme 3–3).301 Unlike before, since the catalytic 
cycle begins with Pd(II), this reaction required the use of Cu(OTf)2 and Ag2O as oxidants to 


































The second strategy for attaining C–H selectivity is to use the innate reactivity, 
particularly π-nucleophilicity, of that carbon.302  If the C–H bond in question is acidic, basic 
conditions can be used to assist cleavage.299 There are many substrates, however, that are not 
acidic and still exhibit sufficient reactivity towards electrophilic palladation.  Electron-rich 
aromatic systems such as phenols, indoles and pyrroles are the commonly used in this type of 
cross-coupling.299, 302, 303 Although a directing group is not present, association of the Pd-
catalyst and substrate is assisted by the π-nucleophilicity of the active double bond.  The 
mechanism is essentially identical to the previously described directing group-assisted 
palladation.  Following η2-coordination of the catalyst, substrate palladation occurs to furnish 
a stabilized cation which is subsequently quenched upon deprotonation (Fig. 3–7).  As 
before, the cleavage of the C–H bond is driven by rearomatization.  






This approach has been applied in numerous settings.299, 302, 303  Ackermann and Barfüsser 
have used this strategy in a direct C3-coupling of indoles and aryl bromides (Scheme 3–4). 
In contrast,  Yang et al. reported a C2-selective cross-coupling of indole C–H donors and 
boronic acids.304  These two examples represent Pathway A and C (Fig. 3–5), respectively. 
However, it should not be concluded from this that the regioselectivity of indole arylation is 
determined by these particular mechanistic pathways.  Both C2- and C3-arylations of indoles 
have been reported for Pd-mediated C–H functionalization reactions.305 Sames and 
coworkers give compelling evidence that the regioselectivity of this reaction is dependent on 
the ease of Pd-migration for specific reaction intermediates (Fig. 3–8).306 It was proposed that 
palladation occurs exclusively at the C3-position generating an iminium which can rearrange 
to stabilize the Pd–C bond through the adjoining nitrogen.  The rate of migration, which is 
influenced by the size of N-substituent and Pd-ligands, determines the regioselectivity of the 
reaction.  In other words, rearomatization precludes Pd-migration and secures the position of 
C–C bond formation. 























                                           
The latter of these two strategies (i.e. taking advantage of π-nucleophilicity) inspired us 
to investigate enaminones in Pd-catalyzed C–H functionalization reactions.  Like indoles and 
pyrroles, the enaminone is endowed with an enamine system which is exceptionally 
nucleophilic.  The major difference between the two substrates is that the enamine in 
enaminones are embedded within an aromatic systems; hence, C–H bond cleavage would not 
be driven by rearomatization.  Instead, deprotonation would be favored by the acidity of the 
C3-proton which is flanked by two electron-withdrawing functionalities: a ketone and the 
transient iminium group (Fig. 3–9).  Given the switchable regioselectivity in indole systems, 
we considered the possibility of a similar C3/C2 palladium migration in the enaminone.  We 
reasoned that this would not be likely based on the instability of the resultant carbocation 





























(being adjacent to a ketone) and the rate of the highly-favored deprotonation that would 
compete with the migration.
The success of this approach would ultimately depend on the innate nucleophilic 
character of the enaminone to give access to the same putative transition-metal species as in 
the two-step process, only in a catalytic and one-step fashion.  If this key intermediate was 
generated in situ, it could presumably be intercepted with a suitable coupling partner.  Thus, 
this strategy uses what was once a liability, namely the nucelophilicity of the enaminone, as 
an asset, allowing us to circumvent pre-activation of the enaminone.   


























3.6  Reaction optimization 
3.6.1 Reoxidant screen
Our first goal was to establish the feasibility of this reaction.  The first conditions we 
investigated were inspired by a Pd(II)-catalyzed alkenylation reaction reported by Garg, 
Caspi and Stoltz.307 Since our aim was to install arenes instead of olefins like the Stoltz 
group, we needed a suitable aryl coupling partner.  One concern was that the use of an acidic 
cosolvent, thought to promote palladation by increasing the electrophilicity of the Pd(II) 
center,308 would limit the potential of basic or nucleophile-promoted organometallic coupling 
partners (i.e. organozinc reagents, boronates, silanes…etc).  With previous success using 
organotrifluoroborates—Molander et al. have found to these to be robust equivalents of 
organoboronic acids309—we chose to employ these for our investigations. 
Initial attempts to couple enaminone 2.55 and trifluoroborate 3.3 using stoichiometric 
Pd(OAc)2 were surprisingly successful (Scheme 3–5).  With good reason to move forward we 



















reaction would proceed through either Pathway B or C (Fig. 3–5), we investigated reoxidants 
to achieve catalytic turnover.  Copper reagents have had longstanding use as palladium 
oxidants, and so we investigated several Cu(II) reagents for such a purpose (entries 1–3, 
Table 3–2).  Each copper reoxidant proved to be effective in driving the reaction to 
completion using catalytic quantities of Pd(OAc)2.  Over two equivalents of each reagent 
were used since palladium undergoes a two-electron oxidation (Pd0 → PdII) and copper, a 
single-electron reduction (CuII → CuI).  
One strategy that has been used to avoid using such high amounts of copper is to carryout 
the reaction in an oxygen atmosphere.  Copper reagents such as Cu(OAc)2 are known to 
undergo aerobic oxidation more readily their palladium counterparts and have been exploited 
in reactions requiring palladium oxidation.  In fact, the aerobic oxidation of CuCl to CuCl2 is 
among the fastest inorganic reactions—a boon for the development of industrial-scale 
Wacker processes.310 Thus, catalytic quantities of the copper reoxidant can be used, because 
a Reaction conditions unless otherwise specified: enaminone 2.55 (0.1 
M), trifluoroborate 3.3 (2-3 equiv), Pd(OAc)2 (0.3 equiv), oxidant, 
K2CO3 (3 equiv) at 60 °C. b Isolated yield of enaminone 3.4.  
entrya oxidant (equiv) yield (%)b
1 CuCl2 (3.0) 66
2 Cu(OTFA)2 (3.0) 82
3 Cu(OAc)2 (3.0) 82
4 Cu(OAc)2 (1.0) / O2 (1 atm) 40
5 BQ (1.0) 14
6 duroquinone (1.0) 75














the active Cu(II) species is regenerated when it reacts with oxygen.  Applying this strategy, 
the reaction was conducted in the presence of oxygen and substoichiometric quantities of 
Cu(OAc)2 (entry 4).  Unfortunately, the reaction yield was significantly lower than when 3 
equivalents of copper were used.
Benzoquinone (BQ) is another widely used palladium oxidant302 but was deleterious in 
this reaction (entry 5).  Unlike when catalytic amounts of Cu(OAc)2 was used, this reaction 
did not simply stop progressing, rather, the starting material was shunted to an undesired 
byproduct (BQ-adduct C).  Under the supposition that enaminone palladation precedes 
transmetallation, this unexpected product could conceivably arise from enaminone-Pd(II) 
complex A following the carbometallation and β-hydride elimination of BQ (Scheme 3–6). 
 
To prevent this side-reaction, we used duroquinone (entry 6)—a BQ analog with four 
methyl groups blocking the equivalent reactive positions.  This reoxidant provided 
significantly higher yields than BQ but was not as effective as Cu(OAc)2 or Cu(OTFA)2 . 
Although Cu(OAc)2 and Cu(OTFA)2 were comparable as reoxidants, we chose to proceed 
with the more economic of the two: Cu(OAc)2.                  






















A greater concern about the fate of the reoxidant arose when we discovered a significant 
amount of biphenyl 3.5 was being generated (Fig 3–10).  This was accounted for by 
considering the potential for homocoupling within our proposed mechanistic model (Fig. 3–
11).  The catalytic cycle deserves further attention at this point.
The mechanism for the palladation of enaminones presumably resembles that of indoles.
296 It is likely initiated by an electrophilic attack of palladium on the enaminone as already 
OMeMeO































Ar  = 4-methoxyphenyl
transmetallation palladationpalladation transmetallation
Fig. 3–11. Proposed catalytic cycle for direct-arylation of enaminones.
3.4 





discussed.  In the presence of an appropriate organometallic substrate, transmetallation and 
reductive elimination would provide the desired coupled product.  Alternatively, 
transmetallation could precede enaminone palladation providing an intermediate that would 
either undergo palladation or another transmetallation.  If the latter occurs, reductive 
elimination would yield homocoupled byproduct 3.5.  The upshot of this side-reaction is that 
both the reoxidant and aryl coupling partner are irreversibly consumed without contributing 
to product formation.  By isolating significant amounts of the homocoupled product,  we 
realized that this process was competing with enaminone palladation and that, if not abated in 
the future, excess reagents—as we have been using—would continue to be necessary to drive 
the reaction to completion.  With that in mind, keeping the amounts of reoxidant and 
coupling partner constant, we sought out conditions that would improve yields and would not 
leave unreacted starting material. 
  
3.6.2 Palladium-catalyst screen
 First investigating palladium sources, we confirmed that palladium was indeed necessary 
and that the reaction was not mediated by the copper reagent or trace impurities therein 
(entry 1, Table 3–3).  Pd(OAc)2 (entry 2) was found to be superior to PdCl2 and Pd(CF3CO2)2 
(entries 3 and 4).  It should be noted here that the use of 0.3 equivalents of the catalyst was 
most effective for complete conversion in this reaction.  Considering the limited stability of 
our enaminone substrate, the higher Pd(II)-catalyst loading allowed us to avoid long reaction 
times and high temperatures which were otherwise required to drive the reaction to 
completion.  Another reason for using high-catalyst loading was because of an apparent 
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inhibition of the Pd-catalyst.  This was confirmed by experiments showing that spiking the 
reaction mixture with additional palladium, but not with other reagents, could drive arrested 
reactions to completion.
3.6.3 Solvent screen
Although a number of solvents were also investigated, we found that the original solvent 
mixture gave the best results (Table 3–4, entry 1).  Each of the three components were 
important in this reaction; any one of them in isolation significantly reduced yields (entries 
2–5).  The presence of DMSO was beneficial and may help to solubilize or stabilize the 
palladium or copper complexes, but the exact role is unknown (entry 2). The use of AcOH as 
a solvent enhanced the rate of the reaction and drove it to completion, but the enaminone 
underwent substantial degradation when it was used as the sole solvent, and less than 10% of 
the product was isolated (entry 3).  The role of the t-BuOH is not entirely clear either; 
however, we were aware that non-tertiary alcohols were prone to Pd-mediated oxidation 
a Reaction conditions unless otherwise specified: 
enaminone 2.55 (0.1 M), trifluoroborate 3.3 (2-3 equiv), 
Pd source (0.3 equiv), Cu(OAc)2 (3 equiv), K2CO3 (3.0 
equiv) at 60 °C. b Isolated yield of enaminone 3.4. 





Table 3–3. Screen of palladium catalysts.
 
166
which would result in a rapid depletion of the reoxidant.311 Nevertheless, t-BuOH was not an 
effective solvent when used by itself.  Realizing that the reaction was extremely slow in the 
absence of AcOH, we attempted to increase the rate of reaction by raising the reaction 
temperature. Using several higher-boiling solvents (entries 5–7), we carried out the reaction 
under acid-free conditions and found that product formation was severely impaired.  
   
3.6.4 Additive screen
Our final effort to improve the yield of this reaction was to investigate the role of 
additives (Table 3–5).  Throughout our optimization studies we had chosen to use K2CO3, but 
we were still uncertain of its necessity.  It soon became clear that K2CO3 was important 
simply by observing that its absence decreased the reaction yield by almost 20% (entry 2).  It 
is extremely difficult to decipher the role of inorganic additives in complex mixtures, but we 
posit that the beneficial effects of K2CO3 were distinct from its basic properties.  This 
entrya solvent temperature (ºC) yield (%)b
1 t-BuOH/AcOH/DMSO 60 82
2 t-BuOH/AcOH 60 < 50
3 AcOH 50 < 10
4 t-BuOH 50 < 10
5 DMSO 100 3
6 DMF 100 6
7 PhMe 120 10
Table 3–4. Screen of solvents.
a Reaction conditions unless otherwise specified: enaminone 2.55 (0.1 M), 
trifluoroborate 3.3 (2-3 equiv), Pd(OAc)2 (0.3 equiv), Cu(OAc)2 (3.0 equiv), K2CO3 
(3 equiv) at 60 °C.   b Isolated yield of enaminone 3.4. 
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conclusion was borne out of the realization that K2CO3 would decompose in the presence of 
AcOH, which is in large excess, to generate KOAc, CO2 and H2O.  Indeed, upon the addition 
of the solvent mixture to the solid reagents, we observed bubbling as evidence of CO2 
production.  We reasoned from this that the reaction was aided by acetate or potassium ions 
or both.  With this in mind, we replaced K2CO3 with KOAc and found a slight improvement 
(entry 4).  On the other hand, when NaOAc was used instead of K2CO3, we observed a 
marked reduction in yield (entry 3).  One possible explanation of this is simply that the 
potassium salt is more soluble than its sodium congener.  However the additives work, 
potassium salts are evidently beneficial.
 
Table 3–5. Screen of additives.
entrya additive A (equiv) additive B (equiv) temperature (ºC) yield (%)b
1 K2CO3  (3.0) – 60 82
2 None – 60 63c
3 NaOAc (3.0) – 60 54
4 KOAc (3.0) – 60 87
5 CF3CO2K (0.2) – 30 54
6 CF3CO2K (1.0) – 60 49
7 CF3CO2K (3.0) – 60 70
8 CF3CO2Ag (3.0) – 60 41
9 K2CO3  (1.0) CF3CO2K (1.0) 50 69
10 K2CO3  (2.0) CF3CO2K (1.0) 50 77
11 K2CO3  (3.0) CF3CO2K (0.5) 50 70
12 K2CO3  (1.0) CF3CO2K (0.2) 50 71
13 K2CO3  (2.0) – 60 93
a Reaction conditions unless otherwise specified: enaminone 2.55 (0.1 M), trifluoroborate 
3.3 (2-3 equiv), Pd(OAc)2 (0.3 equiv), Cu(OAc)2 (3.0 equiv), additives A and B (0.2-3 
equiv) at 30-60 °C. b Isolated yield of enaminone 3.4. 
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 As stated before, we observed that acids enhanced the rate of reaction.  This phenomenon 
reflects the dependence of this reaction on an electrophilic palladation process.  The acid 
presumably enhances the electrophilicity of the palladium complex by assisting anionic 
ligand dissociation.308 Another way to enhance the electrophilicity of the Pd-complex is to 
use ligands that are stable anions, also assisting ligand dissociation.  Thus, we investigated 
the effect of trifluoroacetate salts on the rate and yield of reaction (entries 5–8).  Given the 
apparent benefit of potassium salts, we used potassium trifluoroacetate (CF3CO2K). 
Although the yield was not improved, the reaction time was decreased from 8 to 2 h. 
Quantities as low as 0.2 equivalents conferred complete conversion in less than 3 h at 30 ºC 
(entry 5).  Silver(I) trifluoroacetate (CF3CO2Ag) did not improve yields at all (entry 8).  The 
lower yields are attributed to the production of multiple side-products since all of the starting 
material had reacted, but the side-products could be identified.  Attempting to maintain the 
short reaction times but mitigate the side-reactions, we used K2CO3 in conjunction with 
CF3CO2K (entries 9–12).  Even though the reaction times were improved, the yields did not 
match those in the absence of CF3CO2K.  Settling on K2CO3 as the only additive to be used, 
we took one last measure to improve the reaction, relying on the notion that lowering the 
concentration of the trifluoroborate at any given moment would suppress homocoupling.  To 
do this, the coupling partner was added incrementally over the reaction time.  Seeing that this 
provided the highest yields yet (entry 13), we used these conditions to probe the scope of this 
reaction by using a diverse set of enaminones and coupling partners.
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3.7  Scope of trifluoroborates
With optimized conditions in hand, we first explored coupling partners with a variety of 
electronic and steric properties.  Electron-rich trifluoroborates underwent rapid (2-6 h) and 
high-yielding cross-coupling.  On the other hand, electron-deficient and sterically-
encumbered trifluoroborates (entries 3 and 4, Table 3–6,) required longer reaction times (24 
h) and proceeded in relatively low yields.  This trend should not be taken too strictly given 
several unpredictable results we obtained.  For instance, it was unexpected that the 2-
naphthyl (entry 9) and 3-hydroxyl (entry 11) systems reacted with such high yields. 
Interestingly, the 3-hydroxyphenyl boronic acid was poorly tolerated in our former Pd(0)-
catalyzed approach, which demonstrates that this reaction is not merely a shorter method to 
arylate enaminones, but that it has a unique and complimentary scope as well.213
Although electronic considerations are not acutely predictive, the generalization that 
electron-rich, unhindered trifluoroborates react more rapidly and in higher yields than their 
electron-poor or hindered counterparts is completely consistent with our findings and sheds 
new light on the reaction’s mechanism.  Both electron-deficient and sterically-hindered 
coupling partners are less prone to transmetallation.  That these properties are sufficient to 
alter the rate of reaction suggests that transmetallation is—at least in certain circumstances—
the rate-determining step.  This conclusion does not dismiss the importance of palladation but 
introduces a competing process that must be considered.
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Besides giving valuable information about sterics and electronics, this sample set 
provides a cursory look into functional group compatibility.  The phenol moiety is clearly 
stable under these conditions (entry 11) and the protected aniline group is also well-tolerated 
(entry 12).  More significantly, the scope of this chemistry extends to aryl halides (entry 7 
and 8) which react exclusively at the carbon-boron bond.  The stability of these 
entrya Ar (product) yield (%)b entrya Ar (product) yield (%)b
1 3.6 72 7 Br 3.12 73
2 Me 3.7 86 8 Cl 3.13 71
3
Me
3.8 40 9 3.14 96
4
MeO










3.11 42 12 NHCbz 3.17 80
a Reaction conditions: enaminone 2.55 (0.1 M), R-BF3K (2-3 equiv), Pd(OAc)2 (0.3 equiv), 
Cu(OAc)2 (3 equiv), K2CO3 (2 equiv) in t-BuOH/AcOH/DMSO (20:5:1) at 60 °C. 
b Isolated yield. 
Table 3–6.  Successfully coupled aryltrifluoroborates.
t-BuOH/AcOH/DMSO
Pd(OAc)2 (0.3 equiv) 
Cu(OAc)2 (3 equiv)
K2CO3 (2 equiv)










functionalities (i.e. sp2 halides) under the prescribed conditions reveal the complementarity 
of this protocol with the classical Suzuki-Miyaura reaction.  As discussed already, the classic 
Suzuki-Miyaura protocol is initiated by a Pd(0)-mediated oxidative insertion process of the 
organohalide substrate.  In the presence of Pd(0), aryl halides would normally react, but 
apparently,  Pd(0), which does not contribute to product formation in this reaction, is 
oxidized before it can react with the carbon-halide bond. 
 
entrya R entrya R entrya R














Table 3–7.  Aryltrifluoroborates that did not couple.   
t-BuOH/AcOH/DMSO
Pd(OAc)2 (0.3 equiv) 
Cu(OAc)2 (3 equiv)
K2CO3 (2 equiv)








a Reaction conditions: enaminone 2.55 (0.1 M), R-BF3K (2-3 equiv), Pd(OAc)2 (0.3 equiv), 





The limitations of this reaction were quite clear when we began to investigate more 
challenging coupling partners (Table 3–7).  Fourteen of these organotrifluoroborates were 
intractable (i.e. no coupled product was observed after 24 h).  Knowing that steric congestion 
can hinder efficient coupling, it was not surprising that 2,6-dimethoxyphenyltrifluoroborate 
was unable to be coupled (entry 1).  Attempts to install the benzamide moiety were also 
unsuccessful (entry 2).  Interestingly, the reaction color change (from blue/green to black) 
that normally coincides with cross- or homo-coupling was not observed.  Although one might 
suggest that its electron deficiency hampers transmetallation, this does not explain the 
qualitative difference between equally electron-deficient 4-acetylphenyl group (entry 6, Table 
3–6).  We postulate instead that the free N-H group is responsible for poisoning the Pd-
catalyst.  This effect was presumably overridden in the coupling of the N–H-containing 
anilino group (entry 12, Table 3–6), because the requisite coordinating ability of that nitrogen 
was sufficiently attenuated by two electron-withdrawing groups: the phenyl and carbamate.
Cross-coupling of pyridine and thiophene systems did not furnish the desired product and 
the starting material remained unreacted (entries 3–5, Table 3–7).  Also, attempts to couple 
alkenyl and alkynyl trifluoroborates were unsuccessful (entries 6–10).  This type of organic 
nucleophile generally undergoes transmetallation more rapidly than their phenyl congeners, 
and hence, homocoupling would most likely outcompete palladation of the enaminone.  This 
is consistent with the observation that the reaction mixtures turned black almost 
instantaneously—indicating a coupling of some kind—but the enaminone starting material 
was essentially unreacted.  In contrast, when using sp3 coupling partners, the reaction mixture 
remained its original green/blue color, most likely reflecting the less-favored transmetallation 
process on alkyl centers (entries 11–14).  Again, the starting material was intact after 24 h.   
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3.8  Scope of enaminones  
An initial investigation of enaminone compatibility revealed that monocyclic and 
bicyclic, unattenuated enaminones were viable substrates in this reaction.  Direct arylation of 
the indolizidine and quinolizidine scaffolds showed the potential of this reaction to be used in 
the synthesis of the phenanthropiperidine alkaloids (entries 1 and 2, Table 3–8). 
Interestingly, the reactivity of the two scaffolds were markedly different.  Not only did the 
quinolizidine enaminone give higher yields of product, but it was completely reacted in less 
than half of the time it took for the indolizidine.  One possible explanation of this is that the 
non-bonding orbital of the lone pair on the nitrogen and olefin p-orbitals are poorly aligned 
due to the more constrained 5,6-bicyclic system.  With less orbital overlap, the contribution 
of the nitrogen would be less pronounced, resulting in a less nucleophilic enaminone.  The 
ultimate consequence of this is that transmetallation outcompetes palladation and the 
organoborate and reoxidant are consumed in the production of the homodimer.  
With reason to be concerned about epimerization of stereocenters (see Chapter 2) we 
subjected enaminones 2.36 and 2.50 to our optimized protocol (entries 3 and 4).  We were 
pleased that our mildly-acidic conditions were suitable for these substrates, and they reacted 
with no observable epimerization.
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Despite the success of this reaction in monocyclic and bicyclic systems there were a 
several enaminones that did not react (Table 3–9).  An N-Boc-protected enaminone was 
found to be unreactive under our optimized conditions, which we suggest is owing to its 
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a Reaction conditions: enaminone  (0.1 M), trifluoroborate 3.3 (2-3 equiv), Pd(OAc)2 (0.3 
equiv), Cu(OAc)2 (3 equiv), K2CO3 (2 equiv) in t-BuOH/AcOH/DMSO (20:5:1) at 60 oC. 
b Isolated yield. cStarting material was recovered. PMP = 4-methoxyphenyl.































































OMePh 3.24 7 79
Table 3–8.  Successfully coupled of enaminones.
decreased nucleophilicity (entry 1, Table 3–9).  Likewise, adding another degree of 
unsaturation to the piperidine system is sufficient to suppress the reaction (entries 2–4).  In 
each of these examples, we postulate that palladation is too slow to compete with 
homocoupling.  Another way to impede enaminone palladation is to incorporate steric 
encumberance.  We found that methyl and phenyl substituents could inhibit cross-coupling in 
the ordinarily reactive quinolizidine system (entries 5 and 6).  Notably, the 
phenylquinolizidine can be coupled under Pd(0)-catalyzed conditions when pre-activated via 
C3-iodination,213 showing again that these two methods are complimentary.   
3.9  Extensions and directions for the future  
The success of this reaction seems to rely on a delicate balance between the rates of 
palladation and transmetallation.  This has been a major limitation with respect to both the 
enaminone and trifluoroborate.  The N-alkyl substituted enaminones are on the threshold of 




























a Reaction conditions: enaminone  (0.1 M), trifluoroborate 3.3 (2-3 equiv), Pd(OAc)2 (0.3 
equiv), Cu(OAc)2 (3 equiv), K2CO3 (2 equiv) in t-BuOH/AcOH/DMSO (20:5:1) at 60 oC. 
b Isolated yield. c Starting material was recovered. PMP = 4-methoxyphenyl.
Table 3–9.  Enaminones that did not couple.
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reactivity, and when even subtle changes are introduced, such as a methyl group, the desired 
reaction is overwhelmed by the competing dimerization process.  The same effect can result 
from the use of organotrifluoroborates that are exceedingly prone to transmetallation.  On the 
other hand, alkyl trifluoroborates, which reluctantly transmetallate, fail to react altogether. 
Such obstacles will be challenging to overcome without approaching the problem from this 
mechanistic standpoint.       
One potential solution to this problem is to use coupling partners that are not susceptible 
to dimerization—those that do not undergo transmetallation, for instance.  In this regard, we 
envisioned a Heck-type modification as an apt extension.  Akin to our optimized arylation, 
this reaction would depend on initial enaminone palladation to generate a σ-bonded Pd-
enaminone complex.  The subsequent steps would be identical to the classical Heck-Mizokori 
reaction, involving migratory insertion of an alkene substrate followed by β-hydride 
elimination (Fig. 3–12).  We tested the feasibility of this reaction by replacing our 
trifluoroborate coupling partner with methylacrylate under our optimized conditions (Scheme 
3–7).  Even though this olefination was slower than the arylation, we were able to isolate 
enaminone 3.25 in 62% yield.  This is clearly a promising approach to prepare the previously 















inaccessible C3-alkenyl enaminones.  Furthermore, without the competing transmetallation 
process, enaminones that are less prone to palladation could be still be used.  This has been 
borne out in subsequent studies by Yiyun Yu in our laboratory.       
The Heck-variation of this reaction is a limited solution to the problem, because only 
alkenes can be used as coupling partners.  If this strategy is to be applied to preparing 
phenanthropiperidines from less reactive enaminones, aryl groups must also be 
accommodated.  There is much precedent from the literature that suggests arylhalides could 
be used for this purpose.299 In a strikingly relevant example reported by Pelletier, Larivée and 
Charette, cyclic enamines were coupled with aryl iodides using a Pd(0)-catalyst (Scheme 3–
8).312 This strategy not only minimizes the likelihood of aryl homocoupling but also 
eliminates the need for a reoxidant.  As such, this approach holds great promise to expand the 

















In summary, this methodology provides a direct route for the construction of 3-
arylpiperidine scaffolds, a privileged structure and prevalent motif in many natural products. 
Although the substrate scope of this reaction is somewhat limited, this work provides a 
foundation for future efforts to broaden it.  This method is a significant advance over the 
existing two-step method. Also, this reaction is the first example of C–H functionalization on 
enaminones (a non-aromatic enamine system) and contributes to the rapid accretion of viable 
C–H donors.  Most importantly, the ultimate goal of this work—to synthesize 3-
arylenaminones as intermediates to phenanthropiperidines—has been met.  What remains is 




















SYNTHESIS OF (+)-ANTOFINE AND (+)-IPALBIDINE
4.1  Introduction
The value of synthetic methodologies is often tentative until they validated through 
practical applications.  Hitherto, this work has described the development of two reactions 
that have been designed to facilitate the preparation of phenanthropiperidine alkaloids, but 
now we will turn to how these methods can be utilized.  In Chapter 2, we discussed the 
development of a method that gives ready access to a variety of cyclic enaminones (A, 
Scheme 4–1), including indolizidine and quinolizidine scaffolds.  In Chapter 3, we showed 
how these scaffolds could be elaborated through the development of a Pd(II)-catalyzed 
method that directly functionalizes the C3-position of the enaminone and can be used to 
install the requisite aryl moiety, which constitutes ring C of the phenanthrene system (A → 
B).  As intended, the amino acids and aryl coupling partners are interchangeable building 
blocks providing a means for preparing numerous permutations of the 3-arylpiperidine 
scaffold.  Herein, we demonstrate that that these intermediates can be used as precursors to 
(+)-antofine (4.2), a representative phenanthropiperidine, and (+)-ipalbidine (4.1), a 
structurally-related indolizidine alkaloid (Fig. 4–1).
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These natural products were chosen not only by virtue of their prototypical structure but 
also for their remarkable biological profiles.  (+)-Ipalbidine (4.1) is a non-addictive analgesic, 
an oxygen free-radical scavenger, and has demonstrated inhibitory effects on the respiratory 
burst of leukocytes.313-315 (–)-Antofine, on the other hand, exhibits low nanomolar cytotoxic 
activity (IC50) in drug-sensitive and MDR cancer cell lines alike, already being described in 
Chapter 1. We chose to prepare the unnatural enantiomer, (+)-antofine (4.2), considering that 
both natural products could be synthesized in a divergent fashion from a late-stage 
intermediate.  Although these natural products have been synthesized before,142, 158, 316-327, 149, 
56, 63, 146, 150, 170-172, 181, 184, 328 our method herein gives access to these molecules in a 

























amino acids A B
Scheme 4–1.  Route to phenanthropiperidines using our developed methods.















4.2  Total synthesis of (+)-ipalbidine 
Despite being addressed at this point in this work, our efforts to synthesize (+)-ipalbidine 
predate the full development of our ynone cyclization and direct-arylation protocols that have 
been already described in depth.  In fact, it was not until our total synthesis of (+)-ipalbidine 
was complete that we discovered that the indolizidine stereocenter had partially racemized. 
The details of this discovery and our work to suppress what was later discovered to be an 
acid-mediated process was discussed in Chapter 2.  Our seminal work on (+)-ipalbidine also 
involved pre-activating the enaminone prior to installing the C3-aryl moiety, which was 
greatly improved upon the discovery and development of a direct-arylation method (see 
Chapter 3).  In order to contrast the old with the new routes, the evolution of our synthetic 
strategy to (+)-ipalbidine will be discussed in detail.
4.2.1 First attempt to synthesize (+)-ipalbidine
Starting with Boc-L-proline, Weinreb amide 2.2 was prepared in three steps (Scheme 4–
2).  The amino acid was homologated using a standard Arndt-Eistert reaction, first converting 
the acid into diazoketone 4.3 and then catalyzing the Wolff rearrangement with CF3CO2Ag. 
When using H2O as a solvent during the rearrangement, Boc-L-β-homoproline (4.4) was 
obtained in 49% yield over two steps along with 26% of unreacted starting material.  Though 
the acid could be converted into the desired Weinreb amide 2.2 using a high-yielding EDCI 
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coupling, the difficulty of separating the two homologues following the Arndt-Eistert 
protocol inspired us to look for improvements.
Realizing that the acid functional group was contributing to poor chromatographic 
separation, we switched solvents during the Wolff rearrangement to MeOH in order to obtain 
a more tractable methyl ester.  We were pleased to find that using MeOH was beneficial, not 
only because it facilitated purification, but also because it improved the yield.  Weinreb 
amide 2.2 could then be prepared from methyl ester 4.5 using an easily scalable protocol 
reported by Williams et al.279  This approach served us well in the preparation of multi-gram 
quantities of the Weinreb amide, but our constant search for shorter reaction sequences led us 
to a even shorter route.  It occurred to us that if acids and esters could be prepared from the 
addition of oxygen nucleophiles into ketene intermediate (I, Scheme 4–2), then amides could 
















































in a non-nucleophilic solvent (THF) and added freshly distilled N,O-dimethylhydroxylamine. 
The reaction was successful, and the product (2.2) was isolated in 97%.
 
 Next, we prepared ynone 2.17 by adding excess ethynylmagnesium bromide to amide 
2.2 at 0 ºC (Scheme 4–3).  The outcome of this reaction was highly dependent on the quality 
of the Grignard reagent and on the work-up method.  The reaction was typically quenched 
with a weak acid, since the Boc-protecting group could decompose in strong acids.  The acid 
also served to sequester the nucleophilic N,O-dimethylhyrdroxylamine byproduct as an 
ammonium salt in order to prevent it from adding into the ynone.329 Hence, when the reaction 
was deemed complete, aqueous NaHSO4 was added and the reaction stirred for 1 h.  This 
method consistently provided the ynone product in greater than 95% yield. 
From ynone 2.17, enaminone 2.37 was prepared upon stepwise treatment with 4N HCl in 
dioxane and methanolic K2CO3, the details of which were discussed in Chapter 2.  At the 
time, unbeknownst to us, the stereocenter had racemized during the deprotection step.  This 
was not obvious at the time, since the product had a high optical rotation value ([α]D = –190) 
and no standard to compare it to.  Furthermore, despite numerous attempts,  we were unable 




1) 4N HCl, dioxane
2) MeOH, K2CO3
















































Scheme 4–4. First approach to (+)-ipalbidine.
2.37 3.1 3.2
4.6 4.7
Unaware of its low enantiomeric purity, we subjected enaminone 2.37 to I2 in the 
presence of DMAP, to afford iodoenaminone 3.8 (Scheme 4–4).  The p-methoxyphenyl group 
was installed next using a Buchwald modification of the Suzuki-Miyaura reaction (see 
Chapter 3).291 To install the methyl substituent in the place of carbonyl group we first 
investigated a Pd-catalyzed cross-coupling approach.  This involved the preparation of triflate 
4.6, which could be achieved using L-Selectride to mediate 1,4-reduction and trapping the 
resulting enolate with Comins’  reagent as an triflate source. We attempted a number of 
Suzuki-Miyaura protocols to couple the methyl group to the indolizidine scaffold, but they 
were unsuccessful, providing low yields of difficult-to-purify product.  
4.2.2 Second approach to (+)-ipalbidine
 
Turning to our second approach, enaminone 3.2 was once more reduced in a 1,4-fashion 
with L-Selectride, only this time, without subsequent treatment with Comins’ reagent, and 
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ketone 4.8 was isolated.  Methyl lithium was then added to the ketone to furnish tertiary 
alcohol 4.9.  Our initial attempts to dehydrate indolizidine 4.7 were unsuccessful.  We had 
initial concerns that multiple olefin isomers would be obtained and be difficult to separate but 
hypothesized that the desired isomer would be the most stable—being a tetra-substituted 
olefin and conjugated with the phenyl group—and that the unwanted isomers could be 
channeled to the desired product under thermodynamic conditions.  This rational also 
inspired us to prepare indolizidine 4.7 from a methenylation reaction of ketone 4.8 with 
Tebbe reagent and subsequent isomerization; unfortunately, we could not obtain sufficient 
quantities of indolizidine 4.10.  
Returning to tertiary alcohol 4.9, we explored several conventional methods to dehydrate 
alcohols (Table 4–1).  From of the methods tried, neat POCl3 and SOCl2 (entries 3 and 6) in 
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was complete in less than 30 minutes and that degradation was causing a significant loss in 
yield,  the reaction was: (1) diluted with THF, (2) run at lower temperatures (–30 to –10 ºC) 
and (3) run with only a slight excess of SOCl2 and pyridine (entries 7 and 8).  These 
modifications dramatically improved the outcome of the reaction, providing 88% of the 
product.  From product 4.7, we could prepare (+)-ipalbidine (4.1) by removing the O-methyl 
group with BBr3 (Scheme 4–6).
 
It was at this point that we realized that the natural product was not enantiomerically 
pure.  The optical rotation was significantly lower than reported values.  Fortunately, 
ipalbidine’s enantiomers were easily resolved using chiral HPLC, which showed that we had 
obtained the natural product with an e.r of 70:30.  As already discussed, the root cause of 
entry conditions yield (%)a
1 I2, PPh3, CH2Cl2, 16 h NR
2 BF3•OEt2, CH2Cl2, 16 h NR
3 POCl3, pyridine 30
4 TsOH, AcOH, reflux NR
5 TsOH, PhMe, reflux NR
6 SOCl2, pyridine, rt 52
7 SOCl2 (5 equiv), pyridine (5 equiv), THF, –30 ºC to rt 78
8 SOCl2 (2.5 equiv), pyridine (5 equiv), THF, –30 to –10 ºC 88
NR = no reaction (i.e. starting material was recovered). a Isolated yield. 















racemization was a retro-Michael/Michael process that had occurred during the acidic 
deprotection step of the ynone cyclization reaction.  This was remedied by using HCO2H, a 
much weaker acid, to deprotect the Boc-group, and NaI to activate the ynone prior to 
cyclization.  These conditions virtually eliminated the racemization and the enaminone could 
be prepared in a high enantiomeric purity.  Several other modifications of this third approach, 
which improve the yields and shorten the entire sequence, deserve further attention.
4.2.3 Third approach to (+)-ipalbidine
 A third approach to synthesize (+)-ipalbidine was devised to enhance the enaniomeric 
purity of the final product and also to take advantage of recently developed methods to 
improve the reaction sequence as a whole (Scheme 4–7).  After resynthesizing enaminone 
2.37 with our mild cyclization conditions, we used our just-developed Pd(II)-chemistry to 
bypass the iodination reaction and prepared the intermediate 3.2 in a single step.  We were 
also able to abridge the final sequence by reverting back to triflate intermediate 4.6. 
Previously, we had had little success installing the methyl group with the Suzuki-Miyaura 
protocol using this triflate.  This was, presumably, due to the steric demand of the a tetra-











–78 to 0 ºC
Scheme 4–6.  Final reaction to prepare (+)-ipalbidine.
4.7 (+)-ipalbidine (4.1)
 e.r. = 70:30
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reputation in alkyl cross-couplings, was used instead.  The methyl zincate was prepared 
immediately beforehand from methylmagnesium bromide and ZnBr2 (not shown).  This 
reagent was added to triflate 4.6 and Pd(PPh3)4, and in 4 h at 60 ºC the product was isolated 
in 91% yield.  (+)-Ipalbidine (4.1) was once again completed upon removal of the O-methyl 
group, and the enantiomeric ratio was identical to the enaminone it was derived from (e.r. = 
98:2).  
                            
4.3  Total synthesis of (+)-antofine
Our featured route was employed to synthesize (+)-antofine (4.2) as well (Scheme 4–8). 
Fortuitously, this phenanthropiperidine, which is among the most potent in its class, can be 
accessed from the same triflate intermediate (4.6) used to prepare (+)-ipalbidine.  With 
previous success using the Negishi protocol, we attempted to install the necessary aryl group 
using the same method.  The zinc reagent was prepared from a lithium-halogen exchange 






































zincate was then coupled with triflate 4.6 using the same conditions as before to furnish seco-
antofine in 96% yield.  Finally, a PIFA-mediated biaryl coupling yielded (+)-antofine (4.2), 
which exhibited optical activity that matched those reported in the literature.149, 171, 184, 326
4.4  Summary
Aided by our new approach to arylated cyclic enaminones, the syntheses of (+)-ipalbidine 
(4.1) and (+)-antofine (4.2) can be accomplished in a remarkably concise fashion.  Moreover, 
both of the natural product’s were obtained in high yield and enantiomeric purity.  By these 
total syntheses, the utility of two methodologies are exemplified.  Specifically, we have 
shown that cyclic enaminones can be efficiently prepared from the chiral pool and directly 
functionalized to provide versatile intermediates that can be applied to the synthesis of 
complex molecules which, in this case, are of medicinal interest.
These syntheses can be considered a proof-of-concept.  Although they have been 
validated in a sense, their design was intended to facilitate the production of a library of 
phenanthropiperidines, not just one.  Nevertheless, the two methods, which were developed 





















organic reactions.  The sheer simplicity of the cyclic enaminone and the prevalence of the 
piperidine and 3-arylpiperidine systems suggest that these reactions will be broadly 
applicable.  Our purposes herein are more focused and, therefore, we will now turn to the 




SYNTHESIS AN BIOLOGICAL EVALUATION OF (R)-TYLOCREBRINE AND RELATED ANALOGS 
5.1  Introduction
The phenanthropiperidines are being intensely pursued as drug leads, primarily for the 
treatment of cancer but also for inflammatory conditions, such as arthritis.  Although select 
members of this class are exhibit promising therapeutic potential, there is concern that they 
may also possess undesired neurological activity.  This concern arises from the failed clinical 
trial of tylocrebrine (1.4), the only member of this class to be tested in humans.  Considering 
the highly-conserved structural features across this class, there is reason to speculate that 
other phenanthropiperidines are also neurologically active.  The molecular basis for 
tylocrebrine’s side-effects has not been investigated, nor has the neurological effects of other 
phenanthropiperidine drug leads.  Hence, in order to guide our design of 
phenanthropiperidine analogs, we have begun to study the CNS activity of tylocrebrine and 
its related analogs.  Herein, we report the synthesis and initial biological studies of 
tylocrebrine and some closely related analogs to better understand the neurological liabilities 
of these alkaloids.  
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5.2   Possible mechanisms for neurological effects 
The complete absence of neurological data for the phenanthropiperdines, besides a brief 
reference to tylocrebrine’s clinical trial,2 makes our search extraordinarily difficult.  Suffness 
reported that the patients who were administered the alkaloid experienced “disorientation and 
ataxia”  (ataxia being a motor-neurological condition defined as the loss of coordination).2 
Unfortunately, no other data is available.  Presumably, more detailed descriptions, such as 
dosage, mode of administration and alkaloid source, were recorded at the time of the clinical 
trials, but this data could not be obtained even after correspondence with the NCI.  Without 
this data, we simply concluded that tylocrebrine—in some manner—affects motor centers in 
the CNS.  Although this does not lead us to a molecular target, it does provide a direction for 
our investigations.  
Since little is known of the nature of tylocrebrine’s neurological effects or, for that matter, 
of its pharmacology in general, one cannot rule out the possibility that these two effects are 
inseparable (i.e. the mechanism of tylocrebrine’s anti-proliferative effects is the same as that 
of its neurological effects).  For this scenario, it would be necessary to characterize the 
peripheral and central effects in order to assess the feasibility of designing safer 
phenanthropiperidines.  If both peripheral and central effects were equally severe, this would 
bring the therapeutic potential of these alkaloids into question.  On the other hand, if the side-
effects were primarily induced by CNS interactions, a promising strategy would be to prevent 
BBB permeation.  Nothing suggests, however, that these alkaloids are exerting their CNS and 
anti-cancer effects through the same target(s).  
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In the event that the CNS and anti-cancer mechanisms can be differentiated, different 
strategies could be used.  The most obvious one would involve the design of analogs that 
have greater selectivity for their therapeutic target.  The challenge of this approach lies in the 
difficulty of assessing CNS interactions with adequate throughput.  Identifying the specific 
target(s) responsible for the neurological effects would be highly valuable to this enterprise 
by providing a means to test synthetic leads in vitro.  One advantage of this approach is that it 
is would not be necessary to identify the therapeutic target given that anti-proliferative cell-
based assays are relatively high-throughput already.  If the therapeutic target and off-target 
cannot be differentiated based on binding affinities or functional activity, they can perhaps be 
differentiated based on location.  In other words, if the target(s) responsible for the side-
effects is localized within the CNS or is only implicated therein, designing analogs that do 
not cross the BBB could address this.                   
This latter approach, however, comes with a caveat: namely, that tumors bounded by the 
BBB will be unaffected.  Although this limitation is common to many anti-cancer agents and 
would not be reason to discontinue development, it is one that, if possible, should be avoided. 
The treatment of cancers within the CNS is immensely challenging, primarily because of the 
difficulty of designing active agents that reach tumors within the BBB.330 With tylocrebrine, 
however, the challenge is on another front.  Tylocrebrine is extremely potent and evidently 
reaches the CNS already.  Thus, the remaining obstacle is to impart neurological selectivity 
in order to tune-out unwanted side-effects.  Although this may also be difficult to achieve, it 
has yet to be attempted.                                                                      
Designing phenanthropiperidines that do not cross the BBB is more straightforward than 
designing analogs that do not interact with specific targets.  As described in Chapter 1, CNS 
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exposure has been linked to specific physicochemical parameters that can be adjusted to help 
or hinder BBB-permeation.132 These parameters are essentially descriptors of lipophilicity 
(i.e. cLogP, polar surface area, H-bond donors and cLogD).  When these properties are taken 
into account, it not surprising that tylocrebrine, which is highly lipophilic, passes through the 
BBB.  In this regard, this approach should be directed towards increasing the polarity (or 
hydrophilicity) of the phenanthropiperidines in a manner that does not affect their activity. 
Incidentally, imparting the physicochemical properties that hinder BBB-permeation will also 
improve the water solubility, which is another advantage of this approach (concerns about the 
limited solubility of these alkaloids are discussed in Chapter 1).  From what is already known 
about the SAR of this class, several positions on the phenanthropiperidine scaffold are 
promising for introducing polar functional groups (Fig. 5–1).  The C3-, C6- and C14-
positions, for instance, are relatively insensitive to derivatization and could be used to install 
polarizing groups.  Furthermore, ring E (C11–13) is virtually unexplored and may also 











Fig. 5–1.  Promising sites for derivatization.
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The design of non-BBB–penetrating analogs has the luxury being possible without a 
precise mechanistic understanding of the neurological effects.  A more challenging strategy, 
however, is to design analogs which are neurologically inert yet retain the anti-proliferative 
effects of the parent alkaloids.  We have chosen to pursue this route for the potential it has to 
treat tumors of the CNS.  In order to determine the viability of this approach, we set out to 
elucidate the mechanism for tylocrebrine’s side-effects to assure that they can be separated 
from its anti-proliferative effects.  Before this search commenced, the alkaloid would need to 
be obtained.  It is crucial that tylocrebrine—not other phenanthropiperidines—be studied 
since it is the only alkaloid with demonstrated neurological effects in humans.  Thus, 
attaining sufficient quantities of tylocrebrine was our first goal.  
 
5.3  Synthesis of tylocrebrine and analogs
 To date, the only synthetic strategy that has been used to prepare tylocrebrine relies on the 
isolation of the minor regioisomer (17%) of an unselective Pschorr coupling protocol, which 
furnishes the tetramethoxyphenanthrene system (Scheme 1–8).  This synthesis provides less 
than 1% of racemic tylocrebrine over ten steps.146 Thus, we envisioned the development of a 
new synthetic route to provide a sustainable source of tylocrebrine and, importantly, to 
provide it in enantiomerically pure form. 
In Chapter 4, the synthesis of (+)-antofine was described in which we successfully 
employed our newly developed methodologies.  In relation to previous phenanthropiperidine 
syntheses (see Chapter 1), our approach was unique except for the final step (i.e. the 
oxidative biaryl coupling).  Although the biaryl coupling method is atom economic and 
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presumably versatile with respect to the aryl substituents, the accessibility of certain 
phenthrene regioisomers is limited.  Free rotation around the aryl-alkene bond makes 
possible the formation of multiple regioisomers.  In our synthesis of antofine, for example, 
there was a possibility of forming two regioisomers  (Scheme 5–1).  The major product (IV) 
of these reactions is predictable when considering the steric interactions that arise from 
rotation of the arene (I ⇋ II).  Hence, the oxidative biaryl coupling approach limits the 
accessibility of phenanthrenes with C4- or C5-substituents, because bulky substituents in 
these positions introduce a significant amount of strain.  Indeed, the 1,4-strain energy 
between the C4- and C5-hydrogens in unsubstituted phenanthrene amounts to 5–6 kJ/mol.331, 
332
This synthetic limitation explains the absence of strategies to prepare tylocrebrine (1.4), 
which bears a C5-methoxy group, despite it being one of the most well-studied members in 
this class.  Considering the shortcomings of the biaryl coupling approach and inaccessibility 
of certain phenanthrene substitution patterns, it is surprising that these obstacles are largely 


























tylocrebrine, we had to devise a new strategy allowing construction of C5-substituted 
phenanthrenes.  
  
Our synthetic plan involved three sequential C–C bond forming steps (Scheme 5–2).  The 
key step would be the final ring-closure proceeding through an aryl-alkene oxidative 
coupling.  Unlike, the standard biaryl-coupling approach, this disconnection imposes 
regioselective control by exploiting the once-problematic methoxy substituent to block 
coupling at the C5-position.  The requisite precusor 5.1, in turn, could be derived from a 
Negishi reaction of a organozincate prepared from biphenyl bromide 5.2 and triflate 5.5.  The 
biaryl bond (shown in green) could be prepared from a halogen-selective Suzuki reaction 
from a commercially available boronic acid 5.4 and reported veratrole derivative 5.3.149 
Using our method to prepare 6-membered enaminones, the indolizidine core can be prepared 














































envisioned starting with N-Boc-pyrrolidinone (5.6).  Once the enaminone functionality was 
realized, the indolizidine enaminone could be converted into triflate 5.5 in preparation for the 
Negishi protocol. 
          
First looking to the indolizidine fragment, we began our synthesis with Boc-D-β-
homoproline and Boc-L-β-homoproline, which were to be carried through in parallel 
(Scheme 5–3).  Although each enantiomer of amide 2.2 could be formed directly using an 
EDCI coupling, the two-step homologation procedure (discussed in Chapter 4) was used as 
an economic alternative (Boc-D-β-homoproline > $300/g).  Nevertheless, the use of large 





















Scheme 5–3. Synthesis of (R) and (S)-Weinreb amide.





Considering the amenability of this synthesis to diversification, and thereby library 
development, we thought that the synthesis of racemic precursors would also be of value, 
particularly if they could be obtained in large quantities.  Thus, an alternative approach was 
devised for the synthesis of racemic Weinreb amide 2.2 (Scheme 5–4).  In this approach, 
Boc-pyrrolidinone (5.6) was reduced to hemiaminal 5.7 with DIBAL-H and then subjected to 
Horner-Wadsworth-Emmons conditions in which the putative ring-opened intermediate A 
spontaneously cyclized to provide the β-proline derivative 5.8.  Racemic amide 2.2 could 
then be directly obtained from ester 5.8 using conditions reported by Williams et al.279 
Although this sequence includes a greater number of steps compared with the enantiospecific 
synthesis, the payoff is the ease and cost of scale-up.  Moreover, it avoids the use of large 
quantities of hazardous diazomethane which would otherwise be necessary to prepare multi-




































Constructing the indolizidine fragment was our next goal.  Grignard addition of 
ethynylmagnesium bromide to Weinreb amide 2.2 provided the desired ynone 2.17 in 
excellent yield (Scheme 5–5).  Indolizidine formation could be achieved using our one-pot 
deprotection/cyclization strategy.  Either 4N HCl in dioxane or NaI in HCO2H can be used 
for Boc-deprotection.  Although the yields of the latter conditions (NaI/HCO2H) were 
generally higher, work-up following the cyclization was easier when using the HCl-
deprotection method.  It should be recalled, however, that the use of 4N HCl promotes retro-
Michael/Michael-type racemization of the β-stereocenter and could not be used for 
constructing non-racemic indolizidine 2.37.  With the indolizidine core assembled, the triflate 
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We next turned to the synthesis of the biaryl fragment.  Fürstner and Kennedy have 
previously reported a straightforward route to biarylbromides that were used for the synthesis 
of several phenanthropiperidine alkaloids.149 Although biarenes with ortho substituents 
previously had not been synthesized, the reported conditions showed no impartiality to our 
hindered boronic acid 5.4 (entry 1, Table 5–1).  Notably, this stage of the synthesis is poised 
for diversification considering the collection of boronic acids available for purchase. 
Although our primary focus remained on the synthesis of tylocrebrine (1.4), we also 
synthesized biaryl bromides 5.9–5.13 which bear the substitution pattern of several other 
prominent members of this class—tylophorine, antofine and deoxypergularinine (entries 2, 4 
and 6)—and two unnatural isomers that have never been synthesized before (entries 3 and 5). 
Our intent was not only to demonstrate the feasibility of diversification at this point in the 
synthesis, but, also, to explore the scope of this chemistry and its application for the 
Table 5–1. Synthesis of biaryl fragment.
entry R1 R2 R3 R4 product yield (%)
1 OMe OMe H OMe 5.2 72
2 H OMe OMe OMe 5.9 67
3 OMe H H OMe 5.10 77
4 H OMe H OMe 5.11 68
5 H H OMe OMe 5.12 70






















construction of C5-unsubstituted analogs—these could potentially form regioisomers in the 
final aryl-alkene coupling reaction.  
An important consideration for us was the ease of scale-up and cost efficiency. 
Admittedly, we did not labor over reaction optimization for the Suzuki protocol, in which we 
had encountered an number of drawbacks (e.g. challenges in work-up and purification) when 
preparing multi-gram quantities of product, but realized that a scalable, Pd-free approach to 
biarylbromide 5.9  was possible (Scheme 5–6).  This could be achieved through a PIFA-
mediated dimerization of 4-bromoveratrole (5.14). The resultant dibromide 5.15 was 
desymmetrized upon treatment with one equivalent of n-BuLi and a subsequent MeOH 
quench.  Both steps could be carried out in 20 g batches and, conveniently, without the use of 
column chromatography providing 13 g of product (80% yield over two steps). 
Having had previous success with Negishi cross-couplings of sterically-encumbered 
triflates, we employed analogous conditions to install the biaryl moiety using the appropriate 
coupling partner.  The zincate 5.16 was prepared from biaryl bromide 5.2 via sequential 

























for the cross-coupling.  Using this protocol, the reaction was complete in 30 min.  Because 
this reaction was so rapid, we reduced the reaction temperature from 60 ºC to room 
temperature and decreased the catalyst loading to 2 mol%.  We were pleased to find that this 
cross-coupling proceeded in under an hour to provide near quantitative yields of the desired 
indolizidine 5.1 (Scheme 5–7).   
Having all the desired carbons in place we could now explore conditions for an oxidative 
aryl-alkene coupling.  To our knowledge there has only been only one report of such a 
reaction which used (p-BrC6H4)3N•SbCl6.333  Concerned by this lack of precedent, we 
undertook a systematic investigation using tylocrebrine precursor 5.1 as a model stubstrate, 
and reagents that have found success in the related biaryl coupling reaction (Table 5–2).  In 
our first attempt, (p-BrC6H4)3N•SbCl6 left the starting material unperturbed (entry 1). 
Slightly more success was found under photochemical conditions (entry 2) or when using 
PIFA (entry 3 and 4); however, substantial amounts of degradation were also observed.  We 
were pleased to find that FeCl3 (entry 5) could induce the desired oxidative coupling with 
greatly improved yields. The greatest success was found with the use of VOF3 (entry 7), 

















Scheme 5–7.  Coupling of indolizidine and biaryl fragments.
95%(R)-5.5, (S)-5.5,
(±)-5.5
5.16 (X = ZnBr)




which gave the desired product in 62% yield. With the success of this reaction, this method 
was applied to the both enantiomers of indolizidine 5.1, marking the first asymmetric 
synthesis of (R)- and (S)-tylocrebrine.  The natural products were synthesized in 7 linear 
steps and in up to 39% overall yield from Boc-D-β-homoproline. 
In hopes that this methodology would be applicable to more than tyocrebrine, we also 
attempted the synthesis of various analogs with varying methoxy substitution patterns.  Each 
of the biaryl bromide analogs (5.9–5.13) were coupled with racemic triflate 5.5 using the 











a NMR yield using MeSiPh3 as an internal standard.  b Recovered starting material.  c Isolated 
yield.    
entry conditions yield (%)a
1 (p-BrC6H4)3N•SbCl6 (1.0 equiv), 2,6-lutidine (0.2 equiv), CH2Cl2, rt 0b
2 I2 (1.0 equiv), PhMe, hν 7
3 PIFA (2.0 equiv), CH2Cl2:TFA (2:1), 0 ºC to rt 10
4 PIFA (2.0 equiv), BF3•Et2O, CH2Cl2, –40 ºC 11
5 FeCl3 (6.0 equiv), MeNO2, CH2Cl2, rt 44
6 VOCl3 (1.1 equiv), CH2Cl2, rt decomp.
7 VOF3 (4.0 equiv), CH2Cl2, EtOAc, TFA, TFAA, –78 to  –15 ºC, 4 h 70 (62)c




of these reactions were comparable and, except for compound 5.20, the indolizidine products 
were isolated in 95% yield or greater.  The lower yield for compound 5.20 is probably not an 
accurate reflection of reactivity but more likely resulted from an experimental oversight. 
Having obtained these phenanthropiperidine precursors, we next turned to the final oxidative 
coupling.   
We were initially concerned that when the C5-methoxy group was not present (R1 = H, 
Table 5–3), this would introduce the possibility of producing multiple regioisomeric 
products.  Fortunately, these reactions proceeded in excellent yields, providing 
phenanthropiperidines 5.23–5.26 with no observable regioisomer formation.  Notably, the 
reaction yields were significantly higher without the C5-methoxy group (R1 = H) than with it 
(R1 = OMe), showing that the C5-substituent is not essential and may even retard the 
progression of this reaction.  Indeed, the oxidative coupling of indolizidines 5.18–5.21 were 
complete in 1 h—compared with 4 h for tylocrebrine precursor 5.1—and did not require 
warming above –78 ºC.  Conversely, coupling of indolizidine 5.17 was slow and 
accompanied by numerous side-reactions that left less than 30% of the isolable product. 
Notwithstanding the poor yields of this reaction, all of the products were isolated in sufficient 
quantities to begin an investigation of tylocrebrine’s neurological target.  Each analog was 
prepared in only racemic form, whereas racemic, (R)- and (S)-tylocrebrine were synthesized. 
This route is an improvement over previous routes, being shorter, higher yielding and 





5.4  Biological studies of tylocrebrine and related analogs
5.4.1  Cancer
With six phenanthropiperidine analogs in hand, including tylocrebrine, we began our 
investigation of their neurological activity in search of “CNS-safe”  analogs.  The first task 
was to assess the anti-cancer properties of each compound so that we could eventually 
determine if the therapeutic effect could be separated from the undesired effects.  We chose 



























yield (%)a   product
overall 
yield (%)b
OMe OMe H OMe 95 (±)-5.1 62c (±)-1.4 27
OMe H H OMe 97 (±)-5.17 28c (±)-5.22 12
H OMe H OMe 95 (±)-5.18 70 (±)-4.2 30
H H OMe OMe 98 (±)-5.19 85 (±)-5.23 37
H OMe OMe OMe 70 (±)-5.20 68 (±)-1.1 22
H OMe OMe H 98 (±)-5.21 89 (±)-5.24 39
Table 5–3. Final two steps to prepare (±)-tylocrebrine and its analogs.
(±)-5.1, 5.17–5.21
Conditions: Negishi coupling, Pd(PPh3)4 (2 mol%), THF, rt, 1 h; [O]-coupling, VOF3, TFA, 
TFAA, CH2Cl2, EtOAc, –78 ºC. a Isolated yield. b Yield over 8 steps from N-Boc-
pyrrolidinone c Required warming to 0 ºC. 
(±)-5.5  
(±)-1.1, 1.4, 4.2, 5.22–5.24
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Using the alamarBlue® assay to measure cell proliferation, each analog assessed in the select 
tumor cell lines.  As expected, most of the analogs exhibited potent growth inhibition in each 
cell line.  Unfortunately, exact GI50 values could not be obtained for several analogs since 
lowest concentration used resulted in almost complete growth inhibition.  For these analogs 
we have indicated that their GI50 is less than the lowest concentration used (i.e. 3.1 nM). 
Although this data does not lend itself to ranking each compound in order of its activity, it 
does give valuable qualitative data from which new SARs can be gleaned.
We have found that tylocrebrine’s racemate exhibited anti-tumor activity which exceeded 
that of the (S)-enantiomer alone (Table 5–4).  Furthermore, of tylocrebrine’s analogs, only 
one was significantly less cytotoxic than taxol in COLO-205 or MCF-7 cell lines whereas, 
unlike taxol, each alkaloid retained activity in NCI/ADR-RES, a multi-drug resistant cancer 
cell line.  6-Desmethoxytylophorine (5.23), an unnatural analog, was much less active than 
IC50 (nM)b
compounda COLO-205 MCF-7 NCI/ADR-RES
Taxol 1.8 1.9 NA
 (S)-1.4 (S)-tylocrebrine 8.8 105 207
(±)-1.4 (±)-tylocrebrine < 3.1 < 3.1 < 3.1
(±)-5.22 (±)-6-desmethoxytylocrebrine < 3.1 < 3.1 < 3.1
(±)-4.2 (±)-antofine < 3.1 < 3.1 < 3.1
(±)-5.23 (±)-6-desmethoxytylophorine 265 533 1340
(±)-1.1 (±)-tylophorine < 3.1 < 3.1 < 3.1
(±)-5.24 (±)-deoxypergularinine 8.5 5.8 196
Table 5–4.  Cytotoxicity of phenanthroindolizidines.
a Each phenanthropiperidine is in racemic form unless otherwise specified. b Determined 
using alamarBlue® assay;  COLO-205 = human colorectal adenocarcinoma; MCF-7 = 
human breast carcinoma; NCI-ADR-RES = drug-resistant human ovarian adenocarcinoma; 
NA = Not active at the highest concentration tested (293 nM).
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tylocrebrine (1.4), confirming the importance of the C6-methoxy group, which is present in 
all of the most active phenanthropiperidines.  Corroborating earlier studies, this data shows 
that removal of either the C2-, C5- or C7-methoxy groups is not detrimental.  This 
information will indeed be valuable for designing novel anti-cancer agents.  
 
5.4.2  Neurological side-effects hypothesis 
We next began our investigations into the cause of the adverse neurological effects 
observed in tylocrebrine’s original clinical trial.  The absence of clinical data forced us to 
search for clues elsewhere.  The symptoms alluded to by Suffness2—who seems to have 
acquired his data from a primary source—indicate that, at some level, tylocrebrine interferes 
with normal voluntary movement.  Thus, we chose to explore two potential mechanisms for 
tylocrebrine’s side-effects based on its structural similarity to bioactive molecules known to 
influence motor function in the CNS: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
and dopamine (DA).   
5.4.2.1 MPTP-like toxicity 
In the 1980s, Langston (in collaboration with the NIH) chanced upon a neurotoxin that 
induced parkinsonism.  This substance, later identified as MPTP, affected illicit drug users 
that had self-injected contaminated batches of MPPP, a synthetic opioid.334 The neurotoxin 
was found to have remarkable selectivity for the substantia nigra and DA neurons, thus, 
mimicking the pathophysiology of Parkinson’s disease.  Research over the following decades 
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has shown that MPTP undergoes a fatal sequence of events that leads to DA neuronal cell 
death (Fig. 5–2).  Being highly lipophilic, MPTP passively diffuses across the BBB to enter 
the CNS.  Within glial cells it is oxidized by monoamine oxidase-B (MAO-B) to the active 
toxin, 1-methyl-4-phenylpyridinium (MPP+, Fig. 5–3)—this makes MPTP, strictly speaking, 
a protoxin.  Following this oxidation, MPP+ is actively transported into DA neurons at the 
nerve terminal via the dopamine transporter (DAT); hence, the selectivity for dopaminergic 
neurons.  Within the neuron, the active toxin (MPP+) effectively shuts down cellular 
metabolism in the mitochondria by inhibiting Complex I (NADH dehydrogenase) of the 
electron transport chain, ultimately resulting in cell death. 
 
The basis for investigating tylocrebrine’s similarity to MPTP arose from several 
commonalities.  Firstly, the structure of MPTP (Fig. 5–3) is embedded within tylocrebrine. 
Second, tylocrebrine readily undergoes oxidation to form MPP+-like dehydrotylocrebrine 
(Fig. 5–3).  Phenanthropiperidines are prone to aerobic oxidation while in solution.  The 
exact mechanism of the oxidation is unknown, but the end product is presumably the dubious 
Fig. 5–2. Mechanism for MPTP-induced toxicity.
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pyridinium salt.  This raises the question as to the integrity of the phenanthropiperidines in 
living systems and as to if the side-effects are due to this metabolite rather than the parent 
compound.  Indeed, if oxidation is facile in aerobic conditions, this process may also be 
implicated in physiological conditions. 
 
Another concern is enzymatic oxidation.  Having structural similarities to monoamine 
neurotransmitters and to MPTP, phenanthropiperidines could potentially undergo MAO-
mediated oxidation.  To explore this hypothesis further, each analog was tested in the MAO 
Amplex® Red assay (Graph 5–1).  This assay measures H2O2 (a byproduct of MAO 
oxidation) production as an indicator of MAO activity.  Using p-tyramine as a standard, 
MAO-A and MAO-B activities were measured in the presence of the phenanthropiperidines 
and MPTP.  As expected, MPTP was shown to be a substrate for MAO-B and, to a much 
lesser extent, MAO-A.  Conversely, at concentrations up to 100 μM, none of our analogs 
increased MAO-A or MAO-B activity, showing that oxidation via this mechanism is unlikely. 
This does not, however, rule out oxidation by other metabolic enzymes or non-enzymatic 
oxidation. 














Graph 5–1. Phenanthropiperidines as a substrate for MAO-A and MAO-B.
Monoamine oxidase A (MAO-A)
Monoamine oxidase B (MAO-B)
* Percent activity of the MAO enzyme where the activity induced by p-tyramine (a known 





In another effort to identify similarities between tylocrebrine and MPTP, we determined if 
any phenanthropiperidine analogs were subject to active transport by three major 
neurotransmitter transporters found in the CNS:  DAT, NET and SERT.  Even if 
tylocrebrine’s mechanism was different from MPTP, identifying an active transporter would 
give valuable insight into the region of influence that could aid a physiological explanation 
when juxtaposed with the tylocrebrine’s side-effects.  We also tested dehydrotylocrebrine in 
this assay, which was prepared from tylocrebrine (1.4), to see if this potential metabolite 
might exert CNS effects.  The affinity of each analog for the transporters was determined at a 
single concentration (10 μM) in a radioligand displacement assay.  It was clear from this 
assay that none of the phenanthropiperidines tested exhibited marked affinity for the 
transporters (Table 5–5).
% radioligand displacement @ 10 µMb
entry compounda DAT NET SERT
1 6-desmethoxytylocrebrine 10 31 4.9
2 6-desmethoxytylophorine 39.7 8 32
3 antofine 26.0 25.7 0
4 deoxypergularinine 25.1 20.4 4.7
5 tylocrebrine 30.3 30.1 0
6 tylophorine 1.6 18.5 8.2
7 dehydrotylocrebrine 19.2 41.2 0
a Each phenanthropiperidine is in racemic form unless otherwise specified. b Determined at 
the NIHM-PDSP. DAT = dopamine transporter, NET = norepinephrine transporter, SERT = 
serotonin transporter.
Table 5–5.  Phenanthropiperidine affinity for monoamine transporters.  
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Further testing is required to unambiguously define tylocrebrine’s (or 
dehydrotylocrebrine’s) role in the electron transport chain before it can be dismissed as an 
MPTP-like neurotoxin.  Nevertheless, compelling evidence, here and elsewhere, gives reason 
to conclude tylocrebrine is unique in this respect.  Firstly, MPTP is activated via oxidation by 
MAO-B for which tylocrebrine is not a substrate.  Second, MPTP’s active metabolite, MPP+, 
exploits DAT to reach its cellular target, whereas, dehydrotylocrebrine is not accommodated 
by this transporter.  Thus, if tylocrebrine or an active metabolite exerts its effect in the 
neurons of the substantia nigra, which is yet to be demonstrated, it does so through a different 
pathway.  
Another distinction can be made on the basis of MPTP’s and tyocrebrine’s physiological 
effects.  Administration of MPTP incurs the characteristic parkinsonian rigidity, bradykinesia, 
tremor and postural instability.  These symptoms, as with Parkinson’s disease, result from a 
damaged substantia nigra which is, among other things, responsible for fine motor control. 
Strictly speaking, this differs from the ataxia which is allegedly caused by tylocrebrine. 
Ataxia is defined as the loss of coordination and results from dysfunctional sensory or 
cerebellar systems.  Since ataxia is symptomatically and pathologically distinct from 
parkinsonism, tylocrebrine’s and MPTP’s motor effects are probably unrelated.  
Could the known causes of ataxia shed light on the neurological effects associated with 
the administration of tylocrebrine?  Yes, but uncertainty still remains.  Their is no evidence to 
suggest that tylocrebrine’s side-effects are not simply a manifestation of non-specific 
interactions across the CNS and periphery.  Indeed, among its numerous CNS effects, ethanol 
can induce ataxia.335 Unfortunately, without the original clinical data, nothing is known about 
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how the ataxic symptoms present, and therefore, we cannot assume that tylocrebrine’s effects 
are localized or specific.                                          
         
5.4.2.2 Dopaminergic and other CNS receptors
Another concern we had was that tylocrebrine was interfering with neurotransmission by 
mimicking biogenic amines.  This arose out of the realization that tylocrebrine was endowed 
with the pharmacophore of DA and bore a resemblance to known DA receptor ligands such 
as dihydrexidine (DHX) and dinoxyline (Fig. 5–4).  DA’s pivotal role in the CNS led us to 
explore the dopaminergic system as the culpable source of tylocrebrine’s neurological side-
effects.  The dopaminergic system is intimately connected to motor control, cognition, 
emotion, motivation and many other functions.336 Furthermore, abnormalities of the 
dopaminergic system can have devastating consequences which are manifested, for instance, 
in Parkinson’s disease, schizophrenia, bipolar disorder and drug addiction.  Thus, if 
tylocrebrine is found to modulate the dopaminergic system, there is good reason to attenuate 





















It was not simply the dopaminergic effects, however, that concerned us.  There is 
appreciable overlap between the ligands of DA receptors and other biogenic amine receptors 
(e.g. adrenergic and serotonergic) in the CNS.337  Thus, tylocrebrine could possibly exert 
more extensive effects than those limited to the dopaminergic system.  For this reason, we 
selected a broad panel of CNS targets to investigate rather than focus on a specific receptor.    
Our collection of phenanthropiperidines was submitted to the National Institutes of 
Mental Health-Psychoactive Drug Screening Program (NIHM-PDSP) for a comprehensive 
CNS-target screen (Table 5–6).  A primary screen identified compounds which had significant 
binding (defined as greater than 50% displacement of a radioligand) to receptors at 10 μM. 
For those “hits”, the KD was determined in a secondary assay.  
The results from the primary screen confirmed our suspicions about tylocrebrine having 
DA receptor affinity.  Five of the six phenanthropiperidine analogs (excluding 
dehydrotylocrebrine) bound to the D1 subtype with moderate selectivity.  The uniform 
activity at D1 of each tylocrebrine analog could be indicative of a more universal liability for 
these natural products.  These analogs also showed moderate affinity at the D5 receptor and, 
to a much lesser extent, the D2, D3 and D4 subtypes.  This selectivity profile is typical for D1 
agonists and antagonists.  The D5 receptor, having a high degree of structural homology with 
D1, is often targeted by D1 ligands.  The D2, D3 and D4 receptors, on the other hand, all 
belong to the D2-like family and, therefore, achieving selectivity between these three 
receptors is more difficult than between them and D1-like subtypes.  The D1 selectivity 
exhibited by tylocrebrine is notable, because this receptor is the most highly expressed 
subtype within the dopaminergic system and widely dispersed in the mammalian forebrain.336 







































  To better characterize the alkaloids affinity for each receptor, the KD values for each 
“hit”  in the primary screen were determined (Table 5–7).  This, however, did not settle the 
matter.  If tylocrebrine had displayed high affinity for the D1 receptor, this would have forged 
a promising link to its adverse effects, whereas, if it had weak affinity, it would give good 
reason to pursue another hypothesis.  In reality, tylocrebrine had moderate affinity for the D1 
receptor with a KD of 448 nM, raising new questions about its nature of activity and the 
details of its clinical trial.  To aid interpretation of this result the dosages used in the 
tylocrebrine’s clinical trials would be extremely valuable.  Considering that racemic 
tylocrebrine was used in these experiments, the affinity of each enantiomer should also be 
determined before pursuing this route any further.  Moreover, the functional effect of binding 
should be characterized.  Although this binding information is useful, a physiological 
connection cannot be made until a functional assay elucidates tylocrebrine’s efficacy upon 
KD (nM)b
compounda D1 D2 D3 D4 D5 5-HT1D α1A H2
6-desmethoxytylocrebrine 219 NA NA NA – 1098 2790 885
6-desmethoxytylophorine 89 NA 5078 NA 749 737 105 222
antofine 181 NA 5849 NA 1695 1553 1092 1724
deoxypergularinine 587 NA 7384 NA 5004 2596 1195 2010
tylocrebrine 448 NA NA NA 3644 3123 1784 537
tylophorine 2617 NA NA NA – NA NA 9846
Table 5–7.  Affinity for phenanthropiperidine for biogenic amine receptors.
a Each phenanthropiperidine is in racemic form unless otherwise specified. b Determined at 
the NIHM-PDSP. NA = not active (KD is greater than 10 µM).
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the receptor in question (i.e. whether tylocrebrine is an agonist, antagonist, partial agonist, 
etc.).        
The secondary assay also provided some useful information about how structure 
influences receptor binding.  6-Desmethoxytylophorine had the highest affinity for the D1 
subtype out of  all the phenanthropiperidines tested (KD = 89 nM).  This compound’s 
phenanthrene substitution pattern, which renders it much less active in anti-proliferation 
assays, will therefore be avoided in analog development.  Tylophorine, on the other hand, has 
the least affinity for the D1 receptor and also exceptional anti-cancer activity.  If D1-
interaction is ever linked to adverse side-effects in the phenanthropiperidines, this 
information provides a potential strategy to minimize them.
Besides showing notable affinity for the D1 receptor, tylocrebrine and most of the analogs 
tested also bind to several subtypes within each class (e.g. serotonergic, muscarinic, 
histaminergic, etc.).  Particularly, the 5-HT1D,  α1A and H2 receptors were targeted by each 
analog albeit to a lesser extent than the D1 receptor.  Tylocrebrine had comparable binding to 
the H2 receptor and D1 receptor.  The primary functions of the H2 receptor are in the 
regulation of gastric acid secretion, smooth and cardiac muscle relaxation and in the immune 
response.338 There is little to suggest, however, that H2 ligands could affect the neurological 
responses induced by tylocrebrine.  Likewise, the α1A receptors has not been directly linked 
to motor coordination, but its expression in the ventral and dorsal motor area of rat spinal 
cord suggests that it may regulate movement in some fashion,339 as does its α1B counterpart.
340  Tylocrebrine’s relatively low affinity for this receptor and the 5-HT1D receptor, which also 
has no known connection to motor functions,  renders these implausible targets.  Although 
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these results redirect our search for the mechanism of tylocrebrine’s side-effects, they presage 
other neurological effects that could potentially hamper lead development. 
The primary and secondary assays give further confirmation that 6-
desmethoxytylophorine and closely related structures could indiscriminately modulate 
neurotransmission through the biogenic amine receptors.  Conversely, tylophorine, which 
has weak binding to every target that was tested, may be a good lead to base next generation 
analogs on.  It is surprising, however, that this subtle modification—the presence or absence 
of a single methoxy group—confers such a drastically different CNS receptor profile.  
Another possible explanation for this anomaly is that tylophorine gives a false negative 
result by virtue of its insolubility.  Indeed, in the process of making DMSO solutions of each 
alkaloid it was quite apparent that tylophorine was the least soluble.  Furthermore, it is 
significant that tylophorine’s decomposition point (284–285 ºC) is more than 50 ºC above 
that of the other alkaloids (ranging from 203–230 ºC).  Although the decomposition 
temperature of a chemical entity is not correlated with solubility, as is the melting point,133 
this data demonstrates that the physicochemical properties of tylophorine are significantly 
different from the other alkaloids, and this difference—rather than actual receptor binding—
may be the basis for its anomalous behavior in the PDSP-CNS target screen.
KD (nM)b
compounda M1 M2 M3 M4 M5
tylocrebrine 2664 4602 NA 3176 NA
dehydrotylocrebrine 186 156 339 169 1561
Table 5–8. Tylocrebrine’s and dehydrotylocrebrine’s affinity for muscarinic receptors.
a Each phenanthropiperidine is in racemic form unless otherwise specified. b Determined at 
the NIHM-PDSP. NA = not active (KD is greater than 10 µM).
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It is also worthy to note that dehydrotylocrebrine exhibits a unique binding profile. 
Rather than targeting the monoamine receptors, this derivative of tylocrebrine has 
considerable affinity for the muscarinic receptors (Table 5–6 and 5–8).  This could be a 
concern if dehydrotylocrebrine is generated in vivo.  Muscarinic receptors, like dopaminergic 
systems, are expressed throughout the CNS and PNS, and they are associated with cognition, 
learning, and memory as well as proper functioning of the heart, gastrointestinal tract, lung 
bronchioles and urinary bladder.341, 342 Moreover, these GPCRs are the target of numerous 
toxins, including its eponymous mushroom toxin muscarine.343 However, the muscarinic 
system functions primarily, if not exclusively, in the autonomic nervous system and has not 
been linked to voluntary motor control or coordination.  Therefore, dehydrotylocrebrine’s 
affinity for these receptors does not explain tylocrebrine’s side-effects, but, as before, 
discloses potential off-target interactions that could limit the success of 
phenanthropiperidine-based therapeutics.  If oxidation does occur in vivo, preventing it 
through appropriately designed analogs would be presumably curtail the muscarinic effects.    
5.5  Summary
Tylocrebrine’s early failure in clinical trials, despite precluding characterization of its 
efficacy, established a liability for this class of alkaloids and their use as chemotherapeutic 
agents.  Until now, the neurological effects that derailed the clinical trials have not been 
investigated, despite recent interest in the medicinal properties of the phenanthropiperidines. 
The lack of practical syntheses for tylocrebrine was a major impediment to these studies.  We 
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addressed this by designing a new synthetic approach that accounted for the challenging 
phenanthrene substitution pattern.  Our method provided a simple and high-yielding route to 
tylocrebrine and provided sufficient quantities to assist characterization of its inimical CNS 
effects.  This route was also used to synthesize a small library of tylocrebrine analogs—some 
were known natural products, others were unnatural analogs—to aid SAR studies.      
Herein, we reported preliminary work to understand the CNS effects of tylocrebrine by 
exploring two hypothetical links between its structure and the nature of its side-effects. 
Firstly, we investigated the similarities of tylocrebrine to the known neurotoxin MPTP and 
found that there is unlikely overlap between their biological effects.  Second, we investigated 
tylocrebrine’s and its analogs’  similarity to key biogenic amines in the NIHM-PDSP 
comprehensive CNS target screen.  The screen has uncovered several pitfalls that could be 
encountered in the development of a phenanthropiperidine drug, especially one that is 
designed to treat tumors within the CNS.  It also uncovered risk factors that contribute to the 
off-target interactions that will guide lead optimization studies.  The mechanism of 
tylocrebrine-induced ataxia and disorientation is still not understood, making it difficult, 
without an experimental model, to design “CNS-safe”  analogs at this time.  One strategy that 
is feasible, however, involves the preparation of phenanthropiperidines that do not cross the 
BBB at all.  Since this approach does not require a mechanistic understanding of 






6.1  Materials and methods 
Unless otherwise specified, all starting materials, reagents and solvents are commercially 
available and were used without further purification.  Flash column chromatography was 
carried out on silica gel.  TLC was conducted on silica gel 250 micron, F254 plates. 1H NMR 
spectra were recorded on a 400 MHz NMR instrument.  Chemical shifts are reported in ppm 
with TMS or CHCl3 as an internal standard (TMS: 0.00 ppm, CHCl3: 7.26 ppm).  Data are 
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, b = broad, m = multiplet), integration and coupling constants (Hz). 13C NMR spectra 
were recorded on a 100 MHz NMR spectrometer with complete proton decoupling. 
Chemical shifts are reported in ppm with the solvent as internal standard (CHCl3:  77.2 ppm). 
IR of solids were obtained by dissolving the sample in CHCl3 and letting the solvent 
evaporate on a KBr plate.  High-resolution mass spectrometry was performed by the 
University of Minnesota Mass Spectrometry Facility. 
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6.2  Chapter 2
6.3.1 Preparation of Weinreb amides:

















The β-amino acid (4.0 mmol, 1.0 equiv) was dissolved in anhydrous CH2Cl2 (100 mL) under 
an argon atmosphere and cooled to –15 °C.  To this solution was added N,O-
dimethylhydroxylamine•HCl (4.4 mmol, 1.1 equiv) and N-methylmorpholine (4.4 mmol, 1.1 
equiv) followed by EDCI (4.2 mmol, 1.1 equiv).  The reaction mixture was  then allowed to 
come to room temperature.  After 2 h the reaction was again cooled to 0 °C and quenched by 
the addition of an ice cold 10% HCl solution (25 mL) and allowed to stir at this temperature 
for 5 min. The reaction was diluted with water (50 mL) and extracted with CH2Cl2 (x3). The 
combined organic layers were washed with saturated NaHCO3 (x1), dried over Na2SO4, 
filtered and concentrated.  Purification via SiO2 flash chromatography using EtOAc and 
hexanes as the eluent afforded pure Weinreb amides.




1) TEA, ClCO2Et, Et2O;
then CH2N2












Warning:  Large amounts of diazomethane were used for this transformation.  Proper care 
should be taken when handling this highly explosive reagent.  All glassware used was free of 
cracks, scratches or ground-glass joints and a blast shield was used.  The N-Boc-amino acid 
(50.0 mmol, 1.00 equiv) was taken into THF (100 mL) with stirring and cooled to 0 ºC with 
an ice bath.  The reaction solution was treated with TEA (7.66 mL, 55.0 mmol, 1.10 equiv) 
and allowed to react for 15 min to fully deprotonate the carboxylic acid.  With the addition of 
ethyl chloroformate (5.23 mL, 55.0 mmol, 1.10 equiv), a thick white precipitate formed. 
Stirring was continued for 15 min then stopped.  In a separate flask, an ice-cold ethereal 
solution of diazomethane was prepared and, without stirring, was carefully decanted into the 
freshly prepared anhydride reaction flask using a glass funnel.  The reaction solution was 
lightly stirred for 4 seconds then stirring was stopped.  The mixture was allowed to warm to 
room temperature and react overnight.  Any additional diazomethane was carefully quenched 
with 0.5 N acetic acid (100 mL).  The drop-wise addition of saturated sodium bicarbonate 
regulated the solution back to a basic pH 8-9 with gentle stirring.  The organic and aqueous 
layers were separated.  The organic phase was washed twice each with saturated sodium 
bicarbonate and brine then dried over sodium sulfate.  The solvent was evaporated under 
reduced pressure and placed under high vacuum overnight.  The diazoketone was taken into 
THF (250 mL) and cooled to 0 ºC. Foil was used to cover the reaction flask so as to exclude 
light from the reaction solution.  To this was added freshly distilled N,O-
dimethylhydroxylamine (9.16 g, 150 mmol, 3.00 equiv).344 In a separate foil covered flask, 
silver trifluoroacetate (1.10 g, 5.00 mmol, 0.10 equiv) was dissolved in TEA (130 mL).  This 
solution was added to the diazoketone mixture over 30 min.  The reaction temperature was 
allowed to slowly warm to room temperature and the solution was stirred overnight.  To the 
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reaction mixture was added activated charcoal (~2 g) and the reaction mixture was stirred for 
5 min and filtered.  The filtrate was concentrated and the residue redissolved in EtOAc.  To 
this was added activated charcoal (~2 g) and the process repeated.  When the filtrate had been 
concentrated a second time the residue was purified via SiO2 flash chromatography using a 
mixture of EtOAc and hexane as eluent affording the pure Weinreb amide.












A round-bottomed flask was charged with benzylamine (8.00 mL, 73.1 mmol, 3.00 equiv) 
and cooled to –40 ºC.  Methyl acrylate (2.20 mL, 86.1 mmol, 1.00 equiv) was added 
dropwise over 5 min and the reaction was stirred at this temperature (–40 ºC) for 24 h. 
Excess benzylamine was distilled off of under reduced pressure.  The remaining residue was 
dissolved in MeOH (50 mL) and di-tert-butyldicarbonate (6.40 g, 29.2 mmol, 1.20 equiv) 
was added slowly.  The reaction mixture was stirred for another 30 min and the solvent was 
removed in vacuo.  The concentrated reaction mixture was redissolved in CH2Cl2 (300 mL) 
and washed with cold 10% HCl (100 mL x 2) and brine (100 mL x 2).  The organic layer was 
dried with MgSO4, concentrated and purified via SiO2 flash chromatography (25% EtOAc in 
hexanes) to afford 6.62 g (88%) of the methyl ester as a clear viscous oil.  This oil was 
converted to the corresponding Weinreb amide using the procedure reported by Williams et 
al.279 The crude product was purified via SiO2 flash chromatography (40% EtOAc in 
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hexanes) to give 6.29 g (86%) of the Weinreb amide as a clear viscous oil.  See below for 
spectral data.  
(S)-tert-Butyl 2-(2-(Methoxy(methyl)amino)-2-oxoethyl)piperidine-1-carboxylate (2.1). 
The title compound was obtained as a colorless oil using Method B (64% over 2 steps). 
Spectral data of the title compound was identical to that reported in the literature.255
(S)-tert-Butyl 2-(2-(Methoxy(methyl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate (2.2). 
The title compound could be obtained as a colorless oil using either Method A (98%) or 
Method B (70% over 2 steps). Spectral data of the title compound was identical to that 


















pyrrolidine-1-carboxylate (2.3).  The title compound was obtained as a white solid  from 
Boc-O-benzyl-hydroxyproline using Method B (72% over 2 steps): mp 69.5-70.3 °C; 1H 
NMR (400 MHz, CDCl3) δ (1:1 mixture of rotamers) 1.46 (s, 18H), 1.95-2.03 (bm, 2H), 
2.30-2.38 (bm, 2H), 2.44-2.54 (bm, 2H), 3.03-3.16 (m, 2H), 3.16 (s, 6H), 3.41-3.56 (m, 3H), 
3.67 (s, 6H), 3.67-3.75 (m, 1H), 4.09-4.14 (bm, 2H), 4.27-4.34 (bm, 2H), 4.46-4.54 (m, 4H), 
7.26-7.35 (m, 10H); 13C NMR (100 MHz, CDCl3) δ 28.5, 32.0, 36.4, 36.9, 37.4, 38.1, 51.1, 
51.9, 52.9, 61.2, 70.8, 75.7, 76.4, 79.3, 79.7, 127.6, 127.6, 128.4, 138.1, 154.5, 172.1, 172.4; 
IR (neat) 2974, 1693, 1665, 1397, 1160, 1118 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 





























pyrrolidine-1-carboxylate (2.4).  The title compound was obtained as a colorless oil (98%) 
using the hydrogenation procedure reported by Epperson et al.345  Spectral data of for this 




















pyrrolidine-1-carboxylate (2.5).  The title compound was obtained from a Mitsunobu 
reaction of compound 2.4.  Weinreb amine 2.4 (90 mg, 0.32 mmol, 1.0 equiv) was dissolved 
in THF (10.0 mL) under an argon atmosphere and cooled to 0 °C. Triphenylphosine (164 mg, 
0.62 mmol, 2.0 equiv) and p-nitrobenzoic acid (104 mg, 0.62 mmol, 2.0 equiv) were than 
added sequentially. DIAD (126 mg, 0.62 mmol, 2.0 equiv) was then added slowly and the 
reaction was allowed to come to room temperature. The reaction was monitored via TLC 
(100% EtOAc) and judged complete in less than an hour. The reaction mixture was poured 
into a saturated NaHCO3 solution and extracted thrice with EtOAc. The combined organic 
layers were dried over Na2SO4, filtered and concentrated. This crude material was purified 
via flash chromatography (1 EtOAc/1 hexanes) to provide 134 mg (98%) of a colorless oil: 
1H NMR (400 MHz, CDCl3, 50 °C) δ 1.48 (s, 9H), 2.25 (d, J = 14.6 Hz, 1H), 2.43-2.51 (m, 
1H), 2.75-2.80 (m, 1H), 3.17 (s, 4H), 3.64 (s, 4H), 3.81-3.86 (m, 1H), 4.40-4.50 (bs, 1H), 
5.54-5.57 (m, 1H), 8.21-8.29 (m, 4H); 13C NMR (125 MHz, CDCl3, 50 °C) δ 22.3, 28.9, 
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36.7, 37.5, 52.9, 53.9, 61.6, 75.4, 80.4, 123.9, 131.1, 135.8, 151.2, 154.3, 164.4, 173.3; This 
p-nitrobenzoyl ester (0.12 g, 0.26 mmol) was dissolved in MeOH (10 mL) and K2CO3 
(excess) added. After 5 min the reaction was judged complete by TLC (100% EtOAc) and the 
reaction solvent was removed under reduced pressure. This residue was then dissolved in a 
1:1 CH2Cl2 and water mixture and extracted with CH2Cl2 (x3). The combined organic layers 
were dried over Na2SO4, filtered and concentrated. This crude material was purified via flash 
chromatography (100% EtOAc) to provide 60 mg (91%) of the desired product: 1H NMR 
(400 MHz, CDCl3, 50 °C) δ 1.44 (s, 9H), 1.92 (d, J = 14 Hz, 1H), 2.20-2.31 (m, 1H), 
2.89-3.11 (m, 3H), 3.15 (s, 3H), 3.38 (d, J = 12 Hz, 1H), 3.55 (bs, 1H), 3.68 (s, 3H), 4.22 (bs, 
1H), 4.39 (bs, 1H); 13C NMR (100 MHz, CDCl3, 50 °C) δ 28.9, 32.5, 37.4, 39.8, 54.0, 55.7, 
61.5, 70,7, 79.8, 154.7; IR (neat) 3439, 2974, 2935, 1680, 1400, 1172 cm-1; HRMS (ES+) m/
e calc’d for [M+H]+ C13H25N2O5 : 289.1763, found 289.1752.
tert-Butyl 3-(2-(Methoxy(methyl)amino)-2-oxoethyl)morpholine-4-carboxylate (2.6). 
The title compound was obtained from N-Boc-3-morpholineacetic acid using Method A as a 
white solid (99%) after flash chromatography (80% EtOAc/hexanes): mp 71.9-72.7 °C; 1H 
NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 2.54-2.64 (bm, 1H), 2.97-3.17 (bm, 2H), 3.17 (s, 
3H), 3.45 (dt, J = 5.8, 2.8 Hz, 1H), 3.58 (dd, J = 11.7, 2.2 Hz, 1H), 3.71 (s, 3H), 3.71-3.88 











61.3, 66.8, 69.1, 80.1, 154.5, 171.9; IR (neat) 2975, 1696, 1663, 1408, 1171, 1106 cm-1; 
HRMS (ESI+) m/e calc’d for [M+H]+ C13H25N2O5: 289.1763, found 289.1770.
tert-Butyl (cis)-2-(Methoxy(methyl)carbamoyl)cyclohexyl(methyl)carbamate (2.7). The 
title compound was obtained from N-Boc-cis-2-aminocyclohexanecarboxylic acid  using 
Method A and a subsequent methylation.  The Weinreb amide intermediate (following 
Method A) was isolated as a colorless oil (95%) after purification via flash chromatography 
(25% EtOAc/hexanes): 1H NMR (400 MHz, CDCl3, 50 °C) δ 1.16-1.40 (m, 2H), 1.38 (s, 
9H), 1.48-1.64 (m, 4H), 1.78-1.88 (m, 1H), 2.05-2.12 (m, 1H), 3.10 (bs, 1H), 3.12 (s, 3H), 
3.65 (s, 3H), 3.85 (bs, 1H), 4.98 (bs, 1H); 13C NMR (100 MHz, CDCl3, 50 °C) δ 23.1. 2, 
25.9, 28.7, 30.1, 32.7, 41.4, 48.9, 61.6, 79.2, 155.8, 175.2; IR (neat) 3439, 2930, 2860, 1700, 
1500, 1168 cm-1; HRMS (ES+) m/e calc’d for [M+H]+ C14H27N2O4 : 287.1971, found 
287.1971.  Methylation Procedure:  The Weinreb amide (160 mg, 0.56 mmol, 1.0 equiv) and 
MeI (170 μL, 2.8 mmol, 5.0 equiv) were dissolved in anhydrous DMF (15 mL) under an 
argon atmosphere and cooled to 0 °C. To this solution was added 60% NaH (45 mg, 1.1 
mmol, 2.0 equiv) in one portion and the reaction was allowed to come to room temperature. 
It was found crucial to use high quality NaH for this reaction to proceed. After 8 h the 
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the addition of water and placed in a separatory funnel. This solution was diluted with water 
and extracted with EtOAc (x3). The combined organic layers were back extracted with water 
(x2) to remove any residual DMF then dried over Na2SO4, filtered and concentrated. This 
crude material was purified via flash chromatography (25% EtOAc/hexanes) to provide 162 
mg (92%) of the title compound as a colorless oil: 1H NMR (400 MHz, CDCl3, 50 °C) δ 
1.32-1.52 (m, 3H), 1.45 (s, 9H), 1.55-1.66 (m, 1H), 1.78-1.97 (m, 3H), 2.35-2.44 (m,1H), 
2.72 (s, 3H), 3.13 (s, 3H), 3.42 (bs, 1H), 3.55 (s, 3H), 4.06 (bs, 1H); 13C NMR (100 MHz, 
CDCl3, rotameric) δ 20.9, 25.7, 26.0, 28.4, 28.5, 29.1, 29.6, 32.2, 36.4, 37.1, 55.9, 56.9, 61.3, 
79.1, 155.9; IR (neat) 3400, 1643, 1145 cm-1; HRMS (ES+) m/e calc’d for [M+H]+ 
C15H29N2O4: 301.2127, found 301.2116.
tert-Butyl (trans)-2-(Methoxy(methyl)carbamoyl)cyclohexyl(methyl)carbamate (2.8). 
The title compound was obtained from N-Boc-trans-2-aminocyclohexanecarboxylic acid 
using Method A and a subsequent methylation.  The Weinreb amide intermediate (following 
Method A) was isolated as a colorless oil (96%) after purification via flash chromatography 
(25% EtOAc/hexanes):  1H NMR (400 MHz, CDCl3, 50 °C) δ 1.16-1.58 (m, 4H) 1.38 (s, 
9H), 1.65-1.82 (bm, 3H), 1.98-2.07 (m, 1H), 2.90 (bs, 1H), 3.15 (s, 3H), 3.42-3.53 (m, 1H), 
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52.6, 61.8, 79.2, 155.4, 175.9; IR (neat) 3303, 2977, 2953, 2856, 1767, 1639, 1178 cm-1; 
HRMS (ES+) m/e calc’d for [M+H]+ C14H27N2O4: 287.1971, found 287.1968.  Methylation 
Procedure: The Weinreb amide (70 mg, 0.25 mmol, 1.0 equiv) and MeI (80 μL, 1.3 mmol, 
5.0 equiv) were dissolved in anhydrous DMF (20 mL) under an argon atmosphere and cooled 
to 0 °C.  To this solution was added 60% NaH (20 mg, 0.49 mmol, 2.0 equiv) in one portion 
and the reaction was allowed to come to room temperature. It was found crucial to use high 
quality NaH for this reaction to proceed. After 8 h the reaction was judged complete by TLC 
(50% EtOAc/hexanes). The reaction was quenched by the addition of water and placed in a 
separatory funnel. This solution was diluted with water and extracted with EtOAc (x3). The 
combined organic layers were back extracted with water (x2) to remove any residual DMF 
then dried over Na2SO4, filtered and concentrated. This crude material was purified via flash 
chromatography (25% EtOAc/hexanes) to provide 73 mg (99%) of the title compound as a 
colorless oil: 1H NMR (400 MHz, CDCl3, 50 °C) δ 1.15-1.58 (m, 3H), 1.43 (s, 9H), 
1.65-1.89 (bm, 6H), 2.79 (s, 3H), 3.14 (s, 3H), 3.42-3.53 (bs, 1H), 3.69 (s, 3H); 13C NMR 
(100 MHz, CDCl3, rotameric) δ 25.0, 25.1, 25.5, 25.6, 28.0, 28.5, 29.2, 29.9, 30.0, 32.3, 42.6, 
61.5, 78.8, 79.5, 154.9, 155.8, 175.1, 175.7; IR (neat) 2957, 1680, 1360 cm-1; HRMS (ES+) 
m/e calc’d for [M+H]+ C15H29N2O4 : 301.2127, found 301.2110.
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(R)-tert-Butyl 3-(Methoxy(methyl)amino)-3-oxo-1-phenylpropylcarbamate (2.9).  The 
title compound was obtained using Method A as a colorless oil (99%) after flash 
chromatography (70% EtOAc/hexanes): 1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 2.83 
(dd, J = 15.2, 4.3 Hz, 1H), 3.03-3.10 (m, 1H), 3.10 (s, 3H), 3.50 (s, 3H), 5.11 (bs, 1H), 6.14 
(bs, 1H), 7.20-7.26 (m, 1H), 7.29-7.33 (m, 4H); 13C NMR (100 MHz, CDCl3) δ  28.4, 31.9, 
37.8, 51.3, 61.2, 79.3, 126.1, 127.1, 128.5, 142.1, 155.2, 171.8; IR (neat) 2977, 1712, 1655, 
1496, 1366, 1170 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C16H25N2O4: 309.1814, found 
309.1800; α[ ]D
22 =  –12.0 (c 1.00, CHCl3).
(S)-tert-Butyl 4-(Methoxy(methyl)amino)-4-oxo-1-phenylbutan-2-ylcarbamate (2.10). 
The crude material from Method B was purified via flash chromatography (25% EtOAc/
hexanes) to provide the desired product as a colorless oil (54% 2 steps): 1H NMR (400 MHz, 
CDCl3, 50 °C) δ 1.38 (s, 9H), 2.50-2.62 (bm, 2H), 2.80-2.87 (m, 1H), 2.96-3.02 (m, 1H), 

















MHz, CDCl3, 50 °C) δ 28.8, 32.3, 34.8, 40.7, 49.3, 61.4, 79.3, 126.8, 128.8, 129.7, 138.9, 
155.7, 173.0; IR (neat) 3342, 2975, 2934, 1713, 1660, 1496, 1171 cm-1; HRMS (ES+) m/e 
calc’d for [M+H]+ C17H27N2O4: 323.1971, found 323.1943; α[ ]D
22 =  –21 (c 0.75, CHCl3).
tert-Butyl 3-(Methoxy(methyl)amino)-3-oxopropylcarbamate (2.11). The title compound 
was obtained according to Method A as a colorless oil (95%) after flash chromatography 
(85% EtOAc/hexanes): 1H NMR (400 MHz, CDCl3) δ (1:1 mixture of rotamers) 1.43 (s, 9H), 
2.63-2.67 (bm, 2H), 3.19 (s, 3H), 3.42 (td, J = 5.8, 5.8 Hz, 2H), 3.68 (s, 3H), 5.31 (bm, 1H); 
13C NMR (100 MHz, CDCl3) δ 28.3, 28.3, 31.9, 32.2, 35.7, 61.1, 61.2, 78.9, 155.9, 173.1; IR 
(neat) 3349, 2976, 1713, 1660, 1520, 1173 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 
C10H21N2O4: 233.1501, found 233.1501.
tert-Butyl Benzyl(3-(methoxy(methyl)amino)-3-oxopropyl)carbamate (2.12).  The title 

















chromatography (70% EtOAc/hexanes):  1H NMR (400 MHz, CDCl3) δ (1:1 mixture of 
rotamers) 1.44 (s, 9H), 1.50 (s, 9H), 2.58-2.63 (bm, 2H), 2.67-2,72 (bm, 2H), 3.15 (s, 6H), 
3.43-3.48 (bm, 2H), 3.51-3.55 (bm, 2H), 3.63 (bs, 6H), 4.48 (s, 4H), 7.22-7.35 (m, 10H); 13C 
NMR (100 MHz, CDCl3) δ 28.4, 31.2, 32.1, 42.8, 43.1, 50.6, 51.6, 61.2, 61.3, 79.8, 127.2, 
127.3, 127.8, 128.4, 138.4, 138.8, 155.5, 155.8, 172.5, 172.9; IR (neat) 2974, 1693, 1664, 
1413, 1366, 1167 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C17H27N2O4: 323.1971, found 
323.1957.
tert-Butyl 3-(Methoxy(methyl)amino)-3-oxopropyl(phenyl)carbamate (2.13).  The methyl 
ester precursor was synthesized from aniline (5.0 mL, 53 mmol, 1.0 equiv)  and methyl 
acrylate (4.7 mL, 53 mmol, 1.0 equiv) as reported by Amore et al.346  The crude product was 
redissolved in ethanol (100 mL) and di-tert-butyldicarbonate (12.6 g, 57.8 mmol, 1.10 equiv) 
was added slowly.  The reaction mixure was stirred for 24 h and the solvent was removed in 
vacuo.  The concentrated reaction mixture was redissolved in CH2Cl2 (300 mL) and washed 
with cold 10% HCl (100 mL x 2) and brine (100 mL x 2).  The organic layer was dried with 






















hexanes) to afford 8.71g (57% for 2 steps) of the methyl ester as a clear viscous oil.  This oil 
was converted to the corresponding Weinreb amide using the procedure reported by Williams 
et al.279 The crude product was purified via SiO2 flash chromatography (40% EtOAc in 
hexanes) to afford 7.89 g (82%) of the Weinreb amide as a clear viscous oil:  1H NMR (400 
MHz, CDCl3) δ 1.43 (s, 9H), 2.73 (t, J = 7.5, 2H), 3.12 (s, 3H), 3.65 (s, 3H), 3.96 (t, J = 7.5 
Hz, 2H), 7.22-7.17 (m, 3H), 7.34-7.31 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 28.3, 31.1, 
32.0, 46.3, 61.3, 80.3, 126.1, 127.0, 128.7, 142.3, 154.5, 172.4; IR (neat) 2976, 1698, 1664, 
1456, 1391, 1168 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C16H25N2O4: 309.1814, found 
309.1821.
  
tert-Butyl 2-(3-(Methoxy(methyl)amino)-3-oxopropyl)pyrrolidine-1-carboxylate.  The 
methyl ester precursor to the title compound was prepared in 4 steps (88%) from the 
precedent of Poon et al.347 The title compound was obtained as a colorless oil using step 2 of 
Method C:  1H NMR (400 MHz, CDCl3) δ  (1:1 mixture of rotamers) 1.46 (s, 18H), 1.62-1.76 
(m, 4H), 1.79-2.00 (bm, 8H), 2.40-2.49 (bm, 4H), 3.18 (s, 6H), 3.29-3.34 (bm, 3H), 
3.40-3.47 (bm, 1H), 3.69 (s, 6H), 3.80-3.91 (bm, 2H); 13C NMR (100 MHz, CDCl3) δ 23.0, 












79.2, 154.8, 174.2; IR (neat) 2972, 1692, 1393, 1367, 1172, 1107 cm-1; HRMS (ESI+) m/e 
calc’d for [M+H]+ C16H25N2O4: 287.1971, found 287.1982.
\
tert-Butyl 2-(3-(Methoxy(methyl)amino)-3-oxopropyl)piperidine-1-carboxylate.  The 
methyl ester precursor to the title compound was prepared in 4 steps (85%) from the 
precedent of Poon et al.347 The title compound was obtained as a colorless oil using step 2 of 
Method C:1H NMR (400 MHz, CDCl3) δ 1.33-1.50 (m, 1H), 1.45 (s, 9H), 1.56-1.73 (m, 6H), 
2.05-2.15 (m, 1H), 2.31-2.49 (m, 2H), 2.75-2.81 (m, 1H), 3.17 (s, 3H), 3.66 (s, 3H), 3.99 (bs, 
1H), 4.27 (bs, 1H); 13C NMR (100 MHz, CDCl3) δ 19.1, 24.6, 25.6, 28.5, 28.9, 29.1, 32.2, 
38.5, 50.2, 61.1, 79.1, 155.1, 174.4; IR (neat) 2936, 1687, 1417, 1365, 1273, 1162 cm-1; 













O i)  5N HCl (aq.), reflux
ii) PhCHO, NaOH, 
    MeOH; then NaBH4
iii) Boc2O, NaOH, t-BuOH
iv) EDCI, NMM, CH2Cl2





tert-Butyl Benzyl ((1 - (2- (methoxy (methyl)amino)  2 - oxoethyl)  cyclohexyl)  methyl) 
carbamate. Spirocyclic lactam (4.0 g, 26 mmol, 1.0 equiv) was dissolved in 5N HCl aq. 
(100 mL).  The solution was heated to reflux for 24 h.  The solvent was removed in vacuo 
leaving an off-white solid.  The solid was redissolved in MeOH (60 mL) and to the solution 
was added solid NaOH (2.6 g, 65 mmol, 2.5 equiv). When everything had dissolved 
benzaldehyde (3.7 mL, 37 mmol, 1.4 equiv) was added.  After 10 min of stirring, the reaction 
mixture was cooled to 0 ºC and NaBH4 (1.3 g, 34 mmol, 1.3 equiv) was added and the 
reaction stirred for 2 h.  The solvent was removed under reduced pressure and the residue 
redissolved in MeOH (50 mL).  This was repeated 3 times.  The residue was dissolved in t-
BuOH (60 mL) and di-tert-butyldicarbonate (7.4 g, 34 mmol, 1.3 equiv) was added slowly. 
10% NaOH was added to the reaction mixture until pH = 12.  The reaction was stirred for 5 h 
keeping the pH at 12 by adding 10% NaOH when appropriate.  The reaction was quenched 
by adding 1N NaHSO4  until the pH reached 2 and EtOAc (150 mL) was added.  The product 
was extracted with EtOAc (3x).  The combined organic layers were dried over Na2SO4 and 
purified via SiO2 flash chromatography using 10 % EtOAc in hexanes (1% AcOH) as eluent 
to afford 5.3 g (56%) of the carboxylic acid as a clear viscous oil.  Method A was used to 
convert the acid into the Weinreb amide.  The title compound was obtained as a colorless oil 
after flash chromatography (25% EtOAc/hexanes): 1H NMR (400 MHz, CDCl3) δ 1.33 (s, 
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9H), 1.33-1.56 (m, 8H), 1.64-1.71 (m, 2H), 2.51 (s, 2H), 3.15 (s, 3H), 3.39 (bs, 1H), 3.48 (bs, 
1H), 3.65 (s, 3H), 4.49 (bs, 2H), 7.18-7.23 (m, 3H), 7.27-7.31 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 21.9, 26.0, 28.3, 32.0, 33.9, 35.1, 39.4, 53.3, 54.5, 61.0, 79.4, 126.7, 127.4, 128.3, 
139.5, 157.1, 173.4; IR (neat) 2931, 1695, 1454, 1407, 1248, 1165 cm-1; HRMS (ESI+) m/e 
calc’d for [M+H]+ C23H37N2O4: 405.2753, found 405.2738.
i) PhCHO, NaOH, 
    MeOH; then NaBH4
ii) Boc2O, NaOH, t-BuOH
iii) EDCI, NMM, CH2Cl2









tert-Butyl Benzyl(2-(4-chlorophenyl)–4-(methoxy (methyl)  amino)-4-oxobutyl) 
carbamate. Baclofen (900 mg, 4.2 mmol, 1.0 equiv) was dissolved in MeOH (10 mL) and to 
the solution was added solid NaOH (190 mg, 4.6 mmol, 1.1 equiv). When everything had 
dissolved benzaldehyde (0.60 mL, 5.9 mmol, 1.4 equiv) was added.  After 10 min of stirring, 
the reaction mixture was cooled to 0 ºC and NaBH4 (210 mg, 5.5 mmol, 1.3 equiv) was 
added and the reaction stirred for 2 h.  The solvent was removed under reduced pressure and 
the residue redissolved in MeOH (10 mL).  This was repeated three times.  The residue was 
dissolved in t-BuOH (10 mL) and di-tert-butyldicarbonate (1.2 g, 5.5 mmol, 1.3 equiv) was 
added slowly.  10% NaOH was added to the reaction mixture until pH = 12.  The reaction 
was stirred for 5 h keeping the pH at 12 by adding 10% NaOH when appropriate.  The 
reaction was quenched by adding 1N NaHSO4 until the pH of the reaction mixture had 
reached 2.  The product was extracted with EtOAc (3x).  The combined organic layers were 
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dried over Na2SO4 and purified via SiO2 flash chromatography using 15 % EtOAc in hexane 
(1% AcOH) as eluent to afford 1.2 g (69%) of carboxylic acid as a clear viscous oil.  Method 
A was used to convert the acid into the Weinreb amide.  The title compound was obtained as 
a colorless oil after flash chromatography (35% EtOAc/hexanes):  1H NMR (400 MHz, 
CDCl3) δ (1:1 mixture of rotamers) 1.38 (s, 9H), 1.44 (s, 9H), 2.63-2.84 (m, 4H), 3.08 (s, 6H), 
3.25-3.34 (m, 2H), 3.37-3.42 (m, 1H), 3.55-3.66 (m, 3H), 3.59 (s, 6H), 4.13 (d, J = 15.6 Hz, 
2H), 4.45-4.52 (m, 2H), 7.10-7.31 (m, 18H); 13C NMR (100 MHz, CDCl3) δ 28.3, 32.1, 35.3, 
35.5, 39.2, 39.6, 49.7, 50.1, 50.8, 51.5, 61.2, 79.9, 127.2, 127.9, 128.5, 128.6, 129.3, 132.4, 
132.4, 138.0, 138.1, 140.8, 155.8, 172.1, 172.4; IR (neat) 2975, 1693, 1416, 1366, 1165, 701 
cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C24H32ClN2O4: 447.2051, found 447.2053.
6.3.2 Preparation of ynones:
The Weinreb amide (2.52 mmol, 1.00 equiv) was dissolved in anhydrous THF (40 mL) under 
an argon atmosphere and cooled to 0 °C.  To this reaction vessel, was added dropwise, a 
solution of ethynyl magnesium bromide reagent (12.6 mmol, 5.00 equiv) in THF and allowed 
to come to room temperature. After the reaction was judged complete by TLC it was 
quenched by the addition of an ice cold 10% HCl solution (15 mL) and allowed to stir at this 


















The combined organic layers were washed with saturated NaHCO3 (x1), dried over Na2SO4, 
filtered and concentrated.  This crude material was purified via flash chromatography using 























































Compounds previously reported in Turunen and Georg.255
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(2S*,4R*)-tert-Butyl 4-(Benzyloxy)-2-(2-oxobut-3-ynyl)pyrrolidine-1-carboxylate (2.20). 
The title compound was obtained as a colorless oil (92%) after flash chromatography (20% 
EtOAc/hexanes):  1H NMR (400 MHz, CDCl3) δ (1:1 mixture of rotamers) 1.46 (s, 9H), 1.48 
(s, 9H), 1.77-1.87 (bm, 2H), 2.35 2.35 (dddd, J = 13.3, 7.7, 3.9, 1.0 Hz, 2H), 2.65-2.73 (bm, 
2H), 3.16 (bd, J = 15.3 Hz, 1H), 3.26 (bd, J = 16.9 Hz, 2 H), 3.35-3.42 (m, 3H), 3.56 (bd, J = 
11.3 Hz, 1H), 3.78 (bd, J = 11.6 Hz, 1H), 4.06-4.10 (m, 2H), 4.30-4.38 (bm, 2H), 4.44-4.55 
(bm, 2H), 4.50 (bd, J = 10.2 Hz, 2H), 7.28-7.36 (m, 10H); 13C NMR (100 MHz, CDCl3) δ 
28.5, 36.9, 38.2, 49.7, 50.9, 51.1, 51.9, 52.2, 70.9, 75.6, 76.1, 78.8, 79.1, 79.7, 80.3, 81.5, 
127.6, 127.7, 127.7, 128.5, 137.9, 154.4, 154.5, 185.0, 185.3; IR (neat) 2976, 2091, 1685, 









(2.21).  The title compound was obtained as a colorless oil (90%) after flash chromatography 
(20% EtOAc/hexanes): 1H NMR (400 MHz, CDCl3) δ (1:1 mixture of rotamers) 1.46 (s, 9H), 
1.48 (s, 9H), 1.80-1.88 (m, 2H), 2.01 (s, 6H), 2.33 (dddd, J = 13.5, 7.7, 4.1, 1.5 Hz, 2H), 2.60 
(dd, J = 15.8, 9.2 Hz, 2H), 3.09 (bd, J = 14.7 Hz, 1H), 3.34-3.44 (m, 3H), 3.55 (bd, J = 10.4 
Hz, 1H), 3.75 (bd, J = 11.4 Hz, 1H), 4.09 (p, J = 1.2 Hz, 2H), 4.29-4.37 (m, 2H), 4.46-4.54 
(m, 4H), 7.26-7.36 (m, 10H); 13C NMR (100 MHz, CDCl3) δ 4.1, 28.5, 36.8, 38.1, 49.6, 50.9, 
51.0, 51.9, 52.5, 70.9, 75.7, 76.2, 79.6, 80.0, 80.4, 127.6, 127.7, 127.7, 128.5, 137.9, 154.4, 
185.8, 186.0; IR (neat) 2975, 2219, 1694, 1398, 1366, 1166 cm-1; HRMS (ESI+) m/e calc’d 













carboxylate (2.22).  The title compound was obtained as a yellow oil (85%) after flash 
chromatography (15% EtOAc/hexanes): 1H NMR (400 MHz, CDCl3) δ (1:1 mixture of 
rotamers) 1.46 (s, 9H), 1.50 (s, 9H), 1.87-1.94 (bm, 2H), 2.36-2.42 (bm, 2H), 2.75-2.83 (bm, 
2H), 3.22 (bd, J = 14.5 Hz, 1H), 3.41-3.53 (bm, 3H), 3.58 (bd, J = 10.7  Hz, 1H), 3.79 (bd, J 
= 11.2 Hz, 1H), 4.11 (p, J = 4.1 Hz, 2H), 4.38-4.44 (bm, 2H), 4.46-4.55 (m, 2H), 4.5 (d, J = 
10.7 Hz, 2H), 7.27-7.41 (m, 14H), 7.43-7.48 (bm, 2H), 7.57 (d, J = 7.12 Hz, 4H); 13C NMR 
(100 MHz, CDCl3) δ 28.5, 36.9, 38.2, 49.6, 50.9, 51.1, 52.0, 52.6, 70.9, 75.7, 76.2, 79.6, 
80.2, 88.0, 91.0, 91.4, 119.7, 119.9, 127.6, 127.7, 127.7, 128.4, 128.6, 128.7, 130.7, 130.9, 
133.1, 137.9, 154.5, 185.6, 185.9; IR (neat) 2975, 2203, 1692, 1397, 1366, 1160 cm-1; HRMS 
(ESI+) m/e calc’d for [M+H]+ C26H30NO4: 420.2175, found 420.2157.
tert-Butyl 3-(2-Oxobut-3-ynyl)morpholine-4-carboxylate (2.25).  The title compound was 
obtained as a white solid (95%) after flash chromatography (20% EtOAc/hexanes): mp 
86.3-86.7 °C 1H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 2.87 (dd, J = 15.8, 5.4 Hz, 1H), 
3.08-3.16 (m, 2H), 3.34 (s, 1H), 3.46 (dt, J = 11.8, 2.5 Hz, 1H), 3.59 (dd, J = 11.8, 2.8 Hz, 








47.9, 66.8, 69.0, 79.0, 80.7, 81.5, 154.3, 184.7; IR (neat) 2977, 2092, 1685, 1408, 1367, 1170 
cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C13H20NO4: 254.1392, found 254.1386.
(R)-tert-Butyl 3-Oxo-1-phenylpent-4-ynylcarbamate (2.28).  The title compound was 
obtained as a off-white solid (76%) after flash chromatography (20% EtOAc/hexanes): mp 
94.1-95.4 ºC; 1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H), 3.08 (dd, J = 16.2, 6.1 Hz, 1H), 
3.18-3.24 (bm, 1H), 3.27 (s, 1H), 5.16 (bs, 1H), 5.23 (bs, 1H), 7.25-7.36 (m, 5H); 13C NMR 
(100 MHz, CDCl3) δ  28.3, 50.9, 51.3, 79.9, 79.9, 81.1, 126.3, 127.7, 128.8, 140.7, 154.9, 
184.3; IR (neat) 3270, 2979, 2094, 1687, 1367, 1169 cm-1; HRMS (ESI+) m/e calc’d for [M
+H]+ C16H20NO3: 274.1443, found 274.1452; α[ ]D
22 =  –20 (c 0.61, CHCl3).
tert-Butyl 3-Oxopent-4-ynylcarbamate (2.31).  The title compound was obtained as a 
colorless oil (89%) after flash chromatography (25% EtOAc/hexanes):  1H NMR (400 MHz, 













4.97 (bs, 1H); 13C NMR (100 MHz, CDCl3) δ  28.4, 34.9, 45.6, 79.4, 79.5, 81.2, 155.7, 186.1; 
IR (neat) 3353, 2979, 2093, 1683, 1515, 1172 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 
C10H16NO3: 198.1130, found 198.1121.
tert-Butyl Benzyl(3-oxopent-4-ynyl)carbamate (2.32).  The title compound was obtained as 
a colorless oil (89%) after flash chromatography (20% EtOAc/hexanes):  1H NMR (400 
MHz, CDCl3) δ (1:1 mixture of rotamers) 1.45 (s, 9H), 1.50 (s, 9H), 2.75-2.80 (bm, 2H), 
2.86-2.91 (bm, 2H), 3.24 (s, 2H), 3.45-3.55 (bm, 4H), 4.45 (bs, 4H), 7.21-7.35 (m, 10H); 13C 
NMR (100 MHz, CDCl3) δ 28.4, 41.5, 41.9, 44.3, 44.6, 50.5, 51.6, 79.1, 80.3, 81.3, 127.2, 
127.8, 127.3, 128.6, 138.2, 155.4, 185.3; IR (neat) 2977, 2092, 1684, 1415, 1367, 1165 cm-1; 
HRMS (ESI+) m/e calc’d for [M+H]+ C17H22NO3: 288.1600, found 288.1594.
tert-Butyl 3-Oxopent-4-ynyl(phenyl)carbamate (2.33).  The title compound was obtained 











MHz, CDCl3) δ 1.42 (s, 9H), 2.89 (t, J = 7.2, 2H), 3.24 (s, 1H), 3.99 (t, J = 7.2 Hz, 2H), 
7.16-7.23 (m, 3H), 7.32-7.36 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 28.3, 44.3, 45.1, 79.1, 
80.7, 81.2, 126.5, 127.2, 128.9, 141.9, 154.4, 185.0; IR (neat) 2978, 2092, 1694, 1393, 1368, 
1163 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C16H20NO3: 274.1443, found 274.1445.
tert-Butyl 2-(3-Oxopent-4-ynyl)pyrrolidine-1-carboxylate (2.57).  The title compound was 
obtained as a colorless oil (90%) after flash chromatography (20% EtOAc/hexanes):  1H 
NMR (400 MHz, CDCl3) δ (1:1 mixture of rotamers) 1.47 (s, 9H), 1.58-1.66 (m, 1H), 
1.73-2.01 (m, 5H), 2.59-2.68 (m, 2H), 3.25-3.48 (m, 2H), 3.26 (s, 1H), 3.80-3.91 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ 23.0, 23.7, 28.5, 30.2, 30.9, 42.4, 42.6, 46.1, 46.5, 78.6, 79.1, 
79.5, 81.4, 154.8, 186.6, 186.9; IR (neat) 2974, 2090, 1686, 1396, 1171, 1112 cm-1; HRMS 











tert-Butyl 2-(3-Oxopent-4-ynyl)piperidine-1-carboxylate (2.58).  The title compound was 
obtained as a colorless oil (95%) after flash chromatography (20% EtOAc/hexanes):  1H 
NMR (400 MHz, CDCl3) δ 1.34-1.48 (m, 2H), 1.46 (s, 9H), 1.51-1.75 (m, 5H), 2.06-2.15 (m, 
1H), 2,51-2.67 (m, 2H), 2.72 (bdd, J = 13.0, 13.0 Hz, 1H), 3.25 (s, 1H), 3.98 (bs, 1H), 4.25 
(bs, 1H); 13C NMR (100 MHz, CDCl3) δ 19.0, 23.4, 25.5, 28.4, 29.0, 38.6, 42.3, 49.5, 78.5, 
79.5, 81.5, 155.1, 186.6; IR (neat) 2936, 2090, 1683, 1418, 1366, 1162 cm-1; HRMS (ESI+) 
m/e calc’d for [M+H]+ C15H24NO3: 266.1756, found 266.1750.
tert-Butyl Benzyl((1-(2-oxobut-3-ynyl)cyclohexyl)methyl)carbamate (2.59).  The title 
compound was obtained as a colorless oil (93%) after flash chromatography (15% EtOAc/
hexanes): 1H NMR (400 MHz, CDCl3) δ 1.26-1.68 (m, 19H), 2.73 (s, 2H), 3.15 (s, 1H), 3.35 
(bs, 2H), 4.47 (bs, 2H), 7.16-7.25 (m, 3H), 7.29-7.32 (m, 2H);  13C NMR (100 MHz, CDCl3) 
δ 21.7, 25,9, 28.3, 33.9, 40.3, 49.3, 53.2, 54.5, 79.8, 82.8, 126.8, 126.9, 128.4, 139.0, 157.0, 
186.5; 13C NMR (100 MHz, CDCl3) δ 21.7, 25.9, 28.3, 33.9, 40.3, 49.3, 53.2, 54.6, 79.8, 
80.3, 82.8, 126.8, 126.9, 128.4, 138.9, 157.0, 186.5; IR (neat) 2930, 2090, 1692, 1409, 1248, 







tert-Butyl Benzyl(2-(4-chlorophenyl)-4-oxohex-5-ynyl)carbamate (2.60).  The title 
compound was obtained as a colorless oil (95%) after flash chromatography (15% EtOAc /
hexanes):  1H NMR (400 MHz, CDCl3) δ (1:1 mixture of rotamers) 1.41 (s, 9H), 1.46 (s, 9H), 
2.85-3.04 (m, 4H), 3.20 (s, 2H), 3.21 (dd, J = 13.9, 7.7 Hz, 2H), 3.32-3.39 (m, 1H), 3.55-3.70 
(m, 3H), 4.07 (bs, 1H), 4.11 (bs, 1H), 4.37-4.46 (m, 2H), 7.05-7.18 (m, 8H), 7.23-7.32 (m, 
10H); 13C NMR (100 MHz, CDCl3) δ 28.3, 38.9, 39.3, 48.6, 48.9, 50.2, 50.8, 51.6, 79.1, 80.3, 
81.3, 127.2, 127.3, 127.8, 128.6, 128.8, 129.1, 132.9, 137.9, 139.5, 155.9; IR (neat) 2976, 
2092, 1686, 1413, 1366, 1164 cm-1; HRMS (ESI+) m/e calc’d for [M+Na]+ C24H26NO3ClNa: 
434.1493, found 434.1479.







i) Method A, B or C








Representative procedures for deprotection:
METHOD A:  The ynone (0.50 mmol) was dissolved in a 4N HCl-dioxane solution (1.5 






allowed to evaporate while passing air over the reaction mixture.  The remaining solid was 
placed under vacuum for 15 min and carried on to the cyclization step without further 
purification.    
METHOD B:  The ynone (0.50 mmol, 1.0 equiv) was dissolved in 98% formic acid (5.0 
mL) under a N2 atmosphere and NaI (230 mg, 1.5 mmol, 3.0 equiv) was added. Note: For 
terminal ynones the reaction was left stirring for 6 h.  When internal ynones were used the 
reaction was left for 24 h.  The solvent was removed by passing N2 over the reaction mixture. 
The remaining residue was placed under vacuum for 15 min and was carried on to the 
cyclization step without further purification.   
Large Scale Modification: When using greater that 1.0 gram of ynone, the desired 
deprotected amine can be isolated by pouring the reaction mixture into ether and filtering the 
precipitate.     
METHOD C: The ynone (0.50 mmol, 1.0 equiv) was dissolved in anhydrous CH2Cl2 (10 
mL) under an argon atmosphere and cooled to –78 °C.  A solution of TMS-I ( 0.50 mmol, 1.0 
equiv) in anhydrous CH2Cl2 (5 mL) was then added dropwise at this temperature.  After 20 
min at this temperature the reaction was allowed to warm to 0 °C and additional TMS-I 
(0.50-2.5 mmol) was added until all starting material was consumed (TLC, 25% EtOAc in 
hexanes).  After 20 min the reaction was judged complete and this mixture was concentrated 
under reduced pressure and placed under vacuum for 15 min. 
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Representative procedures for cyclization:
The deprotected intermediates from Methods A, B and C were dissolved in MeOH (50 mL) 
and excess K2CO3 (a minimum of 5.0 equiv) was added.  The reactions were stirred for 
various lengths of time depending on the substrate (For enaminones 2.37, 2.41, 2.35, 2.48, 
2.36 and 2.50 reactions were stirred for 1 h;  for enaminones 2.34, 2.49, 2.52, 2.51, 2.54 and 
2.55 reactions were stirred for 3 h;  for enaminones 2.46, 2.47, 2.39, 2.40, 2.42, 2.43, 2.53, 
2.56, 2.61, 2.62, 2.63 and 2.64 reactions were stirred for 6 h).  At this time CH2Cl2 was 
added, the reaction suction filtered, and the organic solvents concentrated.  To the solid 
residue was added more CH2Cl2 and the precipitates were once again filtered away.  This 
residue was purified via flash chromatography to provide pure enaminone. 
Large Scale Modification: When the reaction was complete, the MeOH was removed in 
vacuo and  the remaining residue redissolved in brine.  The product was extracted with 
CH2Cl2 (3x).  The combined organic layers were dried over Na2SO4 and purified via SiO2 
flash chromatography.  Note: Several of the enaminones (e.g. 2.34, 2.37, 2.35, 2.48, etc.) 
were water soluble and could not be purified by this method.
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(S)-7,8,9,9a-Tetrahydro-1H-quinolizin-2(6H)-one (2.34). Spectral data of the title 
compound was identical to that reported in the literature255 with the exception of optical 
rotation: Comparison to the reported value, α[ ]D
22 =  –146 (c 0.885, CHCl3), indicated an ee 
of 93% and 99% for Method A ( α[ ]D
22 =   –135 (c 0.925, CHCl3))  and Method B     ( α[ ]D
22 =  





























































using a Baker Chiralcel OJ column.  Conditions: i-PrOH 2-15% in hexanes, 60 min, 0.5 mL/
min, 30 °C. (–)-Enantiomer: Rt = 40.1 min;  (+)-Enantiomer: Rt = 41.6 min.  Method A:  ee = 
94%.  Method B: ee = 96%.   
(S)-4-Methyl-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (2.46). Spectral data of the 
title compound was identical to that reported in the literature.255 The optical rotation, 
however, has not been previously reported: Enantiomeric ratios were determined via chiral 
HPLC using a Chiralcel OD column.  Conditions: i-PrOH 1-25% in hexanes, 60 min, 1.0 
mL/min, 30 °C. (–)-Enantiomer: Rt = 36.3 min;  (+)-Enantiomer: Rt = 39.6 min.  Method A: 
ee = 44%;  Method B: ee = 44%.  Method A and B α[ ]D
22 =  –95.0  (c 0.924, CHCl3).
(S)-4-Phenyl-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (2.47).  Spectral data of the 
title compound was identical to that reported in the literature.255 The optical rotation, 












HPLC using a Chiralcel AD-H column.  Conditions: i-PrOH 1-20% in hexanes, 40 min, 1.0 
mL/min, 30 °C. (–)-Enantiomer: Rt = 30.4 min;  (+)-Enantiomer: Rt = 29.0 min.  Method A: 
ee = 16%;  Method B: ee = 38%. Method A α[ ]D
22 =  –4.2 (c 1.00, CHCl3); Method B α[ ]D
22 =  
–10.7 (c 1.00, CHCl3).
(S)-2,3,8,8a-Tetrahydroindolizin-7(1H)-one (2.37). Spectral data of the title compound was 
identical to that reported in the literature255 with the exception of optical rotation.       Method 
A:  ee = 40%.  Method B: ee = 96%; Method A α[ ]D
22 =  –180 (c 1.00, CHCl3); Method B 
α[ ]D
22 =  –727 (c 1.00, CHCl3); Method C α[ ]D
22 =  –628 (c 1.00, CHCl3).  Enantiomeric ratios 
were determined via chiral HPLC using a Chiralcel OJ column after converting enaminone 
2.37 to aryl derivative 3.2. Conditions for arylenaminone 3.2: i-PrOH 70% in hexanes, 30 










(2R*, 8aS*)-2-(Benzyloxy)-2,3,8,8a-tetrahydroindolizin-7(1H)-one (2.41).  The title 
compound was obtained as a colorless oil (Method A, 94%; Method B, 92%) after flash 
chromatography (100% acetone): 1H NMR (400 MHz, CDCl3) δ 1.77 (ddd, J = 13.2, 11.2, 
4.5 Hz, 1H), 2.35 (dd, J = 16.2, 16.2 Hz, 1H), 2.44-2.51 (m, 2H), 3.60 (d, J = 11.8 Hz, 1H), 
3.70 (dd, J = 11.8, 4.9 Hz, 1H), 4.07 (dddd, J = 16.4, 10.9, 5.3, 5.3 Hz, 1H), 4.29 (dd, J = 4.5, 
4.5 Hz, 1H), 4.51 (d, J = 11.8 Hz, 1H), 4.56 (d, J = 11.8 Hz, 1H), 4.99 (d, J = 7.1 Hz, 1H), 
7.17 (d, J = 7.1 Hz, 1H), 7.29-7.38 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 38.5, 41.4, 55.4, 
56.2, 71.0, 77.1, 97.9, 127.6, 128.0, 128.6, 137.5, 149.9, 191.9; IR (neat) 2929, 1631, 1579, 
1460, 1306, 1099 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C15H18NO2: 244.1338, found 
244.1332.
(2R*,8aS*)-2-(Benzyloxy)-5-methyl-2,3,8,8a-tetrahydroindolizin-7(1H)-one (anti-2.42). 
The title compound was obtained as a colorless oil [Method A, 87% (d.r. 63:37); Method B, 
94% (d.r. 68:32)] after flash chromatography (1-10% MeOH/EtOH): 1H NMR (400 MHz, 
CDCl3) δ 1.67 (ddd, J = 13.3, 11.4, 4.5 Hz, 1H), 1.92 (s, 3H), 2.22 (dd, J = 16.1, 16.1 Hz, 
1H), 2.36-2.43 (m, 2H), 3.33 (d, J = 12.16 Hz, 1H), 3.61 (dd, J = 12.2, 4.7 Hz, 1H), 4.00 
(dddd, J = 16.3, 10.7, 5.0, 5.0 Hz, 1H), 4.22 (dd, J = 4.5, 4.5 Hz, 1H), 4.43 (d, J = 11.8 Hz, 








δ 20.4, 38.3, 41.0, 53.5, 56.8, 71.0, 76.3, 98.5, 127.6, 128.0, 128.6, 137.5, 160.8, 191.3; IR 
(neat) 2928, 1622, 1550, 1497, 1431, 1093 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 
C19H20NO2:, 258.1494, found 258.1491.
(2R*, 8aR*)-2-(Benzyloxy)-5-methyl-2,3,8,8a-tetrahydroindolizin-7(1H)-one (syn-2.42). 
This compound is the minor diastereomer of the above reaction.  The compound was 
obtained as a colorless oil after flash chromatography (1-10% MeOH/EtOH): 1H NMR (400 
MHz, CDCl3) δ 1.79 (ddd, J = 12.5, 10.0, 7.7 Hz, 1H), 1.89 (s, 3H), 2.33 (d, J = 16.0 Hz, 
1H), 2.39 (d, J = 16.0 Hz, 1H), 2.49 (ddd, J = 12.7, 6.4, 6.4 Hz, 1H), 3.41 (dd, J = 11.2, 5.6 
Hz, 1H), 3.60 (dd, J = 11.2, 7.0 Hz, 1H), 3.71 (dddd, J = 16.4, 10.0, 6.6, 6.6 Hz, 1H), 4.19 
(m, 1H), 4.44 (d, J = 11.8 Hz, 1H), 4.53 (d, J = 11.8 Hz, 1H), 4.87 (s, 1H), 7.23-7.32 (m, 
5H); 13C NMR (100 MHz, CDCl3) δ  20.4, 38.3, 41.5, 52.3, 57.4, 71.9, 76.0, 98.9, 127.7, 
128.1, 128.6, 137.5, 160.7, 191.3; IR (neat) 2870, 1623, 1551, 1496, 1432, 1125 cm-1; HRMS 









The title compound was obtained as a colorless oil [Method A, 85% (d.r. 63:37); Method B, 
88% (d.r. 60:40)] after flash chromatography (1-10% MeOH/EtOH): 1H NMR (400 MHz, 
CDCl3) δ 1.80 (ddd, J = 13.3, 9.9, 4.7 Hz, 1H), 2.38-2.48 (m, 3H), 3.37 (dd, J = 12.3, 4.8 Hz, 
1H), 3.52 (d, J = 12.3 Hz, 1H), 4.12-4.15 (m, 1H), 4.22 (dddd, J = 15.6, 10.3, 5.9, 5.9 Hz, 
1H), 4.40 (d, J = 11.9 Hz, 1H), 4.48 (d, J = 11.9 Hz, 1H), 5.03 (s, 1H), 7.21-7.36 (m, 10H); 
13C NMR (100 MHz, CDCl3) δ 38.0, 41.4, 54.5, 57.1, 71.1, 76.2, 100.4, 127.5, 127.6, 127.9, 
128.6, 128.6, 129.8, 135.9, 137.6, 162.8, 191.8; IR (neat) 2930, 1627, 1531, 1470, 1241, 701 
cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C21H22NO2: 320.1651, found 320.1638.
(2R*,8aR*)-2-(Benzyloxy)-5-phenyl-2,3,8,8a-tetrahydroindolizin-7(1H)-one (syn-2.43). 











as a colorless oil after flash chromatography (1-10% MeOH/EtOH): 1H NMR (400 MHz, 
CDCl3) δ 1.94-2.00 (m, 1H), 2.34 (dd, J = 16.1, 4.1 Hz, 1H), 2.43 (ddd, J = 13.5, 7.9, 5.6 Hz, 
1H), 2.74 (dd, J = 16.2, 16.2 Hz, 1H), 3.32 (dd, J = 11.8, 3.0 Hz, 1H), 3.53 (dd, J = 11.8, 5.2 
Hz, 1H), 4.05-4.14 (m, 2H), 4.35 (d, J = 11.9 Hz, 1H), 4.43 (d, J = 11.8 Hz, 1H), 5.08 (s, 
1H), 7.18-7.38 (m, 10H); 13C NMR (100 MHz, CDCl3) δ 36.9, 41.8, 54.9, 57.9, 71.3, 77.3, 
100.6, 127.5, 127.8, 127.9, 128.5, 128.6, 130.1, 136.0, 137.5, 162.9, 192.4; IR (neat) 2926, 
1626, 1529, 1467, 1242, 700 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C21H22NO2: 
320.1651, found 320.1640.
3,4,9,9a-Tetrahydropyrido[2,1-c][1,4]oxazin-8(1H)-one (2.49).  The title compound was 
obtained as a white solid (Method A, 80%; Method B, 95%) after flash chromatography 
(100% acetone):  mp 58.1-60.2 °C; 1H NMR (400 MHz, CDCl3) δ  2.27 (dd, J = 16.3, 14.2 
Hz, 1H), 2.33 (dd, J = 16.5, 6.2 Hz, 1H), 3.21-3.29 (m, 2H), 3.39 (dd, J = 10.9, 10.9 Hz, 1H), 
3.49-3.57 (m, 1H), 3.65 (ddd, J = 11.5, 10.0, 4.6 Hz, 1H), 3.91-3.98 (m, 2H), 5.06 (d, J = 7.7 
Hz, 1H), 6.89 (d, J = 7.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 37.9, 50.2, 55.3, 66.5, 70.7, 
100.6, 154.1, 191.1; IR (neat) 2854, 1639, 1590, 1445, 1223, 1121 cm-1; HRMS (ESI+) m/e 










(R)-2-Phenyl-2,3-dihydropyridin-4(1H)-one (2.51).  The title compound was obtained as a 
white solid [Method A, 50% (e.r. > 99:1); Method B, 50% (e.r. > 99:1)] after flash 
chromatography (90% acetone/hexanes): mp 107.7-110.9 °C; 1H NMR (400 MHz, CDCl3) δ 
2.39 (dd, J = 16.3, 5.0 Hz, 1H), 2.62 (dd, J = 16.3, 14.6 Hz, 1H), 4.68 (dd, J = 14.6, 5.0 Hz, 
1H), 4.99 (d, J = 7.3 Hz, 1H), 5.93 (bs, 1H), 7.25-7.38 (m, 6H); 13C NMR (100 MHz, CDCl3) 
δ 44.3, 58.2, 99.0, 126.6, 128.4, 128.9, 139.9, 151.8, 192.4; IR (neat) 3234, 3030, 1620, 1571, 
1233, 699 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C11H12NO: 174.0919, found 174.0918; 
α[ ]D
22 = +233 (c 0.720, CHCl3) [Lit. +332.3 (c 2.42, EtOH)].236 Enantiomeric ratios were 
determined via chiral HPLC using a Chiralcel OD column.  Conditions: i-PrOH 1-25% in 
hexanes, 60 min, 1.0 mL/min, 30 °C. (–)-Enantiomer: Rt = 48.0 min;  (+)-Enantiomer: Rt = 
45.2 min.  
2,3-Dihydropyridin-4(1H)-one (2.54).  The title compound was obtained as a colorless oil 
(Method A, 70%; Method B, 92%) after flash chromatography (10% EtOH/EtOAc): 1H NMR 






1H), 7.32 (d, J = 7.0 Hz, 1H) 13C NMR (100 MHz, CD3OD) δ 36.1, 41.9, 99.3, 151.8, 192.8; 
IR (neat) 3041, 1575, 1409, 1351, 1245, 1174 cm-1; HRMS (ESI+) m/e calc’d for [M+Na]+ 
C5H7NO2Na: 120.0425, found 120.0423.
1-Benzyl-2,3-dihydropyridin-4(1H)-one (2.55).  The title compound was obtained as an 
colorless oil (Method A, 50%; Method B, 86%) after flash chromatography (85% EtOAc). 
Spectral data of the title compound was identical to that reported in the literature.348
  
1-Phenyl-2,3-dihydropyridin-4(1H)-one (2.56).  The title compound was obtained as an off 
white solid (Method A, 50%; Method B, 70%) after flash chromatography (100% EtOAc): 
mp 89.0-90.5 °C; 1H NMR (400 MHz, CDCl3) δ 2.67 (t, J = 7.6 Hz, 2H), 4.01 (t, J = 7.6 Hz, 
2H), 5.24 (d, J = 7.8 Hz, 1H), 7.09-7.18 (m, 3H), 7.37-7.41 (m, 2H), 7.45 (d, J = 7.8 Hz, 1H); 









(neat) 3057, 1647, 1579, 1495, 1316, 1220 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 
C11H12NO: 174.0919, found 174.0913.
(Z)-2,3,9,9a-Tetrahydro-1H-pyrrolo[1,2-a]azepin-7(8H)-one (2.61).  The title compound 
was obtained as a light yellow solid (Method A, 60%; Method B, 64%) after flash 
chromatography (100% acetone): mp 106.2-114.4 °C; 1H NMR (400 MHz, CDCl3) δ 
1.29-1.39 (m, 1H), 1.58-1.69 (m, 1H), 2.09-2.34 (m, 4H), 3.00-3.09 (m, 1H), 3.12-3.25 (m, 
2H), 3.41-3.50 (bm, 1H), 3.93-4.00 (m, 1H), 4.99 (d, J = 8.4 Hz, 1H), 9.34 (bd, J = 6.8 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 28.0, 29.5, 31.4, 34.2, 43.3, 66.8, 95.7, 166.0, 186.8; IR 
(neat) 2860, 1623, 1583, 1398, 1190, 802 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 
C9H14NO: 152.1075, found 152.1068.
(Z)-1,2,3,4,10,10a-Hexahydropyrido[1,2-a]azepin-8(9H)-one (2.62).  The title compound 
was obtained as a light yellow solid (Method A, 64%; Method B, 63%) after flash 







(m, 1H), 1.38-1.52 (m, 2H), 1.55-1.65 (m, 1H), 1.74-1.81 (m, 1H), 1.87-1.94 (m, 1H), 1.98 
(d, J = 13.3 Hz, 1H), 2.20-2.28 (m, 1H), 2.81-2.90 (m, 2H), 3.13-3.21 (bm, 1H), 3.38-3.46 
(m, 1H), 3.72 (d, J = 13.0 Hz, 1H), 5.10 (bd, J = 5.7 Hz, 1H), 9.42 (bs, 1H); 13C NMR (100 
MHz, CDCl3) δ 23.4, 24.2, 27.8, 28.8, 32.6, 43.7, 62.4, 94.7, 167.6, 187.2; IR (neat) 2940, 
1624, 1583, 1394, 1189, 779 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C10H16NO: 
166.1232, found 166.1223.
8-Benzyl-8-azaspiro[5.6]dodec-9-en-11-one (2.63).  The title compound was obtained as a 
yellow oil (Method A, 81%; Method B, 84%) after flash chromatography (100% acetone):  1H 
NMR (400 MHz, CDCl3) δ 1.36-1.55 (m, 10H), 2.91 (bs, 2H), 3.22 (s, 2H), 4.38 (s, 2H), 5.27 
(d, J = 7.5 Hz, 1H), 7.18 (d, J = 6.8 Hz, 2H), 7.28-7.36 (m, 3H), 9.41 (d, J = 6.6 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 23.1, 25.5, 36.0, 39.5, 42.5, 50.1, 63.1, 95.7, 127.5 (2C), 127.9, 
128.9, 135.2, 168.0, 187.5; IR (neat) 2925, 1632, 1591, 1552, 1397, 1188 cm-1; HRMS (ESI






(Z)-1-Benzyl-6-(4-chlorophenyl)-6,7-dihydro-1H-azepin-4(5H)-one (2.64).  The title 
compound was obtained as a yellow oil (Method A, 66%; Method B, 65%) after flash 
chromatography (100% acetone):  1H NMR (400 MHz, CDCl3) δ 3.13-3.22 (m, 1H), 3.44 
(dd, J = 10.0, 6.6 Hz, 1H), 3.54-3.66 (m, 2H), 3.80 (dd, J = 10.0, 8.0 Hz, 1H), 4.46 (d, J = 2.8 
Hz, 2H), 5.36 (d, J = 7.9 Hz, 1H), 7.11 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 6.64 Hz, 2H), 
7.27-7.37 (m, 5H), 9.46 (bd, J = 4.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ  38.0, 39.5, 50.2, 
59.2, 95.7, 127.6, 128.1, 129.0, 133.1, 134.8, 139.7, 166.9, 187.5; IR (neat) 1625, 1590, 
1549, 1398, 1190, 702 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C19H19ClNO: 312.1155, 
found 312.1155.







(E)-2-(4-Iodo-2-oxobut-3-enyl)pyrrolidinium Iodide (2.38).  Ynone 2.17 (0.50 mmol, 1.0 







1.5 mmol, 3.0 equiv) was added.  After 6 h, Et2O (200 mL) was slowly added to the reaction 
mixture allowing a precipitate to form.  The precipitate was filtered and washed several times 
with Et2O.  The filtered precipitate was air dried and used without further purification.  To 
obtain crystals for X-ray analysis, the precipitate was recrystallized from formic acid.  See 
below for X-ray crystal structure report.  1H NMR (400 MHz, CD3OD) δ 1.59-1.69 (m, 1H), 
1.82-1.92 (m, 1H), 1.94-2.04 (m, 1H), 1.12-2.20 (m, 1H), 2.97 (dd, J = 18.9, 9.8 Hz, 1H), 
3.13-3.24 (m, 3H), 3.76-3.83 (m, 1H), 7.16 (d, J = 15.2 Hz, 1H), 8.17 (d, J = 15.2 Hz, 1H); 
13C NMR (100 MHz, CD3OD) 24.6, 31.2, 42.6, 46.6, 56.8, 102.8, 145.2, 196.4; 1H NMR 
(400 MHz, (CD3)2SO) δ 1.49-1.58 (m, 1H), 1.74-1.95 (m, 2H), 2.04-2.12 (m, 1H), 3.04 (dd, J 
= 18.7 , 9.2 Hz, 1H), 3.04-3.17 (m, 2H), 3.17 (dd, J = 18.7, 4.3 Hz, 1H), 3.71-3.78 (m, 1H), 
7.21 (d, J = 15.3 Hz, 1H), 8.26 (d, J = 15.3 Hz, 1H), 8.28 (bs, 1H), 8.85 (bs, 1H); 13C NMR 
(100 MHz, (CD3)2SO) δ 23.1, 29.7, 41.4, 45.0, 54.3, 104.7, 143.7, 195.4.
5-Phenylpent-1-yn-3-one (2.65).  The title compound was prepared using Method A for 
Weinreb amide formation and subsequent Grignard addition as described above.  The product 
was obtained as a colorless oil (86% over 2 steps) after flash chromatography (5% EtOAc/
hexanes):  1H NMR (400 MHz, CDCl3) δ 2.89-2.93 (m, 2H), 2.96-3.00 (m, 2H), 3.22 (s, 1H), 





126.3, 128.3, 128.6, 139.9, 186.2; IR (neat) 3029, 2093, 1683, 1454, 1102, 699 cm-1; HRMS 
(EI+) m/e calc’d for [M+H]+ C11H11O: 158.0732, found 158.0722.













Vinyl iodide 2.38 was prepared according to Method B.  Et2O was added to the reaction 
mixture prior to HCO2H evaporation and the precipitate (2.38) was collected via filtration. 
The precipitate was dried in vacuo for 1 h.  Vinyl iodide 2.38 (10 mg, 0.025 mmol) was 
dissolved in CD3OD (1.0 mL) and added (0.60 mL) to an NMR tube.  An initial NMR 
spectrum was recorded.  To the NMR tube was added 0.30 mL of a saturated solution of 
K2CO3 in CD3OD and the NMR tube was rigorously agitated.  Although an NMR spectrum 
was recorded immediately, enaminone formation was complete prior to spectrum acquisition 
(~2 min).  
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EXPERIMENT 1: NMR 
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EXPERIMENT 2: METHYLYNONE CYCLIZATION.
Vinyl iodide I was prepared from ynone 2.18 (20 mg, 0.080 mmol) according to Method B. 
Following evaporation of HCO2H, the residue containing vinyl iodide I was dissolved in 
CD3OD (2.0 mL) and added (0.60 mL) to an NMR tube.  An initial NMR spectrum was 
recorded.  To the NMR tube was added 0.30 mL of a saturated solution of K2CO3 in CD3OD 
and the NMR tube was rigorously agitated. NMR spectra were recorded at various time 
increments from 2.0 min to 22.0 min.  Deuteration of the α-position was immediate and 
complete, whereas γ-deuteration was slow, proceeding almost to completion over 22 min, 
























EXPERIMENT 3: PHENYLYNONE CYCLIZATION.
Vinyl iodide II was prepared from ynone 2.19 (25 mg, 0.080 mmol) according to Method B. 
Following evaporation of HCO2H, the residue containing vinyl iodide II was dissolved in 
CD3OD (2.0 mL) and added (0.60 mL) to an NMR tube.  To the NMR tube was added 0.30 
mL of a saturated solution of K2CO3 in CD3OD and the NMR tube was rigorously agitated. 
NMR spectra were recorded at various time increments from 2.0 min to 70.0 min. 





















EXPERIMENT 4: POST-CYCLIZATION DEUTERIUM EXCHANGE.
Enaminone 2.37 (10 mg, 0.070 mmol) and 2.39 (11 mg, 0.070 mmol) were dissolved in 
CD3OD (1.0 mL) each and added (0.60 mL of each solution) to separate NMR tubes.  An 
initial NMR spectrum was obtained.  To each NMR tube was added 0.30 mL of a saturated 
solution of K2CO3 in CD3OD and the NMR tubes were rigorously agitated.  NMR spectra 
were recorded at various increments over 24 h.  Enaminone 2.37 was completely intact at 24 



















EXPERIMENT 4: NMR 
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STUDIES OF YNONE AND VINYL CHLORIDE REACTIVITY IN ABSENCE OF AN INTERNAL 
NUCLEOPHILE
The ynone 2.65 (79 mg, 0.50 mmol) was dissolved in a 4N HCl/dioxane solution (1.5 mL) 
and allowed to react for 15 min.  After this time the dioxane and excess HCl were allowed to 
evaporate while passing air over the reaction mixture.  A 1:6 mixture of 2.66 and 2.67 was 
obtained.  From the residue containing 2.66 and 2.67 10 mg was taken and dissolved in 
MeCN-d3 (1.0 mL) and added (0.60 mL) to an NMR tube.  After an NMR spectra was 
obtained for the mixture, one drop of TEA was added and NMR spectra were recorded at 
various intervals over 2 h.  Dichloride 2.67 had completely reacted to form vinyl chloride 
2.66 in less than 2 min.  After 2 h, a drop of D2O was added to the reaction mixture and the 
NMR tube was vigorously shaken.  NMR spectra were recorded at various interval over 























(E)-1-Chloro-5-phenylpent-1-en-3-one (2.66). The title compound was isolated as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 2.76-2.80 (m, 2H), 2.85-2.90 (m, 2H), 6.45 (d, J 
= 13.6 Hz, 1H), 7.11 (m, 3H), 7.19-7.23 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 29.6, 42.9, 
126.3, 128.3, 128.6, 132.3, 136.8, 140.6, 196.2;  IR (neat) 2926, 1682, 1586, 1454, 1169, 942 
cm-1; HRMS (EI+) m/e calc’d for [M+H]+ C11H12ClO: 194.0498, found 194.0479.
1,1-Dichloro-5-phenylpentan-3-one (2.67).  The title compound was isolated as a colorless 
oil upon evaporation of HCl: 1H NMR (400 MHz, CDCl3) δ 2.72 (t, J = 7.5 Hz, 2H), 2.86 (t, 
J = 7.5 Hz, 2H), 3.25 (d, J = 6.4 Hz, 2H), 6.05 (t, J = 6.4 Hz, 1H), 7.10-7.16 (m, 3H), 
7.20-7.24 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 29.2, 45.0, 55.5, 67.2, 126.4, 128.3, 128.6, 
140.3, 203.4;  IR (neat) 2925, 1721, 1454, 1405, 1371, 1092 cm-1; HRMS (EI+) m/e calc’d 









The mixture of chlorides 2.66 and 2.67 (10 mg) were dissolved in methanol-d4 (1.0 mL) and 
added (0.60 mL) to an NMR tube.  An initial NMR spectrum was recorded as a reference. A 
saturated solution of K2CO3 in methanol-d4 (0.30 mL) was added to the NMR tube and the 
tube was vigorously agitated.  NMR spectra were recorded at various intervals.  After 2 h the 
spectra showed complete consumption of dichloroketone 2.67 and a 1:2 mixture of ether 2.68 
and vinyl chloride 2.66, respectively.  NMR spectra for vinyl ether 2.68 matched those found 
in the literature.349    
6.3  Chapter 3
6.3.1 Preparation of starting materials 
(S)-6-iodo-2,3,8,8a-tetrahydroindolizin-7(1H)-one (3.1).  Enaminone 2.37 (421 mg, 3.07 
mmol, 1.00 equiv) and DMAP (751 mg, 6.15 mmol, 2.00 equiv) were dissolved in CH2Cl2 


























dropwise over 20 min and the reaction mixture was stirred for 5 h.  The reaction mixture was 
poured into a saturated solution of Na2S2O3 (200 mL) and vigorously stirred for 5 min.  The 
product was extracted with CH2Cl2 (3x), dried over Na2SO4 and purified via SiO2 flash 
chromatography (100% EtOAc).  The title compound was isolated as a yellow solid (782 mg, 
92%).  Spectral data matched those found in the literature.213 
Compound 3.18 was prepared from 4-hydroxypyridine using alkylation/reduction 
methodology developed by Guerry and Neier.350 NMR spectra matched those found in the 
literature. 
1-Benzyl-2-phenyl-2,3-dihydropyridin-4(1H)-one (3.19) was prepared from 4-
hydroxypyridine using N-alkylation351 and conjugate addition of PhMgCl using methodology 











6.3.2 Pd(II)-catalyzed C3-arylation of enaminones
Representative procedure for enaminone arylation:
Enaminone (0.20 mmol), Pd(OAc)2 (14 mg, 0.06 mmol), anhydrous Cu(OAc)2 powder (110 
mg, 0.60 mmol) and granular K2CO3 (55 mg, 0.40 mmol,)5 were combined in a 20:5:1 
mixture of t-BuOH/AcOH/DMSO (2.0 mL) under N26 and stirred for 5 min (Note: Solvents 
were used without purification or degassing).    The reaction mixture was heated to 60 oC and 
the potassium trifluoroborate (0.40-0.60 mmol) was added slowly over 5 h as a solid.  The 
amount of trifluoroborate needed depends on the rate of addition.  Typically  0.20 equivalents 
of trifluoroborate were added every  30 minutes.  The reaction was stirred for an additional h 
and was monitored by TLC using 100% EtOAc as the mobile phase.  The reaction mixture 
was diluted with EtOAc (8 mL) and excess K2CO3 (~1 g) was added to neutralize the AcOH. 
After stirring this mixture for 5 min the precipitate was filtered over Celite using EtOAc as 






















1-Benzyl-5-(4-methoxyphenyl)-2,3-dihydropyridin-4(1H)-one (3.4).  Potassium (4-
methoxyphenyl)trifluoroborate was added slowly over 6 h and the reaction was stirred for an 
additional hour.  The title compound was isolated as a yellowish oil.  (1H NMR (400 MHz, 
CDCl3) δ 2.60 (t, 2H, J = 7.8 Hz), 3.44 (t, 2H, J = 7.8 Hz), 3.80 (s, 3H), 4.43 (s, 2H), 6.87 (d, 
2H, J = 8.8 Hz), 7.29-7.42 (m, 8H);  13C NMR (100 MHz, CDCl3) δ 36.4, 46.9, 55.34, 60.2, 
111.1, 113.7 (2C), 127.7 (2C), 128.4, 128.8, 129.0 (2C), 129.1 (2C), 135.8, 152.8, 157.8, 
188.9; IR (neat) 2835, 1629, 1595, 1298, 1245, 1126 cm-1; HRMS (ESI+) m/e calc’d for [M
+H]+ C19H20NO2: 294.1494, found 294.1482.
1-Benzyl-5-phenyl-2,3-dihydropyridin-4(1H)-one (3.6).  Potassium phenyltrifluoroborate 
was added slowly over 6 h and the reaction was stirred for an additional hour.  The title 
compound was isolated as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 2.60 (t, 2H, J = 7.8 










13C NMR (100 MHz, CDCl3) δ 36.3, 46.8, 60.2, 111.2, 125.7, 127.7 (2C), 127.8 (2C), 128.2 
(2C), 128.4, 129.1 (2C), 135.7, 136.3, 153.2, 188.6; IR (neat) 3029, 1628, 1595, 1495, 1299, 
1127 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C18H18NO: 264.1383, found 264.1388.
1-Benzyl-5-(4-tolyl)-2,3-dihydropyridin-4(1H)-one (3.7). Potassium (4-tolyl)-
trifluoroborate was added slowly over 4 h and the reaction was stirred for an additional hour. 
The title compound was isolated as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 2.32 (s, 
3H), 2.60 (t, 2H, J = 7.8 Hz), 3.44 (t, 2H, J = 7.8 Hz), 4.42 (s, 2H), 7.12 (d, 2H, J = 8.0 Hz), 
7.28-7.42 (m, 8H); 13C NMR (100 MHz, CDCl3) δ 21.1, 36.3, 46.8, 60.2, 111.3, 127.7 (2C), 
127.8 (2C), 128.4, 128.9 (2C), 129.1 (2C), 133.3, 135.3, 135.8, 152.9, 188.7; IR (neat) 2919, 
1634, 1595, 1382, 1298, 1125 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C19H20NO: 
278.1539, found 278.1551.
1-Benzyl-5-(2-tolyl)-2,3-dihydropyridin-4(1H ) -one (3.8) . Potassium (2-










12 h.  The title compound was isolated as a white solid (mp 94-97 oC).  1H NMR (400 MHz, 
CDCl3) δ 2.22 (s, 3H), 2.60 (t, 2H, J = 7.8 Hz), 3.45 (t, 2H, J = 7.8 Hz), 4.37 (s, 2H), 
7.07-7.42 (m, 10H); 13C NMR (100 MHz, CDCl3) δ 20.4, 36.0, 47.1, 60.0, 112.2, 125.6, 
127.1, 127.7 (2C), 128.4, 129.1 (2C), 130.0, 130.6, 135.8, 136.1, 137.9, 153.9, 188.3; IR 
(neat) 2960, 1635, 1595, 1322, 1303, 1135 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 
C19H20NO: 278.1539, found 278.1547.
1-Benzyl-5-(2-methoxyphenyl)-2,3-dihydropyridin-4(1H)-one (3.9). Potassium (2-
methoxyphenyl)trifluoroborate was added slowly over 12 h and the reaction was stirred for 
an additional 12 h.  The title compound was isolated as a colorless oil.  1H NMR (400 MHz, 
CDCl3) δ 2.63 (t, 2H, J = 7.8 Hz), 3.46 (t, 2H, J = 7.8 Hz), 3.79 (s, 3H) 4.41 (s, 2H), 6.90 
(dd, 1H, J = 1.1, 8.2 Hz), 6.93 (ddd, 1H, J = 1.1, 7.4, 7.4 Hz), 7.19 (ddd, 1H, J = 1.8, 7.4, 8.2 
Hz), 7.28-7.42 (m, 7H); 13C NMR (100 MHz, CDCl3) δ 36.1, 46.9, 55.7, 60.2, 107.2, 111.3, 
120.5, 125.0, 127.5, 127.7 (2C), 128.3, 129.0 (2C), 132.0, 135.9, 154.9 157.0, 188.3; IR 
(neat) cm-1 2960, 1631, 1593, 1302, 1132, 1028; HRMS (ESI+) m/e calc’d for [M+H]+ 







1-Benzyl-5-(4-(trifluoromethyl)phenyl)-2,3-dihydropyridin-4(1H)-one (3.10).  Potassium 
(4-trifluoromethylphenyl)trifluoroborate was added slowly  over 12 h and the reaction was 
stirred for an additional 12 h.  The title compound was isolated as a white solid (mp  118-119 
oC).  NMR (400 MHz, CDCl3) δ 2.61 (t, 2H, J = 7.8 Hz), 3.49 (t, 2H, J = 7.8 Hz), 4.45 (s, 
2H), 7.29-7.44 (m, 5H), 7.48 (s, 1H), 7.54 (s, 4H); 19F NMR (377 MHz, CDCl3) δ -65.9; 13C 
NMR (100 MHz, CDCl3) δ 36.2, 46.8, 60.5, 109.8, 124.6 (q, J = 271.7 Hz), 125.2 (q, 2C, J = 
3.8 Hz), 127.5 (q, J = 32.3 Hz), 127.6 (2C), 127.8 (2C), 128.7, 129.3 (2C), 135.4, 140.2, 
153.5, 188.36; IR (neat) 3032, 1637, 1599, 1327, 1113, 1068 cm-1; HRMS (ESI+) m/e calc’d 
for [M+H]+ C19H17F3NO: 332.1257, found 332.1259.
1-Benzyl-5-(4-acetylphenyl)-2,3-dihydropyridin-4(1H)-one (3.11). Potassium (4-
acetylphenyl)trifluoroborate was added slowly over 12 h and the reaction was stirred for an 
additional 12 h.  The title compound was isolated as a colorless oil.  1H NMR (400 MHz, 












7.30-7.42  (m, 5H), 7.54 (s, 1H),  7.55 (d, 2H, J = 8.6 Hz), 7.90 (d, 2H, J = 8.6 Hz);  13C 
NMR (100 MHz, CDCl3) δ 26.5, 36.2, 46.6, 60.5, 109.7, 127.0 (2C), 127.7 (2C), 128.4 (2C), 
128.6, 129.2 (2C), 134.1, 135.2, 141.6, 153.5, 188.2, 197.8; IR (neat) 3030, 1672, 1635, 
1592, 1271, 1129 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C20H20NO2: 306.1489, found 
306.1503.
1-Benzyl-5-(4-bromophenyl)-2,3-dihydropyridin-4(1H)-one (3.12). Potassium (4-
bromophenyl)trifluoroborate was added slowly over 5 h and the reaction was stirred for an 
additional hour.  The title compound was isolated as a yellowish oil.  1H NMR (400 MHz, 
CDCl3) δ 2.59 (t, 2H, J = 7.8 Hz), 3.46 (t, 2H, J = 7.8 Hz), 4.45 (s, 2H), 7.27-7.43 (m, 10H); 
13C NMR (100 MHz, CDCl3) δ 36.2, 46.7, 60.3, 109.9, 119.3, 127.6 (2C), 128.5, 129.1 (2C), 
129.3 (2C), 131.2 (2C), 135.3, 135.5, 152.9, 188.3; IR (neat) 3029, 1631, 1598, 1378, 1293, 







1-Benzyl-5-(4-chlorophenyl)-2,3-dihydropyridin-4(1H)-one (3.13). Potassium (4-
chlorophenyl)trifluoroborate was added slowly over 7 h and the reaction was stirred for an 
additional hour.  The title compound was isolated as a yellowish oil.  1H NMR (400 MHz, 
CDCl3) δ 2.59 (t, 2H, J = 7.8 Hz), 3.4 (t, 2H, J = 7.8 Hz), 4.45 (s, 2H), 7.25-7.43 (m, 10H); 
13C NMR (100 MHz, CDCl3) δ 36.2, 46.7, 60.3, 109.9, 127.7 (2C), 128.2 (2C), 128.5, 128.9 
(2C), 129.1 (2C), 131.2, 134.8, 135.5, 153.0, 188.4; IR (neat) 3030, 1632, 1599, 1493, 1294, 
1128 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C18H17ClNO: 298.0993, found 298.0996.
1-Benzyl-5-(naphthalen-2-yl)-2,3-dihydropyridin-4(1H)-one (3.14). Potassium (2-
naphthalene)trifluoroborate was added slowly over 3 h and the reaction was stirred for an 
additional hour.  The title compound was isolated as a colorless oil.  1H NMR (400 MHz, 
CDCl3) δ 2.63 (t, 2H, J = 7.8 Hz), 3.46 (t, 2H, J = 7.8 Hz), 4.45 (s, 2H), 7.30-7.43 (m, 7H), 
7.52 (s, 1H), 7.59 (dd, 1H, J = 1.9, 8.7 Hz), 7.76-7.80 (m, 3H), 7.83 (d, 1H, J = 1.2 Hz); 13C 










127.7 (2C), 127.7, 128.4, 129.1 (2C), 131.9, 133.7, 134.1, 135.7, 153.5, 188.7; IR (neat) 
3055, 1636, 1600, 1320, 1297, 1135 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C22H20NO: 
314.1539, found 314.1545.
1-Benzyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydropyridin-4(1H)-one (3.15). Potassium 
(3,4,5-trimethoxyphenyl)trifluoroborate was added slowly  over 5 h and the reaction was 
stirred for an additional hour.  The title compound was isolated as a yellowish oil.  1H NMR 
(400 MHz, CDCl3) δ 2.60 (t, 2H, J = 7.8 Hz), 3.46 (t, 2H, J = 7.8 Hz), 3.83 (s, 3H), 3.86 (s, 
6H), 4.45 (s, 2H), 6.64 (s, 2H), 7.29-7.44 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 36.3, 46.7, 
56.1, 60.2, 60.8, 105.3, 111.1, 127.7 (2C), 128.4, 129.1 (2C), 132.1, 135.7, 136.4, 152.9, 
153.1, 188.6; IR (neat) 2937, 1630, 1596, 1453, 1328, 1239, 1125 cm-1; HRMS (ESI+) m/e 













1-Benzyl-5-(3-hydroxyphenyl)-2,3-dihydropyridin-4(1H)-one (3.16). Potassium (3-
hydroxyphenyl)trifluoroborate was added slowly over 2 h and the reaction was stirred for an 
additional h.  The title compound was isolated as white solid which later turned pink (mp 
145-155 oC).  1H NMR (400 MHz, CDCl3) δ 2.64 (t, 2H, J = 7.9 Hz), 3.44 (t, 2H, J = 7.9 
Hz), 4.45 (s, 2H), 6.69 (ddd, 1H, J = 1.0, 2.5, 8.0 Hz) 6.72 (ddd, 1H, J = 1.0, 1.5, 8.0 Hz), 
7.15 (t, 1H, J = 8.0 Hz), 7.27-7.42 (m, 5H), 7.46 (dd, 1H, J = 1.5, 2.5 Hz), 7.50 (s, 1H), 8.1 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 36.0, 46.5, 60.5, 110.3, 113.3, 115.8, 117.8, 127.8 
(2C), 128.6, 129.3 (2C), 129.4, 135.5, 137.4, 154.5, 156.8, 189.3; IR (neat) 3168, 1594, 
1452, 1324, 1303, 1126 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C18H18NO2: 280.1332, 
found 280.1339.
1-Benzyl-5-(4-aminobenzyloxycarbonyl)-2,3-dihydropyridin-4(1H)-one (3.17). Potassium 
(4-Cbz-aminophenyl)trifluoroborate was added slowly over 4 h and the reaction was stirred 
for an additional hour.  The title compound was isolated as a pale yellow solid (mp 153.5-155 
oC).  1H NMR (400 MHz, CDCl3) δ 2.58 (t, 2H, J = 7.8 Hz), 3.43 (t, 2H, J = 7.8 Hz), 4.43 (s, 
2H), 5.19 (s, 2H), 6.71 (s, 1H), 7.30-7.40 (m, 15H); 13C NMR (100 MHz, (CD3)2CO) δ 37.2, 
47.3, 60.2, 66.8, 110.3, 118.7, 128.5 (2C), 128.8 (2C), 128.8 (2C), 128.8 (2C), 128.9 (2C), 







1724, 1593, 1529, 1220 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C26H25N2O3: 413.1860, 
found 413.1874.
3-(4-Methoxyphenyl)-7,8,9,9a-tetrahydro-1H-quinolizin-2(6H)-one (3.20). 
Trifluoroborate 3.3 was added slowly  over 2 h and the reaction was stirred for an additional 
h.  4a was isolated as a pale yellow solid (mp 97-99 oC).  1H NMR (400 MHz, CDCl3) δ 
1.35-1.68 (m, 3H), 1.76-1.89 (m, 3H), 2.45-2.62 (m, 2H), 3.01 (dt, 1H, J = 2.6, 6.3 Hz), 
3.32-3.45 (m, 2H), 3.78 (s, 3H), 6.85 (d, 2H, J = 8.8 Hz), 7.05 (s, 1H), 7.29 (d, 2H, J = 8.8 
Hz); 13C NMR (100 MHz, CDCl3) δ 20.7, 23.2, 29.2, 41.4, 50.7, 52.9, 54.8, 109.5, 111.1 
(2C), 126.1, 126.6 (2C), 151.3, 155.3, 187.4; IR (neat) 2937, 1636, 1596, 1511, 1243, 1133 
cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C16H20NO2: 258.1494, found 258.1488.
6-(4-Methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-7(1H)-one (3.2). Trifluoroborate 3.3 











compound was isolated as a pale yellow solid (mp 118-119 oC).  Note:  See Section 6.4 for a 
more detailed description of the preparation of enantiomerically pure 3.2.  1H NMR (400 
MHz, CDCl3) δ 1.68-1.76 (m, 1H), 1.92-2.02 (m, 1H), 2.11-2.15 (m, 1H), 2.28-2.33 (m, 1H), 
2.49 (t, 1H, J = 16.0 Hz), 2.58 (dd, 1H, J = 5.0, 16.0 Hz), 3.53-3.63 (m, 2H), 3.79-3.87 (m, 
1H), 3.79 (s, 3H), 6.85 (d, 2H, J = 8.8 Hz), 7.30 (d, 2H, J = 8.8 Hz), 7.38 (s, 1H); 13C NMR 
(100 MHz, CDCl3) δ 24.4, 33.1, 42.4, 49.8, 55.4, 57.8, 109.5, 113.5 (2C), 128.8 (2C), 129.6, 
148.8, 157.4, 189.0; IR (neat) 2953, 2885, 2833, 1620, 1574, 1510, 1277, 837, 733 cm-1; 
HRMS (ESI+) m/e calc’d for [M+H]+ C15H18NO2: 244.1338, found 244.1327.
(cis)-3-(4-Methoxyphenyl)-1-methyl-4a,5,6,7,8,8a-hexahydroquinolin-4(1H)-  one (3.21). 
Trifluoroborate 3.3 was added slowly  over 6 h and the reaction was stirred for an additional 
h.  The title compound was isolated as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 
1.31-1.54 (m, 4H), 1.60-1.75 (m, 2H), 1.85-1.96 (m, 1H), 2.22-2.33 (m, 1H), 2.73-2.77 (m, 
1H), 3.08 (s, 3H), 3.45 (ddd, 1H, J = 3.5, 5.5, 9.0 Hz), 3.78 (s, 3H), 6.84 (d, 2H, J = 8.8 Hz), 
7.05 (s, 1H), 7.31 (d, 2H, J = 8.8 Hz); 13C NMR (100 MHz, CDCl3) δ 22.8, 23.5, 23.7, 24.5, 










2932, 1629, 1599, 1512, 1243, 1035 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C17H22NO2: 
272.1645, found 272.1652.
(trans)-3-(4-Methoxyphenyl)-1-methyl-4a,5,6,7,8,8a-hexahydroquinolin-4(1H)-one 
(3.22). Trifluoroborate 3.3 was added slowly  over 6 h and the reaction was stirred for an 
additional h.  The title compound was isolated as an off-white solid (mp 151-152.5 oC).   1H 
NMR (400 MHz, CDCl3) δ 1.08-1.47 (m, 4H), 1.83-1.90 (m, 2H), 2.15-2.25 (m, 2H), 
2.46-2.50 (m, 1H), 3.00 (s, 3H), 3.09 (ddd, 1H, J = 3.6, 11.3, 14.8 Hz), 3.78 (s, 3H), 6.84 (d, 
2H, J = 8.8 Hz), 7.16 (s, 1H), 7.31 (d, 2H, J = 8.8 Hz); 13C NMR (100 MHz, CDCl3) δ 24.4, 
24.9, 25.0, 30.4, 39.6, 48.7, 55.3, 62.0, 110.9, 113.5 (2C), 128.9, (2C) 129.1, 153.7, 157.7, 
191.2; IR (neat) 2919, 1621, 1591, 1513, 1247, 1159 cm-1; HRMS (ESI+) m/e calc’d for [M










5-(4-Methoxyphenyl)-1-methyl-2,3-dihydropyridin-4(1H)-one (3.23). Trifluoroborate 3.3 
was added slowly  over 5 h and the reaction was stirred for an additional h.  The title 
compound was isolated as a yellowish oil.  1H NMR (400 MHz, CDCl3) δ 2.62 (t, 2H, J = 7.8 
Hz), 3.08 (s, 3H), 3.47 (t, 2H, J = 7.8 Hz), 3.78 (s, 3H), 6.85 (d, 2H, J = 8.8 Hz), 7.13 (s, 1H), 
7.28 (d, 2H, J = 8.8 Hz); 13C NMR (100 MHz, CDCl3) δ 36.3, 43.5, 49.3, 55.5, 110.8, 113.8 
(2C), 129.1 (2C), 129.1, 153.8, 157.9, 188.7; IR (neat) 2957, 1626, 1598, 1512, 1299, 1245 
cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C13H16NO2: 218.1181, found 218.1176.
1-Benzyl-5-(4-methoxyphenyl)-2-phenyl-2,3-dihydropyridin-4(1H)-one (3.24). 
Trifluoroborate 3.3 was added slowly  over 6 h and the reaction was stirred for an additional 
h.  The title compound was isolated as a yellowish oil.  1H NMR (400 MHz, CDCl3) d 2.83 
(dd, 1H, J = 7.5, 16.3 Hz), 2.98 (dd, 1H, J = 7.5, 16.3 Hz), 3.80 (s, 3H), 4.19 (d, 1H, J = 15.1 













(m, 12H), 7.49 (s, 1H); 13C NMR (100 MHz, CDCl3) d 44.4, 55.3, 57.5, 61.0, 111.3, 113.8 
(2C), 127.1 (2C), 127.8 (2C), 128.3, 128.4, 128.6, 128.9 (2C), 129.0 (2C), 129.1 (2C), 136.0, 
138.5, 152.6, 157.9, 187.8; IR (neat) 3030, 1634, 1595, 1512, 1245, 1178 cm-1; HRMS (ESI
+) m/e calc’d for [M+H]+ C25H24NO2: 370.1802, found 370.1811.
Oxidative Heck coupling:
(E)-Methyl 3-(1-Benzyl-4-oxo-1,4,5,6-tetrahydropyridin-3-yl)acrylate (3.25). Enaminone 
2.55 (37 mg, 0.20 mmol), methylacrylate (34 mg, 0.40 mmol), Pd(OAc)2 (14 mg, 0.06 
mmol), Cu(OAc)2 (110 mg, 0.60 mmol) and K2CO3 (55 mg, 0.40 mmol) combined in a 
20:5:1 mixture of t-BuOH/AcOH/DMSO (2.0 mL) and stirred for 5 min.  The reaction 
mixture was heated to 80 oC and stirred until judged complete by TLC.  The reaction mixture 
was diluted with EtOAc (8 mL) and excess K2CO3 (~1 g) was added to neutralize the AcOH. 
After stirring this mixture for 5 min the precipitate was filtered over Celite using EtOAc as 
the eluent.  The filtrate was concentrated and purified by chromatography  on SiO2 (65% 
EtOAc/ hexanes).  The title compound was isolated as a waxy yellow solid.  1H NMR (400 
MHz, CDCl3) δ 2.53 (t, 2H, J = 7.8 Hz), 3.46 (t, 2H, J = 7.8 Hz), 3.71 (s, 3H), 4.51 (s, 2H), 
6.66 (d, 1H, J = 15.6 Hz), 7.22 (d, 1H, J = 15.6 Hz), 7.26-7.28 (m, 2H), 7.36-7.43 (m, 3H), 
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7.51 (s, 1H);  13C NMR (100 MHz, CDCl3) δ 35.9, 46.2, 51.1, 60.7, 106.0, 110.9, 127.8 (2C), 
128.9, 129.3 (2C), 134.4, 140.4, 156.9, 169.6, 188.7; IR (neat) 2948, 1696, 1653, 1596, 1436, 
1224 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C16H18NO3: 272.1287, found 272.1275.
6.4  Chapter 4
(S)-tert-butyl 2-(2-diazoacetyl)pyrrolidine-1-carboxylate (4.3). Warning:  Large amounts 
of diazomethane were used for this transformation.  Proper care should be taken when 
handling this highly explosive reagent.  All glassware used was free of cracks, scratches or 
ground-glass joints and a blast shield was used.  Boc-L-proline (10.8 g, 50.0 mmol, 1.00 
equiv) was taken into THF (100 mL) with stirring and cooled to 0 ºC with an ice bath.  The 
reaction solution was treated with TEA (7.66 mL, 55.0 mmol, 1.10 equiv) and allowed to 
react for 15 min to fully deprotonate the carboxylic acid.  With the addition of ethyl 
chloroformate (5.23 mL, 55.0 mmol, 1.10 equiv), a thick white precipitate formed.  Stirring 
was continued for 15 min then stopped.  In a separate flask, an ice-cold ethereal solution of 
diazomethane was prepared and, without stirring, was carefully decanted into the freshly 
prepared anhydride reaction flask using a glass funnel.  The reaction solution was lightly 













temperature and react overnight.  Any additional diazomethane was carefully quenched with 
0.5 N acetic acid (100 mL).  The drop-wise addition of saturated sodium bicarbonate 
regulated the solution back to a basic pH 8-9 with gentle stirring.  The organic and aqueous 
layers were separated.  The organic phase was washed twice each with saturated sodium 
bicarbonate and brine then dried over sodium sulfate.  The solvent was evaporated under 
reduced pressure.  At this point the crude diazoketone could be used for subsequent Wolff 
rearrangement reactions.  Alternatively, the diazoketone could also be purified by 
chromatography on SiO2 (15% EtOAc/hexanes) to provide the title compound as a yellow oil 
(72%).  The spectral data matched that in the literature.352, 353  
(S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)acetic acid (4.4). Diazoketone 4.3 (8.61 g, 
36.0 mmol, 1.00 equiv) was dissolved in 220 mL of a 1:10 mixture of water and THF and 
cooled to –25 ºC and stirred for 30 minutes. Foil was used to cover the reaction flask so as to 
exclude light from the reaction solution.  In a separate foil covered flask, silver 
trifluoroacetate (795 mg, 3.60 mmol, 0.10 equiv) was dissolved in TEA (110 mL).  This 
solution was added dropwise to the diazoketone mixture over 30 min.  The reaction 
temperature was allowed to slowly warm to room temperature and the solution was stirred 
overnight.  To the reaction mixture was added activated carbon (~2 g) and the reaction 










redissolved in EtOAc.  To this was added activated carbon (~2 g) and the process repeated. 
When the filtrate had been concentrated a second time the residue was purified via SiO2 flash 
chromatography (30% EtOAc/hexanes) affording the title compound (68%) as a white solid. 
The spectral data matched that in the literature.353 
(S)-tert-butyl 2-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylate (4.5). Diazoketone 4.3 
(2.53 g, 10.6 mmol, 1.00 equiv) was dissolved in 45 mL of MeOH and the reaction flask was 
covered with foil to exclude light from the reaction solution.  In a separate foil covered flask, 
silver trifluoroacetate (240 mg, 1.4 mmol, 0.13 equiv) was dissolved in TEA (30 mL).  This 
solution was added dropwise to the diazoketone mixture over 30 min.  The reaction 
temperature was allowed to slowly warm to room temperature and the solution was stirred 
overnight.  To the reaction mixture was added activated carbon (~1 g) and the reaction 
mixture was stirred for 5 min and filtered.  The filtrate was concentrated and the residue 
redissolved in EtOAc.  To this was added activated carbon (~1 g) and the process repeated. 
When the filtrate had been concentrated a second time the residue was purified via SiO2 flash 
chromatography (15% EtOAc/hexanes) affording the title compound (86%) as a clear oil. 












(S)-tert-Butyl 2-(2-(Methoxy(methyl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate (2.2). 
Amino acid 4.4 (920 mg, 4.0 mmol, 1.0 equiv) was dissolved in anhydrous CH2Cl2 (100 mL) 
under an argon atmosphere and cooled to –15 °C.  To this solution was added N,O-
dimethylhydroxylamine•HCl (430 mg, 4.4 mmol, 1.1 equiv) and N-methylmorpholine (0.49 
mL, 4.4 mmol, 1.1 equiv) followed by EDCI (810 mg 4.2 mmol, 1.1 equiv).  The reaction 
mixture was  then allowed to come to room temperature.  After 2 h the reaction was again 
cooled to 0 °C and quenched by the addition of an ice cold 10% HCl solution (25 mL) and 
allowed to stir at this temperature for 5 min.  The reaction was diluted with water (50 mL) 
and extracted with CH2Cl2 (x3). The combined organic layers were washed with saturated 
NaHCO3 (x1), dried over Na2SO4, filtered and concentrated.  Purification via SiO2 flash 
chromatography (50% EtOAc/hexane) afforded the title compound as a clear oil (98%).  See 
Section 6.2 for spectral data.
Methyl ester 4.5 was converted to the Weinreb amide 2.2 using the procedure reported by 



























EtOAc in hexanes) to give the Weinreb amide (86%) as a clear viscous oil.  See Section 6.2 
for spectral data.
Diazoketone 4.4 (7.37 g, 30.8 mmol, 1.00 equiv)was taken into THF (130 mL) and cooled to 
0 ºC. Foil was used to cover the reaction flask so as to exclude light from the reaction 
solution.  To this was added freshly distilled N,O-dimethylhydroxylamine (4.00 g, 92.4 
mmol, 3.00 equiv).344 In a separate foil covered flask, silver trifluoroacetate (1.37 g, 6.20 
mmol, 0.20 equiv) was dissolved in TEA (86 mL).  This solution was added to the 
diazoketone mixture over 30 min.  The reaction temperature was allowed to slowly warm to 
room temperature and the solution was stirred overnight.  To the reaction mixture was added 
activated charcoal (~2 g) and the reaction mixture was stirred for 5 min and filtered.  The 
filtrate was concentrated and the residue redissolved in EtOAc.  To this was added activated 
charcoal (~2 g) and the process repeated.  When the filtrate had been concentrated a second 
time the residue was purified via SiO2 flash chromatography (50% EtOAc/hexanes) affording 
















(S)-tert-butyl 2-(2-oxobut-3-yn-1-yl)pyrrolidine-1-carboxylate (2.17).  The Weinreb amide 
(4.66 g, 17.1 mmol, 1.0 equiv) was dissolved in anhydrous THF (200 mL) under nitrogen 
atmosphere and cooled to 0 °C.  To this reaction vessel, was added dropwise, a solution of 
ethynyl magnesium bromide reagent (171 mL, 85.6 mmol, 5.0 equiv, 0.5 M in THF) and 
allowed to come to room temperature. After the reaction was judged complete by TLC it was 
quenched by the addition of an ice cold 10% HCl solution (15 mL) and allowed to stir at this 
temperature for 5 minutes. The reaction was diluted with water and extracted with EtOAc 
(x3). The combined organic layers were washed with saturated NaHCO3 (x1), dried over 
Na2SO4, filtered and concentrated.  The title compound was obtained as a clear oil (3.94 g, 
97% yield) after SiO2 flash chromatography (20% EtOAc/Hexanes): Spectral data was 
identical to that reported.255
 
(S)-2,3,8,8a-tetrahydroindolizin-7(1H)-one (2.37). Ynone 2.17 (3.74 g, 15.8 mmol, 1.0 






















47.3 mmol, 3.0 equiv) was added. The reaction was left stirring for 6 h at room temperature. 
The solvent was removed by passing N2 over the reaction mixture.  The remaining residue 
was placed under vacuum for 15 minutes and then dissolved in MeOH (100 mL).  A separate 
flask was charged with 700 mL of MeOH and K2CO3 (10.9 g, 79.0 mmol, 5.0 equiv).  To this 
flask was added the solution of deprotected ynone over 15 minutes.  The reaction was stirred 
for 1 h and the solvent was evaporated.  At this time CH2Cl2 was added to redissolve the 
product (but not the inorganic salts), the slurry was suction filtered, and the filtrate 
concentrated.  To the solid residue was added more CH2Cl2 and the precipitates were once 
again filtered away.  This residue after removal of solvent was purified via SiO2 flash 
chromatography to provide the title compound as an off-white solid (2.05 g, 95% yield) after 
SiO2 flash chromatography (100% acetone): See Section 6.2 for spectral data.
(S)-6-(4-methoxyphenyl)-2,3,8,8a-tetrahydroindolizin-7(1H)-one (3.2).  Freshly purified 
enaminone (750 mg, 5.5 mmol, 1.0 equiv), Pd(OAc)2 (370 mg, 1.7 mmol, 0.30 equiv), 
anhydrous Cu(OAc)2 powder (3.0 g, 17 mmol, 3.0 equiv) and granular K2CO3 (1.5 g, 11 
mmol, 2.0 equiv) were combined in a 20:5:1 mixture of degassed t-BuOH/AcOH/DMSO (55 
mL) under N2 and stirred for 5 min (Note: Solvents were used without purification).  The 
reaction mixture was heated to 60 oC and the potassium trifluoroborate (3.5 g, 17 mmol, 3.0 















equiv) was added slowly over 5 h as a solid.  Approximately, 0.20 equivalents of 
trifluoroborate were added every 30 min.  The reaction was stirred for an additional hour and 
was monitored by TLC using 100% EtOAc as the mobile phase.  The reaction mixture was 
diluted with EtOAc and added to a separatory funnel containing brine.  The product was 
extracted with EtOAc (3x).  The combined organic layers were washed brine (2x) and sat. 
NaHCO3 (aq.) (2x), dried over Na2SO4 and concentrated in vacuo.  The title compound was 
obtained as a pale yellow solid (930 mg, 70% yield) after SiO2 flash chromatography (80% 
EtOAc/hexanes).  The spectral data was identical to that of (±)-3.2 (See Section 6.2). α[ ]D
22 =  
–97.5 (c 1.00, CHCl3).
(6S*,8aS*)-6-(4-methoxyphenyl)hexahydroindolizin-7(1H)-one (4.8).  Enaminone 3.2 
(120 mg, 0.50 mmol, 1.0 equiv) was dissolved in anhydrous THF (5 mL) under a N2 
atmosphere.  The solution was cooled to –78 ºC at which point L-Selectride (0.55 mL, 0.55 
mmol, 1.1 equiv, 1.0 M in THF) was added over 15 minutes.  After stirring for 1 h, the 
reaction was slowly warmed to 0 ºC over 1.5 h and stirred at room temperature for an 
additional 2 h.  The reaction was quenched with a saturated solution of NaHCO3 (aq.) and 
added to a separatory funnel.  The product was extracted with EtOAc (3x). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo.  The title compound (110 













chromatography [60% EtOAc/hexanes (1% TEA)].  Spectral data was identical to that 
reported.318   α[ ]D
22 = +6.05  (c 1.14, CHCl3).
(6S,7R,8aS)-6-(4-methoxyphenyl)-7-methyloctahydroindolizin-7-ol (4.9).  Ketone 4.8 
(105 mg, 0.43 mmol, 1.00 equiv) taken in anhydrous THF (3.5 mL) in a flame dried RBF and 
cooled to –78 ºC.  Methyl lithium (0.32 mL, 0.52 mmol, 1.2 equiv, 1.6 M in Et2O) was added 
dropwise and stirred for 45 min at –78 ºC.  The reaction was quenched with MeOH (1 mL) 
and allowed to warm to room temperature.  The quenched reaction mixture was added to a 
separatory funnel containing 10% NaOH (aq.) and the product was extracted with EtOAc 
(3x). The combined organic layers were dried over Na2SO4 and concentrated in vacuo.  The 
title compound (85 mg, 75% yield) was obtained as a white crystalline solid (mp 92–96 ºC) 
after SiO2 flash chromatography [50% EtOAc/hexanes (1% TEA)].  1H NMR (400 MHz, 
CDCl3) δ  1.05 (s, 3H), 1.37–1.49 (m, 2H), 1.71–1.78 (m, 1H), 1.81–1.91 (m, 2H), 1.97 (dd, J 
= 13.2, 2.5 Hz, 1H), 2.23 (dd, J = 17.9, 8.9 Hz, 1H), 2.34–2.39 (m, 1H), 2.67 (dd, J = 11.3, 
11.3 Hz, 1H), 2.83 (dd, J = 11.9, 3.8 Hz, 1H), 2.94 (dd, J = 10.6, 3.9 Hz, 1H), 3.07 (dd, J = 
8.6, 8.6 Hz, 1H), 3.8 (s, 3H), 6.86 (d, J = 8.5 Hz, 2H), 7.20 (d, J = 8.6 Hz, 2H); 13C NMR 

















131.9, 158.6 ; IR (neat) 3416, 2961, 1611, 1512, 1246, 1178, 833 cm-1 ; HRMS (ESI+) m/e 
calc’d for [M+H]+ C16H24NO2: 262.1807, found 262.1790.  α[ ]D
22 =  –6.54  (c 1.10, CHCl3).
6-(4-Methoxyphenyl)-7-methyl-1,2,3,5,8,8a-hexahydroindolizine (4.7).  Indolizidine 4.9 
(62 mg, 0.24 mmol, 1.0 equiv) was dissolved in anhydrous THF (4.0 mL) and cooled to –50 
ºC.  Pyridine (0.1 mL) followed by SOCl2 (0.043 mL, 0.59 mmol, 2.5 equiv) in 0.5 mL THF 
was added dropwise to the reaction mixture.  The reaction mixture was kept between –30 and 
–10 ºC for 1.5 h.  The reaction was quenched with 10% NaOH (aq.).  The quenched reaction 
mixture was added to a separatory funnel containing 10% NaOH (aq.) and the product was 
extracted with EtOAc (3x). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo.  The title compound was obtained as a colorless oil (51 mg, 88% 
yield) after SiO2 flash chromatography [20% EtOAc/hexanes (1% TEA)].  See below for 















(S)  - 6 - (4-Methoxyphenyl) - 1, 2, 3, 5, 8, 8a – hexahydroindolizin – 7 – yl –
trifluoromethanesulfonate (4.6).  Enaminone 3.2 (590 mg, 2.4 mmol, 1.0 equiv) was 
dissolved in anhydrous THF (30 mL) under  a N2 atmosphere.  The solution was cooled to –
78 ºC at which point L-Selectride (0.23 mL, 0.23 mmol, 1.0 equiv, 1.0 M in THF) was added 
over 15 min.  After stirring for 1 h, the reaction was slowly warmed to 0 ºC over 2 h.  The 
reaction mixture was once again cooled to –78 ºC  and Comins’  reagent (1.1 g, 2.7 mmol, 1.1 
equiv) was added all at once.  The mixture was stirred for another hour at –78 ºC and then 
slowly warmed to 0 ºC over 2 h.  The reaction was quenched with a saturated solution of 
NaHCO3 (aq.) and added to a separatory funnel.  The product was extracted with EtOAc 
(3x). The combined organic layers were dried over Na2SO4 and concentrated in vacuo.  The 
title compound was obtained as a colorless oil (690 mg, 76% yield) after SiO2 flash 
chromatography (10% EtOAc/hexanes (1% TEA):  1H NMR (500 MHz, CDCl3) δ 1.49-1.57 
(m, 1H), 1.76-1.84 (m, 1H), 1.87-1.96 (m, 1H), 2.00-2.07 (m, 1H), 2.22 (dd, J = 18.1, 9.2 Hz, 
1H), 2.47-2.62 (m, 3H), 3.06 (d, J = 15.8 Hz, 1H), 3.18 (dt, J = 4.4, 2.1 Hz, 1H), 3.72-3.75 
(m, 1H), 3.74 (s, 3H), 6.83 (d, J = 8.8 Hz, 2H), 7.14 (d, J = 8.8 Hz, 2H);  13C NMR (125 
MHz, CDCl3) δ 22.2, 30.5, 35.2, 53.4, 55.3, 55.6, 60.5, 113.9, 118.1 (q, JCF = 320 Hz), 126.6, 
129.2, 129.5, 142.0, 159.5 ; IR (neat) 2959, 1610, 1512, 1416, 1209, 1146 cm-1;  HRMS (ESI
+) m/e calc’d for [M+H]+ C16H19F3NO4S: 378.0987, found 378.0974; α[ ]D

















(S)-6-(4-Methoxyphenyl)-7-methyl-1,2,3,5,8,8a-hexahydroindolizine (4.7).  Preparation 
of organo zinc reagent.  A flame dried RBF under N2 was charged with anhydrous THF (10.0 
mL) and cooled to –78 ºC.  Methyl lithium (1.6 mL, 2.5 mmol, 5.0 equiv, 1.6M in Et2O) was 
added and the solution was allowed to sit.  A separate RBF was charged with anhydrous 
ZnBr2 (590 mg, 2.6 mmol, 5.2 equiv).  The ZnBr2 was dried by heating the RBF under a 
vacuum with a heat gun for 5 min.  When the ZnBr2 had cooled to room temperature it was 
dissolved in anhydrous THF (6.0 mL) under N2.  This ZnBr2 solution was slowly cannulated 
into the methyl lithium solution and the resulting solution was stirred at –78 ºC for 5 min and 
then allowed to warm to room temperature.
Triflate 4.6 (190 mg, 0.50 mmol, 1.0 equiv), dissolved in a minimal amount of THF, and 
Pd(PPh3)4 (29 mg, 0.025 mmol, 5.0 mol%) were added sequentially to the zinc reagent.  If 
the reaction had not gone to completion after 1 h at room temperature, the reaction mixture 
was heated to 50 ºC.  Upon consumption of the triflate starting material (as judged by TLC) 
SiO2 was added to the reaction mixture and the solvent was evaporated to leave a free 
flowing powder. Following flash chromatography (20% EtOAc/hexanes (1% TEA)) 110 mg 
(91%) of the title compound was obtained as a colorless oil:  1H NMR (400 MHz, CDCl3) δ 
1.46-1.54 (m, 1H), 1.60 (s, 3H), 1.73-1.81 (m, 1H), 1.85-1.94 (m, 1H), 2.00-2.32 (m, 5H), 
2.91 (d, J = 15.4 Hz, 1H), 3.22 (dd, J = 3.2, 3.2 Hz, 1H), 3.62 (d, J = 15.4 Hz, 1H), 3.82 (s, 













21.4, 30.8, 38.5, 54.2, 55.2, 57.8, 60.2, 113.5, 127.9, 130.0, 130.3, 133.8, 158.1; IR (neat) 
2907, 1609, 1510, 1244, 1175, 831 cm-1;  HRMS (ESI+) m/e calc’d for [M+H]+ C16H22NO: 
244.1701, found 244.1688; α[ ]D
22 = +142 (c 1.00, CHCl3).
(+)-Secoantofine (4.11). Preparation of organo zinc reagent.  A flame dried RBF under N2 
was charged with anhydrous THF (15.0 mL) and cooled to –78 ºC.  tert-Butyllithium (6.6 
mL, 11 mmol, 11 equiv, 1.7 M in pentane) was added carefully and the solution was allowed 
to sit for 5 min at –78 ºC.  4-Bromoveratrole (1.2 g, 5.4 mmol, 5.0 equiv) was then added 
dropwise and the resulting reaction mixture was stirred for 2 h and –78 ºC.  A different RBF 
was charged with anhydrous ZnBr2 (1.3 g, 5.6 mmol, 5.2 equiv).  The ZnBr2 was dried by 
heating the RBF under a vacuum with a heat gun for 5 min.  When the ZnBr2 had cooled to 
room temperature it dissolved in anhydrous THF (12.0 mL) under N2.  This ZnBr2 solution 
was slowly cannulated into the yellow aryllithium reagent solution.  The resulting cloudy 
white solution was stirred at –78 ºC for 5 min and then allowed to warm to room 
temperature.  Upon warming the solution became clear.  Triflate 4.6 (400 mg, 1.1 mmol, 1.0 
equiv) (dissolved in a minimal amount of THF) and Pd(PPh3)4 (62 mg, 0.054 mmol, 5.0 mol


















after 1 h at room temperature, the reaction mixture was heated to 50 ºC.  Upon consumption 
of the triflate starting material (as judged by TLC) SiO2 was added to the reaction mixture 
and the solvent was evaporated to leave a free flowing powder. Following flash 
chromatography [40% EtOAc/hexanes (1% TEA)] 380 mg (96%) of the title compound was 
obtained as a yellow oil:  1H NMR (400 MHz, CDCl3) δ 1.51-1.63 (m, 1H), 1.78-2.01 (m, 
2H), 2.06-2.14 (m, 1H), 2.25 (dd, J = 9.0, 9.0 Hz, 1H), 2.36-2.45 (m, 2H), 2.69-2.77 (m, 1H), 
3.07 (td, J = 16.0, 3.1 Hz, 1H), 3.29 (dt, J = 4.3, 2.0 Hz, 1H), 3.54 (s, 3H), 3.72 (s, 3H), 3.81 
(s, 3H), 3.86 (d, J = 15.8 Hz, 1H), 6.47 (d, J = 1.1 Hz, 1H), 6.66-6.69 (m, 4H), 6.97 (d, J = 
8.8 Hz, 2H);  13C NMR (100 MHz, CDCl3) δ 21.5, 30.8, 38.6, 54.3, 55.1, 55.5, 55.7, 57.9, 
60.4, 110.4, 113.1, 113.4, 120.7, 130.2, 132.6, 132.7, 133.6, 135.1, 147.1, 147.9, 158.0; IR 
(neat) 2955, 1607, 1511, 1245, 1030, 755 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 
C23H28NO3: 366.2064, found 366.2068; α[ ]D
22 = +169 (c 1.00, CHCl3).
(+)-Ipalbidine (4.1).  O-Methylipalbidine (4.7) (56 mg, 0.23 mmol, 1.0 equiv) was dissolved 
in CH2Cl2 (1.0 mL) and cooled to –78 ºC under N2.  To this solution was added BBr3 (0.23 
mL, 0.23 mmol, 1.0 M in CH2Cl2).  The reaction was allowed to warm to room temperature 
over night.  The reaction was quenched with water (1.0 mL) and then 5.0 mL of a saturated 
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(3x).  The combined organic layers were dried with Na2SO4, concentrated and purified via 
flash chromatography [80% EtOAc/hexane (1% TEA)] to provide 42 mg (80%) of (+)-
ipalbidine as a white crystalline solid (mp 122.2-124.6 ºC).  1H NMR (500 MHz, CDCl3) δ 
1.60 (s, 3H), 1.75-1.84 (m, 1H), 1.91-1.99 (m, 1H), 2.06-2.23 (m, 2H), 2.35-2.45 (m, 2H), 
2.54-2.61 (m, 1H), 2.79-2.87 (m, 1H), 3.21 (d, J = 14.7 Hz, 1H), 3.45-3.50 (m, 1H), 3.77 (d, 
J = 15.5 Hz, 1H), 6.83 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.5 Hz, 2H);  13C NMR (100 MHz, 
CDCl3) δ 20.0, 21.0, 29.7, 36.0, 53.4, 55.9, 61.0, 115.6, 127.9, 128.6, 129.8, 130.9, 155.7; IR 
(neat) 2913, 1609, 1513, 1445, 1269, 1169 cm-1;  HRMS (ESI+) m/e calc’d for [M+H]+ 
C15H20NO: 230.1545, found 230.1531; α[ ]D
22 = +202 (c 1.00, CHCl3). [Lit. S-enantiomer: 
+233.5 (c 1, CHCl3); R-enantiomer: –237 (c 1, CHCl3), –190.5 (c 1, MeOH)].326
(+)-Antofine (4.2). Secoantofine (4.11) (48 mg, 0.13 mmol, 1.0 equiv) was dissolved in 
CH2Cl2 (2.0 mL) and cooled to –78 ºC.  To this solution was added PIFA (62 mg, 0.14 mmol, 
1.1 equiv) and BF3•Et2O (16 mg, 0.14 mmol, 1.1 equiv) sequentially.  The solution was 
stirred for 4 h while being monitored by TLC.  A solution of PIFA (62 mg in 2.0 mL CH2Cl2) 
was added dropwise to the reaction mixture until the reaction had gone to completion.  Upon 















mixture was vigorously stirred for 1 h.  The product was extracted from the aqueous layer 
with CH2Cl2 (3x).  The combined organic layers were dried with Na2SO4, concentrated and 
purified via flash chromatography [70% EtOAc/hexane (1% TEA)] to provide 34 mg (70%) 
of (+)-antofine as a white crystalline solid: mp 226-227 °C (decomp.) 1H NMR (400 MHz, 
CDCl3) δ 1.65-1.75 (m, 1H), 1.80-2.02 (m, 2H), 2.13-2.22 (m, 1H), 2.35-2.46 (m, 2H), 
2.79-2.86 (m, 1H), 3.28 (ddd, J = 15.8, 3.7, 1.5 Hz, 1H), 3.38 (dt, J = 4.3, 2.1 Hz, 1H), 3.63 
(d, J = 14.9 Hz, 1H), 3.95 (s, 3H), 3.99 (s, 3H), 4.04 (s, 3H), 4.63 (d, J = 14.9 Hz, 1H), 7.13 
(dd, J = 9.0, 2.5 Hz, 1H), 7.25 (s, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.83 (d, J = 2.5 Hz, 1H), 7.85 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 21.6, 31.3, 33.7, 53.8, 55.0, 55.5, 55.9, 56.0, 60.3, 
104.0, 104.7, 114.9, 123.5, 124.1, 124.2, 125.5, 126.7, 127.0, 130.2, 148.4, 149.4, 157.5; 
HRMS (ESI+) m/e calc’d for [M+H]+ C23H26NO3: 364.1913, found 364.1909; α[ ]D
22 =  +111 
(c 1.00, CHCl3). [Lit.  R-enantiomer: –113.4 (c 1.23, CHCl3),149 −125.2 (c 1.27, CHCl3),184 
–108.2 (c 0.71, CHCl3);171 S-enantiomer: +66 (CHCl3)355]. 
6.5  Chapter 5 
6.5.1 Preparation of tylocrebrine and analogs












(4.21g, 22.7 mmol, 1.0 equiv) was dissolved in THF (65 mL) under a N2 atmosphere and 
cooled to –78 ºC.  DIBAL-H (32.0 mL, 32.0 mmol, 1.4 equiv, 1.0 M  in hexanes) was added 
slowly (over 15 minutes) and reaction mixture was stirred for 1 h.  The reaction was 
quenched with saturated NH4Cl (80 mL) and warmed to room temperature.  The quenched 
reaction was then treated with 10% Na2CO3 (60 mL) and vigorously stirred for 20 minutes. 
The product was then extracted with CH2Cl2 (3x) and the combined organic layers were dried 
over Na2SO4 and concentrated in vacuo.  The title compound was obtained as a clear oil 
(3.92 g, 92% yield) after SiO2 flash chromatography  (30% EtOAc/Hexanes): Spectral data 
was identical to that reported.356
tert-butyl 2-(2-ethoxy-2-oxoethyl)pyrrolidine-1-carboxylate (5.8).  To a flame-dried flask 
was added anhydrous DMF (100 mL) and the flask was purged with N2.  Sodium hydride 
(1.01 g, 25.2 mmol, 1.2 equiv, 60% in mineral oil) was added to the flask followed by 
triethylphosphonoacetate (5.0 mL, 25.2 mmol, 1.2 equiv).  The mixture was stirred for 1 h at 
room temperature.  To this solution was added hemiaminal 5.7 (3.92 g, 21.0 mmol, 1.0 equiv) 
in a solution of DMF (100 mL).  The reaction was stirred for 12 h at  room temperature and 
quenched with saturated NH4Cl (80 mL).  The product was then extracted with EtOAc (3x) 
and washed with brine (2x).  The combined organic layers were dried over Na2SO4 and 













after SiO2 flash chromatography (25% EtOAc/Hexanes): Spectral data was identical to that 
reported.357
tert-butyl 2-(2-(methoxy(methyl)amino)-2-oxoethyl)pyrrolidine-1-carboxylate (2.2). 
Ester 5.8 (4.65 g, 18.1 mmol, 1.0 equiv) and HN(OMe)Me•HCl (2.65 g, 27.1 mmol, 1.5 
equiv) were dissolved in anhydrous THF (55 mL) and cooled to –30 ºC under a N2 
atmosphere.  To a flame dried dropping funnel was added i-PrMgCl (27.0 mL, 54.3 mmol, 
3.0 equiv, 2.0 M in THF).  This Grignard reagent was added dropwise to the reaction mixture 
over 15 minutes and the reaction was stirred for 30 minutes at –15 ºC.  The reaction was 
quenched with saturated NH4Cl (80 mL) and the product was extracted with EtOAc (3x). The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo.  The title 
compound was obtained as a clear oil (4.18 g, 85% yield) after SiO2 flash chromatography 
















[(R)-2.2].  Boc-D-β-homoproline (4.0 g, 17.4 mmol, 1.0 equiv) was dissolved in anhydrous 
CH2Cl2 (50 mL) under argon atmosphere and cooled to –0 °C.  To this solution was added 
N,O-dimethylhydroxylamine•HCl (1.87 g, 19.2 mmol, 1.1 equiv) and N-methylmorpholine 
(2.1 mL, 19.2 mmol, 1.1 equiv) followed by EDCI (3.68 g, 19.2 mmol, 1.05 equiv).  The 
reaction mixture was  then allowed to come to room temperature.  After 2 hours the reaction 
was again cooled to 0 °C and quenched by the addition of an ice cold 10% HCl solution (50 
mL) and allowed to stir at this temperature for 5 minutes. The reaction was diluted with water 
(100 mL) and extracted with CH2Cl2 (x3). The combined organic layers were washed with 
saturated NaHCO3 (x1), dried over Na2SO4, filtered and concentrated.  The title compound 
was obtained as a clear oil (4.66 g, 98% yield) after SiO2 flash chromatography (40% EtOAc/















Compounds 2.17 and 2.37 were prepared according the procedure in Section 6.2 Optical 
rotations for the R-enantiomers can be found below.  
(R)-tert-butyl 2-(2-oxobut-3-yn-1-yl)pyrrolidine-1-carboxylate (R-2.17). α[ ]D
22 = +21.3 (c 
1.00, CHCl3).
(R)-2,3,8,8a-tetrahydroindolizin-7(1H)-one (R-2.37).  α[ ]D
22 = +770 (c 1.00, CHCl3).
(R)-1,2,3,5,8,8a-hexahydroindolizin-7-yl trifluoromethanesulfonate (R-5.5). Enaminone 
(R)-2.17 (1.35 g, 9.81 mmol, 1.0 equiv) was dissolved in anhydrous THF (30 mL) under  a 
N2 atmosphere.  The solution was cooled to –78 ºC at which point L-Selectride (10.8 mL, 
10.8 mmol, 1.1 equiv, 1.0 M  in THF) was added over 15 minutes.  After stirring for 1 h, the 
reaction was slowly  warmed to 0 ºC over 2 hours.  The reaction mixture was once again 



















–78 to 0 ºC;
then 
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The mixture was stirred for another hour at –78 ºC and then slowly warmed to 0 ºC over 2 
hours. The reaction was quenched with a saturated solution of NaHCO3 (aq.) and added to a 
separatory funnel.  The product was extracted with ethyl acetate (3x).  The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo.  The title compound was obtained 
as a colorless oil (2.67 g, 73% yield) after SiO2 flash chromatography (20% EtOAc/Hexanes 
(1% TEA): 1H NMR (400 MHz, CDCl3) δ ; 1.40-1.49 (m, 1H), 1.70-2.01 (m, 3H), 2.14 (dd, J 
= 17.9, 8.9 Hz, 1H), 2.27-2.46 (m, 3H), 2.82 (d, J = 16.3 Hz, 1H), 3.11 (dt, J = 4.3, 2.3 Hz), 
3.51 (dd, 16.3, 4.8 Hz, 1H), 5.72-5.73 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 22.1, 30.4, 
35.0, 49.6, 53.3, 60.2, 116.7, 118.5 (q, J = 320 Hz), 147.8;  IR (neat) 2794, 1689, 1419, 1210, 
1143, 1024, 879 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C9H13F3NO3S: 272.0568, found 
272.0574; (R)-Enantiomer: α[ ]D
22 =  –74.5 (c 1.00, CHCl3). (S)-Enantiomer:  α[ ]D
22 =  +75.2 (c 
1.00, CHCl3). 
SUZUKI COUPLINGS
























2'-bromo-2,3,4',5'-tetramethoxy-1,1'-biphenyl (5.4).  DME (60 mL) and Na2CO3 (21.1 
mL, 42.3 mmol, 5.0 equiv, 2.0 M aq. solution) were added to a round-bottomed flask and 
degassed under reduced pressure for 30 minutes.  Iodobromoveratrole (2.90 g, 8.45 mmol, 
1.0 equiv), arylboronic acid (2.0 g, 11.0 mmol, 1.3 equiv), LiCl (1.07 g, 25.4 mmol, 3.0 
equiv) and (dppf)PdCl2 (310 mg, 0.42 mmol, 0.05 equiv) were added all at once and the 
reaction mixture was heated to 80 ºC under a N2 atmosphere.  After 16 h the reaction was 
quenched with a saturated solution of NH4Cl (aq.) and added to a separatory funnel.  The 
product was extracted with ethyl acetate (3x).  The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo.  The title compound was obtained as a colorless oil (2.15 
g, 72% yield) after SiO2 flash chromatography (20% EtOAc/Hexanes):  1H NMR (400 MHz, 
CDCl3) δ 3.63 (s, 3H), 3.83 (s, 3H), 3.91 (s, 3H), 3.91 (s, 3H), 6.82 (dd, J = 7.6, 1.5 Hz, 1H), 
6.83 (s, 1H), 6.96 (dd, J = 8.2, 1.5 Hz, 1H), 7.09 (dd, J = 7.9, 7.9 Hz, 1H), 7.12 (s, 1H); 13C 
NMR (100 MHz, CDCl3) δ 55.8, 56.0, 56.2, 60.7, 111.9, 113.5, 114.2, 115.2, 123.3, 123.4, 
131.3, 135.4, 146.7, 147.9, 148.8, 152.8; IR (neat) cm-1 2935, 1579, 1506, 1473, 1262, 1210, 










2-bromo-3',4,4',5-tetramethoxy-1,1'-biphenyl (5.9) and 2-bromo-3',4',5-trimethoxy-1,1'-
biphenyl (5.13).  Spectral data was identical to that reported.149
2-bromo-2',4,5-trimethoxy-1,1'-biphenyl (5.10).  1H NMR (400 MHz, CDCl3) δ  3.81 (s, 
3H), 3.85 (s, 3H), 3.91 (s, 3H), 6.81 (s, 1H), 6.99 (d, J = 8.3 Hz, 1H), 7.03 (ddd, J = 7.4, 7.4, 
1.8 Hz, 1H), 7.12 (s, 1H), 7.19 (dd, J = 7.4, 1.8 Hz, 1H), 7.38 (ddd, J = 8.3, 7.4, 1.7 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ   55.7, 56.0, 56.2, 111.1, 114.2, 114.2, 115.3, 120.3, 129.3, 130.2, 
131.2, 131.7,  148.0, 148.7, 156.7; IR (neat) cm-1 2937, 1597, 1490, 1463, 1245, 1207, 1026, 


















2-bromo-3',4,5-trimethoxy-1,1'-biphenyl (5.11).  1H NMR (400 MHz, CDCl3) δ  3.85 (s, 
3H), 3.86 (s, 3H), 3.91 (s, 3H), 6.84 (s, 1H), 6.90–7.00 (m, 3H), 7.12 (s, 1H), 7.34 (dd, J = 
7.9, 7.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ  55.3, 56.1, 56.2,  112.4, 112.9, 113.8, 115.3, 
115.8, 122.0, 129.0, 134.6, 142.4, 148.2, 148.8, 159.1; IR (neat) cm-1 2936, 1602, 1507, 1485, 
1464, 1246, 1205, 1028, 932, 857; HRMS (ESI+) m/e calc’d for [M+H]+ C15H15BrO3: 
322.0205, found 325.1938.
2-bromo-4,4',5-trimethoxy-1,1'-biphenyl (5.12).  1H NMR (400 MHz, CDCl3) δ  3.85 (s, 
3H), 3.86 (s, 3H), 3.91 (s, 3H), 6.82 (s, 1H), 6.96 (d, J = 8.7 Hz, 2H), 7.11 (s, 1H), 7.34 (d, J 













130.6, 133.6, 134.4, 148.2, 148.6, 158.9; IR (neat) cm-1 2937, 1601, 1507, 1486, 1464, 1205, 
1028, 932, 857; HRMS (ESI+) m/e calc’d for [M+H]+ C15H15BrO3: 322.0205, found 
325.1855.
 
2-bromo-3',4,4',5-tetramethoxy-1,1'-biphenyl (5.9). Dimerization: 4-Bromoveratrole (20.0 
g, 92.1 mmol, 1.0 equiv) was dissolved in  CH2Cl2 (1.0 L) in a 2 L round-bottomed flask and 
cooled to –78 ºC.  To this solution was added dropwise (over 1 h) a pre-mixed solution of 
PIFA (21.8 g, 50.7 mmol, 0.55 equiv) and BF3•Et2O (12.7 mL, 101.4 mmol, 1.1 equiv) in 
CH2Cl2 (500 mL).  The reaction mixture was stirred until the starting material was 
completely consumed (~ 1 h). The reaction was quenched by adding 10% NaOH (500 mL) 
and the reaction mixture was vigorously stirred for 1 h.  The product was extracted with 
CH2Cl2 (3x).  The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo and recrystallized from EtOH.  Veratrole dimer 5.15 was obtained as a white 
crystalline solid (18.8 g, 95% yield).  Spectral data was identical to that reported.358
Dehalogenation:  Veratrole dimer 5.15 (10.0 g, 23.0 mmol, 1.0 equiv) was dissolved in 
















23.0 mmol, 1.0 equiv, 2.5M in hexanes) dropwise via syringe pump (0.62 mL/min).  Upon 
complete addition of n-BuLi the reaction was stirred for another 20 minutes before 2.0 mL of 
MeOH was added as a proton source.  The quenched reaction mixture was stirred for 5 
minutes at –78 ºC and then poured into a separatory funnel with 100 mL of H2O.  The 
product was extracted with ethyl acetate (3x). The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo and recrystallized from MeOH.  The title compound was 
obtained as an off-white crystalline solid (6.79 g, 84% yield).  Spectral data was identical to 
that reported.149
NEGISHI COUPLINGS
Compounds 5.1, 5.17, 5.18, 5.19, 5.20 and 5.21 were prepared according the procedure 


























(R-5.1).  Representative procedure for preparing zincate solution: A dry RBF containing 
anhydrous ZnBr2 (412 mg, 1.83 mmol, 1.65 equiv) was heated with heat gun under vacuum. 
The flask was then cooled to 25 °C, and anhydrous THF (15 mL) was added.  To a separate 
flask containing 20 mL of THF at –78 °C was added tert-butyllithium (2.06 mL, 3.50 mmol, 
3.15 equiv, 1.7 M in THF), and then the biarylbromide 5.4 (590 mg, 1.67 mmol, 1.5 equiv) in 
a minimal amount of THF (~5 mL) was added dropwise. The mixture was stirred at –78 °C 
for 2 h, and the solution of ZnBr2 in THF was transferred via a cannula. The resulting zinc 
reagent was stirred at -78 °C for 10 min and warmed to 25 °C. 
Representative procedure for Negishi Coupling: Triflate 5.5 (300 mg, 1.11 mmol, 1.0 equiv) 
and Pd(PPh3)4 (26 mg, 0.02 mmol, 0.02 equiv) were added sequentially to the solution of 
zinc reagent.  The resulting yellow mixture was stirred at room temperature until the triflate 
had been consumed (~1 h).  The reaction was quenched with SiO2 the solvent removed as to 
provide a free-flowing powder. The SiO2 was loaded onto a SiO2 column and purified by 
flash chromatography (60 % EtOAc/hexanes [1% TEA]). The title compound was obtained 
as a yellowish foamy solid (415 mg, 95%).  1H NMR (400 MHz, CDCl3) δ 1.28-1.38 (m, 
1H), 1.63-1.73 (m, 1H), 1.75-1.89 (m, 2H), 1.95-2.16 (m, 4H) 2.72 (dd, J = 16.2, 1.5 Hz, 








1H), 3.15 (dt, J = 8.6, 2.1 Hz, 1H), 3.50 (dd, J = 16.2, 4.7 Hz, 1H), 3.59 (s, 3H), 3.85 (s, 3H), 
3.89 (s, 3H), 3.90 (s, 3H), 5.53 (m, 1H), 6.82 (dd, J = 7.9, 1.4 Hz, 1H), 6.82 (s, 1H), 6.87 (dd, 
J = 7.9, 1.4 Hz, 1H), 7.00 (dd, J = 7.9, 7.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 21.3, 
30.6, 36.4, 52.7, 54.2, 55.8, 55.9, 55.9, 60.1, 60.4, 111.1, 111.9, 113.8, 123.3, 123.6, 124.7, 
127.9, 134.9, 135.7, 137.3, 146.4, 147.1, 147.8, 152.8; IR (neat) 2935, 1515, 1469, 1262, 
1008, 751 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C24H30NO4: 396.2175, found 
396.2163.  (R)-Enantiomer: α[ ]D
22 =        –62.8 (c  1 .00, CHCl3).  
7-(2',4,5-trimethoxy-[1,1'-biphenyl]-2-yl)-1,2,3,5,8,8a-hexahydroindolizine (±-5.17). 
Using the same proportions as above, the title compound was obtained after flash 
chromatography (60 % EtOAc/hexanes [1% TEA]) as a yellowish foamy solid (467 mg, 
97%). 1H NMR (400 MHz, CDCl3) δ 1.30-1.40 (m, 1H), 1.63-1.73 (m, 2H), 1.76-1.97 (m, 
3H), 2.03-2.16 (m, 3H), 2.64 (d, J = 16.2 Hz, 1H), 3.14 (dt, J = 8.6, 2.0 Hz, 1H), 3.46 (ddd, J 
= 16.2, 4.6, 1.7 Hz, 1H), 3.75 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 5.43-5.44 (m, 1H), 6.81 (d, J 
= 8.1 Hz, 2H), 6.91 (d, J = 8.1 Hz, 1H), 6.95 (dt, J = 7.4, 1.0 Hz, 1H), 7.19 (dd, J = 7.4, 1.7 
Hz, 1H), 7.28 (ddd, J = 8.1, 7.4, 1.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 21.3, 30.7, 36.4, 








131.5, 135.4, 137.1, 147.2, 147.8, 156.4; IR (neat) 2935, 1515, 1491, 1246, 1028, 753 cm-1; 
HRMS (ESI+) m/e calc’d for [M+H]+ C23H28NO3: 366.2069, found 366.2067.
  
7-(3',4,5-trimethoxy-[1,1'-biphenyl]-2-yl)-1,2,3,5,8,8a-hexahydroindolizine (±-5.18). 
Using the same proportions as above, the title compound was obtained after flash 
chromatography (60 % EtOAc/hexanes [1% TEA]) as a yellowish foamy solid (432 mg, 
95%). 1H NMR (400 MHz, CDCl3) δ ;1.24-1.34 (m, 1H), 1.64-1.87 (m, 3H), 1.91-2.00 (m, 
3H), 2.11 (dd, J = 18.0, 9.0 Hz, 1H), 2.84 (dd, J = 16.3, 1.8 Hz, 1H), 3.18 (dt, J = 8.6, 2.1 Hz, 
1H), 3.59 (dd, J = 16.3, 4.7 Hz, 1H), 3.82 (s, 3H), 3.89 (s, 3H), 3.89 (s, 3H), 5.70-5.71 (m, 
1H), 6.81 (s, 1H), 6.82-6.85 (m, 1H), 6.84 (s, 1H), 6.96-7.00 (m, 2H), 7.27 (dd, J = 7.9, 7.9 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 21.3, 30.6, 36.6, 52.9, 54.2, 55.2, 55.9, 56.0, 60.3, 
112.3, 113.0, 113.2, 114.4, 121.5, 125.1, 129.0, 131.8, 134.3, 138.5, 143.1, 147.8 147.9, 
159.2; IR (neat) 2956, 1502, 1464, 1238, 1040, 753 cm-1; HRMS (ESI+) m/e calc’d for [M









Using the same proportions as above, the title compound was obtained after flash 
chromatography (60 % EtOAc/hexanes [1% TEA]) as a yellowish foamy solid (444 mg, 
98%). 1H NMR (400 MHz, CDCl3) δ 1.24-1.34 (m, 1H), 1.63-1.73 (m, 2H), 1.75-2.02 (m, 
3H), 2.12 (dd, J = 17.9, 9.0 Hz, 1H), 2.84 (dd, J = 16.3, 1.8 Hz, 1H), 3.19 (dt, J = 8.5, 2.0 Hz, 
1H), 3.59 (ddd, J = 16.3, 4.7, 1.6 Hz, 1H), 3.84 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 5.69-5.70 
(m, 1H), 6.80 (s, 1H), 6.81 (s, 1H), 6.90 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.8 Hz, 1H);  13C 
NMR (100 MHz, CDCl3) δ  ; 21.3, 30.6, 36.6, 52.9, 54.3, 55.3, 55.9, 56.0, 60.2, 113.0, 113.2, 
113.5, 125.1, 128.5, 129.9, 131.6, 134.2, 138.5, 147.6, 147.8, 158.4; IR (neat) 2956, 1514, 










(R-5.20)    Using the same quantities and proportions as above, the title compound was 
obtained as  a yellowish foamy solid (429 mg, 98%). 1H NMR (400 MHz, CDCl3) δ 
1.23-1.32 (m, 1H), 1.62-1.72 (m, 1H), 1.74-1.85 (m, 2H), 1.87-2.98 (m, 3H), 2.09 (dd, J = 
9.0 Hz, 1H), 2.82 (dd, J = 16.3, 1.8 Hz, 1H), 3.17 (dt, J = 8.5, 1.8 Hz, 1H), 3.60 (dd, J = 16.3, 
4.6 Hz, 1H), 3.87 (s, 3H), 3.87 (s, 3H), 3.88 (s, 3H), 3.91 (s, 3H), 5.73-5.74 (m, 1H), 6.81 (d, 
J = 6.0 Hz, 1H), 6.87 (d, J = 8.2 Hz, 1H), 6.94 (dd, J = 8.2, 1.9 Hz, 1H), 6.98 (d, J = 1.9 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 21.3, 30.6, 36.6, 53.0, 54.3, 55.8, 55.9, 56.0, 56.0, 60.4, 
110.9, 112.3, 113.1, 113.2, 120.9, 124.9, 131.6, 134.1, 134.5, 138.9, 147.7, 147.8, 147.8, 
148.2; IR (neat) 2954, 1504, 1464, 1249, 1028, 762 cm-1; HRMS (ESI+) m/e calc’d for [M
+H]+ C24H30NO4: 396.2175, found 396.2177.  (R)-Enantiomer: α[ ]D
















Using the same proportions as above, the title compound was obtained after flash 
chromatography (60 % EtOAc/hexanes [1% TEA]) as a yellowish foamy solid (485 mg, 
98%). 1H NMR (400 MHz, CDCl3) δ 1.22-1.32 (m, 1H), 1.63-1.98 (m, 6H), 2.09 (dd, J = 
17.9, 8.9 Hz, 1H), 2.83 (dd, J = 16.2, 1.6 Hz, 1H), 3.18 (dt, J = 8.5, 1.9 Hz, 1H), 3.61 (ddd, J 
= 16.2, 4.5, 1.1 Hz, 1H), 3.83 (s, 3H), 3.87 (s, 3H), 3.92 (s, 3H), 5.69-5.70 (m, 1H), 6.82 (dd, 
J = 8.4, 2.7 Hz, 1H), 6.86 (d, J = 2.7 Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 6.98 (dd, J = 8.2, 2.0 
Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
21.3, 30.6, 36.5, 53.0, 54.3, 55.3, 55.8, 55.9 60.3, 110.9, 112.1, 112.2, 115.5, 120.9, 124.7, 
130.9, 134.4, 134.5, 138.5, 140.4, 148.0, 148.3, 158.6; IR (neat) 2955, 1517, 1464, 1248, 





Compounds 1.1, 1.4, 4.2, 5.22, 5.23 and 5.24 were prepared according the procedure shown 
for compound 1.4.
(R)-Tylocrebrine (R-1.4).  Indolizidine 5.1 (400 mg, 1.01 mmol, 1.0 equiv) was dissolved in 
anhydrous CH2Cl2 (100 mL) and cooled to –78 ºC.  Two drops of TFAA was then added to 
this solution.  In a separate flask containing VOF3 (500 mg, 4.04 mmol, 4.0 equiv) was added 
anhydrous CH2Cl2 (10 mL), anhydrous EtOAc (5 mL), TFA (0.5 mL) and TFAA (2 drops). 











TFA, TFAA, -78 ºCR1 R1
R3 R3
1.1, 1.4, 4.2, 5.22–5.24
tylocrebrine








reaction mixture was stirred for 1 h at –78 ºC and then slowly warmed over 3 h to ~ –15 ºC 
or until the starting material had been consumed.  To the reaction mixture was added 10% 
NaOH (50 mL) and the biphasic mixture was vigorously stirred for 1 h at room temperature. 
The product was extracted with CH2Cl2.  The combined organic layers were washed with 
brine and dried over anhydrous Na2SO4.  Filtration and concentration in vacuo gave the crude 
product. Purification by flash chromatography (80 % EtOAc/hexanes [1% TEA]) provided 
the title compound as  white crystalline solid (247 mg, 62%): mp 227–229 ºC (decomp.) [Lit. 
mp 218–220 ºC];20 1H NMR (400 MHz, CDCl3) δ 1.73-1.83 (m, 1H), 1.87-1.96 (m, 1H), 
1.99-2.10 (m, 1H), 2.19-2.31 (m, 1H), 2.42-2.52 (m, 2H), 2.91 (dd, J = 14.8, 11.3 Hz, 1H), 
3.33 (dd, J = 15.8, 3.5 Hz, 1H), 3.46 (t, J = 8.2 Hz, 1H), 3.68 (d, J = 14.7 Hz, 1H), 3.92 (s, 
3H), 4.03 (s, 3H), 4.07 (s, 3H), 4.07 (s, 3H), 4.66 (d, J = 14. 8 Hz, 1H), 7.28 (d, J = 9.1 Hz, 
1H), 7.33 (s, 1H), 7.65 (d, J = 9.1 Hz, 1H), 9.33 (s, 1H);  13C NMR (100 MHz, CDCl3) δ 
21.6, 31.3, 34.0, 54.2, 55.1, 55.7, 56.5, 60.0, 60.2, 103.5, 109.1, 112.1, 118.8, 123.3, 123.6, 
125.8, 126.5, 127.9, 146.3, 147.7, 148.7, 150.6;  IR 2936, 1601, 1514, 1467, 1255, 1114, 
1033, 913 (neat) cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ C24H28NO4: 394.2013, found 
394.2021. α[ ]D
22 =  –105 (c 1.00, CHCl3).  [Lit. –45 (c 0.74, CHCl3)]20
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(R)-Tylophorine (R-1.1).  Using the same quantities and proportions as above, the title 
compound was obtained after flash chromatography (5% MeOH/CH2Cl2) as a white 
crystalline solid (354 mg, 89%).  mp 284–285 ºC (decomp.) [Lit. mp 274–276 ºC,359, 360 275 
ºC11, 14] ; 1H NMR (400 MHz, CDCl3) δ 1.72-1.97 (m, 2H), 1.99-2.10 (m, 1H), 2.20-2.28 (m, 
1H), 2.43 (m, 2H), 2.90 (dd, J = 15.6, 10.6 Hz, 1H), 3.35 (dd, J = 15.8, 2.5 Hz, 1H), 3.46 (dt, 
J = 4.2, 1.6 Hz, 1H), 3.65 (d, J = 14.6 Hz, 1H), 4.05 (s, 3H), 4.05 (s, 3H), 4.11 (s, 6H), 4.61 
(d, J = 14.6 Hz, 1H), 7.15 (s, 1H), 7.30 (s, 1H), 7.81 (s, 1H), 7.82 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 21.6, 31.3, 33.8, 54.1, 55.2, 55.9, 55.9, 56.1, 60.3, 103.2, 103.4, 103.5, 104.0, 
123.5, 123.6, 124.4, 125.9, 126.0, 126.3, 148.4, 148.5, 148.7, 148.7; IR (neat) 2960, 1619, 
1515, 1248, 1151, 1017, 841 cm-1; HRMS (ESI+) m/e calc’d for [M]+ C24H24NO4+: 394.2013, 
found 394.2011. α[ ]D











(±)-6-Desmethoxytylocrebrine (5.22).  Using the same proportions as above, the title 
compound was obtained after flash chromatography (5% MeOH/CH2Cl2) as a white 
crystalline solid (28 mg, 28%). 1H NMR (400 MHz, CDCl3) δ 1.72-1.82 (m, 1H), 1.87–1.97 
(m, 1H), 1.98-2.10 (m, 1H), 2.42-2.52 (m, 2H), 2.94 (dd, J = 15.8, 10.5 Hz, 1H), 3.38 (dd, J 
= 16.0, 2.2 Hz, 1H), 3.48 (dt, J = 4.3, 2.0 Hz, 1H), 3.70 (d, J = 14.9 Hz, 1H), 4.07 (s, 3H), 
4.09 (s, 3H), 4.12 (s, 3H), 4.68 (d, J = 14.9 Hz, 1H), 7.11 (d, J = 7.7, 1H), 7.36 (s, 1H), 7.48 
(dd, J = 8.0, 8.0 Hz, 1H), 7.54 (dd, J = 8.3, 1.1 Hz, 1H); HRMS (ESI+) m/e calc’d for [M+H]
+ C23H28NO3: 364.1913, found 364.1898. 13C NMR and IR data could not be obtained, 









(±)-Antofine (4.2).  Using the same proportions as above, the title compound was obtained 
after flash chromatography (5% MeOH/CH2Cl2) as a white crystalline solid (141 mg, 70%). 
See Section 6.4 for spectral data.
(±)-Desmethoxytylophorine (5.23).  Using the same proportions as above, the title 
compound was obtained after flash chromatography (5% MeOH/CH2Cl2) as a white 
crystalline solid (190 mg, 85%).  mp 203–205 ºC (decomp.)  1H NMR (400 MHz, CDCl3) δ 
1.72-1.96 (m, 2H), 1.98-2.09 (m, 1H), 2.20-2.28 (m, 1H), 2.42–2.54 (m, 2H), 2.90 (dd, J = 
15.6, 10.5 Hz, 1H), 3.33 (dd, J = 15.8, 2.4 Hz, 1H), 3.46 (dt, J = 8.6, 1.7 Hz, 1H), 3.69 (d, J = 















9.0, 2.5 Hz, 1H), 7.30 (s, 1H), 7.81 (d, J = 9.0 Hz, 1H), 7.89 (d, J = 2.5 Hz, 1H) 7.91 (s, 1H); 
13C NMR (100 MHz, CDCl3) δ 21.6, 31.3, 33.6, 53.8, 55.0, 55.5, 55.9, 56.0, 60.2, 103.8, 104.0, 
104.7, 114.9, 123.5, 124.1, 124.2, 125.5, 126.5, 127.1, 130.2, 148.4, 149.4, 157.5; IR (neat) 
2914, 1615, 1512, 1257, 1033, 912, 843 cm-1; HRMS (ESI+) m/e calc’d for [M+H]+ 
C23H28NO3: 364.1913, found 364.1909.
(±)-Deoxypergularinine (5.24).  Using the same proportions as above, the title compound 
was obtained after flash chromatography (5% MeOH/CH2Cl2) as a white crystalline solid 
(170 mg, 68%).  mp 221–222 ºC (decomp.)  1H NMR (400 MHz, CDCl3) δ 1.71-1.81 (m, 
1H), 1.87–1.97 (m, 1H), 1.98-2.09 (m, 1H), 2.20-2.28 (m, 1H), 2.46 (dd, J = 18.0, 9.0 Hz, 
1H), 2.43–2.52 (m, 1H), 2.94 (dd, J = 16.0, 10.6 Hz, 1H), 3.41–3.50 (m, 2H), 3.66 (d, J = 
14.7 Hz, 1H), 4.02 (s, 3H), 4.06 (s, 3H), 4.10 (s, 3H), 4.61 (d, J = 14.6 Hz, 1H), 7.17 (s, 1H), 
7.22 (dd, J = 9.0, 2.5 Hz, 1H), 7.90 (d, J = 2.5 Hz, 1H), 7.92 (s, 1H), 7.95 (d, J = 9.1 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 21.6, 31.3, 33.7, 54.0, 55.2, 55.5, 55.9, 56.0, 60.2, 103.2, 104.0, 









2928, 1604, 1528, 1468, 1205, 1165, 1031, 913 HRMS (ESI+) m/e calc’d for [M+H]+ 
C23H28NO3: 364.1913, found 394.1910.
6.5.2 Biological procedures 
6.5.2.1 Anti-proliferation assay
MCF-7, COLO-205 and NCI-ADR-RES cancer cells were harvested (125 G centrifuge for 5 
min) from a exponential-phase maintenance culture.  The cells were resuspended in a new 
culture medium (RPMI Medium 1640) and the cell density was adjusted to 105 cells/mL and 
dispensed in 96-well culture plates at a density 5,000 cells per well (50 µL ).  The cells were 
incubated overnight growth to allow cells to adhere to the wells.  The culture medium in each 
well was replaced with fresh culture medium (50 µL) containing varying concentrations (50, 
12.5, 3.125, 0.8, 0.2, 0.05, 0.0125, 0.003 µL) of the test  and control (Taxol) compounds.  The 
cultures were grown for an additional 48 h and alamarBlue® (20ul) was added.  After 1–2 h, 
the fluorescence excitation (530 nm) and emission (590 nm) of each well were measured to 
determine the optical density.  (This assay was performed by Dr. Harry Tian at the ITDD)
6.5.2.2 MOA assay 
The following stock solutions were prepared:  MAO-A (5 mg/mL, 75 U/mg), MAO-B (5 mg/
mL, 58 U/mg), p-tyramine (100 mM), Amplex® Red reagent (20 mM), HRP (200 U/mL), 
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reaction buffer. Amplex® Red reagent solution (400 µL) was prepared that consisted of 
Amplex® Red (50 µL, 20 mM  stock solution),  p-tyramine (50 µL, 100 mM  stock solution) 
and HRP (2 U/mL).  Varying concentrations (100, 20, 4, 0.8, 0.16, 0.032, 0.0064, 0.0013 
µM) of test and control compounds were added wells in a 360-well plate using the ECHO 
550 acoustic liquid handler.  MAO-A or MAO-B stock solutions (25 µL) were added to the 
appropriate wells by  hand and the plate was incubated at  room temperature for 15 min. 
Amplex® Red solution (25 µL) was added to the appropriate wells by hand and the plate was 
incubated at room temperature for 30 minutes.  The fluorescence excitation (530 nm) and 
emission (590 nm) were measured for each well.  (This assay was performed by Dr. Jonothan 
Soldberg at the ITDD)
6.5.2.3 Comprehensive CNS target screen and binding assays
Receptor binding profiles and KD determinations were generously provided by the National 
Institute of Mental Health's Psychoactive Drug Screening Program, Contract # 
HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth 
MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie 
Driscol at NIMH, Bethesda MD, USA.  For experimental details please refer to the PDSP 
web site http://pdsp.med.unc.edu. 
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6.6 X-Ray crystal structure
REFERENCE NUMBER: 08053a
CRYSTAL STRUCTURE REPORT
[C8 H13 I N O]+ IReport
prepared for:
M. Niphakis / Prof. G. Georg
March 25, 2008




207 Pleasant St. S.E.
Minneapolis, MN 55455
DATA COLLECTION
A crystal (approximate dimensions 0.45 x 0.20 x 0.05 mm3) was placed onto the tip of a 0.1 
mm diameter glass capillary and mounted on a CCD area detector diffractometer for a data 
collection at 173(2) K.1 A preliminary set of cell constants was calculated from reflections 
harvested from three sets of 20 frames. These initial sets of frames were oriented such that 
orthogonal wedges of reciprocal space were surveyed. This produced initial orientation 
matrices determined from 122 reflections. The data collection was carried out using MoKα 
radiation (graphite monochromator) with a frame time of 10 seconds and a detector distance 
of 4.9 cm.  A randomly oriented region of reciprocal space was surveyed to the extent of one 
sphere and to a resolution of 0.77 Å.  Four major sections of frames were collected with 0.30º 
steps in ω at four different φ settings and a detector position of -28º in 2θ. The intensity data 
were corrected for absorption and decay (SADABS).2 Final cell constants were calculated 
from 2533 strong reflections from the actual data collection after integration (SAINT).3 
Please refer to Table 1 for additional crystal and refinement information.
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STRUCTURE SOLUTION AND REFINEMENT 
The structure was solved using Bruker SHELXTL4 and refined using Bruker SHELXTL.4 
The space group P21 was determined based on systematic absences and intensity statistics. A 
direct methods solution was calculated which provided most non-hydrogen atoms from the 
E-map. Full matrix least squares / difference Fourier cycles were performed which located 
the remaining non-hydrogen atoms. All non-hydrogen atoms were refined with anisotropic 
displacement parameters.  All hydrogen atoms were placed in ideal positions and refined as 
riding atoms with relative isotropic displacement parameters. The final full matrix least 
squares refinement converged to R1 = 0.0192 and wR2 = 0.0483 (F2, all data).
STRUCTURE DESCRIPTION
The structure is the one suggested. CHECKCIF determined the P21 structure to be pseudo-
centric (83%), but the structure is clearly chiral with the absolute configuration at C4 being S.
Data collection and structure solution were conducted at the X-Ray Crystallographic 
Laboratory, 192C Kolthoff Hall, Department of Chemistry, University of Minnesota. All 





1.  SMART V5.054, Bruker Analytical X-ray Systems, Madison, WI (2001).
2.   An empirical correction for absorption anisotropy, R. Blessing, Acta Cryst. A51, 33-38 
(1995).
3.  SAINT+ V6.45, Bruker Analytical X-Ray Systems, Madison, WI (2003).
4.  SHELXTL V6.14, Bruker Analytical X-Ray Systems, Madison, WI (2000).
Some equations of interest:
Rint = Fo
2− < Fo




wR2 = w Fo
2 − Fc
2( )2⎡⎣∑⎡⎣⎢ ⎤⎦⎥ / w Fo
2( )2⎡⎣ ⎤⎦∑ ⎤⎦⎥
1/2
where  w = q / σ 2 Fo
2( ) + a *P( )2 + b *P + d + e*sin(θ)⎡⎣ ⎤⎦
GooF = S = w Fo
2 – Fc












Unit cell dimensions a = 8.7128(13) Å α = 90°
b = 7.4839(11) Å β = 96.339(2)°
c = 9.3223(13) Å γ = 90°
Volume 604.15(15) Å3
Z 2
Density (calculated) 2.160 Mg/m3
Absorption coefficient 5.168 mm–1
F(000) 364
Crystal color, morphology Colorless, Plate
Crystal size 0.45 x 0.20 x 0.05 mm3
Theta range for data collection 2.20 to 27.46°
Index ranges –11 ≤ h ≤ 11, –9 ≤ k ≤ 9, 0 ≤ l ≤ 12
Reflections collected 6149
Independent reflections 2704 [R(int) = 0.0252]
Observed reflections 2619
Completeness to theta = 27.46° 99.00%
Absorption correction Multi-scan
Max. and min. transmission 0.7821 and 0.2045




Data / restraints / parameters 2704 / 1 / 109
Goodness-of-fit on F2 1.025
Final R indices [I>2sigma(I)] R1 = 0.0192, wR2 = 0.0479
R indices (all data) R1 = 0.0203, wR2 = 0.0483
Absolute structure parameter 0.00(3)
Largest diff. peak and hole 0.570 and –0.438 e.Å–3
Table 2. Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2 x 
103) for 08053a. Ueq is defined as one third of the trace of the orthogonalized Uij tensor.
x y z Ueq
N1 6388(3) 3 088(3) 4160(3) 24(1)
C1 8059(4) 2548(5) 4568(4) 34(1)
C2 8981(4) 4079(6) 4066(4) 43(1)
C3  8007(3)  4677(7) 2684(4)  38(1)
C4  6372(3) 4679(5) 3141(3) 28(1)
C5 5083(3) 4517(6) 1903(3)  27(1)
C6 3522(3) 4553(6) 2435(3) 32(1)
O1 3376(2) 4524(5) 3716(2)  40(1)
C7 2115(3)  4615(7) 1377(3) 35(1)
C8 2079(3) 4606(6) -25(3) 32(1)
I1 -43(1) 4668(1) -1311(1)  36(1)
I2 4346(1) -506(1) 2402(1) 29(1)
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Symmetry transformations used to generate equivalent atoms
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Table 4. Anisotropic displacement parameters (Å2 x 103) for 08053a. The anisotropic 
displacement factor exponent takes the form: –2π2[ h2 a*2U11 + ... + 2 h k a* b* U12 ]
U11 U22 U33 U23 U13 U12
N1 22(1) 27(1) 22(1)  -1(1) 4(1) -3(1)
C1 21(2) 43(2) 37(2) 6(2) 3(1) 4(1)
C2 26(2) 62(3) 39(2) 10(2) 3(2) -8(2)
C3 24(1) 48(2) 44(2) 14(2) 7(1)  -6(2)
C4 25(1) 29(2) 30(1) 5(2) 2(1) 0(2)
C5 27(1) 30(2) 25(1) 2(2) 5(1)  5(2)
C6 27(1) 37(2) 30(1) -3(2)  2(1) 8(2)
O1 32(1) 64(2) 25(1)  2(2) 6(1) 8(2)
C7 22(1) 50(2)  32(1)  0(2) 5(1) 4(2)
C8 27(1) 32(2)  35(1) 1(2) 1(1)  -2(2)
I1 32(1) 43(1) 32(1) 1(1) -4(1) 0(1)
I2 32(1) 29(1) 25(1) 1(1) 3(1) -6(1)
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Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 x 103) for 
08053a.
x y z Ueq
H1A 5842 2152 3713 28
H1B 5938 3394 4973 28
H1C 8277 2380 5624 41
H1D 8299 1425 4078 41
H2A 10020 3683 3866 51
H2B 9091 5051 4791 51
H3A 8097 3827 1884 46
H3B 8312 5884 2385 46
H4A 6217 5799 3693 34
H5A 5162 5514 1217 33
H5B 5206 3384 1379 33
H7A 1149 4667 1759 42
H8A 3014 4570 -461 38
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Symmetry transformations used to generate equivalent atoms.
Table 7. Hydrogen bonds for 08053a [Å and °].
D-H...A d(D-H)  d(H...A) d(D...A) 
N1-H1B...I2#1 0.92 2.62 3.498(2) 
N1-H1A...I2 0.92 2.61 3.528(3) 





No syntax errors found.        CIF dictionary        Interpreting this report 
Datablock: 08053a 
Bond precision:  C-C = 0.0044 A  Wavelength=0.71073 
Cell:    a=8.7128(13)  b=7.4839(11) c=9.3223(13) 
   alpha=90  beta=96.339(2)  gamma=90 
Temperature:  173 K 
Calculated Reported 
Volume 604.15(15) 604.15(15) 
Space group P 21  P2(1) 
Hall group P 2yb ? 
Moiety formula C8H13INO, I C8H13INO, I 
Sum formula C8H13I2NO C8H13I2NO 
Mr 392.99 392.99
Dx,g cm-3 2.160 2.160
Z 2 2
Mu (mm-1) 5.168 5.168
F000 364.0 364.0
F000’ 362.24
h,k,lmax 11,9,12 11,9,12 
Nref 1488( 2761) 2704 




Correction method = AbsCorr = MULTI-SCAN 
Data completeness = 1.82(0.98) Theta(max) = 27.460 
R(reflections) = 0.0192( 2619) wR2 (reflections) = 0.0483( 2704) 
S = 1.025 Npar = 109 
The following ALERTS were generated. Each ALERT has the format test-name_ALERT_alert-type_alert-level. 
 
Alert level B 
PLAT111_ALERT_2_B ADDSYM Detects (Pseudo) Centre of Symmetry ..…   83 PerFi 
Alert level C 
PLAT850_ALERT_2_C Check Flack Parameter Exact Value 0.00 and su ..         0.03      
 
Alert level G 
REFLT03_ALERT_4_G Please check that the estimate of the number of Friedel pairs is 
            correct. If it is not, please give the correct count in the 
            _publ_section_exptl_refinement section of the submitted CIF. 
           From the CIF: _diffrn_reflns_theta_max             27.46 
           From the CIF: _reflns_number_total                 2704 
           Count of symmetry unique reflns            1488 
           Completeness (_total/calc)               181.72% 
           TEST3: Check Friedels for noncentro structure 
           Estimate of Friedel pairs measured         1216 
           Fraction of Friedel pairs measured        0.817 
           Are heavy atom types Z>Si present          yes 
PLAT791_ALERT_1_G Confirm the Absolute Configuration of C4     …           S      
PLAT860_ALERT_3_G Note: Number of Least-Squares Restraints    …            1   
   
   0 ALERT level A = In general: serious problem 
   1 ALERT level B = Potentially serious problem 
   1 ALERT level C = Check and explain 
   3 ALERT level G = General alerts; check 
   1 ALERT type 1 CIF construction/syntax error, inconsistent or missing data 
   2 ALERT type 2 Indicator that the structure model may be wrong or deficient 
   1 ALERT type 3 Indicator that the structure quality may be low 
   1 ALERT type 4 Improvement, methodology, query or suggestion 
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